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Abstract
Introduction: The transmission of RSV in the human population is characterised by seasonal 
epidemics displaying cyclic alternation in dominance of the two antigenic groups A and B. 
The mechanisms that underlie this population-level competition between RSV A and B, and 
heterogeneity in transmission fitness of RSV genotypes are not clearly defined. The dynamics 
of neutralising antibody response following birth and primary infection as well as pro- and 
anti- inflammatory cytokines/chemokines following natural infection in infants, especially in 
relation to RSV antigenic variation, have not been well characterised.
Methods: Neutralising antibodies were measured in the acute and convalescent sera of 
infants with RSV-associated pneumonia as well as from a birth cohort. Additionally, 10 
cytokines/chemokines were measured in nasal secretions obtained from infants recruited 
within the household setting and from whom samples were obtained twice weekly during an 
RSV epidemic.
Results: The proportion of RSV A infected individuals seroconverting to a contemporary 
group A test virus was significantly higher than the proportion seroconverting to a 
contemporary group B virus (p=0.0005). The proportion of RSV B infected individuals 
seroconverting to a contemporary group B virus was higher than the proportion 
seroconverting to a contemporary A virus (p=0.008). The mean duration of maternal 
neutralising antibodies above a putative protective threshold was 2.8 months (95%CI 2.5-3.1 
months). Primary neutralising antibodies declined to pre-infection levels within 3-4 months. 
The levels of some cytokines/chemokines correlated with viral load but not with RSV group.
Conclusion: The data suggest that population-level competition between RSV A and B is 
related to development of transient group-specific immunity following natural infection. Thus 
it might be argued that future RSV vaccines should include strains from both groups in order 
to maximise the indirect protective effect of a vaccination programme. No evidence was 
found for strain-specificity in cytokine/chemokine responses following RSV infection.
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Chapter 1 - General Introduction
The significance of RSV in the context of the global burden of respiratory 
illness due to bacterial and viral pathogens
Respiratory infections are a leading cause of the global infectious disease burden (Lozano et 
a l, 2012). Infections caused by such pathogens as Mycobacterium tuberculosis, 
Streptococcus pneumoniae and human influenza A virus have in the past exerted a heavy 
mortality and morbidity burden in different parts of the world, and for many continue to do 
so, particularly in low resource countries. For example, it is estimated that in 2000 
approximately 14.5 million cases of severe pneumococcal disease occurred as a result of 
infection with Streptococcus pneumoniae, resulting in about 826,000 deaths worldwide 
among children who were less than 5 years of age (O'Brien et a l, 2009). Haemophilus 
influenzae type b which has been a leading cause of pneumonia in children is estimated to 
have caused about 8.13 million cases of serious illness worldwide in 2000, resulting in 
approximately 371,000 deaths among children who were less than five years of age (Watt et 
a l, 2009). It has been reported that in 2011, there were an estimated 8.7 million new cases of 
tuberculosis caused by Mycobacterium tuberculosis of which 13% were co-infections with 
HIV (World Health Organization, 2012). In the same year about 1.4 million deaths due to 
tuberculosis occurred, of which only about 430,000 were attributed to individuals with human 
immunodeficiency virus (HIV) (World Health Organization, 2012).
Respiratory infections caused by viruses have been associated with death and serious illness 
on a massive scale throughout the world. The influenza pandemic of 1918-1919 which was 
caused by an influenza A virus is thought to have infected about 500 million individuals 
worldwide with very high case fatality rates (Taubenberger and Morens, 2006). It is
estimated to have resulted in approximately 50 million deaths worldwide (Johnson and 
Mueller, 2002). More recently, the 2009 influenza A H1N1 pandemic is estimated to have 
resulted in 201,200 deaths from respiratory illness and 83,300 deaths as a result of 
cardiovascular complications (Dawood et al., 2012).
Respiratory Syncytial Virus (RSV) is considered to be the most important viral cause of 
lower respiratory tract infection in infants and young children globally. It is estimated that in 
2005 about 33.8 million new cases of acute lower respiratory infection attributable to RSV 
occurred among children who were less than 5 years of age (Nair et a l , 2010). Of these, at 
least 3.4 million episodes were of sufficient severity to necessitate hospitalisation. Between 
66,000 and 199,000 children who were less than five years of age are estimated to have died 
in 2005 as a result of acute respiratory illness caused by RSV, with 99% of these deaths 
occurring in developing countries (Nair et al., 2010). In Kenya for example, incidence rates 
for hospitalisation of RSV of 1,107 per 100,000 infants have been reported, with an estimated 
mortality rate of 2.2% among infants with severe RSV pneumonia (Nokes et a l , 2009). An 
analysis of the aetiology of severe pneumonia in children (figure 1 .1) has shown that a large 
proportion of the severe pneumonia burden is attributable to RSV and other respiratory 
viruses relative to bacterial causes (Scott et a l, 2008). Viewed together, these estimates 
suggest that RSV is responsible for a significant proportion of the burden of respiratory 
illness caused by viral and bacterial pathogens, suggesting the need to design and conduct 
studies to understand both its clinical and epidemiological characteristics in order to develop 
effective control strategies.
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No pathogen 
identified
\
S aureus
Gram-neg bacteria
Mycobacterium
tuberculosis
RSV and 
respiratory viruses
S. pneumoniae
\
H. influenzae
Figure 1.1 Pie chart showing the relative contribution of RSV and different bacterial pathogens 
in causing severe pneumonia in developing countries (Scott et al., 2008).
D efining the question
RSV can be divided into two distinct groups A and B, which vary in terms o f  their sequence 
characteristics as well as in their reaction with certain monoclonal antibodies (Mufson et al., 
1985, Anderson et al., 1985, Johnson et al., 1987b). Within the group structure exist strains 
or genotypes that are variant in their sequence characteristics (Cane and Pringle, 1991). The 
transmission o f  RSV in most parts o f  the world is inherently cyclical and is characterised by 
regular outbreaks of  acute respiratory infection at specific times o f  the year (Stensballe et al., 
2003). Studies on the strain structure o f  these epidemics have shown evidence o f  population 
level competition between the two antigenic groups A and B (Waris, 1991, Zlateva et al., 
2007) as well as between different genotypes (Cane, 2001). In some communities, this 
competition is manifested in alternating patterns o f  dominance o f  RSV A and B in successive 
epidemics (Waris, 1991, Zlateva et al., 2007). This pattern o f  group and genotype 
replacement strongly implicates the involvement o f  an underlying selection mechanism.
3
A mechanism that potentially underlies the observed variations is immune selection. 
Following natural infection with one antigenic group, it is reasonable to assume that the 
resulting immune response would be more effective against the infecting group relative to the 
alternative group. If this host level response is extrapolated to the population level, it is likely 
that the transmission of one RSV group in a particular epidemic would lead to a build-up of 
population-level group-specific immunity, that would generally preclude the re-introduction 
of that group in the subsequent transmission season, but that would be permissible to the 
transmission of the alternative group.
RSV is known to repeatedly infect throughout life. The ability of the virus to re-infect may be 
related to antigenic variation, transient protective immunity or both. Recent studies have 
shown that repeat infections are often caused by viruses that are genetically different from 
those that caused the initial infections (Agoti et a l, 2012) although prior work had shown that 
re-infecting strains did not appear to be antigenically different from strains that had caused 
prior infection (Beem, 1967). The duration of protective immunity following primary RSV 
infection in infants has not been exhaustively investigated. There is general consensus that 
protective immunity correlates strongly with development of serum neutralising antibody 
(Glezen et al., 1981a, Piedra et al., 2003) suggesting the possibility that the duration of these 
antibodies correlates with the duration of protection. Previous studies have estimated that 
antibody responses to primary RSV decline to pre-infection levels within one year of 
infection (Welliver et a l, 1980, Kaul et al., 1981). However, many of these studies were 
based on enzyme immunoassays that detected total antibodies and not neutralising antibodies 
which are likely to correlate more strongly with protection. The lack of data on the duration
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of neutralising responses has hindered the ability to accurately predict the duration of 
protective immunity induced by natural primary infection.
The natural history of cytokine/chemokine responses following natural RSV infection is 
imperfectly understood. While animal models have provided in-depth data on the kinetics of 
different cytokines/chemokines in the course of infection (Sun et a l , 2011, Hussell et a l, 
1996), there has been little validation of these results in infant disease. The most 
comprehensive data available in the human infant are based on samples obtained following 
the failed formalin-inactivated vaccine studies conducted in the 1960s. In this model severe 
disease was associated with development of an intense inflammatory infiltrate in the lungs of 
vaccinees who developed severe pneumonia following natural exposure (Openshaw and 
Tregoning, 2005). In addition to this, the role of RSV antigenic variation in driving 
differential cytokine/chemokine responses to RSV is not clearly understood. It is possible that 
variation in virus proteins that interact with elements of the host immune system could 
potentially result in variable cytokine/chemokine responses and ultimately variations in 
clinical disease.
The research presented in this thesis was designed to contribute to the understanding of the 
host immune response to RSV and its implications on both the transmission dynamics of the 
virus as well as in the modification of the host-virus interaction at the acute stage of illness.
Thesis research objectives
The key objective was to define the group and strain-specificity of the serum neutralising 
antibody response generated upon natural infection in infants. Two secondary objectives were 
to define the kinetics of the neutralising antibody response following natural infection and to
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describe the natural history of different cytokine/chemokine cytokine/chemokine responses at 
the acute stage of RSV infection in infants, within the context of RSV strain diversity.
Specific objectives
1. Describe the development of the serum neutralising antibody response in the acute 
and convalescent phase of infection
2. Compare the partial G and F gene sequences of infecting RSV A and B viruses
3. Compare homologous and heterologous serum neutralising antibody responses to both 
RSV A and B
4. Evaluate the effect of the novel 60 nucleotide G gene duplication (BA genetic 
change) on the neutralising antibody response
5. Measure the average duration of neutralising antibodies following primary infection 
in infants
6 . Evaluate the kinetics of different cytokine/chemokine responses over the course of 
natural RSV infection in infants and assess the effect of RSV strain variation on these 
responses
Approach
The research studies reported in this thesis were based on the measurement of neutralising 
antibody titres in both acute and convalescent phase sera obtained from infants with severe or 
very severe pneumonia admitted to a district hospital serving a rural coastal Kenyan 
community. Neutralising antibodies were also measured in serum obtained from a birth 
cohort that was recruited and followed up for up to 30 months of age, with active and passive 
surveillance of respiratory infection. Cytokine/chemokine responses were measured in nasal
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samples collected at regular intervals prior to, during and after natural RSV infection in 
infants.
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Overview of the thesis
Chapter 2 of the thesis contains a review of the literature. The aim of this review is to provide 
a description of RSV in terms of its burden, transmission, molecular and antigenic
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characteristics, and vaccine development. This chapter comprehensively reviews early 
published cross neutralisation studies that aimed to define the extent of antigenic 
heterogeneity between different strains of the virus. Chapter 3 provides a detailed description 
of the study design as well as the laboratory methods used in the different studies discussed in 
the thesis. Chapter 4 describes the development of a high throughput plaque reduction and 
neutralisation assay. Chapter 5 provides a description of the development of neutralising 
antibody responses following natural infection. In this chapter, age dynamics of the 
neutralising response are explored. The genetic characteristics of infecting strains are 
described in this chapter and finally, group homologous and heterologous neutralising 
antibody responses are compared. In Chapter 6, the kinetics of the RSV neutralising antibody 
response are described. Neutralising antibodies in a birth cohort recruited and prospectively 
followed up for approximately 30 months are described. The duration of the neutralising 
antibody response following natural infection is also described. Chapter 7 deals with 
genotype-specific neutralising antibody responses to RSV. In this chapter, neutralising 
responses to strains isolated between 40-50 years apart are assessed. Further, the effect of the 
recent 60 nucleotide duplication on the attachment protein gene of group B strains on the 
neutralising response is described. Chapter 8 describes the natural history of 
cytokine/chemokine responses following natural RSV infection in infants. In this chapter, the 
kinetics of different cytokines/chemokines over the entire course of natural RSV infection is 
described. The effect of strain variation on different cytokine/chemokine responses is also 
described in this chapter. Chapter 9 offers a summary and. overall discussion of the main 
findings in this thesis. This chapter discusses limitations in the studies described and proposes 
potential avenues for future research.
Chapter 2 - Literature Review
Burden of disease of RSV
RSV is the most important viral cause of acute lower respiratory infection (ALRI) among 
infants globally. In 2005 at least 33.8 million cases of RSV associated ALRI occurred in the 
under 5 age group and of these, 3.4 million cases were associated with severe illness that 
necessitated hospital admission (Nair et al., 2010). Between 66,000 and 199,000 deaths were 
estimated to have occurred in the same year as a result of RSV associated ALRI, with a vast 
majority of the deaths occurring in developing countries (Nair et a l , 2010). RSV mortality 
is associated with certain risk factors. A recent systematic review of co-morbidities 
associated with increased risk of death following RSV infection showed the mortality rate in 
children with congenital heart disease (CHD) was between 2 -  37%, while that of premature 
infants and those with chronic lung disease (CLD) was between 0 -  6.1% and 2 -37% 
respectively (Welliver et al., 2010). These rates contrast sharply with the RSV associated 
mortality rate in otherwise healthy children which is reported to be less than 1% (Welliver et 
al., 2010). Apart from its effect on the health of the patient, RSV imposes a heavy economic 
cost. In the United States for example, the average total cost of hospitalisation for term and 
pre-term infants infected with RSV exceeds the hospitalisation costs of infants admitted with 
other conditions by an average of $9,151 and $17,465 respectively (Palmer et al., 2010). In 
view of the fact that the burden of severe RSV disease is highest among infants, these data 
suggest that the monetary cost associated with severe RSV infection among infants is 
substantial. The cost of RSV infection may also be measured in terms of days of work or 
school missed as a result of infection. Previous studies have shown that RSV infection in 
previously healthy adults is associated with periods of absence from work of up to one week
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(O'Shea et a l, 2007, Hall et al., 1978). As a result of the health and economic costs linked 
with infection, development of an RSV vaccine is considered to be a research priority.
Molecular structure of RSV
RSV belongs to the subfamily Pneumovirinae in the family Paramyxoviridae, order 
Mononegavirales (Pringle, 1997, Kingsbury et al). RSV virions exhibit pleomorphic 
characteristics with virions budding from the plasma membranes of infected cells assuming a 
rounded or kidney shape of between 150 -  250 nm in diameter (Bachi and Howe, 1973). 
Alternatively budding virions may appear as filaments with a uniform diameter of 50 to 100 
nm (Bachi and Howe, 1973). RSV is an RNA virus (Hamparian et a l, 1963) which contains 
10 genes that code for 11 proteins (Dubovi, 1982, Huang et a l, 1985, Collins et a l, 1984). 
This is due to the fact that one of the 10 genes (M2) contains an internal overlapping open 
reading frame (ORF) that codes for an 11th protein (M2-2) (Collins et a l, 1990a). The viral 
genome is of negative sense polarity (Lambert et a l, 1980, Huang and Wertz, 1982) and 
contains a functional polymerase within the viral nucleocapsid. Transcriptional mapping 
studies have demonstrated that the transcription of RSV occurs in a sequential manner in the 
order: NS1, NS2, N, P, M, SH, G, F, M2 and L (Dickens et a l,  1984). Figure 2.1 is an 
illustration of the molecular structure of RSV.
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Figure 2.1 Schematic diagram of the structure of RSV (Empey et al., 2010)
Sequential virus transcription by the viral polymerase is controlled by conserved gene start 
(GS) and gene end (GE) sequences at the beginning and end of every gene (Collins et al., 
1986). The RSV genome contains a single transcription promoter at the 3’ region of the 
genome (Dickens et al., 1984) which is used to initiate mRNA synthesis for all 10 genes. 
Once the polymerase binds to the promoter region, it initiates RNA synthesis and progresses 
until it encounters the GE region. This triggers the release of the nascent positive sense 
mRNA molecule that is specific for a particular viral protein (Cowton et al., 2006) and that 
can be translated into protein by the host cell machinery. mRNA synthesis of the subsequent 
gene is initiated when the polymerase encounters the GS region of the gene and progressively 
synthesises a new mRNA strand until it encounters the GE region, where the process 
described above is repeated. This process progresses until the mRNA of the last gene on the 
RSV genome (L gene) is synthesised (reviewed by Cowton et al. (Cowton et al., 2006) ).
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Viral proteins translated using the mRNA transcripts are then assembled into new, infectious 
virion particles along with a copy of the viral genome (Cowton et al., 2006).
The epidemiology of RSV
The transmission of RSV is characteristically seasonal. In countries within the northern 
hemisphere with temperate climates, RSV typically causes epidemics of acute lower 
respiratory infection among infants and young children between the months of November and 
April. The temporal transmission cycles may occur at an annual (Hall et a l, 1990, Cane, 
2001, Cane et al., 1994, Hall et al., 2009, Zlateva et al., 2007) or biennial (Waris, 1991, 
Mlinaric-Galinovic et al., 2008, Reyes et al., 1997, Anestad, 1987) frequency depending on 
the geographical location. Countries with tropical and semitropical climate experience RSV 
at equally regular intervals but with different patterns of seasonality. In northern tropical 
countries, the increase of RSV transmission is associated with increase in rainfall and 
decrease in temperature (Cherian et al., 1990, Weber et al., 1998). In southern tropical 
countries, RSV epidemics are associated with decreases in both temperature and rainfall 
(Madhi et al., 2006). In equatorial countries the association between climatic conditions and 
seasonal increases in transmission is less well defined. Some equatorial countries with 
perennial rainfall appear to experience RSV all year round (Reese and Marchette, 1991, 
Berman et al., 1983, Tsai et al., 2001), while others appear to experience seasonal epidemics 
at specific times of the year. The group replacement dynamics in Kilifi over a period of 9 
years are depicted in Figure 2.2.
The onset of RSV epidemics in different geographical areas varies considerably. In general, 
RSV epidemics appear to occur in a south to north direction in the northern hemisphere and a 
north to south direction in the southern hemisphere (Stensballe et al., 2003). In the United
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States for example, over a 10 year period, epidemics on average began in the South on week 
47 of the year followed by those in the Northeast at week 49, the West at week 52 and the 
Midwest at week 1 of the subsequent year. (Mullins et al., 2003). Notably, the respective 
onset times of RSV seasons were found to vary widely year on year in the same geographical 
locations in the United States (Panozzo et al., 2007).
Group replacement dynamics of RSV epidemics
RSV can be classified into two main groups A and B on the basis of both reaction with 
monoclonal antibodies and sequence data (Mufson et a l, 1985, Anderson et al., 1985, 
Johnson, 1987). Each group can further be categorised into strains or genotypes which vary to 
a lesser extent than the 2 main groups, both at the nucleotide and amino acid sequence level. 
Table 2.1 shows the extent of nucleotide and amino acid identity in some virus genes.
Protein
Nucleotide 
identity (%)
Amino acid 
identity (%) Reference
G 67 53 (Johnson et al., 1987b)
F 79 91 (Johnson and Collins, 1988)
SH 78 76 (Collins et al., 1990b)
NS1 78 87 (Johnson and Collins, 1989)
M2 78 92 (Collins et al., 1990a)
NS2 78 92 (Johnson and Collins, 1989)
N 86 96 (Johnson and Collins, 1989)
Table 2.1 Nucleotide and amino acid identity estimates between RSV A and B strains
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RSV epidemics exhibit extensive genotype variability. Generally RSV A strains appear to 
circulate at a higher frequency than RSV B strains throughout the world (Hall et a l, 1990, 
Reiche and Schweiger, 2009, Zhang et al., 2010, Zlateva et al., 2007). Studies of the group 
replacement dynamics in successive RSV epidemics have shown that the two RSV groups 
cyclically alternate in a generally predictable manner. For example, data collected in England 
and Wales over an 11 year period showed a cyclic triennial pattern in RSV A and B 
transmission (Cane, 2001). A similar pattern of population level competition between RSV A 
and B in successive epidemics has also been reported in Belgium (Zlateva et al., 2007). The 
pattern of cyclic alternation in Finland is markedly different from that in England and Wales 
and Belgium, where the dominant group alternates every two years (Waris, 1991). In 
Uruguay between two and three successive epidemics of RSV A are followed by one RSV B 
epidemic (Arbiza et al., 2005) while in France and Boston in the United States, less regular 
patterns of group replacement have been reported in which successive seasons of co­
dominance are followed by dominance by either RSV A or B (Hendry et al., 1989, Freymuth 
et al., 1991). The mechanisms though which certain epidemics display co-dominance in 
transmission between strains from the two groups are not understood. While determinants 
such as relative reproductive rates, degree of cross-protection and rate of waning immunity 
will be important (White et al., 1998) stochastic effects will undoubtedly play a role. It 
might be speculated that co-dominance could by chance arise due to the proportion of the 
population that is exposed to infection in any given epidemic. For example if only half the 
population is exposed to infection by one group during an epidemic while the other half 
remains un-infected, it may be that in the subsequent epidemic, the previously exposed group 
would be at an elevated risk of infection with the alternative group, while individuals who 
were not infected in the previous epidemic could be equally at risk of infection by both RSV 
A and B.
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Studies of the genotype diversity of RSV epidemics in different parts of the globe have 
yielded largely similar results. Multiple genotypes appear to constitute most epidemics, with 
the predominant genotype being successively replaced from one year to the next. For 
example a study in Birmingham in the United Kingdom found that different genotypes of 
both RSV A and B were predominant in each of 5 successive epidemics between 1988 and 
1993 and that the predominant genotypes appeared to decline over time and were replaced by 
alternative genotypes in epidemics that followed (Cane et a l , 1994). These data are 
graphically shown in figure 2.3. A Korean study that looked at genotype prevalence over 9 
consecutive epidemics found that multiple genotypes were in circulation and the predominant 
genotype in each epidemic was replaced in subsequent epidemics. Phylogenetic analysis of 
sequences in this study as well as others derived from other parts of the world, showed that 
similar strains were simultaneously circulating in other parts of the world (Choi and Lee, 
2000). These observations were supported by the findings of Cane et a l who also reported on 
the homogeneity of simultaneously circulating genotypes in different parts of the world (Cane 
et a l, 1992). Seki et a l looked at genotype diversity over 15 successive epidemics in Japan 
and found that that the dominant genotypes were similarly replaced in subsequent epidemics 
(Seki et a l, 2001). Similar findings were reported in two separate studies of hospitalised and 
ambulatory children in Rochester, New York (Hall et a l, 1990, Peret et a l, 1998). These 
observations have led to suggestions of the existence of population level competition between 
the two RSV groups as well as competition between different genotypes and that a build up 
of group/genotype-specific immunity at population level underlies the observed 
group/genotype replacement patterns in consecutive epidemics (Cane, 2007).
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Role of G and F proteins in virus binding and membrane fusion
Many paramyxoviruses gain entry into the cell through fusion of the virus and cell 
membranes (Chang and Dutch, 2012). In the case of RSV, prior to the fusion process, the 
virus through the G protein has been shown to attach to nucleolin on the surface of 
susceptible cells (Tayyari et al., 2011). This conclusion is based on the fact the ability of the 
virus to infect cells in vitro is significantly reduced in the presence of anti-nucleolin 
antibodies, soluble nucleolin and RNA interference that is targeted at reduced intracellular 
nucleolin expression (Tayyari et al., 2011). In addition to nucleolin, entry is likely to be 
facilitated by binding of the virus to heparin which is a soluble proteoglycan on the cell 
surface (Krusat and Streckert, 1997). The binding of RSV to heparin and other proteoglycans 
appears to be through recognition of the glycosaminoglycan (GAG) moieties of 
proteoglycans (Hallak et al., 2000, Martinez and Melero, 2000). Heparin sulphate has been 
suggested to be the main GAG involved with this entry mechanism (Hallak et al., 2000, 
Martinez and Melero, 2000). There is evidence that suggests that the interaction of RSV with 
GAGs on the host cell surface occurs through the G protein (Techaarpomkul et al., 2002). 
The region of the G protein consisting of amino acid residues 184-198 for RSV A and 183- 
197 for RSV B has been identified as the heparin binding domains (HBD) for human RSV 
(Feldman et al., 1999).
The role of the G protein in the attachment process has been investigated using recombinant 
viruses in which the G protein has been deleted. Recombinant viruses lacking the G protein 
have been shown to replicate efficiently in vitro in a cell-line dependent manner but poorly in 
mice which are intranasally inoculated with the virus (Teng et al., 2001). This suggests that 
the G protein may be dispensable in the attachment and entry process in some cells but is 
required for efficient replication in vivo. The role of the central conserved region in the
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attachment process has been investigated using recombinant viruses containing a deletion of 
this region. Surprisingly in these studies it was found that deletion of the central conserved 
region did not reduce the efficiency of attachment to susceptible cell lines (Teng and Collins, 
2002) suggesting that despite being conserved this region does not play a significant role in 
the interaction between RSV and it’s cell surface receptors. The role of the conservation of 
the central part of the protein in the attachment process remains to be explained.
Upon attachment of the virus to the host cells, fusion of the virus and cell membranes takes 
place following activation of the F protein. The process of activation of the F protein is 
thought to be dependent on close proximity of the protein to the host cell membrane since this 
process involves exposure of the fusion peptide (Melero, 2007). This proximity requirement 
is crucial for successful infectivity since without it the hydrophobic fusion peptide is instead 
inserted into the virus membrane thus abrogating its infectivity (Lamb and Jardetzky, 2007). 
Upon binding to the host cell, the fusion peptide is exposed and inserted into the cell 
membrane and subsequently folds, bringing the cell and virus membrane into close 
proximity. This is followed by mixing of the two membranes and formation of the fusion 
pore, that connects the interior of the of the virus to the host cell’s cytoplasm (Melero, 2007).
The role of innate and cell mediated immune responses in RSV infection
Activation of the host innate immune system by viruses typically occurs through the 
interaction of virus with pattem-recognition receptors (PRRs) on the host’s innate immune 
cells such as dendritic cells and macrophages (Medzhitov, 2007). PRRs bind to viral 
molecules such as double-stranded RNA (dsRNA) (Yoneyama et al., 2004), single-stranded 
RNA (ssRNA) (Pichlmair et a l, 2006), RNA with 5’-triphosphate ends (Hornung et al., 
2006) and proteins of viral origin (Thompson et al., 2011). Among the PRRs known to
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interact with viral components are Toll-like receptors (TLRs), nucleotide Oligomerization 
domain (NOD)-like receptors (NLRs) and retinoic acid-inducible gene I (RIG-I)-like 
receptors (RLRs) (Takeuchi and Akira, 2009). RLRs and TLRs are important for the 
stimulation of type I IFNs (Kato et al., 2005) which lead to elimination of viral components 
from infected cells. Activation of these receptors also leads to production of pro- 
inflammatory cytokines and chemokines which provoke inflammation and recruit innate and 
acquired immune cells to the site of infection (Kumar et al., 2006). In response to the 
inflammatory response mounted by the host, RSV has evolved mechanisms to antagonise 
these responses. The NS1 and NS2 proteins have been shown to have an inhibitory role in the 
induction of interferon alpha, beta and gamma responses by the host (Spann et al., 2004).
T cells have a key role in the clearance of viral infection and exhibit a number of effector 
functions that are crucial in viral clearance. For example CD8+ effector T cells can provide 
complete protection against influenza infection in the absence of B cell specific responses 
(Graham and Braciale, 1997). The importance of T cell responses in protection is 
underscored by murine studies that have shown that cytotoxic T lymphocytes (CTLs) play a 
key role in the clearance of RSV infection (Cannon et al., 1988). Individuals with defects in 
T cells responses do not effectively control RSV infection, further suggesting a clear role for 
T cell specific responses in viral clearance (Hall et al., 1986).
Immunity to RSV: targets of protective antibody responses
The surface of the infectious virion contains 3 virus encoded proteins; F, G and SH that are 
exposed to the host immune system. Studies with infant and monoclonal antibodies have 
confirmed that these surface proteins, are the targets of antibody responses (Cote et al., 1981, 
Akerlind-Stopner et al., 1993) suggesting that they might be targets of protective immunity. 
Two of these proteins, F and G are thought to be targets of the neutralising antibody response.
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The mechanisms through which virus neutralisation is thought to occur as well as description 
of the antigenic characteristics of the F and G proteins are discussed below.
Mechanisms of virus neutralisation
Virus neutralisation can broadly be defined as the abrogation of virus infectivity by antibody 
mediated mechanisms. The mechanisms through which antibodies neutralise virus can be 
classified on the basis of the event within the replication cycle of the virus that is blocked by 
such antibodies. A number of these mechanisms are discussed below.
Attachment of the virus onto host cells is crucial for successful infection. Antibodies that 
block this step of the infection process effectively curtail the ability of the virus to infect the 
cell (Burton et al., 2000). Abrogation of infectivity can also be mediated by antibodies that 
block both conformational changes and un-coating. This mechanism of neutralisation has 
been well demonstrated in the case of poliovirus (Wetz, 1993). Some neutralising antibodies 
act by preventing intermediate steps in the virus life cycle. For example, some poliovirus 
neutralising antibodies have been found to prevent the formation of the 135S particle 
(Vrijsen et al., 1993), an essential intermediate in the entry of poliovirus into the cell (Fricks 
and Hogle, 1990). Neutralisation of poliovirus has also been associated with aggregation of 
infectious particles by antibodies, with residual infectivity being associated with un­
aggregated virions (Thomas et al., 1986). Neutralising antibodies have recently been found 
to mediate inactivation of virus through cytosolic degradation. A recent study has shown that 
antibody coated adenoviruses are transported into the cytosol where they bind to an 
intracellular cytosolic protein called tripartite motif-containing 21 (TRIM21). TRIM21 has 
been demonstrated to bind with high affinity to an invariant region of antibody molecules 
(James et al., 2007). Virus-antibody complexes within the cytosol bind to TRIM21, which
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targets these complexes to the proteasome for degradation (Mallery et al., 2010). Virus 
infectivity can also be effectively curtailed through antibody dependent cell-mediated 
cytotoxocity (ADCC). ADCC is a mechanism through which immune effector cells target 
infected cells for lysis through the recognition of antibody on the surface of infected cells. 
ADCC has been shown to be mediated by natural killer (NK) cells, macrophages, neutrophils 
and eosinophils. In the case of RSV, specific ADCC responses have been observed as early 
as 3 days following infection and peak at between 2 to 4 weeks after the onset of illness 
(Kaul et al., 1982). Direct cell killing of RSV infected cells has also been reported to be 
mediated through complement. Lysis of RSV infected cells has been shown to involve both 
the classical and alternative complement activation pathways (Edwards et al., 1986). Kaul et 
al. showed that complement mediated killing of RSV infected cells is enhanced in the 
presence of neutrophils. This complement dependent cytotoxicity is not as pronounced in the 
presence of lymphocytes or monocytes (Kaul et al., 1984). Antibody mediated complement 
activation has also been linked to virus clearance. Antibodies that are defective in 
complement activation do not reduce lung titres in RSV challenged mice relative to 
antibodies that are capable of fixing complement, strongly suggesting that antibody activation 
of complement may play a key role in viral clearance upon infection (Mekseepralard et al., 
2006).
There is evidence that suggests RSV may escape the host neutralising antibody response 
through generation of escape mutants. Previous studies have shown that neutralising 
monoclonal antibodies directed at both the G and F protein can be used to select for escape 
mutants that are no longer recognised by the selecting antibodies (Garcia-Barreno et al., 
1990, Zhu et al., 2011). Analysis of the viruses shed by children who are under palivizumab 
immunoprophylaxis have shown the development of escape mutations against this
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immunoprophylactic antibody (Papenburg et a l, 2012). It is possible that the lack of 
proofreading ability by the virus’ RNA polymerase might lead to the generation of a large 
diversity of genetically distinct viruses during replication. Through a process of natural 
selection, only the variants that are capable of surviving the prevailing antibody pressure 
would then be selected for replication and ultimately transmission as escape mutants.
The G Protein
The G protein is the virus attachment protein (Levine et al., 1987), which mediates 
attachment of the virus to a cell surface receptor recently identified to be nucleolin (Tayyari 
et al., 2011). The G protein is synthesised as a 33 kD precursor which is extensively modified 
by the addition of N and O linked carbohydrates (Gruber and Levine, 1985a). These 
carbohydrates contribute about 57 kD to the molecular weight of the mature protein which is 
estimated to be about 90 kD (Gruber and Levine, 1985a). The protein is approximately 300 
amino acids long although this may vary depending on the strain. Two forms of the protein 
are synthesised in the course of infection; a membrane anchored form and a soluble form 
(Hendricks et al., 1987). The soluble forms are 6-9 kD smaller than the membrane anchored 
forms (Hendricks et al., 1988) and are translated through an alternative in-frame start codon 
(Roberts et al., 1994). The soluble form of the molecule is thought to act as an antigenic 
decoy, by binding to host antibody and thus helping the virus to evade antibody-mediated 
restriction both in vivo and in vitro (Bukreyev et al., 2008). The G protein ectodomain can be 
divided into three distinct segments; a central conserved segment sandwiched between two 
hypervariable domains on the N and C terminals of the protein (Cane et a l, 1991). The 
central conserved region contains a 13 amino acid motif (residues 164 -  176) as well as 4 
cysteine residues (173, 176, 182 and 186) that are perfectly conserved in all human RSV 
isolates (Melero et al., 1997, Cane et al., 1991). The high degree of sequence conservation in
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this region is strongly suggestive of functional constraint and the region may therefore 
constitute an effective target for protective antibody responses.
The antigenic structure of the G protein
Identification of antibody epitopes on the primary structure of the G protein has been 
achieved mainly through reactivity with murine monoclonal antibodies. Three distinct 
epitope groups on the G protein have been identified using this approach: conserved, group- 
specific and strain-specific epitopes (Martinez et a l, 1997). Antibodies to conserved 
epitopes bind to all RSV strains, while group-specific antibodies bind to all strains from one 
of the two antigenic groups. Strain-specific antibodies bind to only certain strains of an 
antigenic group.
Escape mutants selected using monoclonal antibodies to conserved epitopes (i.e. antibodies 
that bind to all strains of RSV) contain amino acid changes in the central part of the G 
molecule (Martinez et a l, 1997, Rueda et al., 1994, Walsh et al., 1998) including the loss of 
one of the four conserved cysteines (Rueda et a l, 1994), suggesting that conserved epitopes 
are located on the central part of the molecule. On the other hand, escape mutants selected by 
antibodies to strain-specific epitopes contain amino acid substitutions (Martinez et a l, 1997), 
premature stop codons (Rueda et a l, 1991) or frame shift mutations (Garcia-Barreno et a l, 
1990) in the carboxy terminal region of the G protein. Antibodies to the G protein are thought 
to recognise linear rather than conformational epitopes. This assertion is based on the fact 
that no murine monoclonal antibodies have so far been found to select for non synonymous 
substitutions at sites that are distant from their putative epitopes (Melero et a l, 1997). 
Antibodies to the G protein have also been shown to bind to overlapping stretches of 
synthetic peptides (Cane, 1997) covering different regions of the G protein, further
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suggesting the lack of a conformational requirement for antibody binding. The genetic and 
antigenic structure of the G protein is graphically depicted in figure 2.4.
Sequence conservation in the central part of the G molecule suggests, as previously 
discussed, that it may be functionally constrained and possibly the target of cross-reactive 
antibody responses. Up to 40% of adults with natural RSV infection (Murata et a l, 2010) 
generate antibody responses to the central part of the G molecule. This region is the target of 
a partially neutralising cross-reactive monoclonal antibody (Walsh et al., 1989) providing 
grounds for inferring the importance of responses to this region to neutralising antibody 
protection.
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Human antibody responses to the G protein
Due to its extensive variability, antibody responses to the G protein are thought to be 
genotype-specific (Johnson et a l, 1987a, Anderson et al., 1985, Walsh et al., 1987, Hendry 
et al., 1988, Yamazaki et al., 1994, Cane, 1997). Enzyme linked immunosorbent assays 
carried out using acute and convalescent phase sera from infants with acute RSV infection 
show that the group homologous infant response to purified F protein is cross-reactive but the 
infant response to the G protein is strongly group-specific (Hendry et al., 1988). Due to the 
extensive glycosylation on the G protein, several studies have looked at the role of 
carbohydrate moieties on the infant response to the G protein. Wagner et al. found that the 
infant IgG response to both the G and F protein were primarily of the IgGl and IgG3 subclass 
(Wagner et al., 1986) and that the infant IgG2 response to the G and F proteins was generally 
poor (Wagner et al., 1986). The lack of an infant IgG2 subclass response to these 
glycoproteins was surprising since the natural IgG2 response is typically directed at 
carbohydrate antigens while IgGl and IgG3 responses are typically directed at protein 
antigens (Barrett and Ayoub, 1986). In contrast, the adult anti-G response is characterised by 
high production of both IgGl and IgG2 (Wagner et al., 1987b). The results of these studies 
suggest that the protein moieties on the G glycoprotein may have an immunodominant role 
over sugar moieties in the infant response and that recognition of the sugar moieties of the G 
glycoprotein appears to progressively increase with age. Studies of human serum responses to 
pneumococcal polysaccharide vaccines have confirmed this age structured response to 
carbohydrate antigens; the IgGl:IgG2 ratio decreases significantly with age in response to 
vaccination with both the polysaccharide and protein-polysaccharide conjugate Streptococcus 
pneumoniae vaccines (Lottenbach et al., 1999).
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A number of studies have looked at the antigenic specificity of infant serological response to 
the G protein following natural infection. Norrby et a l investigated the serum responses of 
infants with natural infections against a series of 23 overlapping peptides spanning the entire 
length of the G protein ectodomain (Norrby et al., 1987). They reported that only three of 
these peptides reacted with human sera and none of these was located in the variable region 
of the protein (Norrby et a l, 1987). A possible reason for the failure to recognise the variable 
regions of the G protein could have been the fact that the infant responses were to wild-type 
strains that could have been antigenically different from the A2 strain that was used as a 
template for peptide synthesis. To address this possibility, Cane et a l looked at infant 
serological responses to Glutathione-S-Transferase (GST) fusion proteins representing 84-85 
amino acids on the variable carboxy terminal third of 6 contemporary isolates of RSV A 
(Cane et a l, 1996). They reported that over half of the infants recognised these proteins, 
suggesting that the lack of recognition of this region in the work reported by Norrby et a l 
could be explained by the lack of antigenic similarity between the test and infecting antigens, 
possibly as a result of antigenic drift within this region over time. Interestingly, the pattern of 
recognition of this variable region of the protein was closely related to the infecting genotype 
(Cane et a l, 1996) with infants generating greater responses to sequences that more closely 
resembled the infecting strains (Cane et a l, 1996). These data are shown in figure 2.5. 
Further work on the infant serological response against overlapping peptides spanning the 
terminal 84-85 amino acids of the carboxy terminal end of the protein, showed that single 
amino acid mismatches could abrogate antibody binding (Cane, 1997), providing further 
evidence of the genotype-specificity of the antibody response to the variable region of the G 
protein. More recent evidence shows that the antibody repertoire to this region appears to 
generally broaden with repeated exposure (Scott et a l, 2007).
28
Ba
bi
es
 
in
fe
ct
ed
 
wit
h 
A
:2
o
o
«5
O
CS
Oo
KO
<0cr>
(0
o
CO
CMO)
d
o
o<0
oc
■D3
(/>
« « u 
W 0-2
a s Io> SW M 0)
5A w  . a
-  .a s5 js 5
Os(N
8 a |
■'Q ^ « ca a. "3 « « ^
5 m 8
2 ‘34> 5  ■*£
a <4h &■
y  O  f t
w 4 i £32 JJ o3^ *J7sH fi-s
O  <3
.2 « Hu >d ^
o *  O
f t  ©
O 'g ^  . 
a, S « -a £?>£
' O 
O  ^  ^
■E® 8.2 a a -a o a
— 'Oft
S 2  s.2 a
a S  -S “  4>
,2 -S a
►» a * .2 W3
O  U  K<o "£ i£*i. © qs
S a g
£ § s
w,a m 
.2 ^  »  
a  £  «© rh "2 n u  R4» c;- o> sftxa ^4J »*>*- <n J- 
M O 03
a  — ,2•a © y,2 a 
o  «  2i. ft a
f t  M •-«- ► So K O
1-3-
3  I  o ^  8 w
CZ5 T3 .a 
<u 3O
O 4> CA
<U M Na
a  ^ ^  
ft2 5<z> *2 ■+-< 4> JS L u £
VId
>auao»Cmo
ClIh<u
CA
flj0) ua __ 
#6X) a
&r_. *a X3aft-O (C
an
e 
et 
al
., 
19
96
).
The F protein
The F protein is the viral fusion protein (Walsh and Hruska, 1983). It mediates cell to cell 
fusion of virus infected cells leading to syncytia formation, a characteristic of RSV infected 
cells (Walsh and Hruska, 1983). The protein is synthesised as an inactive 69kD precursor 
(Fo) (Gruber and Levine, 1985a, Gruber and Levine, 1983) which is co-translationally 
modified in the endoplasmic reticulum by the addition of N-linked carbohydrates (Gruber 
and Levine, 1985a, Collins and Mottet, 1991). It is then cleaved into two subunits FI (49 
kD) and F2 (20 kD) which remain linked by a disulphide bond (Gruber and Levine, 1985b) 
and are subsequently transported to the cell surface (Collins and Mottet, 1991).
Antigenic structure of the F protein
Mapping of antibody binding sites on the primary structure of the fusion protein has been 
done using two approaches: generation and sequencing of monoclonal antibody escape 
mutants and use of synthetic peptides to examine regions of binding by monoclonal 
antibodies along the length of the protein. Arbiza et a l used these approaches to define two 
antigenic sites along the F protein that are targets of antibody responses. The first site 
contained a number of overlapping epitopes on the amino terminal third of the FI subunit 
while the second was located on the carboxy terminal end of the FI subunit’s cysteine rich 
region (Arbiza et al., 1992). Sequence comparison between the wild-type RSV Long strain 
and the monoclonal antibody escape mutants showed that a series of non-synonymous 
substitutions between amino acid position 190 and 272 were key to antibody escape in the 
first region while non-synonymous substitutions between amino acid 429 and 447 were 
responsible for antibody escape in the second region (Arbiza et a l, 1992, Lopez et a l, 1998).
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There is evidence that suggests that antibodies to the F protein recognise conformational 
rather than linear epitopes. The conformational nature of epitopes on the F protein can be 
demonstrated by an analysis of the positions of amino acid substitution required for 
abrogation of antibody binding. Arbiza et al reported the generation of a monoclonal 
antibody escape mutant in which a non-synonymous amino acid substitution that was 
necessary for antibody escape, occurred 57 amino acids upstream of the putative monoclonal 
antibody binding site (Arbiza et a l, 1992, Lopez et a l, 1993). Further evidence of the 
conformational requirement for F protein antibodies has been obtained from studies using 
synthetic peptides where it has been found that some F-specific antibodies only bind to long 
peptides and fail to bind to shorter peptides spanning the length on the longer one (Lopez et 
a l, 1993), suggesting that these antibodies can only bind to a peptide that is long enough to 
fold upon itself. More evidence of the need for higher order structures for antibody binding to 
the F protein has been shown in experiments in which fragments of the F protein are pre­
treated with Sodium Dodecyl Sulphate (SDS) prior to reaction with antibodies. The results of 
these experiments have shown that pre-treatment with SDS -  which linearizes proteins by 
conferring a net negative charge -  leads to loss of antibody binding (Lopez et a l, 1993). 
Figure 2.6 is a summary of the antigenic structure of the F protein.
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Figure 2.6 The predicted antigenic structure of the F protein (Lopez et al., 1998).
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Antibody responses to the F protein
Neutralisation studies with monoclonal antibodies suggest that the F protein is the main target 
of cross-reactive neutralising antibodies. These studies show that only F-specific monoclonal 
antibodies mediate complete neutralisation of RSV in vitro while antibodies to the G protein 
mediate incomplete or strain-specific neutralisation (Anderson et al., 1988, Garcia-Barreno 
et a l, 1989). Passive transfer of F-specific monoclonal antibodies in mice and cotton rats 
infected with RSV significantly reduces the titre of virus in the lungs of these animals relative 
to those of controls (Taylor et al., 1984, Walsh et al., 1984) suggesting that F-specific 
antibodies have a protective effect in vivo. Immunisation of cotton rats with recombinant 
vaccinia viruses expressing F protein has been shown to lead to development of neutralising 
antibody titres that are up to 6-fold greater than the response to recombinant vaccinia virus 
expressing the G protein (Olmsted et al., 1986), further supporting the notion that the F 
protein is the major target of neutralising antibody responses.
Potential mechanisms of protection by F and G specific antibodies
The availability of the immunoprophylactic monoclonal antibody palivizumab has provided 
the opportunity to speculate on the potential mechanisms of protection by F specific 
antibodies. While administration of palivizumab has been shown to significantly reduce the 
risk of developing severe disease (The IMpact-RSV Study Group, 1998), infants under 
palivizumab immunoprophylaxis do not appear to have a reduced risk of infection since these 
infants often become infected despite administration of the antibody (Papenburg et al., 2012, 
Zhu et al., 2011). This suggests that F specific antibodies are important in the prevention of 
severe disease but not infection. The role of G specific antibodies in mediating protection 
against either infection or disease in humans remains to be explained.
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Antigenic characteristics of RSV
Early cross neutralisation studies
The question of whether the human neutralising antibody response to RSV is group or 
genotype-specific has been the subject of a number of important studies, but which has to 
date not been conclusively answered. In an attempt to define the group-specificity of the 
neutralising response, Coates et a l conducted studies in both human subjects and animal 
models (Coates et al., 1963). Separate groups of ferrets were infected with representative 
strains from the two groups i.e. the Long strain (an RSV A strain isolated in 1956 in 
Baltimore, (Coates et al., 1963)) and the CH 18537 strain (an RSV B isolated in 1962 
Washington D.C. (Coates et al., 1963)) and the resulting post-infection hyperimmune sera 
were then tested for cross neutralising ability. They found that the ferret post-infection 
response was group-specific with strong evidence that the animals generated a significantly 
greater homologous to heterologous neutralising antibody response (Coates et al., 1963). The 
second arm of the study looked for a similar response in infant convalescent sera following 
natural infection. Infants with serological evidence of RSV infection who were hospitalised 
with a diagnosis of bronchiolitis or pneumonia in the 1956-57 RSV season in Baltimore as 
well as those hospitalised in the 1960 and 1962 RSV seasons in Washington D.C. were 
included in the study (Coates et al., 1963). The authors reported that irrespective of the year 
of hospitalisation, infants developed comparable neutralising antibody responses to both the 
Long and CH 18537 strains of RSV (Coates et al., 1963). This result was surprising since it 
had been expected that infants hospitalised in the 1956-57 season would have had a greater 
response to the Long strain, which was isolated in the same year and from the same city 
relative to the CH 18537 strain which was isolated 5 years later from a different city. It was 
also expected that sera from infants hospitalised in Washington D.C. in 1962 would 
neutralise the CH 18537 strain to a greater extent than the Long strain for similar reasons.
Wulff et al. looked at the ability of both rabbit hyperimmune sera and infant convalescent 
sera to neutralise the Long strain as well as the “87” strain (RSV B) isolated in Kansas in 
1962 (Wulff et al., 1964). The results of the study showed that rabbit anti-Long hyperimmune 
sera had a greater neutralising titre to the Long relative to the “87” strain, indicating that they 
were antigenically distinct (Wulff et al., 1964). In contrast, infant sera obtained following 
natural infection in Kansas in 1962, recognised the Long strain to the same extent as the “87” 
strain, suggesting antigenic homogeneity (Wulff et al., 1964). These results were therefore in 
general agreement with the findings of Coates et al. (Coates et al., 1963). Similar results were 
reported when sera from infants in Japan were reacted against both the prototype Long strain 
and locally circulating Japanese strains (Suto et al., 1965). Despite evidence of antigenic 
heterogeneity between some of the Japanese strains and the Long strain (following reaction 
with hyperimmune guinea pig sera), infant sera neutralised the Long strain to the same extent 
as the local Japanese strains (Suto et al., 1965), supporting previous findings. Subsequent 
studies reported evidence that showed that antigenic heterogeneity was not a requirement for 
natural re-infection. Beem et al. found that strains that caused repeat infections in infants and 
children were not antigenically different (Beem, 1967). Later work found some evidence of 
group-specificity of the infant RSV neutralising antibody response against either RSV A or 
RSV B but not to both (Muelenaer et al., 1991, Roca et al., 2003, Hendry et al., 1988). To 
date no study that has systematically sought to address the group and strain-specificity of the 
immune response has reported a significantly greater homologous to heterologous infant 
neutralising response at both the group and strain/genotype level for both RSV A and B.
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The paradox of lack of cross-reactive immune response and population level 
competition between RSV A and B
Epidemiological surveillance studies have documented evidence of population level 
competition between RSV A and B, as earlier discussed. The lack of strong evidence 
supporting the notion of group-specificity of the convalescent human response presents a 
challenge in explaining the population level competition between RSV A and B. The regular 
and predictable sequence of alternation in transmission between RSV A and B, seen in some 
studies, is strongly suggestive of an underlying selection mechanism. The most plausible 
explanation for this cyclic alternation in dominance is population level immune selection of 
the dominant strain. It is reasonable to hypothesize that cyclic alternation of transmission of 
RSV A or B can be explained by the generation of population level group-specific immunity 
which precludes, albeit transiently, the continued transmission of a particular group in the 
population. A high level of population level group-specific immunity (relative to the 
alternative group) would then reduce the likelihood of re-introduction of the most recently 
predominant group in the population in the subsequent RSV season while giving a 
transmission advantage to the alternative group.
Closer scrutiny of the early cross neutralisation work reveals a number of important study 
design problems that could potentially have confounded interpretation of the results. At the 
time the studies were being conducted, the technology to definitively characterise each 
individual infecting strain did not exist. With the advent of monoclonal antibodies and 
sensitive molecular genotyping techniques such as the polymerase chain reaction (PCR), gene 
sequencing and restriction fragment length polymorphism (RFLP) analysis, detailed 
molecular characterisation of viruses infecting individual patients became possible. Without 
these data, it would have been impossible to ascertain that the infecting group or genotype
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was identical for all infants recruited in from particular RSV transmission season, a key 
assumption of the early studies. If, for example, infants were recruited in an epidemic where 
RSV A and B were co-dominant (as has since been reported in a number of surveillance 
studies (Hendry et a l, 1989, Freymuth et a l, 1991)), there would have been equal 
probability of infection with either RSV A or B, fundamentally invalidating the presumption 
of homotypic exposure in a single epidemic and thereby confounding interpretation of the 
data. In the event that both RSV A and B infected infants were recruited, proper 
interpretation of the data would have been difficult. Further, many of the early studies utilised 
small sample sizes in their analyses. For example the study by Coates et a l (Coates et a l, 
1963) utilised a sample of only 15 infants while that by Wulff et a l (Wulff et a l, 1964) used 
a sample of 18 infants. It is possible the small samples sizes may have obscured the detection 
of a small but biologically significant difference between homologous and heterologous 
neutralising antibody responses.
Comparison of the F and G gene sequences of RSV A and B
The availability of sequence data has enabled direct comparison at the genetic level of the 
differences between RSV A and B. Johnson et a l sequenced the G gene mRNAs of 
representative RSV A and B strains, Long (RSV A) and CH 18537 (RSV B). They then 
compared these sequences (and their deduced amino acid sequences) to the G gene sequence 
of another RSV A strain A2 (Johnson, 1987). When the Long G mRNA sequence was 
compared to the A2 G gene sequence, the authors found that they shared 94% amino acid 
identity. In contrast, the CH 18537 strain only shared 53% amino acid identity with the A2 G. 
The authors found that most of the variation was in the extracellular domain of the G protein 
(Johnson et a l, 1987b). Sullender et a l investigated G gene sequence variation between the 
A2 strain and the 8/60 strain (RSV B). They reported 56% amino acid identity between the 
RSV G genes of A2 and 8/60 (Sullender et a l, 1990). They further reported that the 8/60 G
shared 98% amino acid identity with the CH 18537 strain (Sullender et al., 1990). These 
results were in general agreement with the G gene variability estimates reported by Johnson 
et al. (Johnson et al., 1987b). Cane et al. undertook a more detailed analysis of the nature of 
the variation in the extracellular domain of the G protein. They reported that variation in this 
extracellular domain was not evenly distributed across the length of the protein. An extensive 
hypervariable domain on the carboxy terminus of the protein was separated from a less 
variable domain on the amino terminus by a highly conserved region (Cane et al., 1991).
Johnson et al. studied the degree of relatedness between the F protein sequences of 
representative RSV A and B strains (Johnson and Collins, 1988). They reported that there 
was overall 91% identity between the deduced amino acid sequences of strains A2 and CH 
18537 (Johnson and Collins, 1988). Viewed together, these data present an apparent paradox 
-  of the two proteins that are targets of neutralising antibodies, one shows extensive sequence 
divergence between groups (G protein), while the other appears to be highly conserved 
between groups (F protein). Assuming that diversity in both proteins is driven by host 
immune pressure it is surprising that the F protein, which is the major target of neutralising 
antibody immunity, would be under less selection pressure relative to the G protein. An 
alternative explanation for the greater diversity on the G protein relative to the F is that the F 
protein could be subject to greater functional constraint reducing the level of variation that 
could be viably tolerated. However, the notion of functional constraint in a major 
neutralising target fails to accord with the well documented ability of RSV to re-infect at 
relatively regular intervals (Hall et al., 1991). It appears therefore that relative sequence 
homogeneity in a major neutralising antibody target does not necessarily correlate with 
protection from re-infection. It is possible that neutralising antibodies target only a small but 
functionally important part of the protein and it is these antibodies that drive the limited
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variability within the F protein. There is some evidence that the variable regions of the F 
protein coincide with known neutralising and Cytotoxic T Lymphocyte (CTL) epitopes 
(Agenbach et al., 2005), suggesting that despite extensive sequence conservation on the F 
protein, protective immune responses may be directed at variable parts of the protein.
Analysis of antigenic similarity between RSV A and B
Estimates of genetic relatedness between specific genes from the two groups of RSV provide 
little insight on the effect of variation on the neutralising antibody response. If amino acid 
variation does not occur within neutralising/protective epitopes, its impact on the protective 
response is likely to be limited. In order to obtain an estimate of how the observed inter group 
genetic variability is related to protective immunity, Johnson et a l intranasally infected 
different groups of cotton rats with different strains of RSV A and B and assessed the degree 
of cross reactivity in their respective hyperimmune sera (Johnson et al., 1987a). In order to 
estimate the degree of antigenic relatedness between RSV A and B, they used the Archetti- 
Horsfall formula (Archetti and Horsfall, 1950) -  whose result is a product of two quotients, 
each obtained by dividing the heterologous titre by the homologous titre for each of the two 
strains being compared. Thus in order to infer the degree of antigenic relatedness between the 
Long and CH 18537 strains, the heterologous response to the CH 18537 strain (i.e. 
neutralisation of strain CH 18537 by Long-specific hyperimmune sera) is divided by the 
homologous response to the Long strain (i.e. neutralisation of the Long strain by Long- 
specific hyperimmune sera) and this quotient is then multiplied by the quotient obtained by 
dividing the heterologous response to the Long strain by the homologous response to the CH 
18537 strain. The result, which is multiplied by 100, is the percent antigenic relatedness 
between the 2 strains. The authors reported 25% antigenic relatedness between the Long and 
CH 18537 strains and 28% antigenic relatedness between the A2 and CH 18537 strains 
(Johnson et al., 1987a). A potential problem with the approach taken in this study is that the
estimates are derived on the basis of animal responses, which may be different from human 
responses as suggested by the early neutralisation work. To address this concern, studies to 
estimate the degree of antigenic relatedness using human convalescent sera obtained from 
infants with primary RSV A and B were conducted by Hendry et a l (Hendry et al., 1988). 
An antigenic relatedness estimate of 31% between RSV A and B was calculated using the 
Archetti-Horsfall formula (Hendry et a l, 1988). It is notable that this estimate was 
comparable to the estimates obtained from animal studies of between 25% and 28%. These 
data therefore suggest that the infant neutralising response to RSV is not significantly 
different from that obtained from experimentally infected animal models. This conclusion is 
at odds with the results of the cross neutralisation studies of the 1960s that showed that 
showed no difference between the homologous and heterologous response (Coates et a l, 
1963, Wulff et a l, 1964). It is worth noting that the infecting antigenic groups of all infants 
included in the study by Hendry et a l were determined by use of group-specific monoclonal 
antibodies (Hendry et a l, 1988).
Molecular evolution of RSV
A comparison of the deduced G protein amino acid sequences of strains isolated in the 1960s 
and those isolated in the late 1980s has shown that the rate of non-synonymous amino acid 
substitution is greater than that of synonymous substitution (Cane et a l, 1991), suggesting 
that the G protein is under positive selection pressure. It is estimated that the rate of 
accumulation of amino acid change over the length of the protein is 0.25% per year (Cane 
and Pringle, 1995). The rate of evolution of RSV can be deduced from studies of the most 
common recent ancestor (MRCA) of circulating strains. The MRCA of currently circulating 
RSV A strains has been estimated to be the early 1940s (Cane and Pringle, 1995, Zlateva et 
a l, 2004) with an average evolutionary rate of 1.83 x 1 O'3 nucleotide substitutions per site per
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year (Zlateva et a l, 2004). The rate of evolution of the RSV B G gene has been estimated to 
be 1.95 x 10'3 nucleotide substitutions per site per year with the most recent common ancestor 
of current RSV B strains being estimated to have occurred between 1938 and 1955 (Zlateva 
et al., 2005).
At least 6 positively selected sites have been identified on the G genes of both RSV A and B 
(Woelk and Holmes, 2001). There appears to be an association between the positions of the 
positively selected sites and known antibody epitopes (Woelk and Holmes, 2001), suggesting 
that immune pressure may be driving the evolution of RSV and is key to its endemic 
maintenance. There is however anecdotal evidence that suggests that immune selection may 
not be the key mechanism that drives diversity and maintenance of the virus in the 
population. A study of the molecular characteristics of 23 Cuban strains isolated in 1994- 
1995 showed that they differed from the prototypical Long strain (isolated in the United 
States in 1956) by only 5 amino acids (Valdes et al., 1998). These data clearly conflict with 
the theory that immune selection is an important driver of persistence of the virus in the 
population. It is possible that the relative invariance of Cuban strains may be attributed to 
long-term political isolation that significantly reduced interaction between Cubans and the 
rest of the world, thereby reducing the likelihood of importation of novel strains. If this is in 
fact the case, the implication remains that immune selection is not a key mechanism for 
generation of RSV diversity and persistence of the virus in the population and that the main 
source of diversity may be through importation of novel strains from different populations.
The model of dissemination of different RSV strains around the world has been the focus of 
recent molecular epidemiology studies. The recent emergence of a unique strain of RSV B 
with a 60 nucleotide duplication -  the BA genetic change - (Trento et al., 2003) in the
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hypervariable region of the G gene has provided a convenient tag with which to track both 
the global transmission and the accumulation of natural variation in a single strain of the 
virus. The first RSV B strain with a 60 nucleotide duplication (BA strain) was identified in 
Buenos Aires, Argentina in 1998 (Trento et al., 2003). Subsequent surveillance identified 
this strain in Leuven Belgium between 1999 and 2000 (Zlateva et al., 2005), in Birmingham 
United Kingdom between 2000 and 2001 (Cane, 2007), Sapporo Japan in 2000 (Sato et al., 
2005), in Kilifi Kenya in 2003 (Scott et a l, 2004), in New Delhi India between 2004 and 
2006 (Parveen et al., 2006). This strain has since out-competed previous strains of RSV B 
and as of 2012 is the most prevalent RSV B strain globally, as depicted in figure 2.7. The 
epidemiological success of this strain suggests that BA strains have a fitness advantage or 
other selection advantage over previous RSV B strains, allowing them to rapidly out-compete 
them globally over a relatively short period of time. The nature of this advantage is as yet 
unknown.
There are some data that suggest that RSV strains may become extinct with time. In an 
analysis of the genetic relatedness of RSV strains isolated from different parts of the world 
between 1956 and 1993, Cane and Pringle identified a set of RSV A isolates obtained from 
Northern Europe in the 1970s, which clustered distinctly in a phylogenetic analysis of the G 
gene (Cane and Pringle, 1995). Extensive analysis of RSV A sequences from the 1970s 
onwards has failed to identify similar isolates, strongly suggesting that these viruses have 
become extinct (Cane and Pringle, 1995, Cane, 2007). The mechanism through which 
extinction of strains occurs remains unknown.
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Antigenic evolution of the F protein under immunoprohylactic 
pressure
There is some indirect evidence that the F protein may be under antibody selection 
pressure. The widespread application of immunoprophylaxis provides an opportunity 
to speculate on the likely model of the antigenic evolution of the F protein under 
antibody pressure. Palivizumab is a humanised monoclonal antibody that has been 
licensed for immunoprophylactic use in high risk infants (The IMpact-RSV Study 
Group, 1998). Palivizumab is a potent neutralising antibody that binds to a conserved 
region of the F protein (Beeler and van Wyke Coelingh, 1989). In vitro selection 
studies using palivizumab have shown that some single amino acid substitutions 
(N268S, N262S, S275F/L and K272N/M/T/Q) result in generation of neutralisation 
resistant escape mutants (Crowe et al., 1998, Zhao et al., 2004, Zhao et al., 2006, 
Zhu et al., 2011), some of which have been found to be of greater replication fitness 
relative to the A2 strain in competition assays (Zhao et al., 2006). A number of 
studies have demonstrated that selection for escape mutants against this 
immunoprohylactic antibody can occur under natural infection conditions (Papenburg 
et al., 2012, Zhu et al., 2011). These palivizumab neutralisation resistant mutants have 
been identified among infants hospitalised with severe natural RSV infections and 
who previously were under palivizumab immunoprophylaxis (Papenburg et al., 2012, 
Zhu et al., 2011), suggesting that it can reasonably be speculated that such selection is 
possible with naturally produced antibodies. However the question of whether these 
selected mutants are transmissible and of comparable fitness with unselected wild- 
type strains is unknown.
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Correlates of immunity from severe disease
Association between age and immune function
There appears to be an age related risk for development of severe disease, with infants 
under the age of one year being at greatest risk of developing severe disease. This risk 
appears to progressively decrease with age (Glezen et al., 1986, Nokes et al., 2008, 
Broor et al., 2007, Robertson et al., 2004), suggesting that as individuals grow older, 
they gradually develop natural resistance against severe disease, while remaining 
susceptible to repeated infection (Hall et al., 1991). The risk of severe lower 
respiratory infection in immuno-competent adults is relatively low, with disease 
primarily being manifested as an upper respiratory infection which self-resolves 
within an average of 10 days (Breese Hall et al., 2001, O’Shea et al., 2005). However 
in recent years RSV has become increasingly recognised as a cause of severe 
respiratory illness among elderly adults (Falsey et al., 2005), an outcome that has 
been partly attributed to age-related defects in the cellular immune function (Lee et 
al., 2005, Liu and Kimura, 2007). The risk of severe RSV is also elevated among 
immuno-suppressed organ transplant patients who are typically under heavy 
immunosuppressive therapy to minimise the risk of organ rejection (Ison, 2009). In all 
three instances increased severity of disease may point to underlying immunological 
deficiencies. In the case of infants and elderly adults, severity may be associated with 
immunological immaturity and senescence respectively and in immuno-suppressed 
adults, severe disease may be associated with the depletion of both cellular and 
humoral responses by immunosuppressive drugs.
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Physiological maturity of the lung
The lung pathology associated with acute bronchiolitis caused by RSV in infants is 
characterised by necrosis of virus infected cells in bronchial epithelia (Aherne et al., 
1970, Johnson et al., 2007). Along with increased mucus secretion and a lymphocytic 
infiltrate, these cells form a dense plug which occludes smaller bronchioles, impairing 
respiratory function (Aherne et al., 1970). The reduction in incidence of severe 
disease with age suggests that anatomical and physiological maturation may confer 
some resistance from severe illness. Between infancy and adulthood there is up to a
2.5 fold increase in airway size and alveoli count (Dunnill, 1962), suggesting that age- 
associated physiological changes may influence clinical outcome as a result of the 
increased capacity of the airways. This increased capacity may play a role in 
modulating severity in older individuals by providing reserve capacity through which 
some degree of normal respiration can continue even in the presence of cellular debris 
in the airways brought about by RSV infection.
Protective antibody responses
Protection from infection and disease appears to correlate strongly with the presence 
of neutralising antibodies. Maternal antibodies have been associated with protection 
from severe RSV disease in infants (Glezen et al., 1981a). However, maternal 
antibodies have also been suggested to have a role in limiting the infants’ native 
response to infection (Parrott et al., 1973, Brandenburg et al., 1997). The role of 
maternal antibody in preventing severe disease has been disputed in a study of the risk 
factors for severe RSV infection among Alaskan children, which failed to find a 
protective association between maternal neutralising antibodies and protection from 
hospitalisation (Bulkow et al., 2002). The results of this study have however been
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controversial as a result of potential inequality of exposure between cases and controls 
that may have confounded data interpretation (Munoz and Glezen, 2003).
Administration of high doses of RSV specific intravenous immune globulin (RSVIG) 
has been associated with a reduced risk of severe RSV disease in high risk infants and 
children (Groothuis et al., 1993). The protective role of antibodies in preventing 
serious illness among infants has been further underscored by use of prophylactic 
immunotherapy. Palivizumab, a humanised monoclonal antibody which has been 
licensed for prophylactic use in pre-term and other high risk infants significantly 
reduces the risk of developing severe RSV infection (The IMpact-RSV Study Group, 
1998). Some studies have defined a minimum protective neutralising antibody 
threshold for protection against severe infection. Piedra et a l defined a minimum 
threshold of 6.0 log2 PRNT and 8.0 log2 Plaque Reduction Neutralisation Titre 
(PRNT) as protective against hospitalisation with RSV A and B respectively (Piedra 
et al., 2003). However the reliability of these estimates in predicting protection may 
be confounded by other factors that could independently account for protection such 
as gestational age and age of the infant.
Among elderly adults, antibodies are similarly associated with protection from severe 
illness. Serum IgG and nasal IgA to the F and G proteins as well as serum 
neutralising antibody have been found to be at lower titres in RSV infected adults 
compared to matched controls (Walsh and Falsey, 2004). Low titres of neutralising 
antibodies have also been associated with the risk of hospitalisation among adults 
(Walsh et al., 2004).
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Duration of antibody responses to RSV
The duration of both maternal and acquired antibody responses is an important factor 
for protection. The infant maternal antibody half-life is estimated to be of the order of 
less than three months (Ochola et al., 2009, Ogilvie et a l, 1981). The infant serum 
IgM and IgG response to primary infection declines to pre-infection levels within a 
year (Welliver et al., 1980). The secondary response is of greater magnitude than the 
primary response and potentially lasts for a longer duration of time (Welliver et al.,
1980). On the other hand, the nasal primary IgA, IgM and IgG response to infection 
all appear to decline to pre-infection levels by 3 months post-infection (Kaul et al.,
1981). Conversely, the rate of development, titre and duration of secondary nasal IgA, 
IgM and IgG responses appears to be greater than that of the primary response (Kaul 
et al., 1981). These data suggest that both the acquired secretory and humoral 
responses to RSV are short-lived and may be related to the ability of the virus to 
repeatedly re-infect.
The ability of antibodies to protect not only from severe disease but from infection 
can be gleaned from experimental human infection studies. In a number of such 
studies, the ability of the virus to successfully infect adult volunteers has been shown 
to be inversely related to the pre-inoculation serum neutralising antibody titre (Hall et 
al., 1991, Lee et al., 2004, Mills et al., 1971). These data suggest that antibodies 
probably have a dual role in protection; (i) against infection in the first instance and 
(ii) limiting virus infectivity upon infection. However the short-lived duration of 
antibody responses to RSV (Welliver et al., 1980, Kaul et al., 1981) suggests that 
such protection is likely to be transient.
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Innate immune response to RSV infection
Cytokines are an important element of the early immune response to RSV. RSV 
infection elicits production of an array of cytokines that mediate a number of 
functions that are not only necessary for virus clearance but that may also promote 
pathology. T cells produce pro-inflammatory cytokines/chemokines in response to 
RSV infection. Type 1 T helper (Thl) cells produce IFN-y while Th2 cells produce 
IL-4, -5, -6 and -13. The type of T helper response elicited in response to re-infection 
is largely dependant on the cytokine milieu present at the time of priming (Openshaw, 
2002). An imbalance in Thl/Th2 responses to RSV has been cited as a contributor to 
severe illness (Folkerts et al., 1998). RSV associated disease severity appears to be 
the product of a Th2 skewed response (Becker, 2006) although this has not been 
consistently confirmed in the respiratory secretions of infants with acute RSV 
bronchiolitis (Garofalo et al., 2001).
Respiratory Syncytial Virus Vaccines
The goal of developing an effective vaccine has been hindered by a number of factors. 
The peak of disease severity in the paediatric population occurs among infants who 
are less than 3 months old (Glezen et al., 1986) and who have a high titre of maternal 
antibody (Murphy et al., 1986a). Vaccination at this age faces a number of important 
potential challenges. The response to vaccination may be inadequate due to 
immunological immaturity -  younger infants have up to a 10-fold lower convalescent 
phase response to the G and F protein as well as the neutralising response compared 
to older infants (Murphy et al., 1986b). A limited response to vaccination at this age 
may also be the result of suppression of the infant response by maternal antibodies.
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Evidence of this may be gleaned from studies that shown that the magnitude of the 
convalescent infant antibody response is inversely related to acute phase serum 
antibody levels (Parrott et a l, 1973). It is also possible that the success of any future 
vaccine may depend on its antigenic coverage - monovalent vaccines based on strains 
from one antigenic group may provide insufficient protection from wild-type 
challenge with a diverse range of strains. Two vaccine candidates have been 
extensively characterised over the years are the formalin-inactivated (FI) vaccines 
and live attenuated vaccines. The course of development of these vaccines and their 
postulated mechanisms of action are discussed below.
The formalin-inactivated vaccine
Following the successful development of other formalin-inactivated vaccines such as 
the poliovirus vaccine in the 1950s studies of formalin-inactivated (FI) RSV vaccines 
were conducted in the United States in the mid to late 1960s. In a study carried out in 
1965, Potash et al. used a formalin-inactivated RSV (strain MK5) vaccine 
concentrated 25-fold by alum precipitation to test for safety and immunogenicity. 
Vaccinated guinea pigs developed high titres of post-vaccination serum neutralising 
antibodies (Potash et al., 1966). In the clinical arm of the study, children and adults 
inoculated intramuscularly with the FI vaccine developed modest serum neutralising 
antibodies and did not exhibit any severe vaccine-related adverse effects for up to 10 
days after vaccination (Potash et al., 1966). It was thus concluded that the vaccine 
was safe with no systemic adverse effects associated with vaccination (Potash et al., 
1966). In 1966 two large scale clinical trials of the FI vaccine in infants and children 
were carried out. The first, carried out between September and December 1966, 
recruited infants and children between 4 months and 10 years of age to whom two 0.5
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ml intramuscular doses of 100-fold concentrated formalin-inactivated RSV (Bernett 
strain) vaccine was administered (Chin et al., 1969). A control arm was included in 
the study for the purpose of comparison. The control arm received a trivalent 
parainfluenza vaccine containing parainfluenza 1, 2 and 3. In total 191 children 
received the full dose of FI vaccine while 194 children received the full dose of the 
control parainfluenza vaccine (Chin et al., 1969). 68% of the FI vaccinees had a 4- 
fold or greater rise in antibodies against RSV in their post-vaccination sera, while 
only 0.9% of the control parainfluenza vaccinees had a 4-fold or greater rise in anti 
RSV titre (Chin et al., 1969). However in the subsequent RSV season, the incidence 
of medically attended RSV infection in infants less than 1 year of age in the FI 
vaccine group was approximately 3 times greater than the control group. Overall, the 
incidence of severe disease in the FI vaccine group across all ages (7.9%) was almost 
double that in the control group (4.7%) (Chin et al., 1969). 60% of the FI vaccinees 
who got natural RSV infection were hospitalised compared to 22% of the control 
group vaccinees who were hospitalised following natural RSV infection (Chin et al., 
1969). The severity of disease among hospitalised infants from the FI vaccine group 
was much greater than that of infants in the control group; 44% of the hospitalised 
infants in the FI vaccine group had severe or very severe pneumonia compared with 
5.6% among the controls (Chin et al., 1969). A second clinical trial of the FI vaccine 
was conducted between December 1965 and December 1966 where infants between 2 
and 7 months of age were recruited (Kim et al., 1969). A similar vaccine formulation 
and regimen as in the study described above was administered. Similarly a 
parainfluenza vaccine control group was included in the study. The results of this trial 
showed that post-vaccination neutralisation titres to RSV were 6-fold greater in the FI 
vaccine group compared to the control group (Kim et al., 1969). However despite
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serological evidence of comparable exposure between the two groups in the 
subsequent RSV season, 80% of FI vaccinees in this study required hospitalisation 
following natural infection (Kim et al., 1969). In contrast only 5% of infants in the 
control group who experienced natural RSV infection required hospitalisation. Also, 
the severity of illness was greater among the FI vaccinees relative to the control group 
(Kim et al., 1969). Tragically, two toddlers aged 14 and 16 months who were in the FI 
vaccine group died upon natural exposure to RSV. The two infants had received the 
first of 3 inoculations of FI vaccine at 2 and 5 months respectively. Post-mortem 
examinations found evidence of extensive bronchopneumonia, pneumothorax and 
eosinophilia (Kim et al., 1969).
Postulated models of FI vaccine mediated pathology
The failure of the FI vaccine led to studies to investigate why the vaccine potentiated 
disease upon natural exposure. Using post-vaccination sera from infants and young 
children who had received the FI vaccine, Murphy et al. found that young infants 
developed a high antibody titre to the F protein but had poor response to the G protein 
(Murphy et al., 1986c). In contrast, older infants and young children developed high 
titres to both F and G proteins. None of the vaccinated infants and children developed 
neutralising antibody titres comparable to that of age-matched individuals who had 
undergone natural infection (Murphy et al., 1986c). It was concluded that formalin 
inactivation had somehow altered epitopes on the F and G proteins resulting in the 
development of non-functional (non-neutralising) antibodies. The authors postulated 
3 models in which these non-neutralising antibodies could have potentiated disease; 
(i) through the formation of immune complexes in the lung, (ii) a poorly developed 
anti-G response in young infants could have reduced protection from subsequent
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challenge and (iii) the poor neutralising response could have delayed the 
development of effective responses to clear the virus (Murphy et al., 1986c). 
Subsequent studies found that in addition to the poorly neutralising response, F 
protein specific antibodies to the FI vaccine were deficient in fusion inhibiting 
activity, promoting the spread of the virus in the respiratory tract upon natural 
infection (Murphy and Walsh, 1988). Later work suggested that the failure to develop 
an effective neutralising response following FI vaccination was not due to formalin 
disruption of neutralising epitopes but rather due to the development of low avidity 
anti-virus antibodies due to the lack of affinity maturation (Delgado et al., 2009). 
This interpretation has however been disputed (Shaw et al., 2009). A model of 
immune mediated disease exacerbation has been proposed based on work with 
animals. Connors et al. found that in the absence of CD4+ and CD8+ T cells, 
antibodies are unable to mediate disease enhancement (Connors et al., 1992). Later 
work found that mice vaccinated with FI vaccines had a marked increase in type 2 
CD4+ helper T cell cytokines and lower type 1 T helper cell responses (Waris et al., 
1996). Formalin treatment of RSV antigens was later shown to promote the 
development of type 2 responses (Moghaddam et al., 2006). These data suggested 
that FI vaccine mediated disease exacerbation may have been the result of an over 
exuberant inflammatory response to infection.
Development of live attenuated RSV vaccines
Following the failure of the FI RSV vaccines of the 1960s attention shifted to the 
development of live attenuated vaccines. Live attenuated RSV vaccines were first 
developed through extensive serial passaging of the A2 strain at progressively lower 
temperatures i.e. cold passaging or cp (Friedewald et al., 1968). Adaptation of a live,
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intranasally delivered vaccine for replication at lower temperatures is considered 
important since the temperature at the upper respiratory tract is lower than the core 
body temperature (Polack and Karron, 2004). Experimental infection of adult 
volunteers showed that one such virus that could grow at 26°C had lost virulence in 
adults (Friedewald et a l, 1968), but had retained virulence, despite showing some 
evidence of immunogenicity, in infants under the age of 2 months (Kim et al., 1971). 
To further attenuate the virus, chemical mutagenesis was used to induce a temperature 
sensitive (ts) phenotype in the cp vaccine strains (Kim et a l, 1973). Temperature 
sensitive mutants have a shutoff temperature above which they are unable to replicate 
-  thus mutants with shutoff temperatures that are close to the core body temperature 
are unlikely to replicate in the lower respiratory tract and cause severe disease 
(Murata, 2009). Initial clinical trials with cp-ts live attenuated RSV vaccines showed 
that they were still insufficiently attenuated and were genetically unstable (Kim et a l, 
1973). Subsequent studies reported the generation of cp-ts strains with remarkably 
low shutoff temperatures and greater genetic stability (Crowe et a l, 1994b). One 
such strain {cpts-248) had a shutoff temperature of 38°C and was highly attenuated 
and immunogenic in animal studies (Crowe et a l, 1994b). Further attenuation of the 
cpts-248 mutant was done through chemical mutagenesis, resulting in a highly 
attenuated daughter strain cpte-248/404 with a shutoff temperature of 36°C and with 
up to 1000-fold reduction in its ability to replicate in vivo in animal models (Crowe et 
a l, 1994a). A live attenuated vaccine based on the c/tfs-248/404 mutant was tested in 
infants where some evidence for protection from disease following natural infection 
was reported (Wright et a l, 2000). Nonetheless, the vaccine was considered to be 
insufficiently attenuated as it caused upper respiratory tract congestion in young 
infants (Wright et a l, 2000), a potentially fatal problem for young infants who are
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obligatory nose breathers (Bergeson and Shaw, 2001). The vaccine was however 
considered to be sufficiently attenuated for older children (Wright et al., 2000). 
Further attenuation through reverse genetics, resulted in a vaccine candidate that was 
sufficiently attenuated for young infants but that insufficiently elicited antibody 
responses (Karron et al., 2005).
Potential for indirect protection of vulnerable infants using live attenuated 
vaccines.
As described above, there are currently available live attenuated vaccines that appear 
to provide some protection upon natural exposure and are safe for use in young 
children. Safety concerns however preclude the use of these vaccines in the paediatric 
infant population who are at the greatest risk of severe disease (Wright et al., 2000). 
In the absence of a sufficiently attenuated and immunogenic vaccine for the youngest 
infants, the potential of using these vaccines in older age groups in order to reduce the 
risk of transmission to the infant is clearly worth consideration. Maternal vaccination 
is a potential route through which these vaccines could be given in order to boost the 
titre of trans-placentally transferred antibodies -  and hopefully delay the age at which 
infants first become susceptible to natural infection. The maternal vaccination model 
for infant protection is currently being used for other infectious diseases. Maternal 
vaccination with influenza virus vaccine has been reported to result in significant 
reduction in the number of neonatal hospitalisations with influenza (Poehling et al., 
2011, Benowitz et al., 2010).
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Chapter 3 -  Materials and methods
Overview
This chapter will provide a detailed description of both the participants and the 
laboratory methods used in this study. The first part of the chapter will describe the 
study site as well as general characteristics of the study participants. The studies that 
are presented in this thesis were nested within three previously established studies, i.e. 
the Kilifi District Hospital (KDH) inpatient RSV surveillance study, the Kilifi Birth 
Cohort (KBC) study and the household RSV transmission study. The structure of 
these studies will be described in detail in the first part of this chapter.
The second part of this chapter will provide a detailed description of the laboratory 
assays used in this study. A detailed description of the following assays and 
techniques will be provided: cell and virus culture, plaque assay, immunofluorescent 
Antibody Testing (IFAT), measurement of cytokine/chemokine concentrations in 
nasal samples using the MSD mesoscale platform, RNA extraction, cDNA synthesis, 
polymerase chain reaction (PCR) and gene sequencing on the ABI 3130x1 platform.
Study site, Population and Sampling
This study was conducted in Kilifi, a rural African district located on the Kenyan 
Coast. Kilifi experiences high humidity all year round, with two annual rainy seasons; 
April-July and November-December (Nokes et al., 2009). Although incidence has 
declined in recent years, the area has traditionally been endemic for malaria, with its 
associated high morbidity and mortality burden. The studies described here were 
carried out at the Kilifi District Hospital (KDH) which provides both adult and
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paediatric inpatient and outpatient care. As mentioned earlier, the nasal and serum 
samples used in the study were derived from three established studies. Below is a 
detailed description of these studies.
The RSV Inpatient Surveillance study at KDH
The samples that were derived from the inpatient surveillance study for use in the 
present study were obtained from infants and young children between the ages of 1 
day and 59 months. These individuals had been admitted to the KDH paediatric ward 
between December 2002 and February 2008, during which 6 RSV epidemics occurred 
in Kilifi. The infants included in this study were recruited during 3 of these 6 
epidemics: the 2002/2003 epidemic, the 2005/2006 epidemic and 2007/2008 
epidemic. The 2002/2003 epidemic was characterised by transmission of RSV A and 
B in roughly equal proportions, the 2005/2006 epidemic was dominated by RSV A 
transmission, while the 2007/2008 epidemic was dominated by RSV B transmission. 
These data are shown in figure 2.1 in Chapter 2. Infants who were admitted met the 
World Health Organization (WHO) criteria for the clinical syndromes of (i) severe 
pneumonia, i.e. cough or difficulty in breathing plus lower chest wall indrawing in 
addition to showing no signs of very severe pneumonia, or (ii) very severe 
pneumonia i.e. cough or difficulty in breathing plus at least one of the following: 
hypoxia, defined as an oxygen saturation of less than 90% by fingertip pulse 
oximetry, inability to drink, breast feed or to sit or impaired consciousness (WHO, 
2005). Upon admission, nasal samples were collected for detection of RSV by 
immunofluorescent antibody testing (IFAT). Acute phase sera were collected at the 
time of admission while convalescent phase sera were collected from RSV positive 
infants approximately one month later. Both nasal and serum samples were stored at - 
80°C for later use.
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The Kilifi Birth Cohort (KBC) Study
The second set of samples was derived from the Kilifi Birth Cohort (KBC) study. 
Participants were recruited at the maternity ward and the Maternal and Child Health 
Clinic (MCHC) at KDH. Infants were recruited in two phases over two calendar 
years. Each recruitment phase took place over approximately 6 months and the two 
recruitment phases were separated by approximately 6 months. The cohort was 
monitored for approximately four years, until each respective phase had experienced 
at least 3 RSV epidemics. During RSV epidemics, active surveillance visits by field 
workers were scheduled every week. Surveillance was also carried out if infants 
presented to the research outpatient clinic or if they were admitted at KDH. Home 
visits which identified signs of lower respiratory infection, resulted in referral to the 
clinic. Caregivers were asked to visit the clinic if they identified symptoms of 
respiratory infection in the children recruited in the study. Nasal washes were 
collected during home or clinic visits if in the preceding week, they had been 
observed to have either (i) difficulty in breathing (ii) a runny nose or nasal 
congestion or (ii) an acute cough. In the paediatric ward, infants identified to have 
either a lower respiratory tract infection, bronchiolitis or severe/very severe 
pneumonia had nasal wash or nasal pharyngeal aspirate samples collected. Collected 
nasal samples were tested for presence of RSV antigen by IF AT. If RSV was 
identified in nasal secretions, an acute serum sample was collected and a convalescent 
serum sample was thereafter collected after a period of approximately one month.
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The RSV household transmission Study
This study was designed to characterise the chains of transmission of RSV within the 
household. Between November 2009 and June 2010, the study recruited 43 
households in which all members were repeatedly sampled every 3 to 4 days 
(irrespective of symptoms) over the duration of an RSV epidemic for evidence of 
infection with RSV. A range of other common respiratory viruses was also detected. 
Households were eligible for recruitment if they had a child bom after the previous 
RSV epidemic and had at least one elder sibling to the infant. A total of 19,816 home 
visits were conducted in which 16,284 nasal flocked swabs (NFS) were collected 
from 554 participants. The studies described in this thesis investigated the 
development cytokine/chemokine responses in serially collected nasal flocked swab 
samples obtained from 10 infants within the household transmission study. These 
infants experienced at least one natural RSV infection over the course of follow-up 
and their cytokine/chemokine responses before, during and after infection are 
reported.
Ethical Considerations
In each of the studies detailed above, written informed consent was sought from the 
parents and guardians of the infants and children prior to sample collection. All 
studies received ethical clearance from the Kenya Medical Research Institute Ethical 
Review Committee.
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Laboratory methods
Cell and virus culture
Test viruses were initially propagated on HEp-2 cells to amplify virus titre. Cells were 
grown in T-25 flasks to between 70-80% confluence in a 37°C humidified CO2 
incubator. Contemporary virus strains Ken/A/2006 and Ken/B/2008, were isolated 
from the nasal washes of infants with acute RSV infection while historical strains A2 
(Aus/A/1961) and 8/60 (Swe/B/1960) were kindly provided by Prof Pat Cane. 500pl 
of seed virus was diluted in 500 pi of minimum essential medium (MEM) containing 
2.5% foetal calf serum (FCS) and penicillin/streptomycin (maintenance media). 1 ml 
of seed virus was transferred to the HEp-2 monolayer that had been washed twice 
with sterile Phosphate Buffered Saline (PBS). The flasks were then incubated for 2 
hours at 37°C with intermittent inversion at 15 minute intervals to increase the 
likelihood of successful virus attachment to receptors on HEp-2 cells. The flasks were 
then replenished with 7ml of maintenance media and incubated for up to 5 days. The 
flasks were observed daily for evidence of virus mediated cytopathic effect (CPE). 
Once CPE was seen, the virus infected cells were dislodged from the surface of the 
flask and into the media. The newly established virus stocks were then aliquoted into 
1 ml volumes and stored at -80°C for future use. To confirm successful virus 
infection, the new virus stocks were evaluated using immunofluorescent antibody 
testing (IFAT).
Immunofluorescent Antibody Testing (IFAT)
250 pi of new virus culture stocks were aliquoted into cytospin funnels and 
centrifuged in a desktop centrifuge at 1000 rpm for 10 minutes. Cytoslides were then
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air dried for 30 minutes and fixed in cold acetone for 10 minutes. Following fixing, 
the slides were air dried for a further 5 minutes. A drop o f an RSV detection reagent 
containing a mixture o f a fluorescein isothiocyanate (FITC) conjugated anti-RSV 
antibody and evans blue counterstain was placed on the fixed cells on the cytoslides 
(Millipore). The slides were then incubated at 37°C for 30 minutes in a humidified 
CO2 incubator. The slides were then washed three times in PBS and air dried for an 
hour. The dried slides were prepared using an oil immersion and examined at xlOO 
magnification on a fluorescent microscope. Figure 3.1 (a) is an example o f an
immunofluorescent slide containing successfully cultured virus (Ken/A/2006), while 
figure 3.1 (b) is a negative control (HEp-2 cells).
(a) (b)
Figure 3.1 (a) Immunofluorescence (bright apple-green colour) from an IFAT slide 
containing HEp-2 cells which were infected with the A2 strain of RSV while (b) is a 
negative control containing uninfected HEp-2 cells.
Plaque assay
Virus titre was determined using the plaque assay. HEp-2 cells were seeded on 96 
well cell culture plates at a concentration o f 20,000 cells per well and grown
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overnight to confluence at 37°C in a humidified CO2 incubator. 10-fold dilutions of 
stock virus were prepared as follows for inoculation onto the HEp-2 monolayer.
Neat virus 50 pi + 450 pi MEM = 10'1 dilution.
10'1 dilution 50 pi + 450 pi MEM=10'2 dilution.
10'2 dilution 50 pi + 450 pi MEM=10'3 dilution.
10'3 dilution 50 pi + 450 pi MEM=10‘4 dilution.
Media was removed from the cells on the 96 well plates and 50 pi of each virus 
dilution added to successive wells of the plate in duplicate. The plates were then 
incubated for 2 hours at 37°C in a humidified CO2 incubator with intermittent 
agitation at 15 minute intervals. 150 pi of MEM containing 2.5% FCS was then added 
to each well and the plates incubated for 48 hours in a 37°C CO2 incubator. After the 
48 hour incubation, the cells were fixed with 100 pl/well methanol containing 0.5% 
hydrogen peroxide for 20 minutes. The plates were then washed twice with 200 
pl/well of PBS. 100 pi per well of a 1/300 dilution of a mouse anti-RSV IgG 
(Novocastra, Leica corporation) was then added and the plates incubated at room 
temperature for one hour. The plates were then washed three times with 2 OOpl PBS 
per well followed by the addition of 100 pl/well of a 1/1000 dilution of goat anti­
mouse IgG with a horseradish peroxidase (HRP) tag (Dako Corporation) and one 
hour incubation at 37°C.
A tablet of 3-amino-9-ethylcarbazole (AEC) (Sigma) was dissolved in 6 ml of 
dimethyl sulphoxide (DMSO) to give a 3.3 mg/ml concentration of AEC. The 
development substrate was prepared by adding 600 pi of this solution to 10 ml of 20
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mM sodium acetate buffer containing 16 jul hydrogen peroxide. The sodium acetate 
buffer was adjusted to a pH o f between 5.0 and 5.5 prior to addition o f the AEC 
solution. 100 jal o f the substrate solution then added to the test wells and the plates 
incubated for up to one hour at room temperature or until plaques were clearly 
distinguishable from the cell monolayer background. The substrate solution was then 
removed and the plates washed twice with 200 ql/well o f PBS. Plaques were then 
counted using either low power microscopy or by using an ELISPOT reader with 
optimised read settings. Figure 3.2 is an example o f RSV A2 plaque morphology 
under low power microscopy. To determine the virus concentration in the initial virus 
stock, the virus dilution that resulted in between 10 to 50 plaques was determined and 
this was then multiplied by the dilution factor to give the stock virus concentration in 
plaque forming units per ml (PFU/ml). After determination o f virus titre, 
measurement o f neutralising antibody in infant sera was carried out using a plaque 
reduction microneutralisation assay. This assay along with the modifications 
undertaken to optimise its output are discussed in detail in chapter 4.
Figure 3.2 The appearance of RSV plaques on a HEp-2 monolayer background. The 
plaques were developed using AEC
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Measurement of cytokine/chemokine concentration using the MSD 
mesoscale platform
The concentration of cytokines/chemokines produced following natural infection was 
measured using the MSD mesoscale platform (Meso Scale Discovery, Gaithersburg, 
Maryland, USA). The MSD platform is a proprietary system designed to measure the 
concentration of up to 10 cytokines/chemokines from a single sample. The assay used 
in this study was in the 96 well multi-array format, in which multiple 
cytokines/chemokines were measured in each nasal sample. The assay is designed in a 
sandwich immunoassay format in which capture antibodies are either coated on a 
single spot in one microtitre plate well, or in which multiple spots, each coated with a 
capture antibody specific for a different analyte are arrayed at different positions on a 
single microtitre plate well. The capture antibodies bind to the cytokines/chemokines 
of interest in the patient sample, which are in turn bound by a detection antibody that 
contains a proprietary tag, SULFO-TAG. This tag is activated by the working 
electrode that is attached to the base of each well, resulting in the production of a 
chemiluminescent signal, whose magnitude corresponds to the concentration of the 
cytokine/chemokine of interest in the sample. Figure 3.3 shows an example of a four 
spot array format. In this study, the MSD system was used to measure the 
concentrations of 10 cytokines/chemokines in the nasal secretions of infants: 
interleukin (IL) -6, ILl-b, Tumor Necrosis Factor (TNF)-a, Macrophage Derived 
Chemokine (MDC), Macrophage Inflammatory Protein (MIP)l-p, IL-8, Interferon 
(IFN)-y, IL-10, IL-4 and IL-5.
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Figure 3.3 Illustration of a 4 spot MSD mesoscale plate. Each spot is coated with a 
capture antibody that is specific for a different analyte. These antibodies bind to the 
cytokines/chemokines of interest in the patient samples. The detection antibody, which is 
labelled using a proprietary tag (SULFO-TAG) is used to generate a chemiluminescent 
signal that is activated and subsequently detected by the working electrode.
Protocol for measurement of cytokines/chemokines in the nasal secretions 
of infants using the MSD mesoscale system
Using a mixed calibrator solution provided by the manufacturer, four-fold standard 
dilutions were prepared. After preparation of the calibrator dilutions, plates were 
blocked by addition of 25 pl/well of a blocking solution provided by the 
manufacturer. The plates were then sealed and incubated for 30 minutes at room 
temperature on a vibrating platform (600 rpm). After blocking, 25 pl/well of either 
patient sample or pre-diluted calibrators were added and the plates sealed and 
incubated at room temperature for 2 hours on a vibrating platform. The plates were 
then washed three times with PBS containing 0.05% Tween 20. 25 pl/well of a 
detection antibody solution that was specific for the analytes of interest was added. 
The plates were then incubated for a further 2 hours at room temperature on a 
vibrating platform. The plates were then washed 3 times and 150 pi of a read buffer
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provided by the manufacturer was added to each well. The plates were then read on a 
Sector 2400 Imager and the results analysed. Concentrations of cytokines/chemokines 
in individual patient samples were measured against the standard curves generated 
using manufacturer supplied calibrators.
Sequencing of the F and G genes of infecting RSV strains 
RNA extraction and cDNA synthesis
Ribonucleic Acid (RNA) was extracted from infant nasal wash samples using the 
QIAamp Viral RNA mini kit (Qiagen, Germany) following the manufacturer’s 
instructions. The buffers required for carrying out RNA extraction are proprietary and 
were supplied by the kit manufacturer. 560 pi of buffer AVL (cell lysis buffer) was 
added to 140 pi of nasal samples, vortexed and incubated for 10 minutes at room 
temperature to facilitate cell lysis. 560 pi of absolute ethanol was then added and the 
reaction vortexed prior to its transfer to a QIAamp spin column. The reaction was 
centrifuged at 6000 x g for 1 minute. 500 pi of buffer AW1 was then added and the 
reaction tube centrifuged at 6000 x g for a further 1 minute. 500 pi of buffer AW2 
was then added and the spin column centrifuged at 20,000xg for 3 minutes. Elution 
was done by addition of 60 pi of buffer AVE. The column was thereafter incubated 
for 1 minute, after which, a final spin of 6000 x g was carried for 1 minute resulting in 
the elution of the extracted RNA into a clean collection tube. The eluted RNA was 
subsequently used for complementary DNA (cDNA) synthesis. cDNA synthesis was 
carried out using the Omniscript Reverse Transcriptase Kit (Qiagen) following the 
manufacturer’s instructions. A 20 pi reaction mix containing reverse transcriptase 
buffer, deoxyribonucloside triphosphates (dNTPs), reverse transcriptase enzyme and
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random primers was added to 20 pi of the extracted RNA and incubated at 37°C for 1 
hour. The synthesized cDNA was stored at -80°C for subsequent PCR amplification 
of both the F and G genes.
G Gene amplification and sequencing
G gene amplification was carried out using a nested PCR reaction. For each reaction, 
25 pi of Taq PCR Master Mix was added to 1 pi of 25 mM MgC12, 18 pi of RNase 
free water, 2 pi of the forward primer AG20 (5’-GGGGCAAATGCAAACATGTCC- 
3’) and 2 pi of the reverse primer F164 (5’-GTTATGACACTGGTATACCAACC- 
3’). The region amplified by these primers was between nucleotide 284 of the G gene 
and nucleotide 9 of the F gene. 4 pi of the cDNA sample, was then added to this 
reaction mix and thermocycled using the following conditions: 50° C for 30 min, 95°C 
for 15 min and then 40 cycles of 94°C for 30 sec, 54°C for 30 sec and 72°C for 1 min. 
A final extension of 10 min at 72°C was included. The nested PCR utilised 2 pi of the 
primary PCR product in the reaction mix described above. For the nested PCR, the 
forward primer was BG10 (5’-GCAATGATAATCTCAACCTC-3’) and the reverse 
primer was FI (5’-CAACTCCATTGTTATTTGCC-3’). Thermocycling conditions 
were as follows: 95 °C for 2 min, followed by 30 cycles of 95 °C for 45 sec, 54 °C for 
45 sec, 72 °C for 1 min, followed by a final extension at 72 °C for 5 min. Successful 
amplification was confirmed by running the secondary PCR products on a 2% agarose 
gel. PCR products were purified using the QIAquick purification kit (Qiagen) 
following the manufacturer’s instructions. Sequencing of the G gene products was 
done using the BigDye terminator chemistry on the 3130x1 ABI instrument. For each 
sequencing reaction, 0.5 pi of the ready reaction premix (ABI) was added to 1.75 pi 
of 5X sequencing buffer, 1 pi of 5 pM primers (BG10 and FI) and 5.25 pi of water.
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1.5 pi of the cleaned second round PCR product was used as the template in the 
reaction. Thermocyling then carried out using the following conditions: 25 cycles of 
96°C for 10 seconds, 50°C for 10 seconds, and 60°C for 4 min. The sequencing 
extension products were then purified using ethanol precipitation. For each reaction, 8 
pi of deionised water was added to the reaction tube, followed by 32 pi of 95% 
ethanol. The reaction tubes (on 96 well PCR plates) were then inverted several times 
and incubated at room temperature for 15 minutes to precipitate the sequencing 
extension products. The reaction vessels were then centrifuged at 2000 x g for 45 
minutes after which the supernatants were discarded. The reaction vessels were 
inverted on paper towels and centrifuged for a further 1 minute at 700 x g. The 
resulting pellets were then dissolved in 3 pi of loading buffer consisting of formamide 
and EDTA at a ratio of 1:5. The samples were finally loaded on the ABI 3130x1 
genetic analyser and the sequencing reaction initiated.
F gene amplification and sequencing
RNA extraction and cDNA synthesis was carried out as described in the previous 
section. Amplification of the F gene product was done using similar reaction 
conditions as those of the first round G gene PCR and the following primers: primers 
FRSV-U (5 ’ -GGC AAATA AC A ATGGAGTT G-3 ’) and FRSV-4R (5’-
AAGAAAGATACTGATCCTG -3’). The region amplified by these primers was 
between nucleotide 121 and 918 of the F gene. The thermocycling reaction adopted 
similar reaction conditions as the primary G gene PCR, with an annealing temperature 
of 52°C. The products of this PCR were purified, precipitated and sequenced as 
above.
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Chapter 4 - Development of Plaque reduction 
microneutralisation assay
Introduction
Traditional plaque reduction neutralisation assays suffer from a number of critical 
shortcomings that have limited the widespread use of these assays. Key among these 
is the labour intensive element of microscopic plaque enumeration that is necessary 
for the determination of endpoint titres. The reliability of data obtained using this 
manual enumeration technique is brought into question by its inherent subjective bias. 
Even when carried out by the same individual, the reproducibility the results can be 
reasonably be assumed to vary considerably depending on many intra operator factors 
that vary from assay to assay. For example, operator fatigue could be argued to 
significantly influence the reproducibility of results.
The results presented in this thesis were primarily based on the measurement of serum 
neutralising antibody titres in infant sera. In order to improve the reliability of the 
estimates measured using this assay, a number of modifications were incorporated 
into the assay. This chapter will discuss the general protocol used in the neutralisation 
assays as well as the development of a high throughput plaque enumeration system.
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Methods
Plaque Reduction Neutralisation Assay
Each test serum sample was initially diluted 1:20 in MEM and complement cascade 
proteins inactivated by heating the samples in a 56°C water bath for 30 minutes. The 
samples were then double diluted from 1:20 to 1:10,240 in a volume of 50 jitl /well. 
Each dilution was aliquoted in duplicate. 50 pfu of test virus in a volume of 50 pi 
MEM was then added to the wells containing 50 pi of pre-diluted serum. The 100 pi 
serum/virus mix was then thoroughly mixed by repeated pipetting. Each plate 
contained 3 test samples and One positive control consisting of pooled adult sera to 
track assay reproducibility as well as a virus-only control. The serum/virus mix was 
incubated at 4°C for one hour to facilitate virus neutralization by serum antibodies, 
after which the neutralization reaction was transferred to a confluent monolayer of 
HEp-2 cells on 96 well plates. These plates were incubated for 2 hours at 37°C in a 
humidified CO2 incubator, with intermittent mixing at 15 minute intervals to enhance 
the likelihood of un-neutralized virus attaching to cell surface receptors. After the 2 
hour incubation, the plates were replenished with 100 pl/well of MEM containing 
2.5% FCS and incubated for 48 hours in a 37°C humidified CO2 incubator.
After 48 hours, media was removed from the cells and the plates fixed by addition of 
100 pl/well methanol containing 0.5% hydrogen peroxide for 20 minutes. The plates 
were washed two times with 200 pl/well of PBS. 100 pl/well of a 1/300 dilution of a 
mouse anti RSV IgG (Novocastra, Leica Corporation) in PBS was added and the 
plates incubated at room temperature for 1 hour. The plates were thereafter washed 3 
times with and 100 pl/well of a 1/1000 dilution of goat anti-mouse IgG with a
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horseradish peroxidase (HRP) tag (Dako Corporation) added. The plates were then 
incubated at room temperature for an hour. After this incubation, the plates were 
washed three times and a substrate consisting o f  AEC and sodium acetate added as 
described in chapter 3. Plaques were counted using an ELISPOT reader with 
optimised read settings. A detailed description o f  these optimisations will be 
discussed in the next section. Figure 4.1 shows an example o f  a fully developed plate 
in which the plaques are clearly visible by macroscopic examination.
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Figure 4.1 Illustration of the appearance of a plate at the completion of PRNA assay. 
Plaques can be clearly seen as sharp brown spots by the unaided eye.
Developm ent of high th roughpu t plaque counting using an E L ISPO T 
read er
In order to increase the throughput o f  the neutralisation assay as well as eliminate the 
subjective bias associated with manual microscopic counting, an automated plaque 
enumeration technique was developed. This technique relied on a conventional
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ELISPOT reader (AID, Autoimmun Diagnostika, Germany) for the identification and 
enumeration o f  plaques on 96 well tissue culture plates. Due to variations in the 
plaque phenotypes of different strains o f  RSV, it was necessary to optimise the read 
settings o f  each individual virus in order to increase both the sensitivity and 
specificity o f  enumeration. Figure 4.2 shows the varying plaque morphologies o f  the 
two test strains of  RSV B used in this study.
(b)(a)
8/60 (Swe/B/1960) Ken/B/2008
Maque count -  124 Plaque count = 112
48h culture 48h cu|ture
Figure 4.2 Plaque morphologies of two strains of RSV B which were grown to 
approximately comparable titres are shown, (a) shows the plaque morphology of the 
8/60 (Swe/B/1960) while (b) shows the plaque morphology of Ken/B/2008. After a 48 
hour culture, 8/60 plaques are considerably larger relative to Ken/B/2008 plaques.
Optimisation o f  read settings was carried out by adjusting 2 parameters: plaque size 
and plaque intensity. The intensity parameter was used to set the intensity (darkness) 
threshold for counting plaques. The value o f  this parameter represents the difference 
between the intensity o f  the peak o f  the plaque and its surrounding background. 
Intensity, which is measured in brightness units, took on values between 0 (White) to 
255 (Black). Objects whose intensity values that fell below the set ranges were not 
counted as plaques. The size parameter was used to set the minimum size in pixels
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that an object needed to have in order to be recognized as a plaque. Objects whose 
size in pixels was outside the set values for this parameter were similarly not included 
in the final plaque count. This parameter took on values ranging from 1 to 5000. As a 
result of differing plaque morphologies, optimal plaque settings were determined for 
each virus strain used in the study. These were the settings that resulted in a final 
count that most closely conformed to manual plaque counting. Once the optimal 
parameters had been decided, plates were placed on the ELISPOT reader and read 
with the optimised settings. To facilitate the automated reading, a white sheet of paper 
was attached to the base of each plate prior to insertion into the ELISPOT reader in 
order to maximise the contrast between the dark brown plaques and the clear cell 
monolayer background. The optimal size and intensity parameters for the different 
test strains used in this study are shown in table 4.1.
Virus/Setting Size Intensity
A2 120-5000 50-255
8/60 80-5000 35-255
Ken/A/2006 100-5000 50-255
Ken/B/2008 40-5000 35-255
Table 4.1. The optimal size and intensity and parameters of the four test viruses used in 
this study. These parameters produced automated counts that were most closely related 
to microscopy counts.
Validation of automated plaque counting using an ELISPOT reader
In order to confirm the accuracy of the ELISPOT reader plaque counting technique, 
parallel enumeration of plaques by both the ELISPOT reader and by microscopy was 
carried out. Serial 2-fold dilutions of the A2 strain were used to infect a monolayer of
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HEp-2 cells from a starting titre of approximately 50 pfu/well in duplicate. Three 
experienced laboratory technicians were independently asked to microscopically 
count the number of plaques present in each well. The mean count at each dilution 
was then obtained for all three readers. The same plate was also subjected to 
enumeration by the ELISPOT reader using optimised count settings and the mean 
count at each dilution calculated. A comparison of the mean counts at each dilution of 
virus as determined by both techniques is shown in figure 4.3.
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Figure 4.3 Comparison of mean plaque counts at different dilutions of virus by three 
human readers and the ELISPOT reader. The Y axis contains the number of plaques 
identified in each instance, while the x axis shows the range of serial dilution from a 
starting titre of 50 pfu.
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To assess the level of agreement between counts obtained by the ELISPOT reader and 
manual counting, Spearman correlation analysis was carried out. For this analysis, the 
mean plaque count at different dilutions of virus was obtained. The strength of 
association between the mean manual and ELISPOT counts measured using 
Spearman correlation analysis, was found to be high (r=0.98, pO.OOOl), suggesting a 
high level of agreement between the manual and automated plaque counting 
techniques. The relationship between manual and automated plaque counting is 
shown graphically in figure 4.4. As a result of the high degree of agreement, all 
subsequent enumeration of plaques was carried out using the ELISPOT reader.
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Figure 4.4 The relationship between automated and manual plaque counting is shown 
in this figure. The y axis represents the mean plaque count obtained by the ELISPOT 
reader, while the x axis represents mean counts by 3 manual readers. The association 
between the two methods was tested using Spearman’s correlation analysis. The 
spearman correlation coefficient (r) and its corresponding p value are shown.
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Calculation of neutralising dose 50 (ND50) endpoint using the Spearman- 
Karber method
Neutralizing antibody titres in this study were measured as N D 5 0  endpoint titres using 
the Spearman-Karber method (Cohen et al., 2007). This method approximates the 
serum dilution required to halve the initial titre of virus, which in the case of this 
study, was approximately 50 plaques. Thus the neutralizing titre was estimated as the 
dilution of sera that permitted the development of approximately 25 plaques.
The Spearman-Karber formula is expressed as follows: 
logioND50 = m - A  ( E p-0 .5 )
Where m is the logio dilution of the highest dilution of serum 
(i.e. logio (1/10,240) = -4.01)
and A is the constant interval between dilutions expressed as logio 
(i.e. logio (2) = 0.3010)
and Ep = xl/y  +x2/y+x3/y+x4/y+x5/y+x6/y
where xl is the number of plaques for the first well, x2  for the second well and so on, 
and y is the mean number of plaques for the virus (no-serum) control wells.
Figure 4.5 shows an example of the neutralisation profile of strain A2 by different 
dilutions of infant serum.
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Figure 4.5 The neutralisation profile of RSV A2 by increasing dilutions of sera 
obtained from one infant is shown. The y axis shows the mean number of plaques that 
were observed at varying dilutions of serum (the serum dilutions are shown on the x 
axis). The dotted lines are used to indicate the serum dilution that results in the 
development of 25 plaques.
An example calculation of the neutralizing antibody titre as an ND50 endpoint titre 
using the Spearman-Karber method is shown below. Table 4.2 contains the mean 
plaque count at increasing dilutions of serum -  these data are used in the titre 
calculation example.
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Well
number
1 2 3 4 5 6 7 8 9 10
mean
plaque
count
0 2 11 24 42 46 52 48 53 52
Serum
dilution
(l:x)
20 40 80 160 320 640 1280 2560 5120 10240
Table 4.2 The mean (of two) plaque counts at varying dilutions of infant sera are 
shown. These data are used in the example of titre calculation using the Spearman- 
Karber method
Implementation of the Spearman-Karber formula is shown in expressions i-iv below.
Logio ND50 = - 4.01- (-0.301 (0/50+2/50+11/50+24/50+42/50+46/50+52/50 +48/50
+53/50 +52/50 -  0.5) ) .................i
Logio ND5o= -2.17........................  ii
Anti-log of -2.17=148.................  in
ND50 (PRNT)= 148.......................... iv
For comparison, the neutralizing titre is inferred using the data shown on figure 4.5. 
This is done by using the linear part of the curve to estimate the serum dilution that 
corresponds to a plaque count of 25 on the y axis (shown using the dashed lines on 
figure 7). The ND50 value obtained through the Spearman-Karber formula is 148, 
while that obtained by graphical inference is approximately 160.
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Chapter 5 - Neutralising antibody responses to natural RSV 
infection
Introduction
The group replacement dynamics of RSV at the population level (Cane et al., 1994, 
Waris, 1991) suggest that population level immune selection is a key factor in the 
transmission of the virus. Mathematical modelling studies have shown that the 
assumption of group-specific immunity is sufficient to reproduce the observed group 
replacement dynamics (White et al., 2005).
Despite RSV’s ability to re-infect throughout life (Henderson et al., 1979), individuals 
develop natural resistance against severe disease. While factors such as physiological 
maturation of the respiratory system may account for some resistance from severe 
disease (Dunnill, 1962), neutralising antibodies are thought to be a key feature of 
protective immunity and correlate strongly with protection from severe disease (Glezen 
et al., 1981a) and infection (Hall et a l , 1991, Lee et al., 2004). The role of antigenic 
variation in re-infection has to date not been clearly elucidated, however the extent of 
nucleotide and amino acid variation in the F and G genes of RSV A and B, provides 
some basis to suggest that protective immune responses targeted at these proteins may 
be variant specific. Although animal challenge studies have confirmed that the 
neutralising response is strongly group-specific, no conclusive data on the group- 
specificity of the human neutralising response has been published.
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The failure by previous human cross neutralisation studies to reveal a group-specific 
component to the neutralising response (Coates et al., 1963, Wulff et al., 1964) may be 
attributed to certain study design shortcomings that may have obscured the ability to 
detect a significant difference between homologous and heterologous neutralising 
responses. The lack of definitive analysis of the molecular and antigenic characteristics 
of the infecting strains for example impedes proper interpretation of the data arising 
from these studies.
A number of studies have explored targets of the neutralising response. By use of 
monoclonal antibodies, a number of sites on the F and G proteins have been identified 
to be the targets of the neutralising response (Arbiza et al., 1992, Lopez et al., 1990, 
West et al., 1994, Connor et al., 2001, Agenbach et a l, 2005). Neutralising antibody 
epitopes have been identified in a number of sites on the FI subunit of the F protein 
(Trudel et al., 1987b, Lopez et al., 1990, Martin-Gallardo et al., 1991) as well as the 
central region of the G protein (Murata et al., 2010, Garcia-Barreno et al., 1992). 
Analysis of the location of these neutralising epitopes on the F proteins of wild-type 
strains of RSV has revealed that these epitopes are located on regions of the protein that 
contain a number of group conserved amino acids (Agenbach et al., 2005). It is possible 
that amino acids that are conserved within but not between groups may have an impact 
on the specificity of the neutralising response directed at these epitopes.
The effect of pre-existing antibodies on the infant neutralising antibody response has 
been studied extensively. There is evidence that suggests that the infant neutralising 
response to infection is masked by maternally-derived antibodies (Murphy et al., 
1986b, Parrott et al., 1973). For this reason, it is thought that vaccination in early
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infancy is unlikely to be beneficial since the infant’s native response to vaccination 
would be reduced in the presence of maternal antibody (Murata, 2009). It is however 
possible that the failure of young infants to mount a high neutralising response 
following infection or vaccination may be related to immunological immaturity and not 
solely the presence of pre-existing antibody of maternal origin. There is a paucity of 
data demonstrating the relationship between the ability to seroconvert to vaccination or 
natural infection and age among infants with a diverse range of pre-existing antibody 
titres.
Chapter Aims
This chapter aims to give a general description of the serum neutralising antibody 
response following natural infection in infants. It will explore the natural distribution of 
both acute and convalescent phase neutralising antibodies among paediatric RSV 
admissions. The relationship between acute stage neutralising antibodies and several 
clinical features of severe pneumonia will be explored with a view to identifying 
protective associations. It will further look at the effect of both age and pre-existing 
antibody on the ability of infants to seroconvert following natural infection. The genetic 
relationship between RSV A and RSV B infecting strains in terms of amino acid 
identity at both the F and G gene level will be explored. Regions on the F and G 
proteins of the infecting strains that are thought to be targets of neutralising antibodies 
identified from the published literature will be mapped on F and G protein sequences of 
infecting strains. This chapter will finally look at the group-specificity of the serum 
neutralising response following natural infection.
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Methods
Study population, sampling and molecular characterisation of test and 
infecting viruses
Nasal washing samples were obtained from children less than 60 months of age 
admitted to Kilifi District Hospital (KDH) with syndromically defined severe or very 
severe pneumonia. RSV was diagnosed by Immunofluorescent Antibody Test (IFAT, 
Millipore Corporation). Multiplex RT-PCR (Reverse Transcriptase Polymerase Chain 
Reaction) was used to determine if the infecting virus was from group A or B. An acute 
serum sample was collected from all children at admission and a convalescent serum 
sample from RSV positives approximately 4 weeks later. Nasal wash and serum 
samples were all stored at -80°C prior to use in the present study. Representative 
contemporary and historical strains of RSV were used as the test strains in this study. 
These were: the A2 genotype (RSV A; isolated in Australia in 1961), Kil/A/2006 (RSV 
A; Kenya, 2006), 8/60 (RSV B; Sweden, 1960) and Kil/B/2008 (RSV B; Kenya, 
2008). The attachment and fusion protein genes of all the test viruses as well as a 
number of infecting strains were sequenced using previously described methods 
described in details in Chapter 3.
Plaque assay and microplaque reduction and neutralisation assay.
Titres of test strains were determined by plaque assay. Briefly, tenfold dilutions of test 
virus were made in minimum essential media (MEM) and inoculated onto HEp-2 
cultures for 48 hours in 96-well plates. Cells were then fixed in methanol, washed and 
incubated at room temperature with a primary mouse anti-RSV IgG monoclonal 
antibody (Leica microsystems) followed by a secondary horseradish peroxidase linked
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rabbit anti mouse IgG (Dako, Denmark). Plaques were developed using 
aminoethylcarbazole (AEG). An ELISPOT reader was used to count the number of 
plaques in each well. The plaque reduction neutralisation assay was carried out by 
preparing serial 2-fold dilutions of sera in MEM. 50 pfu of test virus were added to 
each dilution and following incubation for 1 hour at 4°C, the neutralisation reaction was 
inoculated onto HEp-2 cells and incubated at 37°C for 48 hours. Plaque development 
and enumeration were done as above. Neutralising antibody titres were calculated as 
neutralising dose 50 (ND50) values using the Spearman-Karber method (Cohen et al., 
2007) and expressed as Plaque Reduction Neutralisation Titres (PRNT). These titres 
were normalised using logio transformation for statistical analyses. A seroconversion 
was defined as a four-fold or greater rise in the neutralising antibody titre between the 
acute and convalescent phases of infection.
Statistical Analyses
Data analyses were done using Stata (version 11.1; StataCorp). Multiple regression 
analysis was used to compare the acute phase neutralising titres in different age classes. 
Comparison of homologous to heterologous responses in different age classes was done 
by comparing their mean fold rises in titre. Multiple regression analysis was used to test 
if the difference in the magnitude of the neutralising response to homologous virus (in 
terms of log fold rise in titre) in a particular age class was significantly different from 
the magnitude of the heterologous neutralising response in the same age class. 
Spearman rank correlation analysis was used to test the association between age and the 
magnitude of the neutralising response as well as the relationship between the acute 
phase response and the magnitude of the neutralising response. A logistic regression 
model was used to calculate the odds ratios of developing different features of severe
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pneumonia in infants and children who had high or low tires of acute stage neutralising 
antibody. Finally, paired comparison of infant response to both homologous and 
heterologous virus was done using McNemar’s %1 test. The analytical output for the 
data shown in this chapter is presented in appendix 1.
Results 
Age distribution and description of study participants
Neutralising antibodies were measured in the acute or convalescent sera of 118 
paediatric pneumonia admissions with a median age of 4.7 months (range 0.2 -  41 
months). 58.5% of the infants in the study were under 6 months of age, 21.2% were 
between 6 and 11.9 months of age while 20.3% were over 12 months of age. The age 
distribution of study participants is presented in figure 5.1. Most of the study 
participants were admitted with severe pneumonia. Very severe pneumonia was 
restricted to infants below 12 months of age while mild disease occurred only among 
infants who were over 12 months age (Table 5.1)
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Figure 5.1 Distribution of ages at admission for paediatric inpatients whose acute and 
convalescent sera were used in this study
WHO Pneumonia sta tus (%)
Age
(months)
None M ild Severe very
severe
0 1 cn 0 0 82.8 17.2
6 -1 1 .9 0 0 87.0 13.0
12+ 13.0 13.0 74.0 0
Total 2.73 2.73 81.82 12.73
Table 5.1 The pneumonia status of infants and children admitted. The data are stratified 
by age.
The study participants were recruited in the course of 3 RSV epidemics: 20 individuals 
were recruited in the 2002/2003 RSV epidemic in Kilifi, 74 individuals were recruited 
from the 2005/2006 epidemic and 24 individuals were recruited from the 2007/2008 
epidemic. During the 2002/2003 RSV epidemic, RSV A and B appeared to co-circulate 
in roughly equal proportions (Nokes et al. in preparation), while the 2005/2006 and 
2008/2009 epidemics appeared to be strongly dominated by RSV A and B respectively.
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RSV inpatient surveillance data in Kilifi District Hospital over the sampling period is
shown in figure 5.2.
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Figure 5.2 The temporal distribution of RSV A and B transmission over 7 years in Kilifi, 
Kenya. The dark bars represent transmission of RSV A, the grey bars represent 
transmission of RSV B while the red bars represent the samples that were used in this 
study. The temporal group replacement dynamics of RSV in Kilifi are also shown in 
figure 2.2
The infecting viruses isolated from each infant were classified as belonging to antigenic 
group A or B by multiplex PCR (Scott et al., 2004, Stockton, 1998). 20 (100%) of the 
infants recruited in the 2002/2003 epidemic were infected with RSV B viruses that did 
not contain the 60 nucleotide duplication in the G gene (non-BA strains), 73 (98.6%) 
infants in the 2005/2006 epidemic were infected with RSV A while 1 (1.4%) was 
infected with RSV B, while 24 (100%) of the infants recruited in the 2008 epidemic 
were infected with RSV B viruses that contained the 60 nucleotide duplication. These 
data as well as the median ages of the study participants infected with either group are 
presented in table 5.2.
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Infecting group
A B
Epidemic Median ase months fn) Median aue months (rf) Total
2002/2003 N/A 7.1 (20) 7.1 (20)
2005/2006 4.06 (73) 8.2 (1) 4.1 (74)
2007/2008 N/A 6.2 (24) 6.2 (24)
Total 4.6 (73) 7.1 (45) 4.7 (118)
Table 5.2 The median ages of RSV A and B infected infants recruited into the study. The 
data are stratified by the epidemic during which the infections occurred.
Distribution of serum neutralising antibodies
Frequency distribution plots of neutralising antibodies at the acute and convalescent 
phases of infection were generated. The titres used in these analyses were mean titres 
obtained from four test viruses i.e. A2, 8/60, Ken/A/2006 and Ken/B/2008. The 
frequency distributions of the acute and convalescent phase neutralising antibody titres 
showed that both were skewed sharply to the left with median values of 216 PRNT 
(range 27 — 1309 PRNT) and 490 PRNT (range 47 — 1738 PRNT) respectively and 
corresponding mean values of 277 PRNT (SD 213) and 591 PRNT (SD 418) 
respectively (figure 5.3). Since many of the statistical analyses that were to be applied 
on these datasets are based on the presumption of normality, it was necessary to 
transform the data in order to normalise them. A logarithm 10 transformation was 
applied to both acute and convalescent antibody titres and the resulting distributions 
analysed for evidence of normality. The transformed distributions appeared to approach 
normality, with mean and median values generally occurring at the centre of the
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distributions (figure 5.3). The log transformed acute and convalescent phase 
neutralising antibody distributions had medians of 2.3 PRNT (range 1.4 -  3.1 PRNT) 
and 2.7 PRNT (1.7 -  3.2 PRNT) respectively and means of 2.3 (SD 0.33) and 2.6 (SD 
0.35) respectively. Since the log transformed data appeared to be normally distributed, 
they were used as the basis of all subsequent statistical analyses.
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Figure 5.3 Acute and convalescent sera from 118 infants infected with RSV were 
normalised by logarithmic transformation, (a) Acute phase neutralising antibody titres 
expressed as Plaque Reduction Neutralisation Titres (PRNT) (b) Log transformed Acute 
phase titres expressed as logio (PRNT) (c) Convalescent phase neutralising antibody 
titres expressed PRNT (d) Log transformed convalescent phase titres expressed as logio 
(PRNT). The titres used in these analyses were mean titres to four test viruses (A2, 8/60, 
Ken/A/2006 and Ken/B/2008)
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The age dynamics of serum acute and convalescent phase neutralising 
antibody responses of infants and children admitted with pneumonia
Distribution of acute and convalescent phase responses by age 
In order to assess the magnitude of the neutralising response to natural infection an 
overlay of log transformed acute and convalescent titre distributions was generated 
(figure 5.4). Visual observation of the overlaid distributions showed marked separation 
between the acute and convalescent titres. There was a 2-fold difference between the 
mean acute antibody titre (2.3 logio PRNT) and the mean convalescent antibody titre 
(2.6 logio PRNT). The overlay of the acute and convalescent phase distributions is 
shown in figure 5.4.
Figure 5.4 Overlay of log transformed acute and convalescent phase neutralising 
antibody titre distributions from the sera of 118 infants infected with RSV. Sera was 
tested against 4 test viruses (A2, 8/60, Ken/A/2006 and Ken/B/2008) and a mean titre 
obtained for use in these analyses. The light grey bars represent acute phase titres while 
the dark bars represent convalescent phase titres
1 5 - i
1.5 2 2.5 3 3.5
Acute titre - log 10 (PRNT)
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In order to explore the effect of age on the neutralising response, the overlaid 
distributions were stratified by age. Three age classes were defined for these analyses: 
0-5.9 months, 6-11.9 months and 12 months of age and above. The results of this 
stratification showed that age appeared to have a considerable influence on the 
neutralising antibody response to RSV. There was some difference between the acute 
and convalescent phase neutralising antibody distributions in the youngest age class (0-
5.9 months of age) with mean values of 2.46 logio PRNT and 2.54 logio PRNT 
respectively (t=-1.9, p=0.03). This difference increased substantially in the 6-11.9 
month age class, where the convalescent phase distribution shifted sharply to the right 
with a mean of 2.8 logio PRNT and the acute phase distribution shifted to the left with a 
mean of 2.1 logio PRNT. This difference was highly significant (t=-12.4, pO.OOOl). 
In children over 12 months of age, the convalescent phase distribution shifted further to 
the right with a mean of 2.8 logio PRNT relative to the mean acute phase titre of 2.3 
logio PRNT. This difference was also highly significant (t=-8.6, pO.OOOl). These data 
are graphically depicted in figure 5.5.
90
rr?-T"r.rl" .. .1.3
□
on
CL
O
O)o
JU80J8d
Fi
gu
re
 
5.5
 
Ag
e 
str
at
ifi
ed
 
co
m
pa
ris
on
 
of 
ac
ut
e 
an
d 
co
nv
al
es
ce
nt
 
ph
as
e 
tit
re
 
di
str
ib
ut
io
ns
 
Ac
ut
e 
an
d 
co
nv
al
es
ce
nt
 
ph
as
e 
di
st
ri
bu
tio
ns
 
we
re
 
ov
er
la
ye
d 
in 
3 
ag
e 
cla
ss
es
: 
0-
5m
on
th
s 
(n
=6
9)
, 
6-
llm
on
th
s 
(n
=2
5)
 a
nd
 
12+
 
m
on
th
s 
(n
=2
4)
. 
Th
e 
me
an
 
tit
re
 
fro
m 
4 
tes
t 
vi
ru
se
s 
w
as
 
use
d 
in 
thi
s 
an
al
ys
is 
- 
i.e
. 
A2
, 
8/
60
, 
K
en
/A
/2
00
6 
an
d 
K
en
/B
/2
00
8.
Age dynamics of the acute phase response
The age dynamics of pre-existing antibodies were analysed in the acute phase samples 
obtained from infants of different ages. Neutralising titres were stratified into seven 
age classes: 0-0.9 (n= ll), 1-1.9 (n=l8), 2-2.9 (n= 16), 3-3.9 (n=6), 4-4.9 (n=14), 5-
5.9 (n=6), 6-11.9 (n=25) and 12+ (n=24) months of age. The neutralising titres used 
in these analyses were the mean titres to 4 test viruses: A2, 8/60, Ken/A/2006 and 
Ken/A/2008. The results of regression analysis showed that there was a progressive 
decline of acute phase antibodies in the first year of life. However comparison of the 
acute titres of infants in the 6-11.9 month age class with those of infants above 12 
months of age showed that the older infants had a significantly greater mean titre of 
acute stage neutralising antibodies relative to the younger group (pO.OOOl). These 
data are shown in figure 5.6.
1,500-
1 ,0 0 0 - — 1
f-z
50 0 - —
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CM
CDO O O )CO o>t
age  (months)
Figure 5.6 The dynamics of the acute phase response by age. Each bar represents the 
indicated age class. The difference in the mean neutralising titres successive age classes 
were tested for statistical significance (indicated by the p values). The lines in the 
middle of the boxes represent median titres while the lower and upper bounds of the 
boxes represent the 25th and 75th percentiles respectively. The upper and lower whiskers 
represent values that are up to 1.5 times below and above the 25th and 75th percentile 
respectively. The dots represent outliers which are values that fall outside the bounds 
defined by both the upper and lower whiskers.
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Development of the neutralising response with age: comparison of the acute and 
convalescent responses.
The difference between the acute and convalescent phase responses was analysed by 
comparing the differences between these responses within the age structure defined 
above. The results of these analyses showed that in the youngest infants (0-0.9 months 
old) the mean convalescent phase response was significantly lower than the acute 
phase response (p=0.05). This difference was lost in the 1-1.9 (p=0.15), 2 -2.9 
(p=0.09) and 3-3.9 (p=0.6) month age classes, where no difference between the acute 
and convalescent phase responses was seen. However the convalescent phase 
responses were significantly greater than the acute phase responses in the 5-5.9 
(p=0.006), 6-11.9 (pO.OOOl) and 12+ month age classes (pO.OOOl). These data are 
shown graphically in figure 5.7.
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Figure 5.7 Comparison of the acute and convalescent neutralising response in different 
age classes. Description of the different elements of the box and whisker plots are as 
described in figure 5.6. The p values indicated on the line traversing the 
acute/convalescent distributions in a particular age class indicate whether the 
differences in mean titre are significantly different.
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Relationship between seroconversion and age
The relationship between the ability to seroconvert following natural infection and age 
was analysed. A seroconversion was defined as a four-fold or greater rise in the 
convalescent phase response over the acute phase response. The proportions 
seroconverting in different age classes were calculated and presented graphically in 
figure 5.8. Analysis of seroconversion rates in different age classes showed an 
increasing trend with age. In general the seroconversion rate between 0 and 3.9 
months of age was less than 20%. The seroconversion rate between 4 and 5.9 months 
of age was between 20% and 40% while the seroconversion rate among infants who 
were 6 months or older was above 40%.
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Figure 5.8 The proportions of infants seroconverting within different age classes A sero 
conversion was defined as a 4-fold or greater rise in titre from the acute to convalescent 
phases of infection. The height of the bars represent the proportion seroconverting 
within individual age classes while the lines traversing the bars indicate 95% confidence 
intervals about the proportions.
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Next the relationship between the ability to mount a seroconversion and the titre of 
pre-existing antibodies was explored. The neutralising titres used in these analyses 
were the mean responses to 4 test viruses i.e. the . A2, 8/60, Ken/A/2006 and 
Ken/B/2008. Acute stage neutralising titres were stratified into quartiles and the 
proportion of seroconversion in each quartile was calculated. There was a 90.2% 
seroconversion rate in the first quartile, a 59.6% seroconversion rate in the second 
quartile, a 13.5% seroconversion rate in the third quartile and no seroconversions 
(0%) in the fourth quartile (figure 5.9).
3O<
Acute Quartile 1 (1.4 - 2.1)
in
co
SC* rate = 90.2%
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Quartile 2 (2.2 - 2.3)
SC rate = 59.6%
Quartile 3 (2.4 - 2.5)
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SC rate = 13.5%
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m
- Seroconversion
Quartile 4 (2.6 - 2.9)
SC rate = 0%
Figure 5.9 Acute phase titres stratified into quartiles and the proportions 
seroconverting in each quartile determined. The open circles denote the acute phase 
response, while the open diamonds denote the convalescent phase response
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Spearman correlation analysis was used to test the strength of association between the 
magnitude of the neutralising response (in terms of fold rise in titre) and age on one 
hand and the titre of pre-existing antibody present in the acute phase sample on the 
other. The results of these analyses which are presented in figure 5.10, show that there 
was a strong and statistically significant negative association between pre-existing 
(acute stage) titres and the magnitude of the neutralising response (r=-75, pO.OOOl) 
and a moderate but statistically significant positive association between the magnitude 
of the neutralising response and the age (r=0.6, pO.OOOl).
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Figure 5.10 Relationship between the magnitude of the neutralising antibody response 
and (a) the acute phase titre and (b) age of infant. The y axes denote the magnitude of 
the change in neutralising antibody response expressed as logio fold rise in titre from the 
acute to convalescent phase of infect. The x axes in (a) and (b) denote the acute phase 
titres and age of the infant respectively. Spearman correlation coefficients (r) and 
corresponding p values are indicated on each panel.
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The relationship between neutralising antibodies and severe pneumonia
The relationship between the acute phase neutralising antibody titre and severity of 
RSV infection was explored by comparing the clinical outcome of disease and the 
neutralising titre at the acute stage of infection. The neutralising titres used in these 
analyses were the mean titres to 4 test viruses (A2, 8/60, Ken/A/2006 and 
Ken/B/2008). The acute sera of 106 infants for whom clinical pneumonia syndromic 
data were available were included in these analyses. Multivariate logistic regression 
analysis was used to estimate the relationship between acute phase neutralising 
antibodies and the following clinical features of WHO defined severe or very severe 
pneumonia: shock, flaring, indrawing, wheeze, hypoxia and crackles. A cutoff titre of 
logio 2.5 PRNT was selected in order to categorise acute stage titres in two classes: 
high and low level titres. The value of logio 2.5 PRNT was derived from a comparison 
of the frequency distributions of acute and convalescent phase antibodies since it 
appeared to be the point of separation between the two distributions (figure 5.4). The 
results of these analyses showed some evidence of protection by neutralising 
antibodies against shock (OR=0.3; p=0.016). Although not statistically significant, 
the odds ratios for flaring (OR=0.7; p=0.3), hypoxia (OR=0.7; p=0.6) and crackles 
(OR=0.8; p=0.6) were all below 1. There was no protective association between 
wheeze and indrawing and the acute stage neutralising response (figure 5.11).
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Figure 5.11 The Odds Ratios of developing various clinical features of severe 
pneumonia among infants with high (>=2.5 logio PRNT) and low (<2.5 logioPRNT) 
acute phase neutralising antibody titres. A statistically significant association between 
high titres of pre-existing neutralising antibodies and protection from shock was found 
in the analysis.
Analysis of the genetic relationship between infecting RSV A and B strains
The F and G genes of 60 infecting RSV A and B viruses were partially sequenced in 
order to infer the level of genetic and antigenic relatedness between them. The region 
between nucleotide 284 of the G gene and nucleotide 9 of the F gene was sequenced. 
In the case of the F gene, the region between nucleotides 121 and 918 of the F gene 
was sequenced. Nucleotide and deduced amino acid sequences from different 
infecting strains were manually aligned and each position within the alignment 
analysed for evidence of variation. There was 78.7% nucleotide sequence identity 
between the F genes of infecting RSV A and B and 87.6% amino acid identity
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between them. Infecting RSV A and B strains shared 45% nucleotide sequence 
identity at the G gene level and only 28.6% amino acid identity. These data are shown 
in table 5.3.
Protein/gene
% identity (RSV A and B)
Nucleotide Amino acid
F 78.7 87.6
G 45.2 28.6
Table 5.3 The genetic relatedness between infecting strains of RSV A and B at the level 
of the F and G gene.
Analysis of variation on putative neutralising epitopes on the deduced F 
protein amino acid sequences of infecting strains.
Amino acid sequences of four neutralising antibody epitopes on the F protein were 
obtained from the published literature (Trudel et al., 1987b, Lopez et a l, 1990, 
Martin-Gallardo et al., 1991, Bourgeois et a l, 1991) and mapped on the F protein 
amino acid alignments of infecting strains. Each amino acid position was then 
analysed for evidence of conservation between and within groups. Two of the four 
neutralising antibody epitopes that were identified were located in regions of the 
protein that contained amino acids that were conserved within but not between 
groups. The first of these occurred between amino acid 205 and 225 (Bourgeois et 
a l, 1991) where the glutamine (Q) residue at position 209 was perfectly conserved in 
all RSV B isolates sequenced but occurred as a perfectly conserved lysine (K) residue
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in all the RSV A patient isolates. The amino acid residue at position 213 within this 
epitope contained a serine (S) that was perfectly conserved in all RSV A isolates 
sequenced but that changed to isoleucine (R) in all RSV B isolates. Analysis of the 
neutralising antibody epitope that occurs between amino acids 221-236 (Trudel et 
al., 1987b) showed that the amino acid at position 228 within this epitope occurred as 
a conserved asparagine (N) in all RSV A isolates but changed to a Serine (S) in all 
sequenced RSV B isolates. The last two neutralising antibody epitopes that were 
analysed for evidence of group-specific variation occurred between amino acid 
residues 262-268 (Lopez et al., 1990) and 289-298 (Martin-Gallardo et al., 1991) and 
were found to be located on regions of the F protein that were perfectly conserved 
within and between the two groups. Figure 5.12 graphically shows the position of 
these epitopes within the deduced F protein amino acid sequence alignments of 
infecting strains.
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Analysis of variation on putative neutralising epitopes on the deduced G 
protein amino acid sequences of infecting strains.
Analysis of neutralising antibody epitopes on the deduced G protein amino acid 
sequences of infecting strains was then carried out. Two neutralising antibody 
epitopes on the G protein were identified in the published literature (Garcia-Barreno 
et a l, 1992, Murata et al., 2010) and highlighted on an alignment of deduced G 
protein amino acids of infecting strains. The first epitope was located between amino 
acids 151 and 172 of the G protein (Murata et a l, 2010) while the second was located 
between amino acids 201 and 213 (Garcia-Barreno et al., 1992) -  figure 5.13. Both 
epitopes were located on regions of the G protein that contained multiple group 
conserved amino acids as well as a smaller number of genotype-specific amino acids. 
The epitope located between amino acids 151-172 (Murata et al., 2010) contained 7 
amino acids that were conserved within but not between groups, meaning that 32% of 
the amino acid content on this epitope was group-specific. Notably, the terminal 9 
amino acids of this epitope’s 22 amino acids fell within the 13 amino acid motif that 
is perfectly conserved in all human RSV isolates (between amino acids 164 -176). At 
least one amino acid within this epitope was genotype-specific. The amino acid at 
position 160 contained an asparagine residue that was conserved in all the RSV A and 
RSV B isolates from the 2007/2008 epidemic (BA strains) but changed to a lysine in 
the RSV B isolates from the 2002/2003 epidemic (non-BA strains). Within the 
neutralising antibody epitope that fell between amino acids 201-213 (Garcia-Barreno 
et a l, 1992), 3 amino acids (23% of the total epitope amino acid content) were 
conserved within but not between groups. There was one genotype-specific amino 
acid within this epitope: the amino acid at position 207 contained a threonine residue 
that was conserved in all RSV A isolates and all RSV B isolates that did not contain
the 60 nucleotide duplication (non-BA) but which changed to either a leucine or 
proline in BA strains of RSV B. Figure 5.13 is a graphic depiction of the location of 
these epitopes on an alignment of deduced G protein amino acid sequences of 
infecting strains.
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Group-speciflcity of the neutralising antibody response
Neutralising antibody titres were classified as homologous if the group designation of 
the infecting strain matched that of the test strain and heterologous if the test and 
infecting strains were discordant at group level. Analyses of the group-specificity of 
the neutralising response were stratified by age to account for age specific differences 
in the infant response to RSV. Individuals were considered to have made significant 
responses to a specific virus strain if they made a four-fold or greater rise in the 
neutralising antibody response.
Sera from 32 RSV A infected individuals were assayed for neutralising antibody 
against both Kil/A/2006 and Kil/B/2006. Of these, the proportion that seroconverted 
to genotype Kil/A/2006 (50%) was significantly greater than the proportion that 
seroconverted to genotype Kil/B/2008 (12.5%; McNemar’s %2=12; p=0.0005).
Similarly sera from 25 RSV B infected individuals were assayed for neutralising 
antibody against Kil/A/2006 and Kil/B/2006 and of these the proportion who 
seroconverted to genotype Kil/B/2008 (40%) was significantly greater than the 
proportion who seroconverted to genotype Kil/A/2006 (8%; McNemar’s %2=8,
p=0.008).
Of 18 RSV A infected individuals whose sera were tested for neutralising antibody 
against prototype viruses A2 and 8/60, the proportion of individuals who 
seroconverted to the A2 genotype (28%) was greater than the proportion who 
seroconverted to the 8/60 (0%) genotype. This difference was found to be borderline 
significant (McNemar’s %2=5, p=0.06). Among 20 RSV B infected individuals
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whose sera was assayed for neutralising antibody against both the A2 and 8/60 strains, 
there was a statistically significant difference between the proportion that 
seroconverted to genotype 8/60 (65%) and the proportion that seroconverted to the 
A2 strain (10%; McNemar’sx2=l 1, p=0.001).
Comparison of the homologous and heterologous neutralising antibody responses in 
different age classes was also done by analysing the differences between homologous 
and heterologous fold rises in titre. The test viruses in these analyses were local RSV 
A and B strains Ken/A/2005 and Ken/B/2008. In each age class the fold rise in titre to 
both homologous and heterologous virus was calculated by dividing the convalescent 
phase titre with the acute phase titre and the resulting figures normalised using a log 
10 transformation. Multiple regression analysis was used to compare homologous and 
heterologous rises in titre to both RSV A and B. The homologous response to RSV A 
by RSV A infected individuals was significantly greater than their heterologous 
response to RSV B in (a) the 0-5 month age class (1.8 fold rise in titre vs. 0.5 fold 
rise in titre; p<0.0001), (b) the 6-11 month age class (11.2 vs. 3.8; p=0.002) and (c) 
the 12+ month age class (7.1 vs. 2.2; p=0.001). Similarly the homologous response to 
RSV B by RSV B infected individuals was significantly greater than their 
heterologous response to RSV A in (a) the 0-5 month age class (2.7 vs. 0.7; 
p<0.0001), (b) the 6-11 month age class (5.9 vs. 1.7; p<0.0001) and (c) the 12+ 
month age class (4.3 vs. 0.9; p<0.0001). These data are graphically depicted in figure 
5.14.
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Figure 5.14 Group-specific neutralising antibody responses to RSV infection. Acute and 
convalescent neutralising antibody responses to homologous and heterologous virus 
were compared among 118 infants with natural RSV infection. The first letter in each 
panel heading denotes the group designation of the infecting virus while the second 
letter denotes the group designation of the test virus. The light grey bars indicate the 
distribution of the acute phase response while the dark grey bars denote the distribution 
of convalescent responses. The lines in the middle of the boxes represent median titres 
while the lower and upper bounds of the boxes represent the 25th and 75th percentiles 
respectively. The upper and lower whiskers represent values that are up to 1.5 times 
below and above the 25th and 75th percentile respectively. The dots represent outliers 
which are values that fall outside the bounds defined by both the upper and lower 
whiskers. The x axis represents the age classes that were analysed while the y axis 
represents the neutralising antibody titre (PRNT). The number above each 
acute/convalescent pair denotes the mean fold rise in titre from the acute to convalescent 
phases of infection. Comparison of the magnitude of response (in terms of fold rise in 
titre) to homologous virus and heterologous virus is shown by the long bars traversing 
the panels. The p value denotes whether the difference between the homologous and 
heterologous response in a particular age class is statistically significant.
108
To account for the possible confounding of primary responses by prior undetected 
infections, a 69 infants born during an inter-epidemic period and who experienced 
what was assumed to be their first infection in the epidemic immediately following 
their births was selected. The odds ratio of seroconverting to both homologous and 
heterologous virus between this group and everyone else in the study was carried out 
using multiple logistic regression analysis. The results of this analysis showed that 
there was no difference in the ability of infants within the two groups to seroconvert 
to homologous or heterologous virus (Odds Ratio 1.8, p=0.4). Comparison by 
multiple linear regression analysis of the neutralising response of individuals who 
were bom prior to the start of an epidemic and those bom within an epidemic showed 
that there was no difference in their responses to homologous or heterologous virus. 
The mean homologous response to RSV A was no different between individuals bom 
prior to the start of an epidemic and those born during the epidemic (4-fold rise in 
titre vs. 3.1 fold rise in titre; p=0.4) nor was there a difference in their heterologous 
response to RSV B (1.1 vs. 0.7; p=0.3). Similarly, the homologous RSV B response 
by individuals bom prior to an epidemic was no different from the response of 
individuals born in the course of an epidemic (4.2 vs. 3.7; p=0.4). There was 
similarly no difference in their heterologous response to RSV A (1.2 vs. 0.8; p= 0.3). 
These data are presented graphically in figure 5.15.
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Figure 5.15 Comparison of neutralising homologous and heterologous neutralising 
responses among infants born at different times. The first letter in each panel heading 
denotes the group designation of the infecting virus while the second letter denotes the 
group designation of the test virus. The y axis shows the neutralising antibody titre 
(PRNT) while the x axis denotes the time of birth relative to the epidemic in which the 
infection occurred. The number above each acute/convalescent pair denotes the fold rise 
in titre. The p values denote whether the mean fold rise in titre to homologous or 
heterologous virus, varies by time of birth.
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Figure 8.1 The total number of respiratory pathogens identified in the household study 
samples (n=100) analysed in this chapter.
Association between cytokine/chemokine concentration/viral load and URTI in 
infants
The effect of viral load (recorded as the reciprocal of cycle threshold multiplied by 
10) on illness among infants infected with RSV was evaluated by comparing mean 
RSV viral load in samples collected in the presence of Upper Respiratory Tract 
Infection (URTI) to viral loads in samples collected in its absence. Samples collected 
in the presence of URTI had significantly greater viral titres compared to samples 
collected in the absence of URTI. Figure 8.2 shows the distribution of viral loads 
among these two groups.
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Figure 8.2 The relationship between RSV viral load and the presence (n=23) or absence 
(n=10) of URTI in infants who an RSV infection
The contribution of different cytokines/chemokines in the development of URTI 
among infants irrespective of the infecting pathogen was assessed by comparing 
cytokine/chemokine concentrations in nasal samples collected in the presence of 
URTI to concentrations in nasal samples collected in the absence of URTI. 58% 
(n=58) of the nasal samples collected in this study were collected during an URTI 
episode. Nasal secretions collected during URTI episodes had significantly greater 
concentrations of IL-lp, IL-6, IL-8, TNF-a, MCP-4, MDC, MIP-1 p, IFN-y and IL-10 
relative to those collected in the absence of URTI. These data are shown in figure 8.3.
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Figure 8.3 The distribution of different cytokines/chemokines in samples obtained from 
infants in whom symptoms of URTI were present (urti; n=58) or absent (no urti; n=42). 
Geometric mean concentrations and 95% confidence intervals are also indicated
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Comparison of cytokine/chemokine responses in RSV positive and rhinovirus 
positive samples
Samples found to be positive for either RSV or rhinovirus and negative for all other 
respiratory pathogens were compared for evidence of differential cytokine/chemokine 
production. Out of 100 samples tested for 16 respiratory pathogens, RSV was present 
as the only respiratory pathogen detected in 29 samples (out of a total of 33 RSV 
positive samples) while rhinovirus was exclusively detected in 21 samples (out of 21 
rhinovirus positive samples). The total number of RSV and rhinovirus positive 
samples, irrespective of co-infection status is presented in table 8.1.
Rhinovirus
RSV present
present No Yes Total
No 46 21 67
Yes 33 0 33
Total 79 21 100
Table 8.1 Distribution of samples in the household study which were found to be 
positive for RSV, rhinovirus, both viruses or none of the viruses
A comparison of cytokine/chemokine concentrations in nasal secretions in which 
either RSV or rhinovirus was detected as the only respiratory virus is presented in 
figure 8.4. In general the levels of most cytokines/chemokines were higher in the 
presence of rhinovirus relative to RSV. The mean concentrations of IL-1(3, IL-8, TNF- 
a , MDC and MIP-1 p were significantly greater in the presence of rhinovirus 
compared to RSV. In contrast, the mean concentration of IL-17 was greater in the 
presence of RSV relative to rhinovirus, although this difference was just below 
statistical significance (p=0.06). The mean concentrations of IL-6, MCP-4, IFN-y and 
IL-10 were no different in the presence of either RSV or rhinovirus.
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Figure 8.4 Comparison of geometric mean (with 95% Cl) cytokine/chemokine 
concentrations in samples that were positive exclusively either for RSV (n=29) or 
rhinovirus (n=21)
Association between RSV Viral Load and cytokine/chemokine response
The association between RSV viral load and cytokine/chemokine concentration was 
measured using Spearman correlation analysis. In this study, an indirect measure of 
viral load was used. The reciprocal of the diagnostic real-time PCR cycle threshold 
value was presumed to be a good correlate of viral load. This value was multiplied by 
10 to enable more convenient graphical presentation. Figure 8.5 shows the spearman 
correlation coefficients that describe the strength of association between viral load and 
cytokine/chemokine concentration. There was a moderate (r=0.5) and statistically 
significant positive association between the concentration of IL-6 and RSV titre. A
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positive and statistically significant relationship between virus titre and 
cytokine/chemokine concentration was also found for IFN-y (r=0.6, p=0.0004) and 
IL-10 (r=0.4, p=0.01). There Was no statistically significant association between any 
of the remaining cytokines/chemokines and viral titre. These data are shown in figure 
8.5.
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Kinetics of cytokine/chemokine responses following natural infection in infants
Kinetics of the pro-inflammatory cytokine/chemokine response
The kinetics of the pro-inflammatory cytokine/chemokine response following natural 
infection were evaluated by relating temporal variations in the RSV viral load to rises 
in the concentrations of pro-inflammatory cytokines/chemokines IL-6, TNF-a and 
ILl-p. The presence or absence of URTI symptoms was also related to 
cytokine/chemokine and viral load kinetics. For comparison the kinetics of rhinovirus 
viral load were included in the analysis. Figure 8.6 shows the temporal relationships 
between cytokine/chemokine responses, viral load and illness over the surveillance 
period. In general the pro-inflammatory cytokine response appeared to be closely 
related to the titre of both RSV and rhinovirus in infant nasal secretions. The 
relationship between RSV titre and the pro-inflammatory cytokine/chemokine 
response was most clearly evident in instances where RSV infection did not coincide 
with other co-infections or pre-existing URTI symptoms suggestive of an ongoing, 
but undetected infection. An example of this correlation can be seen in the case of 
infant 10182 who experienced 2 RSV infections between 25/02/2010-08/03/2010 and 
on 18/03/2010. In the first episode, the rise in RSV viral load coincided with an 
increase in the concentration of IL-6, TNF-a and IL-lpand correspondingly, the 
subsequent decline in viral titre was associated with a drop in concentration of these 
mediators. Peak RSV viral load in this initial episode was also associated with 
presence of URTI. In the second episode of infection, in which virus was shed for 
only one day there was no noticeable increase in the concentrations of these 
mediators. Towards the end of the surveillance period, there was a sharp rise in the
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concentrations of these cytokines/chemokines that appeared to correspond with an 
increase in rhinovirus viral load.
In total, a good association between RSV viral load and the pro-inflammatory 
response was observed in 6 of the 7 infants analysed (i.e. infants 10239, 10114, 
10182, 10016 10243 and 10157). On the other hand, the relationship between these 
variables and disease (i.e. presence or absence of URTI) was less clearly defined. 
Rises in both pro-inflammatory cytokine/chemokine levels and RSV viral load clearly 
coincided with development of URTI in only 2 of the seven infants in this study 
(10114 and 10182). In the case of infants 10239, 10016, and 10243, although peak 
viral load and pro-inflammatory cytokine/chemokine levels were associated with 
presence of URTI, serial episodes of URTI were observed prior to and after RSV 
infection, confounding interpretation of the significance of RSV alone in development 
of symptoms. In the case of infant 10157, although peak cytokine/chemokine response 
and RSV viral load were related to the development of URTI, a simultaneous 
adenovirus infection was detected in the sample collected on the day in which URTI 
symptoms were observed. Figure 8.6 shows the relationship between 
cytokine/chemokine kinetics, viral load and disease.
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Figure 8.6 The kinetics of pro-inflammatory cytokines/chemokines in serially collected 
nasal secretions
Kinetics of the chemokine response
The kinetics of the chemokine response (i.e. MCP-4, IL-8, M IP-lp and MDC) 
appeared to be closely related with RSV/rhinovirus viral load dynamics in some 
infants and but not in others. For example for infant 10157, the concentrations of 
these chemokines appeared to initially decline with decreasing titres of rhinovirus at 
the beginning of the surveillance period and subsequently rose in correspondence with 
an increase with RSV viral load. This infant shed RSV between 03/03/2010 and 
14/03/2010 and also had a concurrent adenovirus infection that was only detected in 
the sample collected on 07/03/2010. The dynamics of the IL-8, MDC, MCP-4 and 
MIP-1 p responses for this infant appeared to be closely related with variations in RSV
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titre since cytokine/chemokine concentrations initially rose with increasing RSV viral 
load and subsequently declined with decreasing virus titre. The presence of URTI was 
observed on 07/03/2010 while peak RSV viral load occurred on 10/03/2010. After 
viral clearance, a rise in the levels of IL-8, MDC and MIP-1|3 was detected in the 
sample collected on 24/03/10 despite the absence of detectable infection at this time. 
This rise was nonetheless associated with the presence of URTI, indicating possible 
presence of a viral or bacterial infection that remained undetected. In certain 
instances, the dynamics of the chemokine response could not be related to viral load. 
For instance for infant 10243, whilst the initial rise in RSV viral load was associated 
with a rise in the level of MIP-lp, the kinetics of the RSV viral load did not appear 
to correlate with variations in the concentrations of IL-8, MDC and MCP-4. Over the 
surveillance period highlighted in this study, this particular child had multiple 
Coronavirus oc43 (4/3/2010, 8/3/2010 and 11/3/2010) and nl63 (18/03/2010 and 
26/03/2010) co-infections and was also found to have URTI during 10 of 12 
surveillance visits, raising the possibility that an inherent susceptibility to infection 
might have been present in this infant. Unfortunately neither HIV nor atopic status 
data were available and therefore overall individual immune status could not be 
assessed in this study. The dynamics of the chemokine response for the remaining 
infants fell broadly within these two categories and are shown in figure 8.7.
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Figure 8.7 The kinetics of different chemokines in serially collected nasal secretions
Kinetics of the IFN-y and IL-10 response
In order to assess the balance between pro-inflammatory and regulatory responses at 
the initial stages of the host antiviral response, the kinetics of the IFN-y response to 
infection were compared to those of the IL-10 response. For most infants in this study, 
there was strong evidence of co-ordinated production of IFN-y and IL-10 following 
natural infection. The data presented in figure 8.8 highlight the kinetics of these two 
cytokines in the nasal secretions of infants in this study. For most infants peak levels 
of these cytokines coincided with peak viral load or occurred shortly afterwards. This 
strong relationship between peak viral titre and peak IFN-y/IL-10 response was seen
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in the initial RSV infections of 5 of the 7 infants in this study: 10239, 10114, 10182, 
10243 and 10157. In the case of infant 10338 who had two distinct RSV infections, 
this relationship was seen during the second infection. Two of the 7 infants in this 
study (10239 and 10157) had increases in IFN-y/IL-10 levels in the absence of 
detectable infection, raising the possibility that they had been infected with respiratory 
pathogens that were not part of the panel that was detected. Of the 5 infants for whom 
peak RSV viral load correlated with peak IFN-y and IL-10 concentrations, the 
concentrations of IL-10 were greater than those of IFN-y for 4 of these infants 
(10114, 10182, 10243 and 10157). However, for infant 10243 who appeared to have 
acquired a re-infection shortly after the initial infection the pattern of the IL-10/IFN-y 
response was reversed in the second infection. For two of the seven infants, some 
RSV infection events could not be clearly related to strong IFN-y/IL-10 responses. 
The first infection experienced by infant 10338 (between 26/02/2010 and 
04/03/2010) was not associated with clear increases in the levels of either IL-10 or 
IFN-y. However, the second infection (between 22/04/2010 and 26/04/2010) 
appeared to induce increases in the levels of both cytokines. In the case of infant 
10016, the initial rise in RSV titre (between 18/02/2010 and 22/02/2010) was 
associated with a modest increase in the level of IL-10, but no increase in the level of 
IFN-y. The second peak, which was only detected on 04/03/2010 was not associated 
with a clear rise in the concentration of either cytokine. Figure 8.8 shows the 
dynamics of IFN-y and IL-10 responses in the samples of the seven infants in this 
study.
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Figure 8.8 The kinetics of IFN-y and IL-10 in serially collected nasal secretions
Kinetics of T cell associated mediators
Cytokines associated with T lymphocytes (IL-2, IL-4, IL-5, IL-12p70 and IL-13) 
were generally not detectable throughout natural RSV infection. As is evident from 
figure 8.9, except for the second RSV peak in infant 10243, no other infant produced 
high levels of these cytokines. For infant 10243, the rise in T cell associated cytokines 
in the sample collected on 26/03/2010, coincided with both an RSV and coronavirus 
nl63 infection.
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Figure 8.9 The kinetics of T cell cytokines/chemokines in serially collected nasal 
secretions
Summary of cytokine/chemokine responses in the household study
Summary cytokine/chemokine profiles were generated using mean 
cytokine/chemokine concentrations at different time points pre- and post-infection. 
Infants from whom RSV negative samples were collected approximately 3 days prior 
to the collection date of an RSV positive sample were considered to have acquired 
infection between 0-3 days after collection of the RSV negative samples. Similarly, 
infants from whom RSV positive samples were collected approximately 3 days after 
collection of RSV negative samples, were considered to have acquired infection 
between 0-3 days prior to the collection of the RSV positive samples. The mean 
cytokine/chemokine concentrations were measured at 6 time points; 0-3 days pre-
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infection, 0-3, 4-7, 8-11, 12-15 and 16-19 days post infection. Mean viral load as well 
as the proportion of infants who had URTI at these time points were calculated and 
plotted relative to cytokine/chemokine concentrations as shown in figure 8.10. 
Induction and maintenance of cytokine/chemokine responses following natural 
infection was assessed by comparing the mean cytokine/chemokine concentrations at 
different time points post infection, to the mean cytokine/chemokine concentrations at 
between 0-3 days pre-infection. There was a statistically significant increase in the 
concentration of IL-6 at between 0-3 days post infection (p=0.04) as well as between 
4-7 days post infection (p=0.003) relative to the pre-infection control. The mean 
concentration of IL-6 at between 8-11 days post infection, was no different from the 
mean pre-infection control concentration (p=0.1). The proportion of infants who had 
URTI at between 0-3 days pre-infection was 40%, while the proportion of URTI at 0- 
3, 4-7, 8-11, 12-15 and 16-19 days post infection was 60%, 70%, 71% and 86%, 
respectively. The mean concentration of IL -lpa t between 0-3 days post infection, 
was similar to the mean pre-infection control concentration (p=0.4), but was 
significantly raised at between 4-7 days post infection (p=0.047). There was no 
significant difference between the mean concentration of IL-lp at between 8-11 days 
post infection and the mean pre-infection control concentration (p=0.5). In the case of 
all other mediators, there was no statistically significant difference between mean 
cytokine/chemokine concentration in the pre-infection control and mean 
cytokine/chemokine concentrations at between 0-3, 4-7 and 8-11 days post infection. 
Figure 8.10 is a summary of these data.
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Figure 8.10 Comparison of mean cytokine/chemokine concentrations at different 
time points pre- and post-infection
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Mediator responses in nasal secretions of infants admitted with RSV  
associated severe/ very severe pneumonia.
RSV group-specific cytokine/chemokine responses
In order to determine whether virus-specific factors contribute to variations in the 
cytokine/chemokine response, the levels of different cytokines/chemokines in infants 
infected with RSV A or B and who had been admitted with severe RSV-associated 
pneumonia were compared. There were no statistically significant differences in the 
levels of IL-ip, IL-6, IL-8, TNF-a, MDC, MIP-lp, IFN-y, IL-10 and IL-17 in nasal 
samples obtained from RSV A or RSV B infected infants. However, there was a 
statistically significant difference between the levels of MCP-4 in the nasal secretions 
of RSV A and RSV B infected infants (p=0.005) with RSV A being associated with 
higher concentrations of this cytokine/chemokine relative to RSV B. These data are 
graphically shown in figure 8.11.
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Figure 8.11 Comparison of mean cytokine/chemokine concentrations in nasal secretions 
from which RSV A (n=42)orRSVB (n=44) was isolated
Association between cytokine/chemokine responses and severe or very severe 
pneumonia
The role of different cytokines/chemokines in modifying the clinical phenotype of 
RSV associated severe pneumonia was explored by comparing cytokine/chemokine 
concentrations between infants admitted with WHO defined severe (n=49) or very 
severe (n=29) pneumonia. Only 8 infants had mild pneumonia and were not included 
in the analysis. The levels of IL-1(3, IL-6, IL-8, IL-8, TNF-a, MCP-4, MDC, MIP-1 p,
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IFN-y, IL-10, and IL-17 did not vary irrespective of the clinical phenotype of disease. 
These data are graphically presented in figure 8.12.
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Figure 8.12 Comparison of mean cytokine/chemokine concentrations in nasal secretions 
obtained from infants admitted with severe (n=49) or very severe (n=29) pneumonia
Discussion
This study investigated the natural history of the cytokine/chemokine response over 
the course of natural RSV infection in infants. Analysis of cytokine/chemokine 
responses in the presence of RSV or rhinovirus infection showed that in general,
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rhinovirus infection was associated with higher concentrations of a number of 
cytokines/chemokines relative to RSV. The levels of IL-lp, TNF-a, IL-8, MIP-lp 
and MDC were all significantly higher in the presence of rhinovirus infection. One 
possible reason for the discrepancy between RSV and rhinovirus specific 
cytokine/chemokine responses may be differential abilities to antagonise the host 
antiviral response. RSV has evolved mechanisms such as interferon antagonism by 
non-structural proteins NS1 and NS2 (Schlender et al., 2000, Lo et al., 2005), that are 
thought to subvert the host antiviral response and consequently delay viral clearance. 
Comparison of cytokine/chemokine concentrations produced following natural 
influenza and RSV infection shows that RSV infection generally induces significantly 
lower cytokine/chemokine concentrations relative to influenza (Welliver et al., 
2007). The fact that both rhinovirus and influenza infection (both associated with 
reduced clinical pathology in infants relative to RSV) generally induce 
cytokine/chemokine responses at higher levels relative to RSV, suggests that 
antagonism of cytokine/chemokine responses may be a mechanism that is related to 
development of severe RSV disease in infants. Recent work has shown that this 
interferon antagonism has profound downstream effects on multiple host immune 
functions such as the suppression of dendritic cell maturation (Munir et al., 2008) and 
decreased activation of T cells (Munir et al., 2011). It is possible that the observed 
results could be explained by the ability of RSV to antagonise host 
cytokine/chemokine responses, with the ultimate goal of prolonging viral replication.
The role of viral load in driving RSV pathogenesis has been the subject of many 
controversial studies. While some investigators have found that viral titres at the acute 
stage of illness are significantly associated with disease severity (DeVincenzo et al.,
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2005), others have failed to find such an association (Wright et al., 2002). In many 
studies, this association is often evaluated at the time of clinical presentation, which 
often coincides with the peak of illness, meaning that variations in viral titre prior to 
development of symptoms cannot be accounted for. In this study, samples were 
collected shortly before infection, during infection and shortly afterwards, thus 
allowing for the estimation of viral loads over the entire course of infection. Samples 
collected in the presence of URTI in this study, had significantly greater RSV viral 
titres relative to samples collected in the absence of URTI. These results are in 
agreement with observations in adult challenge studies, which have reported that viral 
load over the entire course of illness correlates with clinical symptoms (DeVincenzo 
et al., 2010). These data therefore provide some evidence to suggest that mild RSV 
infection in infants may be driven by viral load. Evaluation of the association between 
viral load and different cytokine/chemokine concentrations showed evidence of a 
positive association between some cytokines/chemokines and viral titre.
Analysis of the kinetics of different cytokine/chemokine responses in the course of 
natural RSV infection showed that temporal rises in viral load generally corresponded 
with rises in the levels of certain mediators. The kinetics of the pro-inflammatory 
response in particular appeared to correlate strongly with virus titre over the course of 
infection. Peak viral load was in some instances associated with peak concentrations 
of IL-6, TNF-a and IL-ip as well as presence of URTI. In infants where there was a 
clear association between virus titre, pro-inflammatory cytokine/chemokine 
concentration and illness, it can be speculated that illness resulted from both virus 
mediated necrotic damage of the respiratory epithelia as well as by an increase in the 
level of pro-inflammatory mediators. This association between rises in the pro-
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inflammatory response and illness accords with previous work that has shown that the 
peripheral production of IL-lp, IL-6 and TNF-a, is linked to activation of 
neurological pathways that induce physiological changes such as fever and fatigue 
(Watkins et a l, 1995), that are sometimes associated with URTI. For some infants 
however, although peak cytokine/chemokine levels and peak viral titres coincided 
with development of URTI, clinical symptoms could not be reliably attributed to RSV 
infection. For instance in some infants, URTI symptoms were recorded over extended 
periods that spanned duration of RSV infection, reducing the likelihood that those 
symptoms occurred exclusively as a result of RSV infection. In some infants, peak 
viral load and cytokine/chemokine levels occurred in the presence of co-infection 
with different respiratory pathogens, and therefore confounding the ability to 
associate symptoms to RSV infection alone.
An interesting association was observed in the kinetic profiles of IFN-y and IL-10. 
The dynamics of these cytokines/chemokines appeared to track closely with viral 
load, despite their clearly antagonistic roles in the host immune response. IFN-y is a 
pro-inflammatory Thl cytokine that has been associated with direct antiviral activity, 
stimulation of antigen presentation through induction of MHC expression and 
induction of NK and T cell Cytotoxic activity (Boehm et a l, 1997). In the mouse 
model, RSV infection is dominated by NK cell IFN-y production, suggesting that this 
is a key feature of RSV infection in vivo (Hussell and Openshaw, 1998, Spender et 
a l, 1998). On the other hand, IL-10 is a potent regulatory molecule, with broad anti­
inflammatory properties and plays a role in the regulation of NK cells, T cells and B 
cells (Moore et a l, 2001). Studies in the murine model of RSV have shown that 
levels of both IFN-y and IL-10 peak at day 5 post primary infection (Sun et a l, 2011)
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and that abrogation of IL-10 signalling in this model leads to a substantial increase in 
disease, manifested as weigh loss (Sun et al., 2011, Loebbermann et a l, 2012). The 
results presented in this chapter are therefore generally consistent with observations in 
the murine model of co-ordinated IL-10/IFN-y production at the acute stage of 
infection. These data provide grounds to suggest that the production of IL-10 in 
concert with IFN-y, similarly acts to moderate the effects of host inflammatory 
responses and thereby limit immune mediated pathology in infants.
An attempt to construct a generic model describing the kinetics of different 
cytokines/chemokines following natural infection was undertaken by comparing the 
mean concentrations of different cytokines/chemokines at different time points pre- 
and post-infection. Mean pre-infection cytokine/chemokine concentrations were 
compared to cytokine/chemokine concentrations at different time points post infection 
in order to determine whether natural infection leads to a significant upregulation of 
certain cytokines/chemokines and also to determine the mean duration of these 
upregulated responses. In these analyses, only IL-6 and IL-lp were found to be 
significantly upregulated after infection. The increase in these cytokine/chemokine 
levels shortly after infection corresponded with an increase in the mean RSV viral 
load and also corresponded initially with an increase in the proportion of infants who 
developed URTI. However, later on in the infection, when both viral load and mean 
IL-6 and ILl-p concentrations were on the decline, the proportion of infants with 
URTI increased. This suggests that the initial rise in the concentration of these 
cytokines/chemokines was insufficient to account for the increase symptoms at the 
initial stages of infection. Unexpectedly, these analyses did not show statistically 
significant increases in any other cytokine/chemokine following infection. It is likely
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that this lack of difference is an analytical artefact arising from the combination of 
responses from different infants with varying baseline cytokine/chemokine levels.
The effect of virus specific factors on the cytokine/chemokine response to RSV was 
evaluated by comparing cytokine/chemokine concentrations in the nasal secretions of 
infants infected with RSV A to those of infants infected with RSV B. With the 
exception of MCP-4, there was no significant difference between the 
cytokine/chemokine concentrations produced during RSV A or RSV B infection. The 
mechanism through which MCP-4 levels were significantly upregulated in the 
presence of RSV A relative to RSV B was not explored in this study. Despite this 
differential MCP-4 response, it can be concluded that in general, the two antigenic 
groups of RSV do not appear to induce broadly variable cytokine/chemokine 
responses. It has been shown in a previous study that severity of disease as well as 
viral load does not vary between the two RSV groups (Devincenzo, 2004). The 
results presented in this chapter suggest that the lack of difference in disease severity 
following infection with RSV A or B could be related to the failure to induce 
differential cytokine/chemokine responses.
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Chapter 9 - Overall Discussion
Summary of key findings
The work presented in this thesis had the primary aim of describing the role of RSV 
antigenic variation on the infant serum neutralising response following natural RSV 
infection. Two secondary goals for this work were to describe the kinetics of the 
serum neutralising response in infants and to investigate cytokine/chemokine 
responses in nasal samples obtained from infants with acute RSV infection. The work 
described in this thesis is the first to comprehensively characterise the group- 
specificity of the RSV neutralising response in the sera of RSV A infected and RSV B 
infected infants. A number of studies have previously been undertaken to describe the 
group-specificity of the infant neutralising response. These studies failed to 
demonstrate significantly greater homologous responses to both RSV A and B, 
relative to the respective heterologous responses. For example, Hendry et al. (Hendry 
et al., 1988) and Muelenaer et al. (Muelenaer et al., 1991) both sought to describe the 
group-specificity of the infant serum neutralising response to RSV. However both 
studies were only able to demonstrate a significantly greater homologous response to 
RSV B, but failed to show the same relationship in regard to RSV A. On the other 
hand Roca et a l (Roca et al., 2003) showed that infants naturally infected with RSV 
A generated significantly greater homologous responses against RSV A test strains 
relative to an RSV B test strain. In addition to the above studies, seminal cross­
neutralisation studies carried out in the 1960s failed to demonstrate significant group- 
specificity to the infant serum neutralising response to both RSV A and B (Coates et 
al., 1963, Wulff et al., 1964).
220
The work presented in this thesis is the first to show that the RSV neutralising 
response to both RSV A and B is significantly group-specific. The work presented 
further shows that despite 40-50 years of genetic evolution, there was no difference in 
neutralisation of contemporary and historical strains of both RSV A and B by 
antibodies generated following natural infection with contemporary virus strains. 
Further, sera from infants infected with previous strains of RSV neutralised the novel 
BA variant as effectively as a representative RSV B strain that did not contain the BA 
duplication.
The duration of the serum neutralising response after primary infection in infants has 
not been reported. The total serum IgA, IgM and IgG responses to primary infection 
measured by enzyme immunoassay have been reported to decline to pre-infection 
levels within one year of infection (Welliver et al., 1980), while the secretory IgA, 
IgM and IgG responses in infant nasal secretions appear to decline to pre-infection 
levels by 3 months post infection (Kaul et al., 1981). The temporal dynamics of the 
neutralising antibody response following primary infection have so far not been 
reported. The data presented in this thesis show that the infant neutralising response to 
natural infection is short-lived. Neutralising antibody titres declined to pre-infection 
levels with 3-4 months post primary infection. Mean neutralising antibody titres in a 
birth cohort showed mean population level neutralising titres were elevated during 
epidemics and declined rapidly with a decline in transmission.
Evaluation of cytokine/chemokine responses in nasal samples obtained from infants 
with acute RSV infection revealed a complex relationship between the kinetics of
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cytokine/chemokine concentrations on the one hand and both viral load and disease 
on the other. There appeared to be some correlation between viral load and the pro- 
inflammatory response and to a lesser extent the chemokine response. The data 
showed some evidence of co-ordinated IFN-y/IL-10 responses in the nasal secretions 
collected successively from RSV infected infants. In general, there was little evidence 
of T cell specific responses in the acute stage of mild RSV illness, since, T cell 
associated cytokines were either undetected or were detected in minimal amounts in 
infant nasal secretions.
Significance of the findings 
Group-specific neutralising antibody immunity
The results presented in this thesis will contribute significantly to the understanding of 
the transmission dynamics of RSV. In this thesis it was hypothesised that the 
alternating transmission of RSV A and B is driven by alternation in population level 
group-specific immunity. The data presented strongly suggest that transient group- 
specific neutralising antibody immunity at the population level sets the stage for 
preferential selection for transmission of one group relative to the alternative group. It 
is likely that following transmission of strains from one group in a particular 
epidemic, there is a build-up of group-specific neutralising antibody immunity to that 
group reducing the likelihood of its transmission in the next epidemic. On the other 
hand as a result of a decline in population level neutralising antibody immunity to the 
alternative group, there would be a greater likelihood of its transmission in the 
subsequent epidemic. On the basis of cross neutralisation estimates reported in this 
thesis the observed alternate transmission patterns of the two groups of RSV in Kilifi 
Kenya, Turku Finland and in England & Wales have been reproduced in a
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mathematical model (White L. Sande CJ et al. in preparation). Figure 9.1 is a 
representation of the model fit, showing that alternating dominance patterns in the 
different locations can be accounted for by the group-specific immunity estimates 
obtained in this study. The results presented suggest that vaccines based on only one 
of the two antigenic groups may provide insufficient coverage against infection with 
strains from the alternative group. For example, vaccination with a live attenuated 
vaccine based on an A2 background, may be only partially protective against wild- 
type group B strains. The implication of this partial protection on population level 
transmission of RSV may be the continued transmission of strains from the alternative 
group against a decline in transmission of the vaccine group. This could result in a 
reduction in the expected indirect protective effect of the vaccine for the vulnerable 
naive early infant. To maximize the likelihood of reduced transmission of all RSV 
strains, it would be beneficial to include representative strains from both RSV A and 
B in future vaccines.
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Duration of neutralising antibody immunity
The estimates of the duration of neutralising antibody immunity following natural 
exposure reported in this thesis provide grounds to suggest that the ability of RSV to 
repeatedly infect is related to short-lived serum neutralising antibodies. The estimates 
reported further provide the basis upon which an attempt to predict the potential 
success of future RSV vaccines in reducing the burden of RSV transmission can be 
undertaken. Many of the viral infections of infancy against which successful vaccines 
have been developed induce long lived neutralising antibody immunity upon natural 
infection. On the basis of long-lived protective neutralising antibodies induced by 
natural infection, it can be argued that the success of vaccination in reducing the 
transmission burden of these viral infections could have been predicted, assuming that 
the kinetics of vaccine induced immunity were no different from those of natural 
infection. For example the introduction of the inactivated polio vaccine in the United 
States in the mid 1950s and subsequently the oral polio vaccine in the 1960s resulted 
in a significant and sustained reduction in morbidity and mortality attributed to 
poliomyelitis (Strebel et ah, 1992). Studies done in the late 1940s prior to the 
introduction of vaccination, demonstrated that natural infection with poliovirus 
induced neutralising antibody responses that were maintained at protective levels for 
several decades in the absence of natural re-exposure (Paul and Riordan, 1950). It can 
therefore be reasonably argued that the success of the poliovirus vaccines could have 
been anticipated on the basis of the longevity of neutralising antibodies induced by 
natural infection. Analysis of the duration of acquired neutralising antibodies to RSV 
show that these antibodies decline to pre-infection levels shortly after natural 
infection. Further, analysis of mean population level neutralising antibodies in the 
birth cohort, showed that in the absence of population level virus transmission, mean
population level neutralising titres decline rapidly. These data suggest if future RSV 
vaccines mediate protection through induction of neutralising antibodies (whose 
longevity is no different from that produced by natural infection), then it can be 
assumed that such vaccines are likely to yield only modest reductions in population 
level virus transmission, since susceptibility to re-infection would be re-established 
shortly after vaccination. Despite this, such vaccines could still result in significant 
clinical protection as a result of the priming of immunological memory thereby 
reducing the potential of subsequent natural challenge resulting in severe illness. 
These conclusions are based on the assumption that neutralising antibodies are the key 
correlate of functional immunity. Previous work has shown that protection in animal 
models can be mediated by antibodies that do not induce in-vitro neutralisation of the 
virus (Plotnicky-Gilquin et al., 1999, Mekseepralard et al., 2006). It is important to 
note that in the event that antibodies with similar mechanisms of protection play a 
significant role in human infection, the interpretation of the data presented may be 
altered by the dynamics of such responses.
The relationship between genetic and antigenic variation of RSV
Genetic studies have produced strong evidence that the attachment protein gene 
undergoes progressive genetic change with time (Cane and Pringle, 1995, Zlateva et 
al., 2005, Zlateva et al., 2004). Some studies have shown compelling evidence that 
suggests that immune selection may underlie the observed changes (Woelk and 
Holmes, 2001). There has, however, been a lack of data demonstrating the antigenic 
consequences of these genetic changes, and in particular their effect in mediating the 
loss of protective antibody responses. The emergence and global distribution of the 
BA strain of RSV B within a within the last 14 years has brought the role of immune
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selection in virus transmission into sharp focus. In this study, no evidence was found 
to suggest that the BA genetic change resulted in the loss of neutralising ability by 
serum antibody. Further, evaluation of neutralising responses against virus strains 
(from the same antigenic group) isolated between 40-50 years apart, showed that 
temporal genetic evolution was similarly not associated with loss in the neutralising 
capacity of serum antibody. The data presented suggest that while inter-group genetic 
differences result in antigenic variation, intra-group genetic differences do not result 
in antigenic changes that result in differential neutralising responses. There is strong 
evidence that the infant IgG response to variable parts of the G protein is strain- 
specific (Cane et a l, 1996, Scott et a l, 2007), suggesting that the neutralising 
response to this protein is potentially strain-specific. In this thesis analysis of 
previously identified neutralising antibody epitopes on the F proteins of infecting 
wild-type viruses, showed that these epitopes were conserved within or across the 
group structure of RSV. Weighed against evidence that shows that the F protein 
contributes more significantly to development of the neutralising response relative to 
the G protein (Anderson et a l, 1988, Olmsted et a l, 1986), it is possible that strain- 
specific neutralising responses targeted at the G protein could have been masked by 
cross-reactive responses targeted at relatively more conserved epitopes on the F 
protein. In this study, no attempt was made to study the strain-specificity of 
neutralising antibodies directed at the G protein exclusive of F-specific responses. It 
remains to be seen whether in the absence of F-specific neutralising antibodies 
(removed by absorbing out F-specific antibodies from infant sera), the G-specific 
neutralising response will be strain-specific. It is also possible that despite the failure 
to detect genotype-specific RSV serum neutralising antibodies, such antibodies may 
nonetheless provide protection as suggested by the results of some studies
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(Mekseepralard et a l , 2006). Therefore while neither the BA genetic change nor 
temporal evolution was associated with differential in vitro neutralising responses, it 
still remains to be seen whether these genetic variants induce differential in vivo 
protection.
The natural history of the cytokine/chemokine response to RSV
Despite availability of data on the early cytokine/chemokine response in animal 
models, not much is known on the course of the early cytokine/chemokine response in 
humans. A key challenge in conducting informative studies in the infant is the 
inherent limitation in the frequency with which young infants who often have 
potentially life threatening illness can be sampled. In addition, safety and practical 
concerns related to sampling of human lung tissue preclude invasive sampling 
procedures. Due to these concerns, most studies designed to look at the early markers 
of infant immune response have been based on samples obtained from the upper 
respiratory tract and presumed to reflect responses in the lower respiratory tract. 
Many such studies are also conducted at the peak of illness, when infants present to 
hospital with symptoms of respiratory infection. The key limitation with this approach 
is that such single time point sampling insufficiently accounts for variations in both 
viral load and cytokine/chemokine response that may have occurred prior to 
development of symptoms. In the studies presented in this thesis, infants were 
sampled at regular intervals during the entire course of infection in order to track the 
kinetics of both RSV viral load as well as host mediators. These are the first data to 
describe the infant cytokine/chemokine response to RSV over the entire course of 
RSV infection and the results reported suggest that RSV viral load drives key 
cytokine/chemokine responses at the early stages of infection. The pro-inflammatory
228
response appeared to be particularly strongly linked to viral load while the chemokine 
response showed moderate correlation with viral load. There was further evidence to 
suggest that both inflammatory and regulatory responses at the early phases of 
infection are produced in a co-ordinated fashion in order to modulate the potential 
pathological effects of unchecked inflammatory responses. Due to limitations in 
sample volume, no attempt was made in this study to identify the cellular sources of 
these mediators. While for many infants, peak cytokine/chemokine and viral load 
responses appeared to be linked with development of URTI, this relationship was not 
firmly established since in some instances disease was present in the absence of these 
factors. This unexpected result may be attributable to potential infection by 
undetected pathogens that resulted in symptoms that were comparable to those 
produced by RSV infection. Evaluation of virus-specific factors on the 
cytokine/chemokine response showed that genetic variability between virus strains 
did not appear to result in differential cytokine/chemokine responses. Most 
cytokines/chemokines were produced at comparable levels irrespective of whether the 
infecting strain was RSV A or B.
Limitations of the study and suggestions for future work
The role of G-specific responses on the neutralising response
The work presented in this thesis was based on an in vitro neutralisation assay that 
detected both G- and F-specific neutralising responses. Although previous studies 
have demonstrated that the anti G-response is strongly genotype-specific (Cane et al., 
1996, McGill et al., 2004), in the studies presented in this thesis, a genotype-specific 
neutralising response was not found. Previous studies have shown that G-specific
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antibodies that do not induce in vitro neutralisation can confer protection in animal 
models (Mekseepralard et al., 2006, Plotnicky-Gilquiii et a l 1999). In this thesis, the 
role of strain-specific G protein antibodies in functional protection was not evaluated. 
Future studies should seek to address the role of antibodies to the G proteins of BA 
and non-BA strains on in vitro protection against experimental challenge with 
representative BA and non-BA variants.
Group and genotype-speciflcity of secretory IgA response
The work presented in this thesis, was solely based on serum anti-RSV responses. It 
can be argued that the key correlate of functional resistance from natural challenge is 
secretory IgA present on the respiratory mucosa, rather that serum antibody, which is 
passively transudated to the mucosal surfaces (Wagner et al., 1987a). It is possible 
that secretory IgA neutralising responses may be slightly different from serum 
responses in terms of group and genotype-speciflcity. Future studies should 
investigate the group and genotype-speciflcity of the secretory IgA response in order 
to complement the findings presented in this thesis.
Kinetics of the secondary neutralising response
The ability to detect the temporal dynamics of the neutralising response upon 
secondary infection was limited by the lack of an adequate number of samples after 
secondary infection. A comprehensive study of the kinetics of the secondary 
neutralising response and its relation with the primary response kinetics would 
advance the understanding of how individuals become resistant to severe infection 
with age. It is known that most immunocompetent adults have a high titre of anti-RSV
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antibodies, relative to infants. The maintenance of these high titres irrespective of 
recent infection history is likely to be related to resistance against severe disease. 
Future studies could seek to look at the dynamics of the neutralising response in a 
birth cohort recruited and followed up for a number of years in order to determine the 
mechanisms through which older individuals maintain high titres of antibodies. Such 
studies may help to define antibody titres that are associated with protection from 
severe disease.
Relative fitness of BA and non-BA strains
Studies on the effect of the BA genetic change on the neutralising response found that 
this change did not correlate with changes in the neutralising response. This study did 
not undertake a comparison of the relative fitness of BA and non-BA strains in order 
to explain variations in transmissibility. Future studies should address the question of 
whether there is a fitness difference between BA and non-BA strains. This could be 
achieved by comparing relative replication efficiencies of these strains both in vivo 
(in animal models) and in vitro in the presence or absence neutralising antibody. Also, 
BA and non-BA variants in this thesis were characterised only by limited sequencing 
of the G gene in order to confirm the presence or absence of the duplication. Since it 
is possible variations in other parts of the genome could potentially explain the 
observed variation in transmissibility, future studies should undertake full genome 
sequencing of these strains in order to determine whether other changes in the genome 
correlate with differences in viral fitness and therefore differences in transmission.
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Relevance of upper respiratory tract sampling to lower respiratory tract 
disease
Studies on the cytokine/chemokine response to natural RSV infection were conducted 
on the basis of samples collected from the upper respiratory tract. It is possible that 
cytokine/chemokine responses in the upper part of the respiratory tract could be 
different from those in the lower respiratory tract, meaning that conclusions derived 
from data obtained from upper respiratory tract sampling, would be of limited use in 
inferring the mechanisms of illness in the lower respiratory tract. A further limitation 
in this study was the lack of evaluation of the cellular sources of these mediators. In 
order to definitively characterise these sources it would have been necessary to 
undertake relatively invasive sampling procedures which are not ethically permissible 
in infants.
Mathematical modelling of the transmission dynamics of RSV
The group cross-neutralisation estimates obtained in this thesis have been used to 
model the group replacement dynamics of RSV in three countries (Finland, Kenya 
and the UK) (White et al., In preparation). The work undertaken so far does not 
comprehensively address the complex group replacement dynamics seen in other parts 
of the world, where the pattern of group recurrence is less obvious. The work does not 
fully address the factors underlying the fact that RSV A is transmitted at a greater 
frequency relative to RSV B in most parts of the world. Future studies should seek to 
model the transmission dynamics in countries with diverse population structures, birth 
rates, and diverse patterns of group recurrence using the estimates provided in this
232
thesis, in order to further clarify the role of differential immune responses in virus 
transmission.
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infecting strains of RSV are not antigenically different from those causing primary 
infection (Beem, 1967), the strain replacement patterns observed in successive RSV 
epidemics (Cane, 2001), suggests that antigenic variation is an important mechanism 
through which re-infection occurs. Also recent data shows that a vast majority of re­
infecting strains are genetically different from previously infecting strains (Agoti et 
al., 2012). It may be that natural re-infection is facilitated by both antigenic variation 
and a short duration of neutralising antibody immunity in young infants. Strain- 
specific neutralising antibody responses to RSV will be discussed in depth in chapter 
7.
The reasons for the short duration of the RSV antibody response following primary 
infection are not well understood. A number of other viral infections, including 
paramyxoviruses such as measles and mumps, have been shown to induce antibody 
responses that are maintained for many years without the need for antigenic 
stimulation (Amanna et al., 2007). A number of studies have shown the existence of 
long-lived plasma cells which produce antibody for extended periods without the need 
for antigenic re-stimulation (Slifka et al., 1998). These data provide the basis to 
assert that long-lived antibody responses following infection with some pathogens 
may be the result of long lived plasma cells specific for those pathogens. However a 
number of studies have also shown than certain plasma cells have a short lived 
phenotype (Schooley, 1961), suggesting that antibodies produced by these cells are 
similarly short-lived. Evidence from the murine model suggests that RSV-specific 
plasma cells after challenge with RSV are not maintained at high levels even after 
boosting (Singleton et al., 2003). These data suggest that the failure to maintain long-
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lived neutralising antibody responses after natural exposure in humans may be related 
to the short duration of RSV-specific antibody secreting plasma cells.
The memory response to RSV re-infection was explored by looking at the rate of 
development of neutralising antibodies during primary and secondary infection. 
Comparison of the mean primary and secondary infection neutralising antibody titres 
in serum collected within 10  days of identification of virus in nasal samples, showed 
that while the primary antibody titre was no greater than that of a pre-infection 
control, it was significantly lower than that of secondary infection. These data suggest 
that following secondary exposure an immunological memory response is activated 
and rapidly generates high titres of neutralising antibodies shortly after infection. 
These data suggest that despite the short duration of primary neutralising antibody 
responses, protection from severe disease during secondary exposure may be the 
result of an anamnestic response that acts to rapidly curtail further spread of virus 
infectivity.
Maternal neutralising antibody protection was analysed by estimating the age 
prevalence of maternally-derived neutralising antibodies that were above a threshold 
titre that has been associated with protection from severe disease (Glezen et al., 
1981a). The data presented show that there is a rapid decline of protective antibodies 
shortly after birth. The mean duration of protection of maternally-derived antibodies 
was found to be of the order of 2.8 months. The proportion of infants who had 
neutralising antibody titres above this putative protective threshold declined steadily 
with age and by 3 months of age, none of the infants in this study had maternal 
neutralising antibodies above this threshold. The results presented have implications
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for vaccine design. As previously discussed, there are currently no safe and 
immunogenic RSV vaccines for use in the early infant population (0-3 months), 
however live attenuated vaccines that induce protection and that are sufficiently 
attenuated for older age groups have been reported (Wright et al., 2000). It has been 
suggested that a realistic vaccination goal under these circumstances might be 
maternal vaccination, with the ultimate aim of boosting the titre of maternal 
antibodies that will be eventually transferred into foetal circulation (Englund, 1999). 
The data presented here suggest that this approach could potentially provide 
protection in the first few months of life when infants are most susceptible to severe 
illness. This approach could be of potential benefit among the most vulnerable infant 
populations such as premature infants - in whom maternally-derived antibody titres 
are likely to be relatively low at birth. This approach would in such cases boost the 
titres of maternally-derived antibody and consequently slightly delay the age at which 
infants first become susceptible to infection and disease.
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Chapter 7 - RSV genotype-specific neutralising antibody
responses
Introduction
One of the targets of neutralising antibody immunity, the G protein, accumulates 
genetic changes in the course of viral evolution. This protein has been shown to 
undergo a rate of molecular evolution of 1.83x1 O' 3 and 1.95x1 O’3 nucleotide 
substitutions/site/year for RSV A (Zlateva et a l, 2004) and B (Zlateva et a l, 2005) 
respectively. Other reports have shown that there is a progressive accumulation of 
amino acid changes at an average rate of approximately 0.25% per year estimated 
over the length of the G protein (Cane and Pringle, 1995). This rate of change is 
comparable to that of the influenza haemagglutinin gene (Cane and Pringle, 1995), 
which is a main target of protective responses against the influenza virus, and in 
which temporal molecular evolution correlates with loss of protective immunity 
(Kilboume et a l, 2002).
The higher rate of non-synonymous to synonymous amino acid substitution observed 
on the G protein suggests that the changes seen on this protein may be immune driven 
(Cane and Pringle, 1995). This notion is supported by reports that show the existence 
of positively selected sites within known antibody epitopes on the G protein (Woelk 
and Holmes, 2001, Zlateva et a l, 2004)). There is indirect evidence that the F protein 
may also be subject to positive selection pressure, under particular circumstances. 
Administration of the immunoprophylactic monoclonal antibody Palivizumab, which 
is specific for the F protein, has been shown to lead to the in vivo selection of escape
146
mutants that contain mutations on the F protein which confer a palivizumab 
neutralization resistance phenotype (Zhu et al., 2011, Papenburg et al., 2012). In vitro 
studies of 2  palivizumab resistant mutants have shown that one of these mutants 
rapidly out-competed the prototype A2 genotype in replication competition assays 
(Zhao et al., 2006), suggesting that immune-selected viruses may be of comparable 
fitness to other viruses.
Molecular epidemiological studies have produced further indirect evidence that the 
virus may be subject to positive evolutionary pressure. A number of studies have 
shown striking similarity between the genotypes of the virus circulating in different 
parts of world at the same time (Cane et al., 1992). However, these dominant 
genotypes are often replaced by alternative genotypes in later outbreaks (Choi and 
Lee, 2000, Seki et al., 2001, Kuroiwa et al., 2005). The molecular evolution of RSV 
has been characterised as consisting of emergence, decline and sometimes extinction 
of once dominant genotypes. For example, certain genotypes that were prevalent in 
the 1970s in Northern Europe but that have not been identified since suggest that they 
have became extinct (Cane and Pringle, 1995). Viewed together, these data suggest 
that the genotype structure of RSV is dynamic and is likely to be subject to selection 
pressures that drive its temporal evolution. Immune pressure is probably key among 
these selection pressures.
In recent years, a new genotype of RSV B has been reported. This genotype, 
commonly referred to as the BA genotype, was first isolated in Buenos Aires 
Argentina in 1998 and has since spread throughout the world and is currently the 
predominant RSV B genotype in global circulation (Trento et al., 2003, Trento et al.,
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2010). Its key distinguishing feature is the incorporation of a 60 nucleotide 
duplication in the variable part of the G protein (Trento et al. , 2003). The nature of 
this mutation as well as the fact that it had not hitherto been identified in any previous 
circulating genotype, suggests that it is unlikely to have arisen from more than one 
infection event in a single individual and accordingly the dynamics of its global 
spread can be used as a model of the transmission dynamics of other genotypes of 
RSV. The remarkable transmission success of BA strains relative to previous RSV B 
genotypes can be hypothesized to have been the result of an immune selection 
advantage that conferred upon it the ability to out-compete other group B genotypes in 
a natural transmission setting. To date there have been no studies published that 
explore this phenomenon. In 2012, a wild-type variant of RSV A was identified which 
incorporates a 72 nucleotide duplication in the variable part of the G gene, 
reminiscent of the BA genotype (Eshaghi et al., 2012). It is yet to be seen whether this 
new variant will achieve comparable epidemiological success to the BA genotype.
This chapter will explore the effect of genotype-specific variation in RSV on the 
neutralising antibody response to natural RSV infection as well the effect of the BA 
genetic change on the neutralising responses of infants infected with different RSV B 
genotypes
Chapter Aims
This chapter will describe the genotype-specificity of the RSV neutralising response. 
Responses to two strains of RSV A and two strains of RSV B will be evaluated in the 
serum of infants infected with wild-type genotypes of RSV A and B. The genetic 
characteristics of both infecting and test genotypes will be related to genotype 
homologous and heterologous neutralising antibody responses. The results will be
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discussed in terms of the effect of molecular evolution on the neutralising response 
and its implications on the development of live attenuated vaccines. The chapter will 
also evaluate infant serum responses to group conserved regions on the attachment 
protein. These results will be discussed in the context of development of bivalent live 
attenuated vaccines comprising representative genotypes from the two RSV groups.
Materials and methods
Study population, sampling and molecular characterisation of test and 
infecting viruses
Nasal washings were obtained from children less than 60 months of age admitted to 
KDH with RSV-associated severe or very severe pneumonia. Laboratory diagnostic 
techniques used in this study are the same as those described in chapter 5. The test 
viruses used in these studies were: the A2 (RSV A; isolated in Australia in 1961), 
Kil/A/2006 (RSV A; Kenya, 2006), 8/60 (RSV B; Sweden, 1960) and Kil/B/2008 
(RSV B; Kenya, 2008). The attachment and fusion protein genes of all the test viruses 
as well as a number of infecting strains were sequenced as described in Chapter 3. 
The neutralisation assays used in this study are described in chapter 4. Complement 
specific neutralisation assays were conducted by addition of 1 0 % guinea pig 
complement (Sigma) to infant sera. Comparison of nucleotide and amino acid 
sequence identity was done using Openoffice.org calc software (Apache software 
foundation, Forest Hill, Maryland USA).
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Enzyme Linked Immunosorbent Assays (ELISA) using synthetic peptides
Infant serum IgG responses to conserved regions on the central portion of the G genes 
of RSV A and B were measured using ELISA. The synthetic peptides spanned amino 
acid 170-189 of the RSV attachment protein. The RSV A constant region comprised 
the following amino acids: FVPCSICSNNPTCWAICKRI while the RSV B constant 
region comprised the following amino acids: FVPCSICGNNQLCKSICKTI. Synthetic 
peptides matching these sequences were diluted in dimethyl sulphoxide (DMSO) to a 
working concentration of 10 pM. A checkerboard titration assay was carried out using 
pooled convalescent sera to determine the optimal serum and synthetic peptide 
concentrations for the assays. The results of this assay are shown in Figure 7.1. On the 
basis of these results it was decided that a serum dilution of 1 :1 0 0  and a synthetic 
peptide concentration of 3.lxlO ' 6 M were optimal for the assay. The ELISA was 
carried by first coating 96 well polystyrene plates (Nunc MaxiSorp, Nunc 
Corporation) overnight at 37°C in a humidified CO2 incubator with the appropriate 
concentration of peptide diluted in phosphate buffered saline. Plates were then 
blocked for an hour, using a blocking buffer consisting of 5% powdered milk 
(Marvel) in PBS. 100 pi of infant sera diluted 1:100 in the blocking buffer, was then 
added to the wells of the 96 well plates and incubated for one and a half hours at 
37°C. The plates were then washed 3 times in PBS containing 0.05% Tween 20, 
followed by addition of 1 0 0  pi per well of a 1 :1 0 0 0  dilution of horseradish peroxidase 
(HRP) tagged rabbit anti human IgG (Dako corporation) diluted in blocking buffer. 
After incubation for 1 hour at 37°C, the plates were washed 3 times as before and 
developed. The development solution was prepared by adding 10 pg 
orthophenylenediamine (OPD) tablets into 10 ml of PBS and aliquoting 100 pi of this 
solution to the appropriate wells of the 96 well reaction plate. This reaction was
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incubated for 10 minutes in the dark and stopped by the addition of 50 pi of 2.5 M 
H2SO4 into the appropriate wells of a 96 well plate. The plates were then read on a 
standard microplate reader at 495nm.
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Figure 7.1 The results of a checkerboard titration assay in which varying dilutions of 
sera were titrated against decreasing concentrations of synthetic peptides in order to 
determine the optimum concentration of either parameter.
Data Analysis
Inference of the genetic relationship between different infecting and test genotypes 
was carried out using Multi Dimensional Scaling (MDS) and phylogenetic analysis. 
Pairwise distance matrices containing the level of variation between different 
sequences in terms of nucleotide substitutions per site were generated using MEGA 
software (Build 5110426) using the maximum composite likelihood model. These 
distance matrices were then subjected to classical MDS analysis using Matlab 
(release R2008b, MathWorks Inc). MDS analysis resulted in the generation of two 
dimensional plots graphically depicting the genetic relationship between different
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genotypes based on their relative pairwise distances from each other. The genetic 
relationship between different genotypes was also assessed by comparing the level of 
amino acid conservation by identification of conserved amino acid residues as well as 
by the use of phylogenetic techniques. Phylogenetic analysis was carried out by 
generation of maximum likelihood phylogenetic trees consisting of G gene sequences 
from different genotypes.
Comparison of the strain homologous and heterologous responses was done by 
analysing differences in fold rise in titre to homologous and heterologous virus as well 
as by differences in the ability to seroconvert. A multiple regression model was used 
to determine whether the magnitude of the neutralising response to the homologous 
virus was statistically different from that to the heterologous response. McNemar’s 
chi square test was used to compare the proportions seroconverting to homologous or 
heterologous virus. Responses to group conserved synthetic peptides in acute and 
convalescent phase sera in terms of optical density changes were compared using 
paired student t tests. The analytical output for the data presented in this chapter is 
presented in appendix 3.
Results
Comparison of sequence data between different genotypes of RSV B
Comparison of F and G gene amino acid sequences of infecting BA (n=20) and non- 
BA (n=20) strains was done in terms of nucleotide and amino acid identity. There 
was 95.1% and 97.1 % nucleotide and amino acid identity, respectively, shared 
between F proteins of all RSV B strains in the study, irrespective of whether they
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were BA or non-BA. On the other hand there was 79.7% and 73.8% nucleotide and 
amino acid identity, respectively, shared by the G proteins of all infecting RSV B 
strains in the study. Analysis of the BA strains alone showed that they shared 98% 
and 98.6% nucleotide and amino acid identity respectively at the F gene level and 
95.2% and 93.8% nucleotide and amino acid identity, respectively, at the G gene 
level. Analysis of the non-BA strains showed that they shared 99.5% and 98.6% 
nucleotide and amino acid sequence identity, respectively, at the F protein level and 
97.6% and 94.3% nucleotide and amino acid sequence identity, respectively, on the G 
protein. These data are presented in tabular form in Table 7.1. Analysis of the 
variation between the 2 RSV B test strains, Ken/B/2008 (BA) and Swe/B/1960 (non- 
BA) showed that they shared 77% amino acid identity on the G protein.
Comparison 
groups (n)
Amino acid identity 
(%)
Nucleotide identity 
(%)
F protein G protein F gene G gene
RSV B only 
(BA & non-BA) 
(40)
97.1 73.8 95.1 79.7
BA only (20) 98.6 93.8 98 95.2
Non-BA only (20) 98.6 94.3 99.5 97.6
Table 7.1 Analysis of the level of nucleotide and amino acid identity among different 
genotypes of RSV A and B
Analysis of level of genetic conservation on some neutralising antibody epitopes 
on the F and G proteins of different RSV B genotypes
The level of amino acid conservation on selected neutralising epitopes was compared 
between BA and non-BA strains of RSV B. The F protein epitopes that were analysed
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were obtained from published literature and are illustrated in figure 5.12 in Chapter 5. 
The four neutralising epitopes were located between the following amino acid 
positions on the primary sequence of the F protein: (i) amino acids 205-225
(Bourgeois et a l, 1991), (ii) amino acids 221-236 (Trudel et a l, 1987b), (iii) amino 
acids 262-268 (Lopez et al., 1990) and (iv) amino acids 289-298 (Martin-Gallardo et 
al., 1991). All the neutralising epitopes on the F protein were found to be perfectly 
conserved on wild-type BA and non-BA strains in this study (shown in Figure 5.12).
Analysis of the level of amino acid conservation on the G proteins of infecting BA 
and non-BA strains was carried out next. Two neutralising epitopes that occurred 
between amino acids 151 - 172 (Murata et a l, 2010) and amino acids 201 - 213 
(Garcia-Barreno et a l, 1992) were evaluated. There were two genotype-specific 
amino acid differences between wild-type BA and non-BA viruses on the epitope 
spanning amino acids 151 and 172, while there was only one amino acid difference in 
the epitope spanning amino acids 201 and 213. There were, however intra-genotype 
variations identified on this epitope. One of the BA sequences varied from other BA 
sequences by containing a Proline to Leucine substitution at position 207. Also, two 
other BA sequences varied from all other group B sequences since they contained a 
Leucine to Isoleucine substitution at position 201 of this epitope. These differences 
are illustrated in figure 5.12.
Analysis of the genetic and antigenic relationship between infecting RSV B 
genotypes
Inference of the genetic relationship between the G genes of BA and non-BA 
genotypes was carried out using both Multi Dimensional Scaling (MDS) and
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phylogenetic analysis. Results of MDS analysis showed that G gene sequences 
obtained from infants infected with wild-type BA strains clustered together on the two 
dimensional MDS space, while those obtained from infants infected with non-BA 
genotypes, similarly clustered together, but on a separate region of the two 
dimensional space. For comparison, both the Swe/B/1960 and Ken/B/2008 test 
genotypes were included in the MDS analysis. The Swe/B/1960 genotype was 
separated from both the BA and non-BA clusters by a considerable genetic distance 
while the Ken/B/2008 test genotype was located within the cluster of wild-type BA 
sequences. The genetic relationship between BA, non-BA, Swe/B/1960 and 
Ken/B/2008 on the two dimensional MDS space is shown in figure 7.2.
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Figure 7.2 The results of MDS analysis in which the relationship between the G genes of 
different infecting (20 BA viruses and 20 non-BA viruses) and test strains of RSV B is 
depicted on a two dimensional space. Each spot represents one sequence and their co­
ordinates on the cartesian plane are based on their relative pairwise distances. Identical 
sequences are represented by a single point on the Cartesian plane. The x and y axes
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represent pairwise distances in terms of number of nucleotide substitutions per 
nucleotide site between different sequences.
For comparison, a maximum likelihood phylogenetic tree showing the genetic 
relationship between different RSV B genotypes was constructed with 100 bootstrap 
replications. Results of the phylogenetic analysis showed that wild-type BA and non- 
BA genotypes were located on separate branches of the phylogenetic tree while the 
Swe/B/1960 genotype was distantly separated from both BA and non-BA infecting 
virus clusters. On the other hand, the Ken/B/2008 genotype was located within the 
branch on which wild-type BA genotypes were located. The phylogenetic tree is 
graphically presented in figure 7.3.
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Figure 7.3 The phylogenetic relationship of partial G gene sequences (between 
nucleotide 284 of the G gene and nucleotide 9 on the F gene) obtained from both 
infecting and test viruses are shown in this maximum likelihood tree. The notational 
convention for the wild-type genotypes is as follows: patient ID/Infecting group/RSV B 
genotype. Notation for test genotypes follows the following order: Place of isolation 
(Swe=Sweden; Ken=Kenya)/Infecting group/Year of isolation.
To assess whether the genetic differences between BA and non-BA genotypes were 
reflected in terms of differential neutralisation, inference of the antigenic relationship 
between the infecting BA and non-BA genotypes was done using classical MDS. This
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analysis utilized cross neutralisation data obtained from genotype homologous and 
heterologous reactivity. The test viruses in these experiments were 8/60 (non-BA) 
and Ken/B/2008 (BA). Titres to either test strain were measured using the plaque 
reduction neutralisation assay. Neutralising responses to homologous or heterologous 
virus were measured in terms of fold rise in titre from the acute to convalescent 
phases of infection. The results of these analyses, shown in figure 7.4, show no 
evidence of differential clustering of antibody responses to the BA or non-BA 
genotypes. Stronger homologous to heterologous to either test genotype neutralisation 
would have resulted in separate clustering of BA and non-BA specific responses on 
the 2 dimensional MDS space, indicating differential patterns of recognition of the 
two genotypes.
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Figure 7.4 Multidimensional scaling (MDS) plot showing the antigenic relationship 
between BA and non-BA strains of RSV B. Sera from infants infected with BA (n=20) 
or non-BA (n=20) viruses were used to neutralise representative non-BA (8/60 virus) 
and BA (Ken/B/2008 virus) strains. The resulting cross neutralisation matrix data 
(expressed as fold rise in titre from the acute to convalescent phase of infection) was 
used to construct a two dimensional MDS plot depicting the antigenic relationship 
between BA and non BA strains of RSV B.
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Statistical Analysis of homologous and heterologous neutralising responses to BA 
and non-BA genotypes of RSV B
Homologous and heterologous neutralising responses to representative BA 
(Kil/B/2008) and non-BA (Swe/B/1960) test strains were next compared for evidence 
of statistically significant differences. There was no significant difference between the 
magnitude of the neutralising response mounted by infants infected with non-BA 
strains (n=20) to the Swe/B/1960 virus (3.7 fold rise in titre) and the Kil/B/2008 
virus (3.42-fold rise in titre; p=0.78). There was also no significant difference 
between the magnitude of the neutralising response mounted by infants infected with 
BA strains (n=20) to the Swe/B/1960 virus (5.13 fold rise in titre) and the 
Kil/B/2008 virus (3.54-fold rise in titre; p=0.1). These data are presented graphically 
in figure 7.5.
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Figure 7.5 Acute and convalescent phase responses to representative BA (Ken/B/2008) 
and non-BA (8/60) test viruses among infants naturally infected with wild-type BA 
(n=20) and non-BA (n=20) viruses. The numbers above each acute/convalescent serum 
pair denote the fold rise in titre from the acute to convalescent phases of infection. The p 
value bars traversing the panels indicate the level of statistical significance between 
genotype homologous and heterologous responses.
Serum neutralising responses from infants infected with BA or non-BA strains were 
compared in terms of their ability to seroconvert to the Kil/B/2008 and Swe/B/1960 
test viruses. Out of 20 individuals infected with wild-type non-BA strains, the 
proportion that seroconverted to the BA test virus Kil/B/2008 (35%) was not
statistically different from the proportion that seroconverted to the non-BA test virus, 
Swe/B/1960 (50%; McNemar’s %2=1.8, p=0.4). Among the 20 individuals infected 
with wild-type BA strains in the study there was no difference between the proportion
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that seroconverted to the BA test virus (50%) and the proportion that seroconverted 
to the non-BA test virus (65%; McNemar’s x2= l.8, p=0.4).
The effect of complement on genotype-specific neutralisation of the group B 
genotypes was evaluated using sera from 20 infants; 10 who had wild-type infections 
with BA strains and 10 who had wild-type infections with non-BA strains. 
Seroconversion rates to both the Kil/B/2008 virus and the Swe/B/1960 virus were 
compared in the presence and absence of complement. The proportion of infants 
infected with non-BA genotypes and who seroconverted to the Swe/B/1960 virus in 
the presence of complement (40%) was no different from the proportion that 
seroconverted m its absence (40%, McNemar’s % =1, p=l). The proportion of infants 
infected with BA strains in the 2007/2008 epidemic who seroconverted to the 
Swe/B/1960 virus was also no different in the presence (50%) or absence of 
complement (60%, McNemar’s %2=l, p=0.16). There was similarly no difference in 
the proportion of infants infected with non-BA strains who seroconverted to the 
Kil/B/2008 virus in the presence (40%) or absence of complement (30%, 
McNemar’s %2=1, p=0.3173). Finally, the proportion of infants infected with BA 
strains that seroconverted to the Kil/B/2008 virus in the presence of complement 
(50%) was similar to the proportion that seroconverted in its absence (30%, 
McNemar’s %2=1, p=0.3173).
Neutralising responses to contemporary and historical genotypes of RSV A
The relationship between 20 infecting RSV A viruses was analysed by identifying 
conserved nucleotide and amino acid residues along the length of the fusion and
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attachment proteins. There was 96.8% and 98.1% nucleotide and amino acid identity 
respectively on the F proteins of infecting RSV A viruses. On the other hand, there 
was 94.8% and 91.4% nucleotide and amino acid identity respectively on the G 
proteins of infecting viruses. These data are shown in table 7.2. Analysis of the level 
of amino acid conservation on some neutralising antibody epitopes on F and G protein 
of infecting RSV A viruses (shown on figure 5.12 and figure 5.13) showed that all 
neutralising antibody epitopes tested on both proteins were perfectly conserved on all 
infecting RSV A viruses sequenced. Comparison of the level of genetic variation 
between the 2 group A test viruses, Ken/A/2006 and A2 showed that they shared 88% 
amino acid identity on the G protein.
Comparison Amino acid identity (%) Nucleotide identity (%)
groups (n) F protein G protein F gene G gene
RSV A only (20) 98.1 91.4 96.8 94.8
Table 7.2 Comparison of genetic relatedness of infecting RSV A genotypes in terms of 
percent nucleotide and amino acid identity
The genetic relationship between the G genes of RSV A viruses was further inferred 
using MDS. Pairwise distances between the G genes of infecting RSV A viruses were 
generated and plotted on a two dimensional MDS plot. The results of these analyses 
are shown in figure 7.6. The results show a high level of clustering of infecting RSV 
A G genes. Due to the high level of genetic conservation in the G protein of infecting 
RSV A viruses, many viruses were located on the same co-ordinates on the two 
dimensional MDS plot shown in Figure 7.6. The Ken/A/2006 test virus was located 
within the cluster of contemporary RSV A infecting viruses, while the A2 test 
genotype was distantly separated from this cluster.
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Figure 7.6 Multidimensional scaling plot showing the genetic relationship between the 
G genes of 20 infecting RSV A strains and the two RSV A test viruses. Closely related or 
identical sequences are represented by overlapping spots on the two dimensional plot. 
The unit of measurement on the x and y axes is number of nucleotide substitutions per 
site.
The genetic relationship between the infecting and test viruses of RSV A was 
confirmed using phylogenetic analysis. A maximum likelihood tree with 100 
bootstrap repetitions was constructed using MEGA software. The results of these 
analyses which are shown in Figure 7.7 show that there was a close genetic 
relationship between all infecting RSV A viruses. However, the A2 test virus was 
found to be distantly related to the infecting RSV A viruses.
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Figure 7.7 Maximum likelihood phylogenetic tree showing the relationship between the 
G genes of infecting and test RSV A viruses. The notational convention for the wild-type 
genotypes is as follows: patient ID/Infecting group/NP genotype/year of isolation. 
Ken/A/2006 refers to the contemporary RSV A test strain while A2/A/1961 refers to the 
historical A2 strain
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Comparison of the neutralising antibody response by infants infected with 
contemporary RSV A genotypes to both the A2 (Aus/A/1961) and Kil/A/2006 
test viruses.
Statistical comparison of genotype-specific neutralising responses in the sera of 
infants infected with contemporary RSV A viruses to the contemporary and historical 
RSV A test viruses was carried out next. There was a mean 3.42-fold rise in titre 
against the A2 test virus and a mean 3.15-fold rise in titre to the Kil/A/2006 test virus. 
Results of regression analysis showed that the difference in these responses was not 
statistically significant (p=0.8). This comparison is graphically depicted in Figure 
7.8.
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Figure 7.8 Comparison of the magnitude of the neutralising response to the A2 and 
Ken/A/2006 test viruses of RSV A. The light grey bars represent acute stage titres while 
the dark grey bars denote convalescent phase responses. The numbers shown above 
each acute/convalescent sera pair denotes the fold rise in titre from the acute to 
convalescent phases of infection. The p-value shows that the magnitude of the 
neutralising response to these two viruses was not significantly different.
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Responses to the A2 and Kil/A/2006 viruses were also evaluated in terms of ability to 
seroconvert. Of the 33 RSV A infected individuals tested against both A2 and 
Kil/A/2006, no significant difference was found between the proportion that 
seroconverted to the A2 virus (39.4%) and the proportion that seroconverted to the 
Kil/A/2006 virus (51.5%; McNemar’s x2=4, p=0.13).
Responses to group conserved regions on the attachment protein
Antibody responses to synthetic peptides matching group conserved regions on the 
central part of the G molecule were evaluated in the sera of infants with RSV A 
(n=57) and B (=34) infections who had been admitted with severe RSV-associated 
pneumonia. Acute and convalescent phase titres from the sera of infants admitted with 
severe RSV were compared using a paired two sided student’s t-test. Comparison of 
responses to the RSV A constant region showed that the convalescent response in the 
sera of RSV A infected infants was significantly greater than their acute phase 
response (t=-6.4, p<0.0001). On the other hand, there was no difference between the 
acute and convalescent phase responses in the sera of RSV B infected infants to the 
constant region of RSV A (t=-0.13, p=0.9). These data are shown graphically in 
figure 7.9.
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Figure 7.9 Comparison of responses to the conserved region of the RSV A G gene in the 
sera of infants with natural RSV A (left panel) or RSV B (right panel) infections
This homotypic response pattern was repeated in the infant response to the constant 
region of RSV B infected individuals. While there was no statistically significant 
difference between the acute and convalescent phase responses in the sera of RSV A 
infected individuals against the RSV B constant region (t=-0.6, p=0.6), the 
convalescent phase response of RSV B infected infants to the RSV B constant region 
was significantly greater than the acute phase response (t=-l 0.3, p<0.0001). These 
responses are graphically represented in figure 7.10.
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Figure 7.10 Comparison of responses to the conserved region of the RSV B G gene in 
the sera of infants with natural RSV A (left panel) or RSV B (right panel) infections
Responses to the RSV A and B constant region were further evaluated in terms of 
seroconversion. Of the 16 infants that seroconverted to the RSV A constant region, 16 
(100%) were infected with RSV A while none (0%) were infected with RSV B. This 
difference was statistically significant (%2=11.6, p=0.001). Similarly of the 7 
individuals who seroconverted to the RSV B constant region, 7 (100%) were infected 
with RSV B while none (0%) were infected with RSV A. This difference was also 
statistically significant (%2=12.7, p<0.0001). These data are shown in table 7.3 and 
table 7.4.
168
Infecting group
Sero­ A B Total
conversion n (%) n (%) n (%)
No 41 (55) 34 (45) 75 (100)
Yes 16 (100) 0 (0) 16 (100)
Total 57 (63) 34 (37) 91 (100)
Table 7.3 Comparison of the proportion seroconverting to the RSV A constant region in 
the sera of RSV A or RSV B infected infants
Infecting group
Sero­ A B Total
conversion n (%) n (%) n (%)
No 57 (68) 27 (32) 84 (100)
Yes 0 (0) 7 (100) 7 (100)
Total 57 (63) 34 (37) 91 (100)
Table 7.4 Comparison of the proportion seroconverting to the RSV B constant region in 
the sera of RSV A or RSV B infected infants
Discussion
The first part of the studies presented in this chapter looked at responses to two 
representative RSV B test viruses among infants who had experienced natural 
infection with wild-type BA or non-BA strains. One of the two representative test 
viruses (Kil/B/2008 -  isolated in Kilifi in 2008) contained the 60 nucleotide 
duplication while the other (Swe/B/1960 -  isolated in Sweden in 1960) did not.
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Direct comparison of the infecting F and G gene sequences showed there was a high 
degree of reiatedness in terms of nucleotide and amino acid identity. The F gene was 
the most highly conserved molecule with over 90% nucleotide and amino acid 
identity within and between the two infecting RSV B genotypes. The G protein was 
less conserved with 73.8% and 79.7% amino acid and nucleotide sequence identity 
respectively shared between infecting BA and non-BA genotypes of RSV B. Analysis 
of four neutralising epitopes on the F proteins of infecting viruses showed that they 
were perfectly conserved both within and between the two infecting group B 
genotypes. Since the F protein, is the major target of neutralising antibody responses 
(Olmsted et al., 1986, Anderson et al.f 1988), these data strongly suggested that 
neutralising responses directed at one genotype were likely to be effective against the 
alternative genotype. Extension of these analyses to neutralising epitopes on the G 
protein found evidence of genotype-specific amino acid differences within 
neutralising epitopes. Of the two G protein epitopes evaluated, the first, spanning 
amino acids 151 and 172, contained two genotype-specific amino acid differences, 
while the other, which spanned amino acids 201 and 213, contained one genotype- 
specific amino acid difference.
Analysis of the genetic relatedness of infecting BA and non-BA genotypes carried out 
by Multidimensional Scaling (MDS), showed evidence of inter-genotype genetic 
variation but little evidence of intra-genotype variation. In general, infecting BA 
viruses tended to cluster closely together on the two dimensional MDS space while 
non-BA viruses clustered together in a similar manner to BA viruses, but were 
separated from the BA cluster by a considerable genetic distance. While the BA test 
virus (Ken/B/2008) was located within the cluster of infecting BA viruses, the non-
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BA test virus (Swe/B/1960) was located distantly from both infecting virus clusters. 
This suggests that the Swe/B/1960 virus has undergone considerable genetic evolution 
relative to the contemporary BA and non-BA infecting genotypes. Non-BA viruses in 
this study were isolated in the 2002/2003 RSV epidemic in Kilifi while the BA 
viruses were collected in the 2007/2008 epidemic, meaning that between 43 and 48 
years respectively of temporal evolution separated the Swe/B/1960 test virus from the 
contemporary group B infecting viruses. This relationship was confirmed by 
phylogenetic analysis, which showed differential clustering of BA and non-BA 
infecting viruses and marked separation of the Swe/B/1960 genotypes from both 
clusters.
The effect of these genetic differences on the serum neutralising antibody response 
was evaluated by measuring neutralising responses in the acute and convalescent sera 
of infants infected with either genotype to both test viruses. Analysis of the serum 
neutralising responses of infants naturally infected by either wild-type BA or non-BA 
viruses, showed that their respective responses both in terms of fold rise in titre from 
the acute to convalescent phases of infection as well as their ability to seroconvert to 
either test virus was not statistically different. MDS analysis confirmed that the 
neutralising response of infants infected with BA viruses was no different from those 
of infants infected with non-BA viruses, since there was no evidence of differential 
clustering of antibody response in the two dimensional MDS space.
The data showing strong genetic variation on the G genes of contemporary and 
historical strains support previous work that showed the existence of strong molecular 
evolution acting on the G protein. There was indirect support for the idea that the
171
observed changes on the G protein could have been driven by immune pressure since 
a number of amino acid changes were identified on neutralising antibody epitopes 
located on the G protein. However, the lack of variation on F protein neutralising 
epitopes (thought to be more important targets of protective immunity) runs counter 
to the notion of immune driven virus evolution. The lack of difference between 
homologous and heterologous genotype responses suggests that G-specific 
neutralising responses may have been masked by cross-reactive responses to the more 
conserved F protein. F-specific responses have been shown to be up to 6-fold greater 
than G-specific neutralising responses (Olmsted et al., 1986). The greater role of the 
F protein in development of neutralising responses is further supported by previous 
work that showed that only F-specific antibodies are capable of mediating complete 
virus neutralisation, while G-specific antibodies mediate only partial neutralisation of 
the virus (Anderson et al., 1988, Walsh et a l , 1989). The lack of a genotype-specific 
component to the RSV neutralising response contrasts with previous work that 
showed that the G protein evokes genotype-specific antibody responses (Cane et al., 
1996, McGill et al., 2004). Previous work has shown protection in the mouse model 
can be conferred by monoclonal antibodies with minimal in vitro neutralization 
activity (Plotnicky-Gilquin et al., 1999), suggesting that failure to induce in vitro 
neutralisation, does not necessarily correlate with lack of protection. Previous studies 
have also shown that one such antibody (1C2) mediates in vitro neutralisation in the 
presence of complement, through Fc-dependent pathways (Mekseepralard et al., 
2006). However, even with the abrogation of Fc binding, this antibody provided 
significant protection against experimental challenge relative to controls 
(Mekseepralard et al., 2006). These data suggest that some G-specific antibodies may 
be capable of inducing functional protection from natural challenge and that the
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absence of neutralising ability in vitro does not suggest the lack of protection. A 
possible source of confounding in this study may be related to the use the lab-adapted 
strain A2. As a result of serial passaging over many years in different cell lines, it is 
possible that this strain has significantly deviated from wild-type strains, as has been 
suggested by some studies (McGill et a l, 2004).
The results of this study suggest that the BA genetic change that has been associated 
with the remarkable epidemiological success of BA variants of RSV B is not 
associated with loss of neutralising ability by the sera of infants infected with non-BA 
viruses. Although the BA genetic change is clearly associated with increased 
transmissibility, the data presented here show that it was not accompanied by changes 
on selected key neutralising epitopes on the F protein. Viewed together, these 
observations support the assertion that the selective advantage conferred by the BA 
genetic change is not associated with escape from serum neutralising responses 
mounted in response to infection with non-BA viruses. As mentioned above, the in 
vitro neutralisation assay used in this study is not an incontrovertible marker of 
protection and as such the failure to detect a differential neutralising response, does 
not necessarily mean that the BA genetic change did not confer an immune selection 
advantage. Further studies using animal models are required to clarify the role of the 
BA genetic change to functional protection.
It is also possible that an alternative genetic change in another part of the RSV 
genome occurred in tandem with the BA mutation, and may be responsible for the 
transmission success of the BA variants. While the transmission advantage conferred 
by either the BA or alternative genetic change are not associated with loss of
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neutralising ability by serum antibody, it is possible that these changes may have 
conferred an intrinsic biological fitness advantage to BA variants relative to previous 
group B viruses.
Analysis of the neutralising responses of RSV A infected individuals to two RSV A 
test viruses A2 and Kil/A/2006 showed a similar pattern of homologous to 
heterologous reactivity. The infecting RSV A viruses were remarkably similar in 
terms of both nucleotide and amino acid identity on both the G and F proteins. 
Analysis of the level of variation between the G genes of RSV A test viruses by MDS 
showed evidence of variation between the A2 and Kil/A/2006 G genes. The 
Kil/A/2006 test virus was located within the cluster of RSV A infecting strains, while 
the A2 virus occurred on a separate region of the two dimensional MDS space. The 
relationship between these viruses was confirmed by phylogenetic analysis of G gene 
sequences. The phylogenetic tree depicting these relationships showed that while the 
Kil/A/2006 G gene clustered together with G gene sequences derived from infecting 
viruses, the A2 G gene was located on a separate branch. Viewed together, these data 
suggested that both the contemporary RSV A infecting viruses as well as the 
Kil/A/2006 test virus had evolved away from the A2 virus which had been isolated 
about 45 years earlier.
Despite evidence of G gene variation between the two RSV A test viruses, there was 
no difference in the ability of infant sera to neutralise either virus. The neutralising 
response to the two RSV A test viruses by sera from infants with contemporary RSV 
A infections both in terms of both fold rise in titre as well as the ability to seroconvert 
was not statistically different. These data suggest that temporal evolution of RSV does
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not lead to loss of neutralising ability by serum antibody that is detectable by the 
neutralisation method employed. These data further suggest that RSV molecular 
evolution is not associated with loss of neutralisation by serum antibody. These 
results have implications for vaccine design. It is possible that future vaccines could 
act by the induction of neutralising antibody. The results presented here suggest that 
such vaccines are likely to retain effectiveness over a long period time without the 
need for recurrent antigenic updates. This might result in substantial cost benefits and 
potentially increase both coverage and effectiveness of future vaccine programmes in 
reducing the burden of illness attributable to RSV infection.
Finally, this study looked at total antibody responses to group conserved regions on 
the G proteins of RSV A and B. The results presented show that antibody responses 
directed at these regions are strongly group-specific. The data presented support the 
results of previous studies that showed that immunisation of mice with similar 
peptides resulted in group-specific protection (Simard et al., 1997). These results also 
provide further support to the idea that the RSV neutralising response is strongly 
group-specific, suggesting the need to consider the parallel development of live 
attenuated vaccines based on an RSV B backbone in order to ensure that protective 
immunity that is induced through vaccination is effective against genotypes from both 
groups of RSV.
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Chapter 8 - C ytokine/chem okine responses follow ing natural 
infection in infants
Introduction
RSV is the most important viral cause of severe pneumonia in infancy (Nair et al., 
2010). Despite this, the mechanisms of pathogenesis among infants who are naturally 
infected are not fully understood. The first point of contact between RSV and the host 
is the epithelium of the upper respiratory tract. Since RSV replication occurs mainly 
in airway columnar epithelial cells, cytokine/chemokine responses generated at this 
site are likely to significantly influence the balance between virus clearance and 
pathology.
RSV infection of epithelial cells leads to significant up-regulation of innate immune 
receptors such as Toll Like Receptor 4 (TLR-4) within 24 hours of infection (Xie et 
al., 2009). TLR-4 and CD 14 on human monocytes have been shown to bind to the F 
protein leading to the production of pro-inflammatory cytokines TNF-a, IL-6 and IL- 
12 (Kurt-Jones et al., 2000). In human infants, TLR4 is up-regulated at the acute 
phase of RSV infection and down-regulated at the convalescent stage, underpinning 
its central role in the recognition of RSV and in the initiation of host antiviral 
responses (Gagro et al., 2004). RSV infection also promotes the secretion if TNF-a, 
IL-6, MCP1 and RANTES through interaction with TLR-2 and TLR 6 expressed on 
leukocytes (Murawski et al., 2009). Human alveolar macrophages have also been 
shown to be a potent source of pro-inflammatory cytokines/chemokines TNF-a, IL6 
and IL8 (Becker and Soukup, 1999).
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Peripheral production of pro-inflammatory cytokines/chemokines has been linked to 
initiation of clinical symptoms such as fever and malaise through activation of 
neurological pathways (Watkins et a l 1995), providing grounds to suggest that rises 
in pro-inflammatory cytokine/chemokine responses may be related to illness 
following natural RSV infection.
Once within human epithelial cells, RSV induces further production of IL-8 
(Harrison et a l, 1999, Arnold et a l, 1994) as well as the C-C chemokines RANTES, 
MCP1 and M IP-la in a dose dependant manner (Olszewska-Pazdrak et a l, 1998). 
RANTES has been shown to induce the migration of CD4+ T cells and monocytes 
(Schall et a l, 1990) to the site of infection. M IPl-a is thought to induce the 
chemotaxis of B cells, CD8+ T cells and CD4+ T cells (Schall et a l, 1993) and has 
further been suggested to have a role in eosinophil degranulation (Harrison et a l, 
1999). MCP1 on the other hand induces the migration of both CD8+ and CD4+ T 
cells (Loetscher etal., 1994).
The factors that promote the development of severe disease in infants have not been 
clearly defined. Among RSV-infected infants admitted to hospital with severe illness, 
the levels of RANTES, M IP-la, IL-6, IL-8 and IL-10 are significantly higher 
compared to non-RSV controls (Sheeran et a l, 1999), suggesting that these 
cytokines/chemokines have a role to play in RSV pathogenesis in infancy. There is 
evidence in the murine model that shows that RSV infection induces simultaneous 
production of both inflammatory (IFN-y) and regulatory (IL-10) cytokines in the 
acute phase of infection (Sun et a l, 2011). It has been suggested that the 
simultaneous production of these antagonistic cytokines is important in achieving a
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balance between virus clearance and prevention of immune mediated pathogenesis 
(Sun et a l, 2011, Loebbermann et a l, 2012).
The role of virus-specific factors on the early host response to RSV has not been 
exhaustively investigated. Murine studies have shown that some strains of the virus 
tend to induce more severe pathology than others. For example comparison of the 
pathogenesis induced by infection of BALB/c mice with either the A2 or line 19 
strains, showed that line 19 induced airway hyper-reactivity and mucus 
overproduction while A2 did not (Lukacs et a l, 2006). In this model, disease severity 
correlated with levels of IL-13 since infection of IL13-/- mice with line 19, abrogated 
airway hyperreactivity (Lukacs et a l, 2006). Later studies showed that certain 
mutations in the F protein are strongly associated with the ability of line 19 to induce 
airway hyperresponsiveness and enhanced mucus production (Moore et a l, 2009), 
raising the possibility that natural variation within this protein in wild-type isolates 
may similarly play a role in differential disease outcome in infants.
In this chapter, cytokine/chemokine responses following natural RSV infection in 
infants were explored. Cytokine/chemokine responses over the entire course of mild 
RSV infection as well as among infants admitted with severe RSV related pneumonia 
were related to disease outcome, viral load and different strains of RSV.
Chapter Aims
This chapter will explore the relationship between mild RSV infection and different 
cytokine/chemokine concentrations with a view to identifying cytokines/chemokines 
that are associated with development of disease following natural infection. The effect
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of viral load on the expression levels of different cytokines/chemokines will also be 
investigated. To evaluate whether other respiratory viruses induce 
cytokine/chemokine responses that vary from those induced by RSV infection, the 
levels of different cytokines/chemokines during RSV and rhinovirus infection will be 
compared. This chapter will also explore the kinetics of different cytokine/chemokine 
responses following natural infection in the household. Cytokine/chemokine 
responses in the nasal secretions of seven infants from whom nasal samples were 
collected at least twice weekly over the course of infection will be investigated. The 
relationship between peaks in cytokine/chemokine response, presence or absence of 
Upper Respiratory Tract Infection (URTI) symptoms (i.e. cough, sore throat, runny 
nose and nasal congestion) and viral load will be explored. The effect of virus specific 
factors on the infant cytokine/chemokine response will be investigated by comparing 
cytokine/chemokine responses in the nasal secretions of infants infected with either 
RSV A or B. Finally, the effect of different cytokine/chemokine concentrations on 
different clinical phenotypes of severe pneumonia will be investigated.
M ethods
The samples used in this study were derived from two studies of natural RSV 
infection in infancy and early childhood. The first set of samples were derived from a 
longitudinal household study in which nasal flocked swab samples were prospectively 
obtained from infants during an RSV epidemic at twice weekly intervals. Diagnosis of 
RSV (both A and B) along with 14 other respiratory pathogens was carried out on 
each sample using a multiplex real time PCR. In the studies whose results are reported 
in this chapter, only samples obtained a few days prior to, during and shortly after 
cessation of RSV shedding are included for analysis, and not the entire sample set
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collected over the six month period during which active surveillance was undertaken. 
Further details on the household study design can be found in chapter 4.
The second set of samples was derived from paediatric hospital inpatients admitted 
with WHO syndromically defined severe or very severe pneumonia and a laboratory 
confirmed RSV diagnosis. Nasal wash and nasopharyngeal aspirate samples were 
collected from these infants and were used in the detection of different 
cytokines/chemokines in this study. Further details on the design of the clinical 
surveillance study from which these samples were obtained can be found in chapter 4.
A total of 100 samples collected from seven infants from the household study are 
included in the analysis described in this chapter. Each of the infants in this study was 
less than 1 year of age at the time of entry into the study. Furthermore, 86 samples 
from infants and young children admitted to KDH with RSV-associated severe or 
very severe pneumonia were included in the study. Viral load was approximated by 
calculating the inverse of cycle threshold (ct) values obtained from real-time PCR 
diagnostic assays. The laboratory assays used in the measurement of 
cytokine/chemokine concentrations are described in detail in chapter 4.
Comparison of cytokine/chemokine concentrations between different groups of was 
done using a two sided student t test based on logio normalised concentrations. 
Samples whose cytokine/chemokine concentrations were below the lower limit of 
detection, were assigned the value 0.0001 pg/ml to enable log transformation and 
statistical analyses. In almost all samples tested, the levels of IL-5, IL-13, IL-4, IL-2 
and IL-12p70 were below the lower limit of detection and as a result, these
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cytokines/chemokines were not subjected to statistical analyses. To describe the 
kinetics of different cytokine/chemokine responses, differences between mean 
cytokine/chemokine concentrations at different time points pre/post infection were 
measured using multiple regression. In these analyses, cytokine/chemokine 
concentrations were the dependent variable while the different time points pre/post 
infection were the independent variable.
Results
Cytokine/chemokine Responses in the Longitudinal Household study 
Diversity of respiratory pathogens detected
In total, cytokine/chemokine levels were evaluated in 100 samples derived from 
different infants in the household study. Figure 8.1 shows the distribution of different 
respiratory pathogens in the study samples that were evaluated. Of the 16 pathogens 
that were included in the detection panel, only 8 were found to be present in the 
samples included in this study. The pathogens that were present at the highest 
proportions were RSV A (14%), rhinovirus (21%) and RSV B (22%).
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Discussion
In this chapter, the neutralising antibody responses in the acute and convalescent 
phase sera of children with a positive RSV diagnosis and who were admitted with 
severe pneumonia are presented. The infants and young children in this study were 
recruited over the course of 3 RSV epidemics in Kilifi. The group designations of 
each infecting strain was characterised using previously described molecular 
techniques (Scott et al., 2004) in addition to F and G gene sequencing of a number of 
infecting viruses. In addition to molecular sequencing and genotyping of infecting 
strains, comprehensive clinical phenotyping of clinical pneumonia was also carried 
out for each of the paediatric pneumonia admission cases recruited in this study.
The availability of comprehensive clinical and molecular diagnostic data in this study 
is an improvement over previous studies that have sought to look at the infant 
neutralising response. Studies done in the 1960s failed to show a difference between 
homologous and heterologous antibody responses in the sera of acutely infected 
infants (Coates et al., 1963, Wulff et al., 1964). These studies were done on the 
presumption that there was homotypic strain exposure in any single epidemic, a 
premise that has since been rendered invalid by studies that show evidence of co­
dominance of RSV A and B strains in some epidemics (Hendry et al., 1989, 
Freymuth et al., 1991). Subsequent studies that looked at the group-specificity of the 
neutralising response failed to show a statistically significant difference between the 
homologous and heterologous response to both RSV A and B (Muelenaer et al., 
1991, Hendry etal., 1988).
I l l
In order to assess the magnitude of the serum neutralising response following 
infection, mean acute and convalescent antibody titres to RSV test strains were 
compared. An overlay of the acute and convalescent phase neutralising antibody titre 
distributions (shown in figure 5.4) showed that in general, the acute antibody titre 
was lower than the convalescent antibody titre, suggesting that infants and children 
generally mount a strong neutralising antibody response following natural infection. 
When the acute and convalescent phase distributions in three age classes (0-5, 6-11 
and 12 months of age and above) were compared there was evidence that age plays an 
important role in the development of the neutralising antibody response. Whilst there 
was a modest difference between the acute and convalescent phase titres in the 0-5 
month age class, in the older age classes (6-11 and 12+ months of age) there was 
evidence of a robust neutralising response at convalescent phase of infection relative 
to the acute phase (figure 5.5). These data suggest that in general infants mount 
neutralising responses to natural infection and this response tends to increase with 
age.
It has been suggested that the inability of very young infants to mount a strong
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neutralising response to infection is related to high titres of maternally-derived 
antibody present in very young infants (Murphy et al., 1986b). To explore the 
relationship between pre-existing antibody and the ability to mount a robust response 
to infection, correlation analysis was carried out between the magnitude of the 
neutralising response and the titre of pre-existing antibody. The results of Spearman’s 
rank correlation analysis showed that there was a strong and statistically significant 
negative association between the magnitude of the neutralising response (measured 
as fold rise in titre) and the titre of acute phase antibodies. A similar pattern was seen
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when acute phase titres were stratified into four quartiles and the proportion of infants 
seroconverting in each quartile determined. Over 90% of the infants in the first 
quartile seroconverted, relative to 59.6%, 13.5% and 0% who seroconverted in the 
2nd, 3rd and 4th quartiles respectively. These data strongly suggest that high titres of 
pre-existing antibody interfere with the infants’ native response to infection. These 
data accord with a previous report by Parrot et al. who showed that the convalescent 
phase neutralising response to infection was negatively associated with the acute 
phase titre (Parrott et al., 1973).
In addition to the interfering effect of pre-existing antibody on the natural infant 
response to infection, it has also been suggested that young age may independently 
account for the relatively poor neutralising antibody response mounted by very young 
infants. A study by Murphy et a l found that age primarily affects the response to the 
F protein while pre-existing antibodies affect the response to the G protein (Murphy et 
al., 1986a). Since neutralising responses are mainly targeted at the F protein this age 
related reduction in response to the F protein could possibly be reflected in the overall 
neutralising response. The data presented in this study shows that there was a 
moderate but statistically significant positive association between age and the 
magnitude of the neutralising response. However, analysis of the proportion of infants 
who seroconverted within different age classes (Figure 5.8) showed that a small 
proportion of even the youngest infants mounted a seroconverting response to 
infection, suggesting that even very young infants are capable of mounting a strong 
neutralising response to natural infection. This suggests, that the key driver of the poor 
infant neutralising response is likely to be the presence of pre-existing maternal 
antibodies and not age. This idea is supported by the work of Shinoff et al. who found
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that pre-existing antibody and not age is the key determinant of the infant neutralising 
response (Shinoff et a l, 2008).
A number of studies have looked at the protective effect of neutralising antibodies 
against severe disease in young infants. Although some studies have shown evidence 
of protection from severe disease by antibodies (Glezen et al., 1981a), some studies 
have reported that maternally-derived neutralising antibodies are not associated with 
protection from severe disease (Bulkow et al., 2002). The data presented in this 
chapter show a protective association between neutralising antibodies and some 
clinical features of severe pneumonia. Out of seven clinical feature that were 
analysed, neutralising antibodies were found to be associated with a lower risk of 
developing shock, flaring, hypoxia and crackles, although statistical significance was 
only reached in the case of shock. These data generally suggest that neutralising 
antibodies, even in this group of severely ill children are associated with protection 
from some features of clinical pneumonia.
A number of studies have looked at the sequence characteristics of different strains of 
RSV both at the F and G gene levels. Comparison of the G protein genes of two RSV 
A strains, A2 and Long found 94% amino acid sequence identity between these two 
strains (Johnson, 1987). However the A2 G protein gene only shared 53% amino acid 
identity with the G protein of the group B strain, 18537 (Johnson, 1987). Sullender et 
al. found that another group B strain, 8/60 shared 98% amino acid identity with the 
18537 strain, but only shared 56% amino acid identity with the A2 strain (Sullender et 
al., 1990). These results strongly suggested that in general, the G protein is highly 
variable between the two groups but is relatively conserved within each group. In
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contrast, comparison of the deduced amino acid sequences of the 18537 and A2 F 
proteins showed that they shared 91% amino acid identity (Johnson and Collins, 
1988), suggesting that the F protein is highly conserved between groups. The data 
presented in this chapter shows that there was 87% amino acid identity in the deduced 
F protein amino acid sequences of infecting RSV A and B isolates and only 28.6% 
amino acid identity at the G protein level. These data are therefore in general 
agreement with previous findings and reinforce the idea that the F protein is highly 
conserved between the 2 groups while the G protein is highly variable. Despite the 
high level of sequence conservation of the F proteins of wild-type isolates, 
neutralising responses to this protein do not appear to correlate with protection from 
natural (Glezen et al., 1986) or experimental (Hall et al., 1991) re-infection. It is 
possible that despite its relatively greater level of conservation, neutralising antibody 
epitopes on the F protein may be located on a small but variable part of the protein.
To explore this possibility, four neutralising antibody epitopes on the F protein were 
identified in the literature (West et a l, 1994, Martin-Gallardo et al., 1991, Lopez et 
al., 1990, Trudel et al., 1987a) and mapped on the deduced amino acid sequences of 
infecting RSV A and B strains. The data presented in figure 5.12 show that two of 
these epitopes; aa205 -225 (Bourgeois et al., 1991) and aa221- 236 (Trudel et al., 
1987a) were located on a region of the F protein that contained a number of group- 
specific amino acids. In other words some amino acid residues within these epitopes 
were perfectly conserved within but not between the two groups. There are studies 
that have shown that such differences could substantially influence the group- 
specificity of the neutralising antibody response. West et al. for example, 
demonstrated that one monoclonal antibody, RS348 that was generated against the A2
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strain (RSV A) (West et al., 1994) and whose target is aa205 -225 on the F protein 
(Bourgeois et al., 1991) mediated a 782-fold greater neutralisation of homologous 
virus (RSV A) relative to heterologous virus (RSV B) (West et al., 1994). Analysis 
of the amino acids of this epitope among the infecting strains presented in this study 
(figure 5.12) showed that it contained two amino acids that were conserved within but 
not between the two RSV groups. This strongly suggests that if the infant response 
similarly targets this neutralising epitope, it is likely that such a neutralising response 
would be highly group-specific.
A similar pattern of group-specific neutralisation has been observed using a 
neutralising monoclonal antibody, 7C2 (West et al., 1994) whose target is aa221-236 
(Trudel et al., 1987a) on the F protein. Analysis of the patient isolates in this study 
showed that aa221-236 contained one amino acid that was conserved within but not 
between the two RSV groups. The 7C2 monoclonal antibody targeting this region has 
been shown to mediate a 2.5 fold greater homologous vs. heterologous neutralisation 
at group level (West et al., 1994), supporting the idea that infant responses targeted at 
this region would be similarly group-specific.
The final two neutralising epitopes that were mapped on the deduced F protein amino 
acid sequence alignments of infecting strains were perfectly conserved in all infecting 
strains irrespective of whether they belonged to group A or B. Previous studies using 
a neutralising monoclonal antibody targeting one of these epitopes (aa262-268) have 
shown that it mediates a 1.4-fold greater homologous to heterologous neutralisation 
(West et al., 1994), suggesting that neutralising responses directed at this region are 
largely cross-reactive.
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In summary, these data suggest that neutralising responses to the F protein are a 
mixture of both group-specific and group cross-reactive responses and that amino 
acids that are conserved within but not between groups could potentially lead to an 
overall greater homologous to heterologous neutralising response.
This study finally looked at the group-specificity of the neutralising antibody 
response. Responses to contemporary strains of RSV A and B were used using acute 
and convalescent sera obtained from infants whose infecting strains were well 
characterised by molecular techniques. The results of these analyses show that the 
proportion of homologous seroconversion was greater than that of heterologous 
seroconversion irrespective of whether the infecting strain was RSV A or B. The 
effect of age on the ability to mount a strong homologous vs. heterologous response 
was also investigated. Infant responses were stratified into 3 age classes, 0-5, 6-11 and 
12+ months of age and their ability to neutralise homologous virus was compared to 
their ability to neutralise heterologous virus. The results of these analyses showed that 
in all three age classes the mean response to homologous virus (in terms of fold rise 
in titre) was significantly greater than the mean response to heterologous virus.
The weakest homologous responses to RSV A and B occurred in 0-5 month age class. 
It is possible that the inability to mount a strong neutralising response within this age 
class may be related to the presence of pre-existing maternal antibody as discussed 
earlier. On the other hand, the strongest neutralising responses to either homologous 
or heterologous virus were seen in the 6-11 month age class. This robust response 
might be attributed to the absence of pre-existing maternally-derived antibody at the
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time if infection. Analysis of the dynamics of the acute phase neutralising response in 
this study showed that maternally-derived antibodies had declined to minimal levels 
by 3 months of age suggesting that infants exposed to primary infection in the 6-11 
month age class would have largely been free of maternal antibody. Analysis of the 
heterologous responses in this age class showed that although the mean heterologous 
responses (in terms of log fold rise in titre) to both RSV A and B were high relative 
to the 0-5 month age class, they were nonetheless below the 4-fold threshold that has 
traditionally been used as a measure of a significant serological response.
It was further observed that although the homologous responses to RSV A and B in 
the 12+ month age class were above the 4-fold threshold, they were nonetheless lower 
than the homologous responses in the 6-11 month age class. A possible explanation 
for this could be that at this age (12 months and above), young children in their 
second year of life are likely to be undergoing secondary infection. The inability to 
detect a homologous response in the 12+ month age class that was of comparable 
magnitude to that in the 6-11 month age class may be attributed to the presence of 
relatively high levels of pre-existing antibody brought about by either (i) maintenance 
of high antibody levels following primary infection or (ii) an extremely rapid rise of 
secondary antibody shortly after exposure. This would imply that the acute sample -  
which is collected after the onset of symptoms and therefore a few days after actual 
infection -  would be partly reflective of the antibody response to the current infection. 
The dynamics of the primary and secondary neutralising antibody responses are 
considered in greater detail in chapter 6.
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In summary, the data presented in this chapter explore the neutralising response to 
RSV and more specifically, the group-specificity of the neutralising response in a 
group of severely infected infants. The data show that the neutralising antibody 
response is strongly group-specific and that group-specific amino acid differences in 
the neutralising epitopes on both the F and G proteins of the infecting strains may be 
associated with this specificity. The data presented in this chapter supports the 
assertion that population level group-specific immunity may underlie the observed 
group replacement dynamics of RSV.
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Chapter 6 - Kinetics of the neutralising antibody response
Introduction
RSV re-infects throughout life (Henderson et al., 1979, Glezen et a l, 1986). The 
ability to repeatedly infect may be related to antigenic variation or short-lived 
protective immunity or both. Studies of the antigenic characteristics of RSV strains 
that cause repeat infections suggest that antigenic variation does not play a central 
role in the ability of RSV to re-infect (Beem, 1967) although there is evidence that 
shows that re-infection with genetically variant strains is a common phenomenon 
(Agoti et al., 2012). The duration of protective immunity post natural infection has 
not been clearly defined, although human experimental challenge studies show that 
re-infection can be induced within 2 months of the primary challenge (Hall et al., 
1991). The correlates of protective immunity in terms of both the duration and strain- 
specificity of the immune responses induced by natural infection are an important 
subject of research since they will provide insights on the likely effectiveness of 
future RSV vaccines.
The mechanisms of antibody-mediated protection have been studied for a number of 
other acute viral infections. Infection with viruses such as the measles virus, 
poliovirus and the mumps virus induce extremely long lived antibody responses 
whose respective half lives are estimated to be over 200 years (Amanna et al., 2007). 
Infections such as poliovirus induce strain-specific antibodies that are maintained for 
a number of years in the absence of natural re-exposure (Paul and Riordan, 1950, 
Paul et al., 1951). On the other hand, natural influenza A infection has been shown to
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induce neutralising antibodies that decline to pre-infection levels within one year of 
infection (Buchy et a l, 2010). Studies of the duration of the total antibody response to 
natural primary RSV infection suggest that RSV-specific antibodies are short-lived. 
Welliver et a l showed that the serum antibody response to RSV declined to pre­
infection levels by one year after primary infection (Welliver et a l, 1980), while the 
secretory IgA response declined to pre-infection levels by 3 months post infection 
(Kaul et a l, 1981). There are currently no data available that show the duration of 
neutralising antibody responses in the serum of infants with natural primary RSV 
infection.
The determinants of the variation in the duration of antibody induced protection 
between different viral infections are not fully understood. A number of murine based 
studies have shown that antibody producing plasma cells can be maintained for long 
periods of time in the absence of antigenic re-stimulation (Slifka and Ahmed, 1998), 
suggesting that that these cells may be a key source of long lived antibody responses. 
However not all plasma cells are long lived (Slifka and Ahmed, 1996). There is some 
evidence that suggests that the longevity phenotype oF-specific plasma cell 
populations is associated with their cognate epitopes (Slifka and Ahmed, 1998), 
meaning that the long term maintenance of antibody responses through this 
mechanism is epitope - and by extension - virus specific. These observations agree 
with the ability of some viral infections to induce short-lived antibody responses 
while others such as those mentioned above appear to induce responses that are 
maintained for many years.
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Despite the evidence of short-lived primary antibody responses, it is well recognised 
that severity of RSV disease declines significantly upon secondary infection (Glezen 
et al., 1986, Nokes et al., 2008). While it is likely that the maturation of the 
respiratory system with age plays a crucial role in moderating disease severity, a 
number of studies have provided indirect evidence that maturation of the respiratory 
system alone is not sufficient to protect from severe disease. RSV is known to be a 
major cause of severe respiratory illness among the elderly and adult organ transplant 
recipients who are under immunosuppressive therapy to reduce the likelihood of 
organ rejection (Falsey et al., 2005, Krinzman et al., 1998). Since severe disease 
frequently occurs in these adult populations, physiological maturity of the airways 
alone cannot account for protection from severe disease. These data therefore suggest 
that protection from severe disease in healthy, immuno-competent individuals may be 
associated with the ability to generate a rapid, protective neutralising response shortly 
after re-infection.
The role of maternal antibodies in protecting from severe infection has been 
extensively studied. Although there are some contradicting data (Bulkow et al., 
2002), it is generally agreed that maternal neutralising antibodies provide protection 
from severe disease in early infancy (Glezen et al., 1981b). It has previously been 
shown that the total maternal antibody response is relatively short-lived with a half 
life of less than three months (Ochola et al., 2009). It has also been suggested that the 
duration of protection by maternal antibodies is related to the titre at birth, and that 
higher cord titres are associated with a longer duration of protection from natural 
infection while lower cord titres protect for a shorter duration (Ogilvie et al., 1981).
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There is a paucity of data however on the mean duration of protective neutralising 
antibodies above thresholds that are commonly associated with protection from severe 
disease.
Chapter Aims.
This chapter explores the serum neutralising antibody responses in a birth cohort that 
was followed for approximately 30 months or until three RSV epidemics had been 
experienced. The cohort was recruited in two phases, which are referred to in this 
chapter as cohort 1 and cohort 2. The chapter aims to explore the relationship between 
exposure to infection, inferred through incidence data obtained from inpatient 
diagnostic records and temporal variations in the mean neutralising antibody titres in 
the two cohorts. The chapter also aims to define the duration of neutralising antibody 
response following primary infection. The mean neutralising responses at different 
time points post infection will be compared to that of a pre-exposure control group. 
The chapter further aims to define the mean duration of protective neutralising 
antibodies of maternal origin using a putative protective threshold obtained from the 
literature. Using this threshold, the mean duration of protective maternal antibodies as 
well as the age prevalence of protective maternal neutralising antibodies will be 
calculated. Finally the dynamics of the primary and secondary neutralising responses 
will be evaluated, by comparing neutralising titres in sera collected within 10 days of 
identification of primary and secondary infection to a pre exposure control group.
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Materials and methods
Study population and design
The study used archived serum and nasal wash samples collected from a birth cohort 
of children recruited between 2002 and 2003 in the rural District of Kilifi on the 
Kenyan Coast. The birth cohort was recruited in 2 phases: phase 1 was recruited 
between January and May 2002 while phase 2 was recruited between December 2002 
and July 2003. At delivery, a cord blood sample was taken, followed by routine blood 
samples scheduled at 3-monthly intervals until each child had experienced three RSV 
epidemics or was lost to follow-up. Through home or clinic surveillance nasal washes 
were collected from children that displayed symptoms of acute respiratory infection 
and detection of RSV done using IF AT. For positive samples the RSV group was 
determined by Reverse Transcriptase (RT)-PCR (Stockton, 1998). An acute blood 
sample was collected as soon as possible after RSV diagnosis and a convalescent 
blood sample was collected about one month later. 28 individuals from the birth 
cohort from whom at least eight serum samples had been collected over the course of 
follow-up were included this study. All had a virus confirmed primary infection 
during the course of the study, while 9 had virus confirmed secondary infections. Of 
the 28 primary infections, 16 were group A infections while 12 were group B. Of the 
9 virus confirmed secondary infections, 3 were RSV A infections while 6 were RSV
B. Out of the 3 individuals who had RSV A secondary infections, 1 had a primary 
RSV A infection while 2 had RSV B primary infections. Similarly, out of the 6 
individuals who had RSV B re-infections, 3 had primary RSV A infections while 3 
had primary RSV B infections. In all the studies outlined in this chapter, serum 
neutralising antibodies were measured to local RSV A and B strains (Ken/A/2006
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and Ken/B/208) and a mean titre calculated. Antibodies were measured in acute and 
convalescent sera as well as in the cord and routine 3 monthly sera. A pre exposure 
control group consisting of sera collected up to six months before infection from 
children who were older than 5 months of age at the time of collection (pre-exposure 
control group) was defined for comparison. Exposure in the presence study was 
estimated using paediatric inpatient RSV surveillance data. The study population, 
design and diagnostic techniques have been described elsewhere (Nokes et al., 2009).
RSV epidemic start and end dates during the period of surveillance were adopted 
from the work of Okiro (E. Okiro PhD Thesis) and are shown in table 6.1.
Year epidemic start
week
finish
week
2002 1 11 26
2 49 52
2003 2 1 15
2004 3 2 22
Table 6.1 Epidemic start and end weeks over the period of follow up of the 2 birth 
cohorts. These definitions are adopted from the work of Okiro (Emelda Okiro thesis, 
2007).
Statistical analyses
Data were analysed using Stata (version 11, Statacorp, College station Texas). For 
the purpose of calculating the duration of the neutralising response, the start of the 
host immune response to RSV was assumed to coincide with the date of collection of 
nasal samples that turned out to be positive for RSV antigen by IFAT. It was further 
assumed that antibody responses had declined to pre-infection levels if they were
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similar to or fell below the mean pre-exposure control titre. The duration of the 
neutralising antibody response following primary infection was determined using a 
multiple linear regression model. In this model the neutralising antibody titres were 
the dependant variable while the number of months before or after infection and age 
were the independent variables. Acute and convalescent phase responses during 
primary and secondary infection were also compared using a multiple linear 
regression model. The rate of decay of maternal neutralising antibody was analysed 
by comparing infant titres to a neutralising antibody titre of 2.48 logioND5o that has 
previously been associated with protection against severe disease (Glezen et al., 
1981a). Time to failure survival analysis was used to determine the average duration 
of protective maternal antibodies. Failure was defined as a decline of maternal titres 
below the titre associated with clinical protection. The average duration of 
neutralising antibody protection by maternal antibodies was obtained by calculating 
the reciprocal of the average rate of decline of maternal titres obtained from survival 
analysis. The analytical output for the data presented in this chapter is presented in 
appendix 2.
Results
General age dynamics of the neutralising response
To describe the age dynamics of the neutralising response in the first two years of life, 
serum neutralising antibodies from the 2 birth cohorts were combined and the mean 
neutralising response calculated in different age classes. Ten age classes were defined 
for these analyses; 0-2 (n=49), 3-5 (n=31), 6-8 (n=22), 9-11 (n=32), 12-14 (n=36), 
15-17 (n=29), 18-20 (n=21), 21-23 (n=22), 24-26 (n=28) and 27+ (n=10) months 
of age. There was a sustained decline of neutralising antibodies in the first 8 months
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of life, followed by an increase in mean neutralising titres between the ages of 11 and 
20 months. There was a sustained increase in titre between the ages of 21 to 26 
months. This was followed by a slight decline among children who were above 27 
months of age. These data are graphically represented in figure 6.1.
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Figure 6.1 The age dynamics of the neutralising antibody titre in the RSV birth cohort. 
Infant neutralising antibody titres are stratified into 10 age classes (x-axis) and mean 
neutralising titres (y-axis) compared in successive age classes. The grey circles indicate 
the distribution of actual titres within respective age classes while the lines cutting 
across the mean values (open cirles) indicate 95% confidence intervals. The p values 
cutting across different age classes indicate whether the differences between the means 
of the groups being compared are statistically significant.
The relationship between exposure and the neutralising antibody response
RSV inpatient surveillance data were used to estimate the periods when RSV 
epidemics were occurring within the community. Infants were considered to be 
exposed to and at risk of infection during epidemic periods and at lower or no risk of 
infection during inter-epidemic periods. To explore the relationship between the
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neutralising response and exposure, neutralising antibody titres from 19 infants in 
cohort 1 and 9 infants in cohort 2 whose sera were collected serially over 
approximately 30 months o f follow up were plotted against RSV incidence data 
obtained from inpatient surveillance. The data in figure 6.2 shows the result of this 
comparison.
Jan 2002 Jan 2003 Jan 2004 Jan 2005 Jan 2006
Year
Figure 6.2 The dynamics of the neutralising antibody response relative to population 
level transmission of RSV. The blue bars show the number of paediatric (<5 yrs old) 
RSV cases in severe and very severe pneumonia admissions to Kilifi District Hospital 
over the follow up period. The dashed grey and dashed red lines indicate temporal 
dynamics of the neutralising response in cohort 1 and 2 respectively. 19 individuals from 
cohort 1 and 9 individuals from cohort 2 were included in this analysis.
To further explore the relationship between population level virus transmission and 
variation in the mean neutralising response, serum samples from cohort 1 and 2 were 
stratified by date of collection into 11 and 10 strata respectively of 3 calendar months 
each. 19 and 9 individuals from cohorts 1 and 2 respectively were included in these 
analyses. The mean neutralising titre within each stratum was then calculated and
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compared to that of the subsequent stratum. Figure 6.3 is a summary of the mean 
neutralising response within each stratum in cohort 1 relative to population level 
transmission. Table 6.2 contains the mean age, dates of sample collection as well as 
total number of samples in each stratum. As an estimate of the level of exposure, the 
proportion of samples that were collected within and outside epidemics are provided 
for each stratum. The mean neutralising antibody titre in stratum 1 (2.8 logio PRNT) 
was significantly greater than the mean neutralising titre in stratum 2 ( 2.27 logio 
PRNT, pO.OOOl). 36% and 71% of the samples in strata 1 and 2 respectively were 
collected during epidemic 1 while the remaining samples were collected during inter­
epidemic periods. The mean neutralising response in stratum 2 was on the other hand 
significantly greater than the mean response in stratum 3 (1.92 logio PRNT,
p=0.012), where all the samples were collected in the inter-epidemic period between 
epidemics 1 and 2. There was no significant difference between the mean titre in 
stratum 3 and 4 (1.92 logio PRNT vs. 1.86 logio PRNT; p=0.74). There was a 
statistically significant difference between the mean neutralising titre in strata 4 and 5 
(1.92 logio PRNT vs. 2.34 logio PRNT; p=0.002). 31% and 96% of the samples in 
strata 4 and 5 respectively were collected in the course of epidemic 2. There was no 
statistically significant difference between the mean neutralising responses in strata 5 
and 6 (2.34 logio PRNT vs. 2.33 logio PRNT; p=0.9). All the samples in stratum 6 
were collected in the inter-epidemic period between epidemics 2 and 3. The mean 
neutralising response in stratum 7 was borderline significantly lower than the mean 
neutralising response in stratum 6 (2.33 logio PRNT vs. 2.03 logio PRNT; p=0.06). 
All the samples collected in stratum 7 were collected in the inter-epidemic period 
between epidemics 2 and 3. The mean neutralising response in stratum 8, where 22% 
of the samples were collected in the course of epidemic 3, was not significantly
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different from the mean neutralising response in stratum 7 (1.97 logio PRNT vs. 2.03 
logio PRNT; p=0.73). However the mean neutralising titre in stratum 9 where all the 
samples were collected during epidemic 3 was significantly greater than that of 
stratum 8 (2.66 logio PRNT vs. 2.03 logio PRNT; p<0.0001). There was no
statistically significant difference between the neutralising responses of strata 9 and 
10 (2.66 logio PRNT vs. 2.92 logio PRNT; p=0.07) and 10 and 11 (2.92 logio PRNT 
vs. 2.78 logio PRNT; p=0.5). These data are summarised in figure 6.3.
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Figure 6.3 The dynamics of the neutralising response in cohort 1 relative to incidence 
of RSV. Sera from 19 individuals who were prospectively recruited and followed up for 
approximately 30 months are included in this analysis. Eleven strata consisting of 3 
calendar months each were generated and the mean neutralising titre in each stratum 
calculated. The mean titre in each stratum was compared to that of the subsequent 
stratum. The p values shown indicate whether there was a significant difference between 
the mean titres of the different strata being compared. The titres used in this analysis 
were mean titres obtained using two local test viruses (Ken/A/2006 and Ken/B/2008). 
The numbers within each stratum are shown in table 6.2
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Stratum First date Last Date Mean ag e - 
Months (range)
n %
within
epidemic
1 01-Feb-02 18-Apr-02 0.2 (0-1.3) 14 36
2 02-May-02 30-Jul-02 3.3 (2.3-5.7) 24 71
3 02-Aug-02 28-Oct-02 6 (5.5-8.3) 17 0
4 30-0ct-02 22-Jan-03 8.6 (8.3-10.2) 13 31
5 29-Jan-03 23-Apr-03 11.8 (10-14.1) 23 96
6 06-May-03 23-Jul-03 15 (14.3-17.3) 14 0
7 31-Jul-03 14-Oct-03 17.9 (17.1-20.3) 15 0
8 29-Oct-03 15-Jan-04 20.8 (20.1-23.2) 9 22
9 23-Jan-04 19-Apr-04 24 (23.1-26.3) 18 100
10 23-Apr-04 14-Jul-04 26.7 (25.3-29.3) 19 74
11 27-Jul-04 20-Aug-04 29.4 (29.1-29.9) 5 0
Table 6.2 The beginning and end dates of each stratum shown in figure 6.3 as well as 
the mean age and total number of samples for each stratum are shown in this table. As a 
measure of the level of exposure in each stratum, the proportion of samples that were 
collected during an epidemic are also indicated
Figure 6.4 contains a summary of the mean neutralising response relative to 
transmission within cohort 2, while table 6.3 contains the mean age, dates of sample 
collection as well as total number of samples in each stratum. The mean neutralising 
response in stratum 1 was significantly greater than that in stratum 2 (2.95 logio 
PRNT vs. 2.45 logio PRNT; p=0.02). All the samples in strata 1 and 2 were collected 
during epidemic 2. There was no significant difference between the mean neutralising 
responses in strata 2 and 3 (2.45 logio PRNT vs. 2.25 logio PRNT; p=0.3). However 
there was a significant difference between the mean titres in strata 3 and 4 (2.25 logio 
PRNT vs. 1.84 logio PRNT; p=0.026). All samples in strata 3 and 4 were collected in
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the inter-epidemic period between epidemics 2 and 3. There was no statistically 
significant difference between the mean neutralising titres in strata 4 and 5 (1.84 
logio PRNT vs. 1.81 logio PRNT; p=0.88), nor was there a difference between the 
mean titres of strata 5 and 6 (1.81 logio PRNT vs. 1.93 logio PRNT; p=0.46). 17% 
and 100% of the samples in strata 5 and 6 were collected in the course of epidemic 3. 
There was however a statistically significant difference between the mean neutralising 
titres in strata 6 and 7 (1.93 logio PRNT vs. 2.53 logio PRNT; pO.OOOl). 67% of the 
samples in stratum 7 were obtained during epidemic 3. There was similarly a 
significant difference between the mean responses of strata 7 and 8 (2.53 logio PRNT 
vs. 1.91 logio PRNT; p=0.001). All samples in stratum 8 were collected in the inter­
epidemic period between epidemics 3 and 4. There was no significant difference 
between the mean responses in strata 8 and 9 (1.91 logio PRNT vs. 2.22 logio PRNT; 
p=0.12), but there was a significant difference between the mean responses in strata 9 
and 10 (2.22 logio PRNT vs. 3.05 logio PRNT; pO.OOOl). 30% of the samples in 
stratum 9 were collected in the course of epidemic 4 while 71% of the samples in 
stratum 10 were collected in epidemic 4. These data are graphically presented in 
figure 6.4.
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Figure 6.4 The temporal dynamics of the neutralising response in cohort 2 relative to 
RSV occurrence as defined through hospital admissions surveillance . Sera from 9 
individuals who were prospectively recruited and followed up for approximately 30 
months are included in this analysis.Ten strata of 3 months were defined and the mean 
neutralising titre in each stratum compared to that of the subsequent stratum. The titres 
used in this analysis were mean titres obtained using two local test viruses (Ken/A/2006 
and Ken/B/2008). The numbers within each stratum are shown in table 6.3
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Stratum First date Last Date Mean ag e- 
Months (range)
n % within 
epidemic
1 12-Dec-02 24-Jan-03 0 (0-0) 5 100
2 29-Jan-03 14-Apr-03 1.4 (0-2.9) 6 100
3 07-May-03 18-Jul-03 3.9 (0-6.9) 8 0
4 05-Aug-03 15-Oct-03 7.1 (3-9.8) 7 0
5 03-Nov-03 19-Jan-04 9.3 (5.8-11) 6 17
6 23-Jan-04 19-Apr-04 13.3 (9.1-15.8) 14 100
7 21-Apr-04 16-Jul-04 15 (11.1-18.1) 15 67
8 27-Jul-04 15-Sep-04 18.1 (15-20.2) 5 0
9 25-Oct-04 07-Jan-05 21.2 (18.1-24.8) 10 30
10 18-Jan-05 26-Feb-05 24.6 (21.1-26.5) 7 71
Table 6.3 The start and end dates, mean age in months, total number of samples and 
proportion of samples collected during an epidemic for each cohort 2 stratum shown in 
figure 6.4.
The ability to maintain high neutralising antibody titres after infection was evaluated 
by comparing mean neutralising responses during epidemics to mean neutralising 
responses during inter-epidemic periods among infants who had experienced a 
primary infection. These analyses only included samples collected from infants who 
were three months or older to reduce the effect of maternal antibody titres on the 
calculated estimates. The results of multiple regression analysis showed that the mean 
neutralising antibody titres during epidemics (1.9 logio PRNT) was significantly 
greater than the mean neutralising titres during inter-epidemic periods (1.6 logio 
PRNT, p=0.001). These data are graphically presented in figure 6.5.
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Figure 6.5 The distribution of neutralising antibody titres during epidemic and inter­
epidemic periods for an infant birth cohort from coastal Kenya.
The duration of the primary neutralising response
In order to calculate the duration of the primary neutralising antibody response, 
antibody titres at different time points post-infection were compared to the pre­
exposure control (figure 6.6). Results from multiple linear regression analysis 
showed that there was no difference between neutralising titres in the pre-exposure 
control group (1.8 logio PRNT) and in sera collected between 0-0.4 months after 
infection (1.9 logio PRNT, p=0.146). There was however a significant difference 
between neutralising titres in the pre-exposure control and at 0.5-0.9 months post 
infection (2.8 logio PRNT, pO.OOOl), 1.0-1.9 months post infection (2.5 logio 
PRNT, pO.OOOl) and at 2.0 - 2.9 months post infection (2.3 logio PRNT, pO.OOOl).
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There was no difference between neutralising titres in the pre-exposure control and 
neutralising titres at 3.0-3.9 months post infection (2.0 logio PRNT, p=0.052). These 
data are graphically shown in figure 6.6.
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Figure 6.6 The duration of the primary neutralising antibody response. The mean 
neutralising titres at various time points post infection were compared to the mean titre 
of a pre-exposure control group. The p values indicate whether there is a significant 
difference between post infection titres at different time points post infection and the 
pre-exposure control. The number of samples within each time point are shown above 
each respective distribution.
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Duration of protective, maternally-derived neutralising antibodies
Neutralising antibody titres measured in sera obtained prior to the identification of a 
primary infection were classified into 2 levels: high and low using a threshold titre 
(2.48 logio PRNT) that has been associated with protection from severe disease in 
infants (Glezen et a i, 1981a). Age specific prevalence estimates of maternal 
neutralising antibody titres above this threshold were then determined. At between 0 
and 0.9 months of age 100% (95% Cl 86%-100%) of infants had titres above the 
protective threshold. This proportion dropped to 37% (95% Cl 16%-62%) at
between 2 and 2.9 months of age. No infants between 3 and 4.9 months of age had 
maternal neutralising antibodies above the protective threshold. These data are 
graphically presented in figure 6.7. Using survival analysis, it was estimated that 
mean duration of protective maternal neutralising antibodies is 2.8 months (95% Cl 
2.5 -  3.1 months).
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Figure 6.7 The proportion of infants in different age classes with mean neutralising 
titres that are above a putative protective threshold (Glezen et'aL, 1981a). The bars 
indicate the proportion of samples that were above the putative protective threshold, 
while the lines traversing the bars indicate 95% confidence intervals. No data were 
available for the 1-1.9 month age class. The number of infants within each age class is 
shown above the proportion bars.
The rate of development of neutralising antibodies following primary and 
secondary infection
Neutralising titres measured in sera collected within 10 days of identification of 
primary and secondary infection by IFAT were compared. There was no difference 
between the mean neutralising antibody titre of the pre exposure control and the mean 
neutralising titre in the sera of primary infected infants collected with 10 days of 
identification of the infection (1.9 logio PRNT, p=0.448). However, the mean 
neutralising titre in the sera collected within 10 days of identification of secondary
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infection (3.02 logio PRNT) was significantly greater than the mean response in the 
pre exposure control (p<0.0001) and the mean response in the sera of primary 
infected infants (pO.OOOl). These data are graphically presented in figure 6.8. Mean 
convalescent responses to both primary and secondary infection were also compared.
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Figure 6.8 Neutralising titres in sera collected within 10 days of identification of RSV 
during primary and secondary infection are compared to a pre-exposure control. The 
dark boxes indicate the mean titre within each group while the whiskers indicate 95% 
confidence intervals. The p values indicate differences in mean titre between the 
comparison groups are statistically significant. The number of samples within each 
group is indicated above the mean and 95% confidence interval symbols.
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Discussion
This chapter looked at the kinetics of the RSV neutralising response following natural 
infection. The data presented in this study was obtained by measuring the serum 
neutralising antibody responses in 2 RSV birth cohorts, which were prospectively 
followed up for up to 30 months or until infants had experienced at least 3 epidemics.
In the first epidemic experienced by either cohort, there was a general decline of 
neutralising antibody, despite indirect evidence of exposure. This lack of response is 
most likely related to the presence of maternally-derived neutralising antibodies that 
are typically present in relatively high titres in the first few months of life. It is 
possible that these antibodies provided some level of protection from natural 
infection, or masked the infants’ native response to infection. This masking of infant 
responses early in life by maternally-derived antibodies has been demonstrated in 
earlier studies (Parrott et a l, 1973). The second epidemic occurred at a time when 
most infants within both cohorts were at an age in which maternal antibodies had 
declined to very low levels. The data show that at the time infants in both cohorts 
were experiencing the second RSV epidemic of their lives, mean neutralising 
antibodies within both cohorts rose in tandem with community level transmission of 
RSV and declined with the waning of population level transmission. These data 
strongly suggest that community level exposure in the form of RSV epidemics, 
triggers herd neutralising responses among infants in whom maternally-derived 
antibody has declined to minimal levels and that these responses are short-lived. 
Analysis of the duration of the primary neutralising response showed that it declined 
to pre-infection levels within 3-4 months post infection. Taken together, these data 
suggest that susceptibility to secondary may be established in part as a result of the
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rapid decline of primary neutralising antibodies. Glezen et a l showed that up to 76% 
of infants who experience primary infection in their first year of life, go on to 
experience secondary infection in their second year of life (Glezen et a l, 1986), 
suggesting that immunity generated following primary infection is not sufficient to 
protect from natural challenge in the subsequent RSV epidemic.
The study by Glezen et a l showed that the risk of re-infection was inversely related to 
the titre of pre-existing neutralising antibody, suggesting that neutralising antibodies 
are associated with protection from infection and disease. This idea has been 
supported by studies of experimental adult infection (Hall et a l, 1991, Lee et a l, 
2004), in which the level of pre-inoculation neutralising titres have been found to be 
negatively associated with susceptibility to experimental infection. The data presented 
in this study suggests that future RSV vaccines may have to be repeatedly 
administered to boost waning protective antibodies among young infants if the goal is 
the prevention of RSV infection and subsequent spread. The data presented in this 
study support previous suggestions of the transient nature of antibody-mediated 
immunity to primary RSV infection. Previous studies have found that the total infant 
serum IgG, IgM and IgA antibody response to primary RSV infection, declined to 
pre-infection levels within one year (Welliver et a l, 1981) while the secretory IgA 
response declined to pre-infection levels within 3 months post infection (Kaul et a l, 
1981). Among adults, serum neutralising responses have been found to decline 
significantly within the one year after natural infection (Falsey et a l, 2006). The data 
presented in this study support the notion that primary immune responses to RSV are 
short-lived and may be related to susceptibility for secondary infection. The role of 
strain variation in facilitating re-infection is not yet clear. Despite evidence that re-
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I - . 0 7 6 4 0 3 4  
I - . 2 4 0 5 9 4 4  
I - . 0 4 6 5 8 5 4
. 0 9 2 1 7 8 4
. 0 9 6 5 7 0 2
. 0 8 3 0 7 2 9
. 0 8 2 4 6 6 2
- 2 . 2 5
- 0 . 7 9
- 2 . 9 0
- 0 . 5 6
0 . 0 2 6
0 . 4 3 0
0 . 0 0 4
0 . 5 7 3
- . 3 8 8 4 2 1 2
- . 2 6 6 5 0 5 2
- . 4 0 4 1 2 6 1
- . 2 0 8 9 2 2 8
. 0 2 5 5 0 8 7
. 1 1 3 6 9 8 4
. 0 7 7 0 6 2 6
. 1 1 5 7 5 2 1
_ c o n s
1
I 2 . 3 4 5 1 7 5 . 0 7 4 8 0 3 3 1 . 3 5 0 . 0 0 0 2 . 1 9 7 9 2 2 2 . 4 9 2 4 2 7
. x i : r e g r e s s l o g i o a c u t e  i b 4 ag6
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 7 ,  278)  
Prob > F = 
R - s q u a r e d  
Adj R - s q u a r e d  = 
Root  MSE
286
1 6 . 8 7
0 . 0 0 0 0
0 . 2 9 8 1
0 . 2 8 0 4
. 2 7 9 8 9
Model
R e s i d u a l
I 9 . 2 4 9 0 5 6 0 8  
I 2 1 . 7 7 7 6 3 5 8
7 1 . 3 2 1 2 9 3 7 3  
278 . 0 7 8 3 3 6 8 1 9
T o t a l I 3 1 . 0 2 6 6 9 1 9 285  . 1 0 8 8 6 5 5 8 6
l o g i o a c u t e  I C o e f . S t d .  E r r . t P> 111 [95% Co n f . I n t e r v a l ]
ag 6  | 
0 I . 5 2 2 5 7 5 9 . 0 7 3 1 3 9 5 7 . 1 4 0 . 0 0 0 . 3 7 8 5 9 8 3 . 6 6 6 5 5 3 5
1 | . 3 8 6 7 6 1 8 . 0 7 4 2 4 6 8 5 . 2 1 0 . 0 0 0 . 2 4 0 6 0 4 4 . 5 3 2 9 1 9 2
2 I . 2 9 9 1 0 8 1 . 0 7 0 8 4 1 9 4 . 2 2 0 . 0 0 0 . 1 5 9 6 5 3 4 . 4 3 8 5 6 2 8
3 I . 2 0 6 9 6 5 . 0 9 2 1 7 8 4 2 . 2 5 0 . 0 2 6 . 0 2 5 5 0 8 7 . 3 8 8 4 2 1 2
5 I . 1 3 0 5 6 1 5 . 0 8 1 4 3 5 2 1 . 6 0 0 . 1 1 0 - . 0 2 9 7 4 6 4 . 2 9 0 8 6 9 4
6 I - . 0 3 3 6 2 9 4 . 0 6 4 8 6 1 2 - 0 . 5 2 0 . 6 0 5 - . 1 6 1 3 1 0 9 . 0 9 4 0 5 2 1
12 | 
■
. 1 6 0 3 7 9 6 . 0 6 4 0 8 2 3 2 . 5 0 0 . 0 1 3 . 0 3 4 2 3 1 4 . 2 8 6 5 2 7 9
1
_ c o n s  | 2 . 1 3 8 2 1 . 0 5 3 8 6 4 3 3 9 . 7 0 0 . 0 0 0 2 . 0 3 2 1 7 6 2 . 2 4 4 2 4 3
. x i : r e g r e s s l o g i o a c u t e  i b 5 . a g 6
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 7 ,  278)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Ro ot  MSE
286
1 6 . 8 7
0 . 0 0 0 0
0 . 2 9 8 1
0 . 2 8 0 4
. 2 7 9 8 9
Model
R e s i d u a l
I 9 . 2 4 9 0 5 6 0 8  7 
I 2 1 . 7 7 7 6 3 5 8  278
1 . 3 2 1 2 9 3 7 3
. 0 7 8 3 3 6 8 1 9
T o t a l I 3 1 . 0 2 6 6 9 1 9  285 . 1 0 8 8 6 5 5 8 6
l o g 10a c u t e  | C o e f . S t d .  Er r . t P> 111 [95% Co n f . I n t e r v a l ]
ag6  | 
0 I . 3 9 2 0 1 4 4 . 0 7 8 6 0 2 5 4 . 9 9 0 . 0 0 0 . 2 3 7 2 8 2 7 . 5 4 6 7 4 6
1 | . 2 5 6 2 0 0 3 . 0 7 9 6 3 3 9 3 . 2 2 0 . 0 0 1 . 0 9 9 4 3 8 3 . 4 1 2 9 6 2 2
2 I . 1 6 8 5 4 6 6 . 0 7 6 4 6 9 2 2 . 2 0 0 . 0 2 8 . 0 1 8 0 1 4 4 . 3 1 9 0 7 8 8
3 I . 0 7 6 4 0 3 4 . 0 9 6 5 7 0 2 0 . 7 9 0 . 4 3 0 - . 1 1 3 6 9 8 4 . 2 6 6 5 0 5 2
4 1 - . 1 3 0 5 6 1 5 . 0 8 1 4 3 5 2 - 1 . 6 0 0 . 1 1 0 - . 2 9 0 8 6 9 4 . 0 2 9 7 4 6 4
6 I - . 1 6 4 1 9 0 9 . 0 7 0 9 6 4 3 - 2 . 3 1 0 . 0 2 1 - . 3 0 3 8 8 6 7 - . 0 2 4 4 9 5 2
282
12 I . 0 2 9 8 1 8 1
i
. 0 7 0 2 5 3 2 0 . 4 2 0 . 6 7 2 - . 1 0 8 4 7 7 7  . 1 6 8 1 1 3 8
_ c o n s
1
I 2 . 2 6 8 7 7 1 . 0 6 1 0 7 6 4 3 7 . 1 5 0 . 0 0 0 2 . 1 4 8 5 4  2 . 3 8 9 0 0 2
. x i : r e g r e s s l o g i o a c u t e  i b 6 ag6
S o u r c e I SS d f MS Number o f  o b s  = 286
F ( 7,  278)  = 16 .
Model I 9 . 2 4 9 0 5 6 0 8 7 1. 3 2129373 Prob > F = 0 . 0 0 0 0
R e s i d u a l I 2 1 . 7 7 7 6 3 5 8 278 . 0 7 8 3 3 6 8 1 9 R - s q u a r e d  = 0 . 2 9 8 1
Adj R - s q u a r e d  = 0 . 2 8 0 4
T o t a l I 3 1 . 0 2 6 6 9 1 9 285 . 1 0 8 8 6 5 5 8 6 Root  MSE = . 2 7 9 8 9
l o g i o a c u t e C o e f .  S t d .  E r r . t P> 111 [95% C o n f .  I n t e r v a l ]
ag6 1
0 I . 5 5 6 2 0 5 3 . 0 6 1 2 6 7 9 . 0 8 0 . 0 0 0 . 4 3 5 5 9 9 2  . 6 7 6 8 1 1 4
1 I . 4 2 0 3 9 1 2 . 0 6 2 5 8 4 7 6 . 7 2 0 . 0 0 0 . 2 9 7 1 9 1 2  . 5 4 3 5 9 1 3
2 I . 3 3 2 7 3 7 5 . 0 5 8 5 0 4 9 5 . 6 9 0 . 0 0 0 . 2 1 7 5 6 8 6  . 4 4 7 9 0 6 5
• 3 I . 2 4 0 5 9 4 4 . 0 8 3 0 7 2 9 2 . 9 0 0 . 0 0 4 . 0 7 7 0 6 2 6  . 4 0 4 1 2 6 1
4 I . 0 3 3 6 2 9 4 . 0 6 4 8 6 1 2 0 . 5 2 0 . 6 0 5 - . 0 9 4 0 5 2 1  . 1 6 1 3 1 0 9
5 I . 1 6 4 1 9 0 9 . 0 7 0 9 6 4 3 2 . 3 1 0 . 0 2 1 . 0 2 4 4 9 5 2  . 3 0 3 8 8 6 7
12 I . 1 9 4 0 0 9  
1
. 0 5 0 1 0 7 8 3 . 8 7 0 . 0 0 0 . 0 9 5 3 7  . 2 9 2 6 4 8
_ c o n s
1
I 2 . 1 0 4 5 8 . 0 3 6 1 3 3 3 5 8 . 2 4 0 . 0 0 0 2 . 0 3 3 4 5 1  2 . 1 7 5 7 1
. 111111111111111111111111111111111111111111111111111111111111111111111111111111 
> / /  T h i s  c o d e  c o mpa r e s  mean a c u t e  and c o n v a l e s c e n t  p h a s e  t i t r e s  u s i n g  a 
. / /  s t u d e n t  t  t e s t
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
> / / a n a l y s i s  o f  d i f f  
. t t e s t  l o g i 0a c u t e =
P a i r e d  t  t e s t
b e t w e e n  a c u t e  and c o n  
= l o g i o c o n v  i f  ag6==0
i n  d i f f  a g e c l a s s e s
V a r i a b l e  | Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
l o g i 0a ~e  | 28 2 . 6 6 5 1 0 1 . 0 3 8 8 9 5 7 . 2 0 5 8 1 6 5 2 . 5 8 5 2 9 3 2 . 7 4 4 9 0 8
l o g i 0c ~ v  | 28 2 . 5 4 3 6 7 1 . 0 5 3 5 1 8 6 . 2 8 3 1 9 3 7 2 . 4 3 3 8 6 2 . 6 5 3 4 8 2
d i f f  | 28 . 1 2 1 4 3 0 2 . 0 6 9 3 6 1 . 3 6 7 0 2 3 9 - . 0 2 0 8 8 6 9 . 2 6 3 7 4 7 2
mean ( d i f f )  = mean ( l o g i o a c u t e  -  l o g i oc o nv )  t  = 1 . 7 5 0 7
Ho: mean ( d i f f )  = 0 d e g r e e s  o f  f r e e d o m  = 27
Ha: mean (diff) < 0 Ha: mean (diff) != 0 Ha: mean (diff) >
Pr (T <: t )  = 0 . 9 5 4 3  Pr ( | T |  > | t | J 1 = 0 . 0 9 1 4 Pr (T > t )  = 0 . 0 4 5 7
. t t e s t l o g i o a c u t e == l o g i o c o n v i f  a g 6 = = l
P a i r e d  t t e s t
V a r i a b l e I Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
l o g 10a~e  | 
l o g 10c ~ v  |
25
25
2 . 5 7 2 6 8 5
2 . 4 7 3 2 5 5
. 0 4 8 1 2 2 9
. 0 7 3 9 7 2 8
. 2 4 0 6 1 4 4
. 3 6 9 8 6 4 2
2 . 4 7 3 3 6 5
2 . 3 2 0 5 8 3
2 . 6 7 2 0 0 6
2 . 6 2 5 9 2 8
d i f f I 25 . 0 9 9 4 3 0 4 . 0 9 5 8 0 3 3 . 4 7 9 0 1 6 6 - . 0 9 8 2 9 7 9 . 2 9 7 1 5 8 7
mean 
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( l o g i o a c u t e  -  l o g i oc o nv )  t  = 1 . 0 3 7 9  
0 d e g r e e s  o f  f r e e d o m  = 24
Ha: mean  
Pr (T <
( d i f f ) .< 0 Ha: mean ( d i f f )  != 0 
t )  = 0 . 8 4 5 2  Pr ( | T |  > | t | )  = 0 . 3 0 9 7
Ha:
Pr
mean ( d i f f )  > 0 
(T > t )  = 0 . 1 5 4 8
. t t e s t l o g i 0a c u t e :== l o g i o c o n v i f  ag6==2
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
l o g i 0a ~e  | 34 
l o g i 0c ~ v  | 34
2 . 4 5 6 1 2 3
2 . 5 6 6 4 5 2
. 0 3 2 7 0 5
. 0 6 2 0 9 1
. 1 9 0 7 0 1 2
. 3 6 2 0 4 9 4
2 . 3 8 9 5 8 5
2 . 4 4 0 1 2 7
2 . 5 2 2 6 6 2
2 . 6 9 2 7 7 7
d i f f  |1 34 - . 1 1 0 3 2 8 8 . 0 8 1 3 2 8 2 . 4 7 4 2 2 1 - . 2 7 5 7 9 2 4 . 0 5 5 1 3 4 7
mean 
Ho : mean
( d i f f )  = 
( d i f f )  =
mean ( l o g i o a c u t e  -  l og i oc o n v )  t  = - 1 . 3 5 6 6  
0 d e g r e e s  o f  f r e e d o m  = 33
Ha: mean 
Pr (T <
( d i f f )  < 0 
t )  = 0 . 0 9 2 1  Pr
Ha: mean ( d i f f )  != 0 
( IT|  > | t | ) = 0 . 1 8 4 1
Ha:
Pr
mean ( d i f f )  > 0 
(T > t )  = 0 . 9 0 7 9
. t t e s t l o g i 0a cu t e = == l o g i o c o n v i f  ag6==3
P a i r e d  t  t e s t
V a r i a b l e  I Obs Mean S t d .  E r r . S t d .  Dev. [95% Co nf . I n t e r v a l ]
l o g 10a ~e  I 
l o g i 0c ~ v  |
. 11 
11
2 . 4 3 7 4 6 5
2 . 4 9 2 9 8 6
. 0 5 9 9 9 4 2
. 1 1 3 0 3 2 7
. 1 9 8 9 7 8 2
. 3 7 4 8 8 7 1
2 . 3 0 3 7 8 9
2 . 2 4 1 1 3 3
2 . 5 7 1 1 4
2 . 7 4 4 8 3 8
d i f f  | 11 - . 0 5 5 5 2 1 . 1 4 3 9 0 1 2 . 4 7 7 2 6 6 3 - . 3 7 6 1 5 2 8 . 2 6 5 1 1 0 9
mean ( d i f f )  = mean ( l o g i o a c u t e  -  l og io co nv )  t  = - 0 . 3 8 5 8
Ho: mean ( d i f f )  = 0 d e g r e e s  o f  f r e e d o m  = 10
Ha: mean (diff) < 0 Ha: mean (diff) != 0 Ha: mean (diff) > 0
284
Pr (T < t )  = 0 . 3 5 3 9  Pr ( | T |  > | t | )  = 0 . 6 0 7 7  Pr (T > t )  = 0 . 6 4 6 1
. t t e s t  l o g i 0a c u t e = =  l o g 10c o n v  i f  ag6==4  
P a i r e d  t  t e s t
V a r i a b l e I Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
l o g 10a ~e  I 
l o g 10c ~ v  |
19
19
2 . 1 9 8 1 2 6
2 . 5 0 2 5 4 2
. 0 5 4 5 4 6 8
. 0 8 2 7 4 5 2
. 2 3 7 7 6 4 1
. 3 6 0 6 7 8 1
2 . 0 8 3 5 2 8
2 . 3 2 8 7 0 1
2 . 3 1 2 7 2 5
2 . 6 7 6 3 8 3
d i f f 1 19 - . 3 0 4 4 1 5 7 . 1 1 4 6 0 3 . 4 9 9 5 4 2 8 - . 5 4 5 1 8 7 6 - . 0 6 3 6 4 3 8
mean 
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( l o g i o a c u t e  -  l og i oc o n v )  t  = - 2 . 6 5 6 3  
0 d e g r e e s  o f  f r e e d o m  = 18
Ha: mean 
Pr (T <
( d i f f )  < 0 Ha: mean ( d i f f )  != 0 
t )  = 0 . 0 0 8 0  Pr ( |T|  > | t | ) = 0 . 0 1 6 1
Ha:
Pr
mean ( d i f f )  > 0 
(T > t )  = 0 . 9 9 2 0
. t t e s t l o g i o a c u t e == l o g i o c o n v i f  ag6==5
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . , I n t e r v a l ]
l o g i 0a ~ e  | 
l o g 10c ~ v  |
19
19
2 . 2 9 2 4 7 7
2 . 6 4 7 8 9 5
. 0 6 3 9 1 3 6
. 1 0 0 4 1 2 8
. 2 7 8 5 9 2 9
. 4 3 7 6 8 9 3
2 . 1 5 8 1 9 9
2 . 4 3 6 9 3 5
2 . 4 2 6 7 5 4
2 . 8 5 8 8 5 4
d i f f  | 19 - . 3 5 5 4 1 8 4 . 1 2 7 9 3 2 2 . 5 5 7 6 4 3 4 - . 6 2 4 1 9 3 9 - . 0 8 6 6 4 2 9
mean  
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( l o g i o a c u t e  -  l o g i oc o nv )  t  = - 2 . 7 7 8 2  
0 d e g r e e s  o f  f r e e d o m  = 18
Ha: mean 
Pr (T <
( d i f f )  < 0 
t )  = 0 . 0 0 6 2  Pr
Ha: mean ( d i f f )  != 0 
{ 1T|  > 11 1 ) = 0 . 0 1 2 4
Ha:
Pr
mean ( d i f f )  > 0 
(T > t )  = 0 . 9 9 3 8
. t t e s t l o g i 0acute=== l o g i o c o n v i f  ag6==6
P a i r e d  t  t e s t
V a r i a b l e  I Obs Mean S t d .  E r r . S t d .  Dev. [95% Co nf . I n t e r v a l ]
l o g 10a ~ e  | 
l o g 10c ~ v  |
58
58
2 . 1 2 5 5 4 2
2 . 7 6 7 6 2 8
. 0 3 2 9 5 5 1
. 0 3 8 6 9 6 9
. 2 5 0 9 7 8 5
. 2 9 4 7 0 6 9
2 . 0 5 9 5 5
2 . 6 9 0 1 3 9
2 . 1 9 1 5 3 3
2 . 8 4 5 1 1 7
d i f f  | 58 - . 6 4 2 0 8 6 5 . 0 5 1 9 8 4 2 . 3 9 5 9 0 0 1 - . 7 4 6 1 8 3 1 - . 5 3 7 9 8 9 9
mean ( d i f f )  = mean ( l o g i o a c u t e  -  l og i oc o nv )  t  = - 1 2 . 3 5 1 6
Ho: mean ( d i f f )  = 0 d e g r e e s  o f  f r e e d o m  = 57
Ha: mean (diff) < 0 Ha: mean (diff) != 0 Ha: mean (diff) > 0
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Pr (T < t )  = 0 . 0 0 0 0  Pr ( IT|  > | t | ) ?= 0 . 0 0 0 0 Pr (T > t )  = 1 . 0 0 0 0
. t t e s t l o g i 0a c u t e :== l o g i o c o n v i f  ag6==12
P a i r e d  t t e s t
V a r i a b l e I Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
l o g i 0a ~ e  | 
l o g i o c ~ v  |
60
60
2 . 3 0 4 7 8 9
2 . 8 1 4 9 4 6
. 0 4 6 1 5 9 2
. 0 4 5 4 4 3 8
. 3 5 7 5 4 7 5
. 3 5 2 0 0 6 1
2 . 2 1 2 4 2 5
2 . 7 2 4 0 1 3
2 . 3 9 7 1 5 4
2 . 9 0 5 8 7 9
d i f f | 60 - . 5 1 0 1 5 6 5 . 0 5 9 1 7 3 8 . 4 5 8 3 5 8 5 - . 6 2 8 5 6 3 1 - . 3 9 1 7 4 9 9
mean 
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( l o g i o a c u t e  -  l og i oc o n v )  t  = - 8 . 6 2 1 3  
0 d e g r e e s  o f  f re e d om .  = 59
Ha: mean 
Pr (T <
( d i f f )  < 0 Ha: mean ( d i f f )  != 0 
t )  = 0 . 0 0 0 0  Pr { |T|  > | t | ) = 0 . 0 0 0 0
Ha:
Pr
mean ( d i f f )  > 0 
(T > t )  = 1 . 0 0 0 0
e nd  o f  d o - f i l e
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
> / /  T h i s  c o d e  c o n d u c t s  s pear man c o r r e l a t i o n  a n a l y s i s  b e t w e e n  l o g  f o l d  r i s e  i n  t i t r e  
. / /  and ( i )  a c u t e  p h a s e  t i t r e s  and ( i i )  a g e  i n  months
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
>
. spear man l o g i o a c u t e  l o g i o f o l d r i s e
Number o f  o bs  = 254
S p ea r m an ' s  rho  = - 0 . 7 4 5 1
T e s t  o f  Ho: l o g i o a c u t e  and l o g i o f o l d r i s e  a r e  i n d e p e n d e n t  
Prob > | t |  = 0 . 0 0 0 0
. s pear man l o g i o f o l d r i s e  age_m i f  age_m<=12
Number o f  o b s  = 194
S p e a rm a n' s  rho  = 0 . 5 5 1 1
T e s t  o f  Ho: l o g i o f o l d r i s e  and age_m a r e  i n d e p e n d e n t  
Prob > | t |  = 0 . 0 0 0 0
e nd  o f  d o - f i l e
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /  
> / /  T h i s  c o d e  c a l c u l a t e s  t h e  p r o p o r t i o n  s e r o c o n v e r t i n g  a t  d i f f e r e n t  a c u t e  s t a g e
286
. / /  t i t r e s  s t r a t i f i e d  by  q u a r t i l e  
. 11111111111111111111111111111111111111111111111111111111111111111111111111111 
>
. t a b  f o l d 4  a c u t e _ q u a r t i l e s  i f  i _ g p = = t _ g p , c o l
+---------------------- +
I Key I
I f r e q u e n c y  |
I co lumn p e r c e n t a g e  |
+  +
I a c u t e _ q u a r t i l e s
f o l d 4  | 1 2 3 4 1 T o t a l
0 I 
1
4
9 . 7 6
19
4 0 . 4 3
32
8 6 . 4 9
26 | 
1 0 0 . 0 0  |
81
5 3 . 6 4
1 1 
1
37
9 0 . 2 4
28
5 9 . 5 7
5
1 3 . 5 1
0 | 
0 . 0 0  |
70
4 6 . 3 6
T o t a l  | 
1
41
1 0 0 . 0 0
47
1 0 0 . 0 0
37
1 0 0 . 0 0
26  | 
1 0 0 . 0 0  |
151
1 0 0 . 0 0
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
> / /  T h i s  c o d e  c a l c u l a t e s  t h e  odds  r a t i o s  o f  d e v e l o p i n g  d i f f e r e n t  f e a t u r e s  o f
. / /  c l i n i c a l  pneumoni a  among i n f a n t s  w i t h  t i t r e s  a b o ve  and b e l o w  t h e  2 . 5 1 o g i 0PRNT 
. / /  t h r e s h o l d
- / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
> p r e s e r v e
u s e  " C: \ Do c ume nt s  and S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a p e r l \ I P _ c l i n i c a l  
s e v e r i t y  d a t a . d
> t a " ,  c l e a r
c a p t u r e : drop  p r o t _ a c u t e
g e n  p r o t _ a c u t e = .
(322 m i s s i n g  v a l u e s  g e n e r a t e d )
r e p l a c e  p r o t _ a c u t e = l  i f  l o g i 0a c u t e > = 2 . 5  & l o g i o a c u t e  ! = .
(85 r e a l  c h a n g e s  made)
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r e p l a c e  p r o t _ a c u t e = 0  i f  l o g i 0a c u t e < 2 . 5  & l o g i o a c u t e  ! = .
(201 r e a l  c h a n g e s  made)
x i : l o g i s t i c  p r o t _ a c u t e  i . f l a r i n g  i . w h e e z e  i . i n d r a w i n g  i . s h o c k
i . h y p o x i a  i . c r a  
> c k l e s  i . a g 6  , o r  
i . f l a r i n g  
i . w h e e z e  
i . i n d r a w i n g  
i . s h o c k  
i . h y p o x i a  
i . c r a c k l e s
_ l f l a r i n g _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l f l a r i n g _ 0  o m i t t e d )  
_ l w h e e z e _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l w h e e z e _ 0  o m i t t e d )  
_ l i n d r a w i n g _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l i n d r a w i n g _ 0  o m i t t e d )  
_ l s h o c k _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l s h o c k _ 0  o m i t t e d )  
_ l h y p o x i a _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l h y p o x i a _ 0  o m i t t e d )  
_ l c r a c k l e s _ 0 - l  ( n a t u r a l l y  c o d e d ;  _ l c r a c k l e s _ 0  o m i t t e d )
i . a g 6 _ I a g 6 _ 0 - 2 4 ( n a t u r a l l y  c o d e d; _ I a g 6 _ 0 o m i t t e d )
n o t e :  I a g 6 _ 9 != 0 p r e d i c t s f a i l u r e p e r f e c t l y
_ I a g 6 _ 9 d r o p pe d  and 22 o b s  n o t u s e d
L o g i s t i c  r e g r e s s i o n Number o f  o b s  = 232
LR c h i 2  (15) 5 3 .
Prob > c h i  2 = 0 . 0 0 0 0
Log l i k e l i h o o d = - 1 2 0 . 0 0 1 7 8 P se u do R2 0 . 1 8 2 2
p r o t _ a c u t e  | Odds R a t i o S t d .  Er r z P > | z | (95% Co n f . I n t e r v a l ]
_ I f l a r i n g _ l  I . 6 5 7 7 1 7 6 . 2 5 0 1 5 2 8 - 1 . 1 0 0 . 2 7 1 . 3 1 2 1 0 3 1 . 3 8 6 0 5 6
_ I w h e e z e _ l  I . 9 6 6 3 1 5 . 4 5 8 1 8 9 4 - 0 . 0 7 0 . 9 4 2 . 3 8 1 5 1 5 1 2 . 4 4 7 5 1 7
_ I i n d r a w i n ~ l  | . 8 2 0 6 5 4 . 6 2 0 1 7 9 2 - 0 . 2 6 0 . 7 9 4 . 1 8 6 5 9 3 1 3 . 6 0 9 3 1 3
_ I s h o c k _ l  | . 2 6 5 6 0 8 1 . 1 4 6 1 3 0 5 - 2 . 4 1 0 . 0 1 6 . 0 9 0 3 5 1 . 7 8 0 8 1 7 7
_ I h y p o x i a  1 | . 7 4 2 2 7 8 8 . 4 3 2 6 9 0 5 - 0 . 5 1 0 . 6 0 9 . 2 3 6 8 0 0 8 2 . 3 2 6 7 5 7
_ I c r a c k l e s  1 I . 8 0 8 8 6 8 7 . 2 9 9 2 5 8 5 - 0 . 5 7 0 . 5 6 6 . 3 9 1 7 0 3 6 1 . 6 7 0 3 1 6
_ I a g 6 _ l  | . 2 9 4 0 1 9 8 . 1 7 3 7 4 1 3 - 2 . 0 7 0 . 0 3 8 . 0 9 2 3 3 9 4 . 9 3 6 1 9 4 4
_ I a g 6 _ 2  | . 2 9 3 3 7 1 2 .173697. - 2 . 0 7 0 . 0 3 8 . 0 9 1 9 2 7 3 . 9 3 6 2 4 7 2
_ I a g 6 _ 3  | . 1 1 8 3 9 0 4 . 0 9 1 9 7 2 - 2 . 7 5 0 . 0 0 6 . 0 2 5 8 2 6 . 5 4 2 7 1 9 7
_ I a g 6 _ 4  | . 0 1 0 9 9 8 3 0126067 - 3 . 9 3 0 . 0 0 0 . 0 0 1 1 6 3 2 . 1 0 3 9 9 3 7
_ I a g 6 _ 5  | . 0 7 8 1 4 7 06 5 32 0 1 - 3 . 0 5 0 . 0 0 2 . 0 1 5 1 8 5 3 . 4 0 2 1 6 0 7
_ I a g 6 _ 6  | . 0 3 1 2 4 4 3 0246607 - 4 . 3 9 0 . 0 0 0 . 0 0 6 6 5 1 6 . 1 4 6 7 6 1 4
_ I a g 6 _ 9  I ( o m i t t e d )
_ I a g 6 _ 1 2  | . 1 3 1 3 5 2 3 1 1 38732 - 2 . 3 4 0 . 0 1 9 . 0 2 4 0 1 6 3 . 7 1 8 4 0 5 5
_ I a g 6  18 | . 1 2 9 1 5 3 4 0859975 - 3 . 0 7 0 . 0 0 2 . 0 3 5 0 2 1 . 4 7 6 3 0 2 8
_ I a g 6 _ 2 4  | . 1 1 6 4 7 7 1 08 0 3751 - 3 . 1 2 0 . 0 0 2 . 0 3 0 1 2 0 9 . 4 5 0 4 1 4 8
p a r m e s t ,  n o r e s t o r e  e f or m
drop  i f  parm=="_cons"  
(1 o b s e r v a t i o n  d e l e t e d )
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drop  i f  parm=="age_months"
(0 o b s e r v a t i o n s  d e l e t e d )
drop  i f  parm== " _ I a g 6 _ l "
(1 o b s e r v a t i o n  d e l e t e d )
d rop  i f  parm== " _I a g 6_ 2 "
(1 o b s e r v a t i o n  d e l e t e d )
drop  i f  parm== " _I a g 6_ 3 "
(1 o b s e r v a t i o n  d e l e t e d )
dr op  i f  parm== " _I a g 6_ 4 "
(1 o b s e r v a t i o n  d e l e t e d )
d rop  i f  parm== "_ Ia g6 _ 5 "
(1 o b s e r v a t i o n  d e l e t e d )
drop  i f  parm== " _I a g 6_ 6 "
(1 o b s e r v a t i o n  d e l e t e d )
dr op  i f  parm== " _I a g 6_ 9 "
(0 o b s e r v a t i o n s  d e l e t e d )
d rop  i f  parm== " _I ag 6 _1 2 "
(1 o b s e r v a t i o n  d e l e t e d )
drop  i f  parm== "_ Ia g 6 _ 18 "
(1 o b s e r v a t i o n  d e l e t e d )
dr op  i f  parm== "_ Ia g 6 _ 24 "
(1 o b s e r v a t i o n  d e l e t e d )
d rop  i f  parm== " o . _ I a g 6 _ 9 "
(1 o b s e r v a t i o n  d e l e t e d )
e g e n  a x i s =  a x i s  ( e s t i m a t e ) , l a b e l  (parm)
twoway s c a t t e r  a x i s  e s t i m a t e ,  x l i n e  (1) y l a b  ( ,  v a l u e l a b e l  a n g l e
( 0 ) )  | |  r e a p  min9
> 5 max95 a x i s ,  h o r i z o n t a l  l e g e n d  ( o r d e r  (1 " p o i n t  e s t i m a t e "  2 "95% c o n f .  i n t . " )
p o s  ( 6 ) )  x t i t l e  ("odds
> r a t i o " )  y t i t l e  ("")
g r a ph  p l a y  "OR_2"
restore
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> / /  T h i s  c o d e  c ompares  t h e  p r o p o r t i o n s  s e r o c o n v e r t i n g  t o  d i f f e r e n t  v i r u s
. 11111111111111111111111111111111111111111111111111111111111111111111111111111
>
. / /  c o m p a r i s o n  b e t w e e n  no i n f e c t e d  w i t h  RSV A s e r o c o n v e r t i n g  a g a i n s t  K i l / A / 2 0 0 6  
K i l / B / 2 0 0 8  
. p r e s e r v e
. k ee p  i f  a_match==2 & f o l d r i s e ! = .  | a _ m a tc h == l  & i _ g p = = l  & f o l d r i s e ! = .
(258 o b s e r v a t i o n s  d e l e t e d )
. k ee p  s e r i a l _ n o  t _ v i r u s _ d e s c  f o l d 4
. s o r t  s e r i a l _ n o  t _ v i r u s _ d e s c
. r e s h a p e  w i d e  f o l d 4 ,  i  ( s e r i a l _ n o )  j ( t _ v i r u s _ d e s c )
( n o t e :  j = 2 4)
Data l o n g - > w i d e
Number o f  o b s . 64 - > 32
Number o f  v a r i a b l e s 3 - > 3
j  v a r i a b l e  (2 v a l u e s ) t _ v i r u s _ d e s c - > ( dr opped)
x i j  v a r i a b l e s :
f o l d 4 - > f o l d 4 2  f o l d 4 4
. mcc f o l d 4 2  f o l d 4 4
I C o n t r o l s
C a s e s  | E x p o s e d  U ne x po s ed
1
I T o t a l
E x p o s ed  | 4 12 
U n ex po s e d  | 0 16
1 16  
1 16
T o t a l  | 4 28 I 32
McNemar's  chi-2 (1) = 1 2 . 0 0  Prob > 
E x a c t  McNemar s i g n i f i c a n c e  p r o b a b i l i t y
c h i 2 = 0 . 0 0 0 5  
= 0 . 0 0 0 5
P r o p o r t i o n  w i t h  f a c t o r
C a s e s  . 5
C o n t r o l s  . 1 2 5
d i f f e r e n c e  . 3 7 5
r a t i o  4
r e l . d i f f .  . 4 2 8 5 7 1 4
[95% C o n f .  I n t e r v a l ]
. 1 7 6 0 1 3
1 . 7 1 1 9 0 2
. 2 4 5 2 7 1 8
. 5 7 3 9 8 7
9 . 3 4 6 3 2 9
. 6 1 1 8 7 1 1
o dds  r a t i o 2 . 7 7 8 5 9 7 ( e x a c t )
restore
. / /  c o m p a r i s o n  b e t w e e n  no i n f e c t e d  w i t h  RSV B s e r o c o n v e r t i n g  a g a i n s t  K i l / A / 2 0 0 6  
K i l / B / 2 0 0 8  
. p r e s e r v e
. k ee p  i f  b_match==2 & f o l d r i s e ! = .  | b _ ma t c h = = l  & i _ gp = = 2  & f o l d r i s e ! = .
(272 o b s e r v a t i o n s  d e l e t e d )
. ke e p  s e r i a l _ n o  t _ v i r u s _ d e s c  f o l d 4
. s o r t  s e r i a l _ n o  t _ v i r u s _ d e s c
. r e s h a p e  w i d e  f o l d 4 ,  i  ( s e r i a l _ n o )  j ( t _ v i r u s _ d e s c )
( n o t e :  j = 2 4)
Data l o n g - > w i d e
Number o f  o b s . 50 - > 25
Number o f  v a r i a b l e s 3 - > 3
j v a r i a b l e  (2 v a l u e s ) t _ v i r u s _ d e s c - > (dr opped)
x i j  v a r i a b l e s :
f o l d 4 -> f o l d 4 2  f o l d 4 4
. mcc f o l d 4 2  f o l d 4 4
I C o n t r o l s 1
C a s e s  | E x p os e d Une x po s e d I T o t a l
E x p o s ed  | 2 0 1 2
U ne xp os e d  | 8 15 I 23
T o t a l  | 10 15 I 25
McNemar's  c h i 2  (1) = 8 . 00 Prob > c h i 2 = 0 . 0 0 4 7
E x a c t  McNemar s i g n i f i c a n c e  p r o b a b i l i t y = 0 . 0 0 7 8
P r o p o r t i o n  w i t h  f a c t o r
C a s e s  . 08
C o n t r o l s  . 4 [95% Conf . I n t e r v a l ]
d i f f e r e n c e  - . 3 2 - . 5 4 2 8 5 5 3 - . 0 9 7 1 4 4 7
r a t i o  . 2 . 0 5 7 9 0 0 6 . 6 9 0 8 3 9 4
r e l . d i f f .  - . 5 3 3 3 3 3 3 - . 9 9 0 9 6 9 3 - . 0 7 5 6 9 7 4
odds  r a t i o 0 0 . 5 8 5 8 3 3 2  ( e x a c t )
. restore
. / /  c o m p a r i s o n  b e t w e e n  no i n f e c t e d  w i t h  RSV A s e r o c o n v e r t i n g  a g a i n s t  A2 & 8 / 6 0  
. p r e s e r v e
. k eep  i f  a _ o l d r s v s _ m a t c h = = 2  | a _ o l d r s v s _ m a t c h = = l  & i _ g p = = l  
(286 o b s e r v a t i o n s  d e l e t e d )
. ke e p  s e r i a l _ n o  t _ v i r u s _ d e s c  f o l d 4
. s o r t  s e r i a l _ n o  t _ v i r u s _ d e s c
. r e s h a p e  w i d e  f o l d 4 ,  i  ( s e r i a l _ n o )  j  ( t _ v i r u s _ d e s c )
( n o t e :  j  = 1 3)
Data  l o n g  - >  w i d e
Number o f  o b s . 36 - > 18
Number o f  v a r i a b l e s 3 - > 3
j  v a r i a b l e  (2 v a l u e s ) t _ v i r u s _ d e s c - > ( dr opped)
x i j  v a r i a b l e s :
f o l d 4 - > f o l d 4 1  f o l d 4 3
. mcc f o l d 4 1  f o l d 4 3  
1
C a s e s  I
C o n t r o l s
E xp os ed U ne x p ose d
1
I T o t a l
E x p o s ed  | 0 5 1 5
U n e x p os e d  I 0 13 1 13
T o t a l  | 0 18 1 18
McNemar's  c h i 2  (1) 5 . 00 Prob > c h i 2 = 0 . 0 2 5 3
E x a c t  McNemar s i g n i f i c a n c e  p r o b a b i l i t y = 0 . 0 6 2 5
P r o p o r t i o n  w i t h  f a c t o r
C a s e s
C o n t r o l s
. 2 7 7 7 7 7 8
0 [95% Conf . I n t e r v a l ]
d i f f e r e n c e . 2 7 7 7 7 7 8 . 0 1 5 3 0 5 3 . 5 4 0 2 5 0 3
r a t i o
r e l .  d i f f . . 2 7 7 7 7 7 8 . 0 7 0 8 6 0 9 . 4 8 4 6 9 4 7
odds  r a t i o . 9 1 6 3 5 5 9 ( e x a c t
restore
/ /  c o m p a r i s o n  b e t w e e n  no i n f e c t e d  w i t h  RSV B s e r o c o n v e r t i n g  a g a i n s t  A2 & 8 / 6 0  
p r e s e r v e
k ee p  i f  b _ o l d r s v s _ m a t c h = = 2  | b _ o l d r s v s _ m a t c h = = l  & i _ gp = =2  
(282 o b s e r v a t i o n s  d e l e t e d )
k e e p  s e r i a l _ n o  t _ v i r u s _ d e s c  f o l d 4
s o r t  s e r i a l _ n o  t _ v i r u s _ d e s c
r e s h a p e  w i d e  f o l d 4 ,  i  ( s e r i a l _ n o )  j ( t _ v i r u s _ d e s c )
( n o t e :  j = 1 3)
Data l o n g - > w i d e
Number o f  o b s . 40 - > 20
Number o f  v a r i a b l e s 3 - > 3
j v a r i a b l e  (2 v a l u e s ) t _ v i r u s _ d e s c - > (dropped)
x i j  v a r i a b l e s :
f o l d 4 - > f o l d 4 1  f o l d 4 3
. mcc f o l d 4 1  f o l d 4 3
I C o n t r o l s 1
C a s e s  | Ex p os e d U ne xp os e d 1 T o t a l
E x p o s e d  | 2 0 1 2
U n e xp o se d  | 11 7 1 18
r
T o t a l  | 13 7 i 20
McNemar's  c h i 2  (1) = 11 . 0 0  Prob > c h i  2 = 0 . 0 0 0 9
E x a c t  McNemar s i g n i f i c a n c e  p r o b a b i l i t y =  0 . 0 0 1 0
P r o p o r t i o n  w i t h  f a c t o r
C a s e s  . 1
C o n t r o l s  . 6 5 [95% C o n f .  I n t e r v a l ]
d i f f e r e n c e  - . 5 5
r a t i o  . 1 5 3 8 4 6 2
r e l . d i f f .  - 1 . 5 7 1 4 2 9
- . 8 1 8 0 3 2 2  - . 2 8 1 9 6 7 8
. 0 4 2 9 9 6  . 5 5 0 4 8 4 7
- 3 . 0 6 0 5 6 2  - . 0 8 2 2 9 5 1
o dds  r a t i o 0 . 3 9 8 4 3 3 5  ( e x a c t )
restore
. 111111111111111111111111111111111111111111111111111111111111111111111111111111
> / /  T h i s  c o d e  compar e s  t h e  m a g n i t u d e  o f  t h e  h omo l og o us  r e s p o n s e  t o  t h e  m ag n i t u d e
. / /  o f  t h e  h e t e r l o g o u s  r e s p o n s e  ( i n  t e r m s  o f  f o l d  r i s e  i n  t i t r e )  among d i f f e r e n t  age  
c l a s s e s
. / /  u s i n g  r e g r e s s i o n  m o de l s  
. / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / / /
>
. / / c a l c u l a t e  f o l d  r i s e s  f o r  d i f f e r e n t  m a t r i x  c a t e g o r i e s  
. / / a n t i l o g  t h e  t a b l e  means t o  g e t  t h e  r e a l  f o l d  r i s e s  
. t a b  i _ g p  t _ g p  i f  ag5==0, summ ( l o g i o f o l d r i s e ) m e a n s
Means o f l o g i o f o l d r i s e
I n f e c t i n g
RSV_Group
I T e s t _ v i r u s  
1 A
;_group
B | T o t a l
A
B
I . 2 5 8 0 3 7 4 4  -  
I - . 1 63 32 7 43
. 3 3 2 8 0 5 3 9
. 4 2 8 0 4 3 5 3
| - . 0 2 1 8 35 4 8  
I . 2 1 1 2 0 7 5 1
T o t a l I . 1 0 8 5 2 0 8 8 . 0 5 7 9 0 0 8 1 I . 0 8 0 9 7 7 6 1
. t a b  i _ g p t _ g p  i f  ag5== 6,summ ( l o g i o f o l d r i s e ) m e a n s
Means o f l o g i o f o l d r i s e
I n f e c t i n g _
RSV_Group
I T e s t _ v i r u s  
1 A
_ g r o u p
B I T o t a l
A
B
I 1 . 0 4 7 3 3 3 5  
I . 2 3 1 7 0 1 8 7
. 5 7 5 7 7 9 6 1
. 7 6 8 1 4 5 5
I . 8 6 5 9 6 6 6 3  
I . 5 7 7 4 0 9 9 9
T o t a l I . 5 0 3 5 7 9 0 9 . 7 3 9 8 5 6 4 I . 6 4 2 0 8 6 4 8
. t a b  i  gp t _ g p  i f  ag5== 12,summ ( l o g i o f o l d r i s e ) m e a n s
Means o f l o g i o f o l d r i s e
I n f e c t i n g _
RSV_Group
I T e s t _ v i r u s _  
1 A
_group
B I| T o t a l
A
B
I . 8 5 3 9 1 1 6 1  
I - . 025 3 8 99 1
. 3 4 7 0 6 0 5 1  | 
. 6 3 2 1 6 2 9 9  |
. 6 5 1 1 7 1 1 7
. 3 6 9 1 4 1 8 3
T o t a l  | . 5 0 2 1 9 1  . 5 1 8 1 2 2  | . 5 1 0 1 5 6 5
. / / t i d l  b e l o w  c o n t a i n s  m a t r i x  AA ( t i d l = = l )  and AB ( t i d l = = 2 )  
. / / t i d 2  b e l o w  c o n t a i n s  m a t r i x  BB ( t i d 2 = = l )  and BA ( t i d 2 = = 2 )  
. c a p t u r e :  drop  t i d l  t i d 2
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g en  t i d l = .
(322 m i s s i n g  v a l u e s  g e n e r a t e d )  
g en  t i d 2 = .
(322 m i s s i n g  v a l u e s  g e n e r a t e d )
r e p l a c e  t i d l  =1 i f  i _ g p = = l  & t _ g p = = l  
(90 r e a l  c h a n g e s  made)
r e p l a c e  t i d l  =2 i f  i _ g p = = l  & t_ g p= =2  
(97 r e a l  c h a n g e s  made)
r e p l a c e  t i d 2  =1 i f  i _ gp = = 2  & t_ g p= =2  
(85 r e a l  c h a n g e s  made)
r e p l a c e  t i d 2  =2 i f  i _ g p = =2  & t _ g p = = l  
(50 r e a l  c h a n g e s  made)
. / /  compare t h e  f o l d  r i s e s  b e t w e e n  d i f f e r e n t horn h e t a g e  c l a s s e s
. x i :  r e g r e s s  l o g i o f o l d r i s e  
i . t i d l  _ I t i d l _ l -
i . t i d l  i f  ag5==0  
-2 ( n a t u r a l l y  c o d e d ; _ I t i d l _ 1  o m i t t e d )
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 1 ,  74)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Root  MSE
76
4 5 .
0 . 0 0 0 0
0 . 3 8 1 5
0 . 3 7 3 2
. 3 8 0 6 5
Model
R e s i d u a l
I 6 . 6 1 4 4 3 6 3 8  
I 1 0 . 7 2 1 9 8 8 9
1
74
6 . 6 1 4 4 3 6 3 8
. 1 4 4 8 9 1 7 4 2
T o t a l I 1 7 . 3 3 6 4 2 5 3 75 . 2 3 1 1 5 2 3 3 7
l o g i 0f o l d r ~ e C o e f . S t d .  E r r .  t P> 111 [95% C o n f .  I n t e r v a l ]
_ I t i d l _ 2
c o n s
I - . 5 9 0 8 4 2 8  
I . 2 5 8 0 3 7 4
. 0 8 7 4 4 7 5  - 6 . 7 6  
. 0 6 0 1 8 5 5  4 . 2 9
0 . 0 0 0
0 . 0 0 0
- . 7 6 5 0 8 5 8
. 1 3 8 1 1 5 2
4 1 6 5 9 9 9
3 7 7 95 97
. x i :  r e g r e s s  
i . t i d l
l o g i o f o l d r i s e
_ I t i d l _ l -
i . t i d l  i f  ag5==6  
2 ( n a t u r a l l y  c o d e d , _ I t i d l _ _1 o m i t t e d )
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 1,  11)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Root  MSE
13
7 . 4
0 . 0 1 9 6
0 . 4 0 3 9
0 . 3 4 9 7
. 3 0 2 9 7
Model
R e s i d u a l
I . 6 8 4 1 9 4 1 1  
I 1 . 0 0 9 7 2 9 2 1
1
11
. 6 8 4 1 9 4 1 1
. 0 9 1 7 9 3 5 6 5
T o t a l I 1 . 6 9 3 9 2 3 3 2 12 . 1 4 1 1 6 0 2 7 7
log10foldr~e | Coef. Std. Err. t P> 111 [95% Conf. Interval]
_ I t i d l _ 2
c o n s
- . 4 7 1 5 5 3 9
1 . 0 4 7 3 3 4
. 1 7 2 7 2 2 1
. 1 0 7 1 1 7 7
- 2 . 7 3
9 . 7 8
0 . 0 2 0
0 . 0 0 0
- . 8 5 1 7 1 2 6
. 8 1 1 5 6 9 1
- . 0 9 1 3 9 5 2
1 . 2 8 3 0 9 8
. x i :  r e g r e s s  l o g i o f o l d r i s e  i . t i d l  i f  ag5==12
i . t i d l  _ I t i d l _ l - 2  ( n a t u r a l l y  c o d e d ;  _ I t i d l _ l  o m i t t e d )
S o u r c e SS
Model  | 1 . 8 4 9 6 6 5 8 8  
R e s i d u a l  | 3 . 4 6 5 2 2 8 0 4
 + -----------------------------
T o t a l  | 5 . 3 1 4 8 9 3 9 3
d f MS
1 1 . 8 4 9 6 6 5 8 8
28 . 1 2 3 7 5 8 1 4 4
29 . 1 8 3 2 7 2 2 0 4
Number o f  o b s  = 30
F ( 1,  28)  = 1 4 . 9 5
Prob > F = 0 . 0 0 0 6
R - s q u a r e d  = 0 . 3 4 8 0
Adj R - s q u a r e d  = 0 . 3 2 4 7
Root  MSE = . 3 5 1 7 9
l o g i 0f o l d r ~ e  | C o e f .  S t d .  E r r .  t  P > I t |  [95% C o n f .  I n t e r v a l ]
I t i d l _ 2  | - . 5 0 6 8 5 1 1  . 1 3 1 1 0 5 4  - 3 . 8 7  0 . 0 0 1  - . 7 7 5 4 0 8 4  - . 2 3 8 2 9 3 8
_ c o n s  | . 8 5 3 9 1 1 6  . 0 8 2 9 1 8 3  1 0 . 3 0  0 . 0 0 0  . 6 8 4 0 6 1 1  1 . 0 2 3 7 6 2
. x i :  r e g r e s s  l o g i o f o l d r i s e  i . t i d 2  i f  ag5==0
i . t i d 2  _ I t i d 2 _ l - 2  ( n a t u r a l l y  c o d e d ;  _ I t i d 2 _ l  o m i t t e d )
S o u r c e  | SS
 + --------------------------
Model  | 4 . 8 7 2 7 5 9 8 5  
R e s i d u a l  I 9 . 2 7 8 9 5 5 6 3
d f MS
1 4 . 8 7 2 7 5 9 8 5
58 . 1 5 9 9 8 1 9 9 4
T o t a l  | 1 4 . 1 5 1 7 1 5 5  59 . 2 3 9 8 5 9 5 8 4
Number o f  o b s  - 60
F ( 1 ,  58)  = 3 0 . 4 6
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 3 4 4 3
Adj R - s q u a r e d  = 0 . 3 3 3 0
Root  MSE = . 3 9 9 9 8
l o g i 0f o l d r ~ e  | C o e f .  S t d .  E r r .  t  P > | t |  [95% C o n f .  I n t e r v a l ]
I t i d 2 _ 2  | - . 5 9 1 3 7 1  . 1 0 7 1 5 3 9  - 5 . 5 2  0 . 0 0 0  - . 8 0 5 8 6 2 8  - . 3 7 6 8 7 9 1
_ c o n s  | . 4 2 8 0 4 3 5  . 0 6 4 8 8 4 9  6 . 6 0  0 . 0 0 0  . 2 9 8 1 6 2 3  . 5 5 7 9 2 4 8
. x i :  r e g r e s s  l o g i o f o l d r i s e  i . t i d 2  i f  ag5==6
i . t i d 2  _ I t i d 2 _ l - 2  ( n a t u r a l l y  c o d e d;  _ I t i d 2 _ l  o m i t t e d )
S o u r c e SS
Model  | 2 . 9 6 7 2 4 6 7 1  
R e s i d u a l  | 3 . 4 3 3 0 0 4 2 4
 +-------------
T o t a l  | 6 . 4 0 0 2 5 0 9 5
d f MS
1 2 . 9 6 7 2 4 6 7 1
43 . 0 7 9 8 3 7 3 0 8
44 . 1 4 5 4 6 0 2 4 9
Number o f  o b s  = 45
F ( 1 ,  43) = 3 7 . 1 7
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 4 6 3 6
Adj R - s q u a r e d  = 0 . 4 5 1 1
Root  MSE = . 2 8 2 5 5
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log10foldr~e | Coef. Std. Err. t P>|t| [95% Conf. Interval]
_ I t i d 2 _ 2  | 
_ c o n s  |
- . 5 3 6 4 4 3 6  . 0 8 7 9 9 3 4  - 6 . 1 0  
. 7 6 8 1 4 5 5  . 0 5 2 4 6 9 1  1 4 . 6 4
0 . 0 0 0
0 . 0 0 0
- . 7 1 3 8 9 9 3  - . 3 5 8 9 8 8  
. 6 6 2 3 3 1 4  . 8 7 3 9 5 9 6
. x i :  r e g r e s s  
i . t i d 2
l o g i o f o l d r i s e  i . t i d 2  i f  ag5==12  
_ I t i d 2 _ l - 2  ( n a t u r a l l y  co d ed ;1 _ I t i d 2 _1 o m i t t e d )
S o u r c e  | SS d f  MS Number o f  o bs  = 30 
F  ( 1,  28)  = 3 1 . 1 
Prob > F  = 0 . 0 0 0 0  
R - s q u a r e d  - 0 . 5 2 8 8  
Adj R - s q u a r e d  = 0 . 5 1 1 9  
Root  MSE = . 3 1 4 7 8
Model  | 
R e s i d u a l  |
3 . 1 1 3 1 0 5 8 6  1 3 . 1 1 3 1 0 5 8 6  
2 . 7 7 4 3 5 2 5 8  28 . 0 9 9 0 8 4 0 2 1
T o t a l  | 5 . 8 8 7 4 5 8 4 4  29  . 2 0 3 0 1 5 8 0 8
l o g i 0f o l d r ~ e  | C o e f .  S t d .  E r r .  t P> 111 [95% C o n f .  I n t e r v a l ]
I t i d 2 _ 2  | - . 6 5 7 5 5 2 9  . 1 1 7 3 1 0 1  - 5 . 6 1  0 . 0 0 0  - . 8 9 7 8 5 1 8  - . 4 1 7 2 5 4
_ c o n s  | . 6 3 2 1 6 3  . 0 7 4 1 9 3 4  8 . 5 2  0 . 0 0 0  . 4 8 0 1 8 4 6  . 7 8 4 1 4 1 4
APPEN DIX  2
DATA ANALYSIS - STATA CODE
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
/ /  Code:  T h i s  c o d e  g e n e r a t e s  3 m o n t h l y  a g e  c l a s s e s ,  f o r  a l l  t h e  i n f a n t s  i n  t h e  k i n e t i c s  
/ /  s t u d y .  The mean PRNT i n  e a c h  c l a s s  i s  t h e n  c a l c u l a t e d  and compared  t o  t h a t  o f
/ /  t h e  n e x t  a g e  c l a s s .
//
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. u s e  " C: \Do cume n ts  and
S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a p e r 2 \ F u l l _ C 0 H 0 R T _ n e u t _ s u r v e i l l a n c e  o v e r l a y . d t a " , c l e a r
. e g e n  a g l 3 = c u t  ( a g e _ m) , a t  (0 ( 3 ) 3 0 )  / / g e n e r a t e  3 m o n t h l y  a g e  c l a s s e s
(2046  m i s s i n g  v a l u e s  g e n e r a t e d )
. c o l l a p s e  (mean) 1 1 0 = l o g i 0meannt  ( sd)  s d l O = l o g i 0meannt  ( c o u nt )  c n t  = l o g i 0m e a n n t , b y  
( a g l 3 )  / / c a l c u l a t e  means ,  SDs and Ns f o r  d i f f e r e n t  a g e  c l a s s e s
. g e n e r a t e  h i  = 110+ i n v t t a i l  ( c n t - 1 , 0 . 0 2 5 ) *  ( sd l O /  s q r t  ( c n t ) )  / /  c a l c u l a t e
u pp er  Cl
(1 m i s s i n g  v a l u e  g e n e r a t e d )
. g e n e r a t e  l o  = 1 1 0 -  i n v t t a i l  ( c n t - 1 , 0 . 0 2 5 ) *  ( sd l O /  s q r t  ( c n t ) )  / /  c a l c u l a t e
l o w e r  Cl
(1 m i s s i n g  v a l u e  g e n e r a t e d )
. c a p t u r e : rename c o h o r t  c o h o r t 2
append u s i n g  " C: \D o c ume n ts  and
S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a pe r 2 \ F u l l _ C OH O RT _ n e u t _s u r v e i l l a n c e  o v e r l a y . d ta"  
/ / m e r g e  w i t h  m a s t e r  f i l e
. / /  c o m p a r i s o n  o f  PRNTs i n  d i f f e r e n t  a g e  c l a s s e s
. x i : r e g r e s s  l o g i 0meannt  i b 0 . a g l 3  / /  B a s e  c l a s s  — > 0 - 2  mont hs  o f  a g e
S o u r c e  | SS d f  MS Number o f  o b s  = 280
--------------- --------- +-----------------------------------------------------------  F ( 9,  270)  = 1 5 . 2 8
Model  | 2 6 . 6 7 8 6 9 9  9 2 . 9 6 4 2 9 9 8 9  Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2  270 . 1 9 3 9 5 8 5 3 4  R - s q u a r e d  = 0 . 3 3 7 5
------------------------- +-----------------------------------------------------------  Adj R - s q u a r e d  = 0 . 3 1 5 4
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T o t a l  | 7 9 . 0 4 7 5 0 3 2 279  . 2 8 3 3 2 4 3 8 4 Root  MSE = . 4 4 0 4 1
log i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
a g l 3  |
3 I - . 5 6 8 3 1 8 8 . 1 0 1 0 6 9 6 - 5 . 6 2 0 . 0 0 0 - . 7 6 7 3 0 3 6 - . 3 6 9 3 3 4 1
6 I - . 6 7 5 3 8 7 5 . 1 1 3 0 2 4 9 - 5 . 9 8 0 . 0 0 0 - . 8 9 7 9 0 9 7 - . 4 5 2 8 6 5 2
9 1 - . 4 3 0 3 9 7 8 . 1 0 0 0 9 7 7
oCO1 0 . 0 0 0 - . 6 2 7 4 6 9 - . 2 3 3 3 2 6 6
12 | - . 3 6 9 4 6 9 3 . 0 9 6 6 7 5 1
CM00CO1 0 . 0 0 0 - . 5 5 9 8 0 2 1 - . 1 7 9 1 3 6 4
15 | - . 3 9 8 3 8 7 3 . 1 0 3 1 8 2 2 - 3 . 8 6 0 . 0 0 0 - . 6 0 1 5 3 1 3 - . 1 9 5 2 4 3 4
18 | - . 5 6 7 7 4 7 6 . 1 1 4 8 6 7 1 - 4 . 9 4 0 . 0 0 0 - . 7 9 3 8 9 6 7 - . 3 4 1 5 9 8 4
21 I - . 3 1 1 0 3 2 7 . 1 1 3 0 2 4 9 - 2 . 7 5 0 . 0 0 6 - . 5 3 3 5 5 4 9 - . 0 8 8 5 1 0 5
24 | . 3 3 7 5 9 0 5 . 1 0 4 3 3 3 3 3 . 2 4 0 . 0 0 1 . 1321804 . . 5 4 3 0 0 0 7
27 | . 2 6 4 4 4 0 1 . 1 5 2 8 2 0 8 1 . 7 3 0 . 0 8 5 - . 0 3 6 4 3 1 7 . 5 6 5 3 1 2
1
_ c o n s  | 2 . 6 0 7 1 8 8 . 0 6 2 9 1 5 3 4 1 . 4 4 0 . 0 0 0 2 . 4 8 3 3 2 1 2 . 7 3 1 0 5 5
. x i : r e g r e s s l og i ome annt  i b 3 . , a g l 3 / /  B a s e  c l a s s — > 3 - 5  mont hs  o f  a ge
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 9,  270)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  
Ro o t  MSE
280
15. ;
0 . 0 0 0 0
0 . 3 3 7 5
0 . 3 1 5 4
. 4 4 0 4 1
Model
R e s i d u a l
I 2 6 . 6 7 8 6 9 9  
I 5 2 . 3 6 8 8 0 4 2
9
270
2 . 9 6 4 2 9 9 8 9
. 1 9 3 9 5 8 5 3 4
T o t a l I 7 9 . 0 4 7 5 0 3 2 279 . 2 8 3 3 2 4 3 8 4
l og i ome annt  | C o e f . S t d .  Er r . t P > | t | [95% Co n f . I n t e r v a l ]
a g l 3  | 
0 1 . 5 6 8 3 1 8 8 . 1 0 1 0 6 9 6 5 . 6 2 0 . 0 0 0 . 3 6 9 3 3 4 1 . 7 6 7 3 0 3 6
6 I - . 1 0 7 0 6 8 6 . 1 2 2 7 7 2 2 - 0 . 8 7 0 . 3 8 4 - . 3 4 8 7 8 1 3 . 1 3 4 6 4 4
9 I . 1 3 7 9 2 1 1 . 1 1 0 9 8 6 2 1 . 2 4 0 . 2 1 5 - . 0 8 0 5 8 7 3 . 3 5 6 4 2 9 4
12 | . 1 9 8 8 4 9 6 . 1 0 7 9 0 9 5 1 . 8 4 0 . 0 6 6 - . 0 1 3 6 0 1 5 . 4 1 1 3 0 0 7
15 | . 1 6 9 9 3 1 5 . 1 1 3 7 7 5 9 1 . 4 9 0 . 1 3 6 - . 0 5 4 0 6 9 2 . 3 9 3 9 3 2 2
18 | . 0 0 0 5 7 1 3 . 1 2 4 4 7 0 3 0 . 0 0 0 . 9 9 6 - . 2 4 4 4 8 4 4 . 2 4 5 6 2 7
21 | . 2 5 7 2 8 6 1 . 1 2 2 7 7 2 2 2 . 1 0 0 . 0 3 7 . 0 1 5 5 7 3 5 . 4 9 8 9 9 8 8
24 | . 9 0 5 9 0 9 4 . 1 1 4 8 2 0 8 7 . 8 9 0 . 0 0 0 . 6 7 9 8 5 1 4 1 . 1 3 1 9 6 7
27 | 
■
. 8 3 2 7 5 9 . 1 6 0 1 6 4 2 5 . 2 0 0 . 0 0 0 . 5 1 7 4 2 9 4 1 . 1 4 8 0 8 9
1
_ c o n s  | 2 . 0 3 8 8 7 . 0 7 9 0 9 9 5 2 5 . 7 8 0 . 0 0 0 1 . 8 8 3 1 3 9 2 . 1 9 4 6
. x i : r e g r e s s  l o g i 0meannt  i b 6 . a g ! 3  / /  B a s e  c l a s s  — > 6 - 8  mont hs  o f  ag e
S o u r c e  | SS d f  MS Number o f  o bs  = 280
--------------+ -----------------------------------------------------------  f  ( 9,  270 )  = 1 5 . 2 8
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Model  | 2 6 . 6 7 8 6 9 9 9 2 . 9 6 4 2 9 9 8 9 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2 270 . 1 9 3 9 5 8 5 3 4 R - s q u a r e d  = 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
T o t a l  | 7 9 . 0 4 7 5 0 3 2 279 . 2 8 3 3 2 4 3 8 4 Root  MSE . 4 4 0 4 1
log i ome annt  | C o e f . S t d .  Er r . t P> 111 [95% Conf . I n t e r v a l ]
a g l 3  |
0 I . 6 7 5 3 8 7 5 . 1 1 3 0 2 4 9 • 5 . 9 8 0 . 0 0 0 . 4 5 2 8 6 5 2 . 8 9 7 9 0 9 7
3 I . 1 0 7 0 6 8 6 . 1 2 2 7 7 2 2 0 . 8 7 0 . 3 8 4 - . 1 3 4 6 4 4 . 3 4 8 7 8 1 3
9 1 . 2 4 4 9 8 9 7 . 1 2 1 9 7 3 4 2 . 0 1 0 . 0 4 6 . 0 0 4 8 4 9 9 . 4 8 5 1 2 9 5
12 | . 3 0 5 9 1 8 2 . 1 1 9 1 8 0 7 2 . 5 7 0 . 0 1 1 . 0 7 1 2 7 6 6 . 5 4 0 5 5 9 8
15 | . 2 7 7 0 0 0 1 . 1 2 4 5 1 7 2 2 . 2 2 0 . 0 2 7 . 0 3 1 8 5 2 1 . 5 2 2 1 4 8 1
18 | . 1 0 7 6 3 9 9 . 1 3 4 3 5 9 3 0 . 8 0 0 . 4 2 4 - . 1 5 6 8 8 5 2 . 3 7 2 1 6 5
21 I . 3 6 4 3 5 4 8 . 1 3 2 7 8 7 8 2 . 7 4 0 . 0 0 6 . 1 0 2 9 2 3 6 . 6 2 5 7 8 5 9
24 | 1 . 0 1 2 9 7 8 . 1 2 5 4 7 2 7 8 . 0 7 0 . 0 0 0 . 7 6 5 9 4 8 8 1 . 2 6 0 0 0 7
27 | 
1
. 9 3 9 8 2 7 6 . 1 6 7 9 6 4 7 5 . 6 0 0 . 0 0 0 . 6 0 9 1 4 0 5 1 . 2 7 0 5 1 5
1
c o n s  | 1 . 9 3 1 8 0 1 . 0 9 3 8 9 5 1 2 0 . 5 7 0 . 0 0 0 1 . 7 4 6 9 4 1 2 . 1 1 6 6 6 1
. x i : r e g r e s s  l og i ome annt  i b 9 . a g l 3  / /  B a s e  c l a s s — > 9 - 1 1 mont hs  o f  a g e
S o u r c e  | SS d f MS Number o f  o b s  = 280
F ( 9,  270) 15. :
Model  | 2 6 . 6 7 8 6 9 9 9 2 . 9 6 4 2 9 9 8 9 Prob > F = 0 . 0 0 0 0
R e s i d u a l  I 5 2 . 3 6 8 8 0 4 2 270 . 1 9 3 9 5 8 5 3 4 R - s q u a r e d  = 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
T o t a l  | 7 9 . 0 4 7 5 0 3 2 279 . 2 8 3 3 2 4 3 8 4 Root  MSE . 4 4 0 4 1
l og i ome annt  | C o e f . S t d .  Er r . t P> 111 [95% Conf . I n t e r v a l ]
a g l 3  | 
0 I . 4 3 0 3 9 7 8 . 1 0 0 0 9 7 7 4 . 3 0 0 . 0 0 0 . 2 3 3 3 2 6 6 . 6 2 7 4 6 9
3 I - . 1 3 7 9 2 1 1 . 1 1 0 9 8 6 2 - 1 . 2 4 0 . 2 1 5 - . 3 5 6 4 2 9 4 . 0 8 0 5 8 7 3
6 I - . 2 4 4 9 8 9 7 . 1 2 1 9 7 3 4 - 2 . 0 1 0 . 0 4 6 - . 4 8 5 1 2 9 5 - . 0 0 4 8 4 9 9
12 | . 0 6 0 9 2 8 5 . 1 0 6 9 9 9 7 0 . 5 7 0 . 5 7 0 - . 1 4 9 7 3 1 4 . 2 7 1 5 8 8 4
15 | . 0 3 2 0 1 0 4 . 1 1 2 9 1 3 4 0 . 2 8 0 . 7 7 7 - . 1 9 0 2  922 . 2 5 4 3 1 3
18 | - . 1 3 7 3 4 9 8 . 1 2 3 6 8 2 4 - 1 . 1 1 0 . 2 6 8 - . 3 8 0 8 5 4 2 . 1 0 6 1 5 4 7
21 | . 1 1 9 3 6 5 1 . 1 2 1 9 7 3 4 0 . 9 8 0 . 3 2 9 - . 1 2 0 7 7 4 7 . 3 5 9 5 0 4 9
24 | . 7 6 7 9 8 8 3 . 1 1 3 9 6 6 2 6 . 7 4 0 . 0 0 0 . 5 4 3 6 1 2 9 . 9 9 2 3 6 3 7
27 | . 6 9 4 8 3 7 9 . 1 5 9 5 5 2 7 4 . 3 5 0 . 0 0 0 . 3 8 0 7 1 2 4 1 . 0 0 8 9 6 3
1
_ c o n s  | 2 . 1 7 6 7 9 1 . 0 7 7 8 5 3 7 2 7 . 9 6 0 . 0 0 0 2 . 0 2 3 5 1 3 2 . 3 3 0 0 6 8
. x i : r e g r e s s  l og i ome annt  i b l 2 . a g l 3  / /  B a s e  c l a s s  - - >  1 2 - 1 4  months  o f  a ge
300
S o u r c e  I SS d f MS Number o f  o b s  = 280
F ( 9,  270) 15. ;
Model  | 2 6 . 6 7 8 6 9 9 9 2 . 9 6 4 2 9 9 8 9 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2 270 . 1 9 3 9 5 8 5 3 4 R - s q u a r e d  = 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
T o t a l  | 7 9 . 0 4 7 5 0 3 2 279 . 2 8 3 3 2 4 3 8 4 Root  MSE . 4 4 0 4 1
l o g i 0meannt I C o e f .  S t d .  Er r . t P> 111 [95% Co n f . I n t e r v a l ]
a g l 3
0
1
I . 3 6 9 4 6 9 3 0 9 6 67 5 1 3 . 8 2 0 . 0 0 0 . 1 7 9 1 3 6 4 . 5 5 9 8 0 2 1
3 I - . 1 9 8 8 4 9 6 1 07 9 09 5 - 1 . 8 4 0 . 0 6 6 - . 4 1 1 3 0 0 7 . 0 1 3 6 0 1 5
6 I - . 3 0 5 9 1 8 2 1 1 9 1807 - 2 . 5 7 0 . 0 1 1 - . 5 4 0 5 5 9 8 - . 0 7 1 2 7 6 6
9 I - . 0 6 0 9 2 8 5 1 06 9997 - 0 . 5 7 0 . 5 7 0 - . 2 7 1 5 8 8 4 . 1 4 9 7 3 1 4
15 I - . 0 2 8 9 1 8 1 1 09 8907 - 0 . 2 6 0 . 7 9 3 - . 2 4 5 2 6 9 7 . 1 8 7 4 3 3 5
18 I - . 1 9 8 2 7 8 3 1 2 0 92 9 1 - 1 . 6 4 0 . 1 0 2 - . 4 3 6 3 6 2 3 . 0 3 9 8 0 5 7
21 I . 0 5 8 4 3 6 6 1 19 1807 0 . 4 9 0 . 6 2 4 - . 1 7 6 2 0 5 1 . 2 9 3 0 7 8 2
24 | . 7 0 7 0 5 9 8 11 09 7 22 6 . 3 7 0 . 0 0 0 . 4 8 8 5 7 8 9 . 9 2 5 5 4 0 6
27 I . 6 3 3 9 0 9 4  
1
. 1 5 7 4 2 8 4 . 0 3 0 . 0 0 0 . 3 2 3 9 6 6 8 . 9 4 3 8 5 2
_ c o n s
1
I 2 . 2 3 7 7 1 9 0 7 3 40 1 2 3 0 . 4 9 0 . 0 0 0 2 . 0 9 3 2 0 8 2 . 3 8 2 2 3 1
. x i : r e g r e s s l og i ome annt  i b l 5 . a g l 3  / / B a s e  c l a s s — > 15 - 1 7  mont hs  o f a g e
S o u r c e  | SS d f MS Number o f  o b s  = 280
F ( 9,  270) 15. :
Model  | 2 6 . 6 7 8 6 9 9 9 2 . 9 6 4 2 9 9 8 9 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2 270 . 1 9 3 9 5 8 5 3 4 R - s q u a r e d  - 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
T o t a l  | 7 9 . 0 4 7 5 0 3 2 279 . 2 8 3 3 2 4 3 8 4 Ro ot  MSE . 4 4 0 4 1
log i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Co nf . I n t e r v a l ]
a g l 3  | 
0 I . 3 9 8 3 8 7 3 . 1 0 3 1 8 2 2 3 . 8 6 0 . 0 0 0 . 1 9 5 2 4 3 4 . 6 0 1 5 3 1 3
3 I - . 1 6 9 9 3 1 5 . 1 1 3 7 7 5 9 - 1 . 4 9 0 . 1 3 6 - . 3 9 3 9 3 2 2 . 0 5 4 0 6 9 2
6 | - . 2 7 7 0 0 0 1 . 1 2 4 5 1 7 2 - 2 . 2 2 0 . 0 2 7 - . 5 2 2 1 4 8 1 - . 0 3 1 8 5 2 1
9 | - . 0 3 2 0 1 0 4 . 1 1 2 9 1 3 4 - 0 . 2 8 0 . 7 7 7 - . 2 5 4 3 1 3 . 1 9 0 2 9 2 2
12 | . 0 2 8 9 1 8 1 . 1 0 9 8 9 0 7 0 . 2 6 0 . 7 9 3 - . 1 8 7 4 3 3 5 . 2 4 5 2 6 9 7
18 | - . 1 6 9 3 6 0 2 . 1 2 6 1 9 1 7 - 1 . 3 4 0 . 1 8 1 - . 4 1 7 8 0 5 1 . 0 7 9 0 8 4 6
21 | . 0 8 7 3 5 4 6 . 1 2 4 5 1 7 2 0 . 7 0 0 . 4 8 4 - . 1 5 7 7 9 3 4 . 3 3 2 5 0 2 7
24 | . 7 3 5 9 7 7 9 . 1 1 6 6 8 4 7 6 . 3 1 0 . 0 0 0 . 5 0 6 2 5 0 3 . 9 6 5 7 0 5 4
27 | . 6 6 2 8 2 7 5 . 1 6 1 5 0 5 7 4 . 1 0 0 . 0 0 0 . 3 4 4 8 5 6 9 . 9 8 0 7 9 8 1
1
_ c o n s  | 2 . 2 0 8 8 0 1 . 0 8 1 7 8 1 6 2 7 . 0 1 0 . 0 0 0 2 . 0 4 7 7 9 2 . 3 6 9 8 1 2
x i : r e g r e s s  l og iome annt  i b l 8 . a g l 3  / /  B a s e  c l a s s  — > 1 8 - 2 0  mont hs  o f  a ge
S o u r c e SS d f MS
Model  | 2 6 . 6 7 8 6 9 9  9 2 . 9 6 4 2 9 9 8 9
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2  270 . 1 9 3 9 5 8 5 3 4
T o t a l  | 7 9 . 0 4 7 5 0 3 2  279  . 2 8 3 3 2 4 3 8 4
Number o f  o b s  = 280
F ( 9,  270 )  = 1 5 . 2 8
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
Root  MSE = . 4 4 0 4 1
log i ome annt  | C o e f .  S t d .  E r r .  t  P > | t |  [95% Co n f .  I n t e r v a l ]
a g l 3  |
0 1 . 5 6 7 7 4 7 6 . 1 1 4 8 6 7 1 4 . 9 4 0 . 0 0 0 . 3 4 1 5 9 8 4 . 7 9 3 8 9 6 7
3 I - . 0 0 0 5 7 1 3 . 1 2 4 4 7 0 3 - 0 . 0 0 0 . 9 9 6 - . 2 4 5 6 2 7 . 2 4 4 4 8 4 4
6 I - . 1 0 7 6 3 9 9 . 1 3 4 3 5 9 3
o00o1 0 . 4 2 4 - . 3 7 2 1 6 5 . 1 5 6 8 8 5 2
9 1 . 1 3 7 3 4 9 8 . 1 2 3 6 8 2 4 1 . 1 1 0 . 2 6 8 - . 1 0 6 1 5 4 7 . 3 8 0 8 5 4 2
12 | . 1 9 8 2 7 8 3 . 1 2 0 9 2 9 1 1 . 6 4 0 . 1 0 2 - . 0 3 9 8 0 5 7 . 4 3 6 3 6 2 3
15 | . 1 6 9 3 6 0 2 . 1 2 6 1 9 1 7 1 . 3 4 0 . 1 8 1 - . 0 7 9 0 8 4 6 . 4 1 7 8 0 5 1
21 | . 2 5 6 7 1 4 9 . 1 3 4 3 5 9 3 1 . 9 1 0 . 0 5 7 - . 0 0 7 8 1 0 2 . 5 2 1 2 3 9 9
24 | . 9 0 5 3 3 8 1 . 1 2 7 1 3 4 6 7 . 1 2 0 . 0 0 0 . 6 5 5 0 3 6 8 1 . 1 5 5 6 3 9
27 | . 8 3 2 1 8 7 7 . 1 6 9 2 0 9 9 4 . 9 2 0 . 0 0 0 . 4 9 9 0 4 9 2 1 . 1 6 5 3 2 6
1
_ c o n s  | 2 . 0 3 9 4 4 1 . 0 9 6 1 0 4 7 2 1 . 2 2 0 . 0 0 0 1 . 8 5 0 2 3 1 2 . 2 2 8 6 5 1
x i : r e g r e s s  l og i ome annt  i b 2 1 . a g l 3  / /  B a s e  c l a s s  — > 2 1 - 2 3  months  o f  a g e
S o u r c e  | SS d f MS
Model  | 2 6 . 6 7 8 6 9 9  9 2 . 9 6 4 2 9 9 8 9
R e s i d u a l  | 5 2 . 3 6 8 8 0 4 2  270 . 1 9 3 9 5 8 5 3 4
 +-----------------------------------------
T o t a l  | 7 9 . 0 4 7 5 0 3 2  279  . 2 8 3 3 2 4 3 8 4
Number o f  o b s  = 280
F ( 9,  270)  = 1 5 . 2 8
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 3 3 7 5
Adj R - s q u a r e d  = 0 . 3 1 5 4
R o o t  MSE = . 4 4 0 4 1
l og i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Co nf . I n t e r v a l ]
a g l 3  | 
0 I . 3 1 1 0 3 2 7 . 1 1 3 0 2 4 9 2 . 7 5 0 . 0 0 6 . 0 8 8 5 1 0 5 . 5 3 3 5 5 4 9
3 I - . 2 5 7 2 8 6 1 . 1 2 2 7 7 2 2 - 2 . 1 0 0 . 0 3 7 - . 4 9 8 9 9 8 8 - . 0 1 5 5 7 3 5
6 | - . 3 6 4 3 5 4 8 . 1 3 2 7 8 7 8 - 2 . 7 4 0 . 0 0 6 - . 6 2 5 7 8 5 9 - . 1 0 2 9 2 3 6
9 I - . 1 1 9 3 6 5 1 . 1 2 1 9 7 3 4 - 0 . 9 8 0 . 3 2 9 - . 3 5 9 5 0 4 9 . 1 2 0 7 7 4 7
12 | - . 0 5 8 4 3 6 6 . 1 1 9 1 8 0 7 - 0 . 4 9 0 . 6 2 4 - . 2 9 3 0 7 8 2 . 1 7 6 2 0 5 1
15 | - . 0 8 7 3 5 4 6 . 1 2 4 5 1 7 2 1 o o 0 . 4 8 4 - . 3 3 2 5 0 2 7 . 1 5 7 7 9 3 4
18 | - . 2 5 6 7 1 4 9 . 1 3 4 3 5 9 3 - 1 . 9 1 0 . 0 5 7 - . 5 2 1 2 3 9 9 . 0 0 7 8 1 0 2
24 | . 6 4 8 6 2 3 2 . 1 2 5 4 7 2 7 5 . 1 7 0 . 0 0 0 . 4 0 1 5 9 4 . 8 9 5 6 5 2 4
27 | . 5 7 5 4 7 2 8 . 1 6 7 9 6 4 7 3 . 4 3 0 . 0 0 1 . 2 4 4 7 8 5 7 . 9 0 6 1 6
I
_ c o n s I 2 . 2 9 6 1 5 6 . 0 9 3 8 9 5 1 2 4 . 4 5 0 . 0 0 0 2 . 1 1 1 2 9 6 2 . 4 8 1 0 1 5
. x i : r e g r e s s log i ome annt  i b 2 4 . a g l 3  / / B a s e  c l a s s  — > 24 - 2 6  mont hs  o f age
S o u r c e | SS d f MS Number o f  o b s 280
r  / q on  m — i c ; oi: \ j I
Model I 2 6 . 6 7 8 6 9 9 9 2 . 9 6 4 2 9 9 8 9 ■Prob > F = 0 . 0 0 0 0
R e s i d u a l I 5 2 . 3 6 8 8 0 4 2 2 70  . 1 9 3 9 5 8 5 3 4 R - s q u a r e d = 0 . 3 3 7 5
D _ o rri ia rfiH = 0 . 3 1 5 4riUJ i\ o LI a. I. LI
T o t a l I 7 9 . 0 4 7 5 0 3 2 279  . 2 8 3 3 2 4 3 8 4 Ro o t  MSE = . 4 4 0 4 1
l og i ome annt C o e f .  S t d .  E r r . t P > | t | [95% Conf . I n t e r v a l ]
a g l 3
0 I - . 3 3 7 5 9 0 5 1 04 3 3 33 - 3 . 2 4 0 . 0 0 1 - . 5 4 3 0 0 0 7 - . 1 3 2 1 8 0 4
3 I - . 9 0 5 9 0 9 4 1 1 4 82 0 8 - 7 . 8 9 0 . 0 0 0 - 1 . 1 3 1 9 6 7 - . 6 7 9 8 5 1 4
6 I - 1 . 0 1 2 9 7 8 1 2 5 4727 - 8 . 0 7 0 . 0 0 0 - 1 . 2 6 0 0 0 7 - . 7 6 5 9 4 8 8
9 | - . 7 6 7 9 8 8 3 1 1 3 9662 - 6 . 7 4 0 . 0 0 0 - . 9 9 2 3 6 3 7 - . 5 4 3 6 1 2 9
12 | - . 7 0 7 0 5 9 8 1 10 9722 - 6 . 3 7 0 . 0 0 0 - . 9 2 5 5 4 0 6 - . 4 8 8 5 7 8 9
15 I - . 7 3 5 9 7 7 9 1 16 6847 - 6 . 3 1 0 . 0 0 0 - . 9 6 5 7 0 5 4 - . 5 0 6 2 5 0 3
18 I - . 9 0 5 3 3 8 1 1 27 13 46 - 7 . 1 2 0 . 0 0 0 - 1 . 1 5 5 6 3 9 . - . 6 5 5 0 3 6 8
21 I - . 6 4 8 6 2 3 2 1 25 4727 - 5 . 1 7 0 . 0 0 0 - . 8 9 5 6 5 2 4 - . 4 0 1 5 9 4
27 | - . 0 7 3 1 5 0 4 1 62 2435 - 0 . 4 5 0 . 6 5 2 - . 3 9 2 5 7 3 6 . 2 4 6 2 7 2 8
_ c o n s | 2 . 9 4 4 7 7 9 08 32 2 91 3 5 . 3 8 0 . 0 0 0 2 . 7 8 0 9 1 8 3 . 1 0 8 6 4
/ / ---------------------
/ /  Code:  T h i s c o d e  g e n e r a t e s a b i n a r y v a r i a b l e b a s e d  on a p u t a t i v e  n e u t r a l i s i n g
/ /  a n t i b o d y  p r o t e c t i v e  t h r e s h o l d  o b t a i n e d  f rom G l e z e n  e t  a l .  (1981)  . On t h e
b a s i s
/ /  o f  t h i s  v a r i a b l e ,  s u r v i v a l  a n a l y s i s  i s  c a r r i e d  o u t  t o  d e t e r m i n e  t h e  mean
/ /  d u r a t i o n  o f  p r o t e c t i o n  by  m a t e r n a l  a n t i b o d i e s  and t h e  a g e  p r e v a l e n c e  o f  t h e s e
/ /  p r o t e c t i v e  t i t r e s
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. u s e  " C: \Do cume n ts  and S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a p e r 2 \ F u l l _ C 0 H 0 R T _ n e u t . d t a " ,  
c l e a r
. g en  p r o t _ s e v = .
. r e p l a c e  p r o t _ s e v = l  i f  l o g i 0m e a n nt > = 2 . 48
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replace prot_sev=0 if logi0meannt<2.48
ge n  f a i l = l
r e p l a c e  f a i l = 0  i f  p r o t _ s e v = = l  
(106 r e a l  c h a n g e s  made)
r e p l a c e  f a i l = l  i f  s a m p l e _ d > = i n f l _ d  
(80 r e a l  c h a n g e s  made)
. b y s o r t  s am p l e :  e g e n  mx=max ( sa mple _d)
. f o r m a t  mx %d
. s t s e t  s a m p l e _ d ,  i d  ( sa mp le )  f  ( f a i l )  o r  ( d _ b i r t h )  e x  ( mx) s c  ( 3 0 . 5 )
i d :  s a m pl e
f a i l u r e  e v e n t :  f a i l  != 0 & f a i l  < .
o b s .  t i m e  i n t e r v a l :  ( s a m p l e _ d [ _ n - l ] , s a mp le _ d ]
e x i t  on o r  b e f o r e :  t i m e  mx
t  f o r  a n a l y s i s :  ( t i m e - o r i g i n ) / 3 0 . 5
o r i g i n :  t i m e  d _ b i r t h
280  t o t a l  o b s .
24 o b s .  end  on o r  b e f o r e  e n t e r  ()
25 6  o b s .  r e m a i n i n g ,  r e p r e s e n t i n g  
28 s u b j e c t s
251  f a i l u r e s  i n  m u l t i p l e  f a i l u r e - p e r - s u b j e c t  d a t a  
6 9 6 . 1 3 1 1  t o t a l  a n a l y s i s  t i m e  a t  r i s k ,  a t  r i s k  f rom t  =
e a r l i e s t  o b s e r v e d  e n t r y  t  = 
l a s t  o b s e r v e d  e x i t  t  =
0
0
2 9 . 9 3 4 4 3
. s t r a t e
f a i l u r e  _ d:  f a i l
a n a l y s i s  t i m e  _ t :  ( s a m p l e _ d - o r i g i n ) / 3 0 .5
o r i g i n :  t i m e  d _ b i r t h
e x i t  on  o r  b e f o r e :  t i m e  mx
i d :  sa mpl e
E s t i m a t e d  r a t e s  and l o w e r / u p p e r  b ounds  o f  95% c o n f i d e n c e  i n t e r v a l s  
(256  r e c o r d s  i n c l u d e d  i n  t h e  a n a l y s i s )
D Y R a te Lower Upper
251 6 9 6 . 1 3 1 1 0 . 3 6 0 5 6 0 . 3 1 8 6 1 0 . 4 0 8 0 5
. d i  1 / 0 . 3 6 0 5 6  
2 . 7 7 3 4 6 3 5
/ / a g e  p r e v a l e n c e
. c i  p r o t _ s e v  i f  
p r o p o r t i o n s
o f  p r o t e c t i v e  a n t i b o d i e s
s a mp l e  d<= i n f l  d , b y  (ag6)  b i n o m i a l / / c a l c u l a t e  b i n o m i a l
- >  ag6  = 0
—  B i n o m i a l  E x a c t  —
V a r i a b l e  | Obs Mean S t d .  Er r . [95% C o n f .  I n t e r v a l ]
p r o t  s e v  | 24 1 0 . 8 5 7 5 2 6 4  1*
(*) o n e - s i d e d , 97.5% c o n f i d e n c e  i n t e r v a l
- >  a g6  = 1
—  B i n o m i a l  E x a c t  —
V a r i a b l e  | Obs Mean S t d .  E r r . [95% C o nf .  I n t e r v a l ]
p r o t _ s e v  | 0
- >  ag6  = 2
V a r i a b l e  | Obs Mean S t d .  Er r .
—  B i n o m i a l  E x a c t  —  
[95% C o n f .  I n t e r v a l ]
p r o t  s e v  | 19 . 3 6 8 4 2 1 1  . 1 1 0 6 6 4 7 . 1 6 2 8 8 5 9  . 6 1 6 4 2 2 1
- >  ag6  = 3
V a r i a b l e  | Obs Mean S t d .  Er r .
—  B i n o m i a l  E x a c t  —  
[95% C o n f .  I n t e r v a l ]
p r o t _ s e v  | 16 0 0 0 . 2 0 5 9 0 7 2 *
(*) o n e - s i d e d , 97.5% c o n f i d e n c e  i n t e r v a l
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-> ag6 = 6
—  B i n o m i a l  E x a c t  —
V a r i a b l e  | Obs Mean S t d .  E r r .  [95% C o nf .  I n t e r v a l ]
p r o t _ s e v  | 22 0 0 0 . 1 5 4 3 7 2 5 *
(*) o n e - s i d e d ,  97.5% c o n f i d e n c e  i n t e r v a l
- >  ag6  - 12
—  B i n o m i a l  E x a c t  —
V a r i a b l e  | Obs Mean S t d .  E r r .  [95% C o n f .  I n t e r v a l ]
p r o t _ s e v  | 9 . 1 1 1 1 1 1 1  . 1 0 4 7 5 6 6  . 0 0 2 8 0 9 1  . 4 8 2 4 9 6 5
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
/ /  Code:  T h i s  c o d e  c a l c u l a t e s  t h e  d u r a t i o n  o f  n e u t r a l i s i n g  a n t i b o d i e s  f o l l o w i n g  
/ /  p r i m a r y  i n f e c t i o n .  I t  c a l c u l a t e s  t h e  mean n e u t r a l i s i n g  a n t i b o d y  t i t r e  a t
/ /  d i f f e r e n t  t i m e  p o i n t s  p r e  and p o s t  i n f e c t i o n .  A p r e - i n f e c t i o n  c o n t r o l  w h i c h
/ /  e n c o m p a s s e s  n e u t r a l i s i n g  t i t r e s  up t o  s i x  mont hs  p r i o r  t o  p r i m a r y
/ /  i n f e c t i o n  i s  d e f i n e d .
/ /
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. g en  d a y s _ p o s t _ i n f l = s a m p l e _ d - i n f l _ d  / / d a y s  p r e / p o s t  RSV P o s i t i v e  s a m p l e  f o r  f i r s t  
i d e n t i f i e d  i n f e c t i o n
. g e n  m o n t h s _ p o s t _ i n f 1= d a y s _ p o s t _ i n f 1 / 3 0 . 5  / /  t h e  number o f  mo nt hs  b e f o r e  o r  a f t e r
t h e  d a t e  o f  t h e  f i r s t  i d e n t i f i e d  i n f e c t i o n
. / / e g e n  m o n t h s _ p o s t _ i n f l _ c l a s s e s = c u t  ( m o n t h s _ p o s t _ i n f 1 ) , a t  ( - 6 , 0 , 1 , 2 , 3 , 4 , 5 , 6 )
. e g e n  m o n t h s _ p o s t _ i n f l _ c l a s s e s = c u t  ( m o n t h s _ p o s t _ i n f 1 ) , a t  ( - 6 , 0 , 0 . 5 , 1 , 2 , 3 , 4 , 5 , 6 )
. r e p l a c e  m o n t h s _ p o s t _ i n f l _ c l a s s e s = .  i f  age_m<5 & m o n t h s _ p o s t _ i n f l _ c l a s s e s = = - 6  / / g e t  
r i d  m a t e r n a l  a n t i b o d i e s  i n  p r e  e x p o s u r e  c o n t r o l  
(8 r e a l  c h a n g e s  made,  8 t o  m i s s i n g )
. gr a ph  b ox  log i ome annt  i f  s a m p l e _ d > = i n f l _ d - 9 0  & sa mp le _ d <=  d a t e _ r e s p l _ e n d , o v e r  ( 
m o n t h s _ p o s t _ i n f l _ c l a s s e s )  / /  b ox  p l o t
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. x i : r e g r e s s  l og i ome annt  i . m o n t h s _ p o s t _ i n f l _ c l a s s e s  a g e _ m , c l u s t e r  ( sa mple )  / /  means  
compared  u s i n g  r e g r e s s i o n  mode l  w i t h  c l u s t e r e d  s a n d w i c h  e s t i m a t i o n  f o r  r e p e a t e d  
me a s u r e m en t s
i . m o n t h s _ p o s t ~ s  _ I m o n t h s _ p o _ l - 8  ( _ I m o n t h s _ p o _ l  f o r  m o n t h s _ ~ s = = - 6  o m i t t e d )
L i n e a r  r e g r e s s i o n  Number o f  o b s  = 123
F ( 8,  27)  = 6 8 . 7 1
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 6 5 5 3
Root  MSE = . 2 5 3 3 7
( S t d .  E r r .  a d j u s t e d  f o r  28 c l u s t e r s  i n  sa mp le )
1
log i ome annt  | C o e f .
Ro b us t  
S t d .  E r r . t P>l t | [95% Co n f . I n t e r v a l ]
_ I m o n t h s  p~2 | . 0 9 7 7 8 1 5 . 0 6 5 3 4 3 7 1 . 5 0 0 . 1 4 6 - . 0 3 6 2 9 2 7 . 2 3 1 8 5 5 6
_ I mo n t h s _ p ~ 3  | . 9 8 0 3 5 4 7 . 0 5 8 6 5 2 6 1 6 . 7 1 0 . 0 0 0 . 8 6 0 0 0 9 5 1 . 1 0 0 7
_ I m o n t h s _ p ~ 4  | . 7 6 5 7 1 8 6 . 0 6 2 7 0 7 6 1 2 . 2 1 0 . 0 0 0 . 6 3 7 0 5 3 2 . 8 9 4 3 8 3 9
_ I m o n t h s _ p ~ 5  | . 4 8 0 9 4 4 7 . 0 7 9 9 1 0 1 6 . 0 2 0 . 0 0 0 . 3 1 6 9 8 2 8 . 6 4 4 9 0 6 6
_I.months p~6  | . 2 1 4 7 1 5 . 1 0 5 6 7 2 6 2 . 0 3 0 . 0 5 2 - . 0 0 2 1 0 7 3 . 4 3 1 5 3 7 3
_ I m o n t h s _ p ~ 7  | . 2 0 7 2 2 5 2 . 1 1 1 2 5 3 3 1 . 8 6 0 . 0 7 3 - . 0 2 1 0 4 7 7 . 4 3 5 4 9 8 1
_ Im on t h s _ p ~ 8  I . 0 9 6 3 6 2 1 . 0 8 0 1 3 7 6 1 . 2 0 0 . 2 4 0 - . 0 6 8 0 6 6 7 . 2 6 0 7 9 0 8
age_m | . 0 0 4 3 2 4 4 . 0 0 6 1 5 5 5 0 . 7 0 0 . 4 8 8 - . 0 0 8 3 0 5 7 . 0 1 6 9 5 4 4
_ c o n s  | 1 . 7 7 3 2 4 . 0 5 6 9 9 5 2 3 1 . 1 1 0 . 0 0 0 1 . 6 5 6 2 9 5 1 . 8 9 0 1 8 4
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
/ /  Code:  T h i s  c o d e  c o mpa re s  t h e  mean n e u t r a l i s i n g  t i t r e s  a t  t h e  a c u t e  s t a g e  o f  p r i m a r y  
/ /  and s e c o n d a r y  i n f e c t i o n  u s i n g  a l i n e a r  r e g r e s s i o n  mode l
/ /
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
ge n  e p i d = .  / / g e n e r a t e  e p i d e m i c  s t a r t  and e nd  b o u n d a r i e s  
(280 m i s s i n g  v a l u e s  g e n e r a t e d )
r e p l a c e  e p i d = l  i f  s a m p l e _ d  > t d  ( 0 1 / 0 3 / 2 0 0 2 )  & s a m p l e _ d  < t d  ( 0 1 / 0 8 / 2 0 0 2 )  & e p i d = = .
(35 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 2  i f  s a m p l e _ d  > t d  ( 0 1 / 1 2 / 2 0 0 2 )  & s a m p l e _ d  < t d  ( 0 1 / 0 5 / 2 0 0 3 )  & e p i d = = .
(45 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 3  i f  s a m p l e_ d  > t d  ( 0 1 / 1 2 / 2 0 0 3 )  & s a m p l e _ d  < t d  ( 0 1 / 0 7 / 2 0 0 4 )  & e p i d = = .
(71 r e a l  c h a n g e s  made)
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r e p l a c e  e p i d = 4  i f  s a m p l e_ d  > t d  ( 0 1 / 1 1 / 2 0 0 4 )  & s a m p l e _ d  < t d  ( 0 1 / 0 4 / 2 0 0 5 )  & e p i d = = .
(15 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 5  i f  s a m p l e _ d  > t d  ( 0 1 / 1 1 / 2 0 0 5 )  & s a m p l e _ d  < t d  ( 0 1 / 0 8 / 2 0 0 6 )  & e p i d = = .
(0 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 6  i f  s a m p l e _ d  > t d  ( 0 1 / 1 2 / 2 0 0 6 )  & s a m p l e _ d  < t d  ( 0 1 / 0 5 / 2 0 0 7 )  & e p i d = = .
(0 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 7  i f  s a m p l e _ d  > t d  ( 0 1 / 1 1 / 2 0 0 7 )  & s a m p l e _ d  < t d  ( 0 1 / 0 6 / 2 0 0 8 )  & e p i d = = .
(0 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 8  i f  s a m p l e _ d  > t d  ( 0 1 / 1 1 / 2 0 0 8 )  & s a m p l e _ d  < t d  ( 0 1 / 0 6 / 2 0 0 9 )  & e p i d = = .
(0 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 9  i f  s a m p l e _ d  > t d  ( 0 1 / 1 1 / 2 0 0 9 )  & s a m p l e _ d  < t d  ( 0 1 / 0 7 / 2 0 1 0 )  & e p i d = = .
(0 r e a l  c h a n g e s  made)
r e p l a c e  e p i d = 0  i f  e p i d = = .  / / d e f i n e  i n t e r - e p i d e m i c  p e r i o d  
(114 r e a l  c h a n g e s  made)
g e n  d i s p l _ d l = s a m p l e _ d - i n f l _ d  / / d i s p l a c e m e n t  i n  d a y s  b e t w e e n  s a m pl e  d a t e  and p o s i t i v e
i f a t  s amp le  d a t e  i n  p r i m a r y  i n f e c t i o n
g e n  d i s p l _ d 2 = s a m p l e _ d - i n f 2 _ d  / / d i s p l a c e m e n t  i n  d a y s  b e t w e e n  s am p l e  d a t e  and p o s i t i v e
i f a t  s a mp l e  d a t e  i n  s e c o n d a r y  i n f e c t i o n
g e n  d l =  d i s p l _ d l  i f  d i s p l _ d l  >=0 & d i s p l _ d l < = 1 0  / / p i c k  o n l y  t h e  s a m p l e s  c o l l e c t e d
w i t h i n  10 d ay s  o f  i n f e c t i o n  and a ss ume  t h e s e  a r e  " a c u t e "  s a m p l e s  
g e n  d2= d i s p l _ d 2  i f  d i s p l _ d 2  >=0 & d i s p l _ d 2 < = 1 0
g e n  d i s  / /  c o n t a i n s  1 o r  2 i f  s amp le  f u l f i l l s  t h e  " a c u t e "  s a m pl e  c r i t e r i a  ( c o l l e c t e d
<=10 d a y s  a f t e r  IFAT p o s  s ampl e)
/ /  f o r  p r i m a r y  & s e c o n d a r y  i n f e c t i o n  r e s p e c t i v e l y
r e p l a c e  d i s = l  i f  d l ! = .  
r e p l a c e  d i s = 2  i f  d 2 ! = .
. g e n  d i s 2 = .  / / i n i t i a l l y  c o p y  o f  d i s  
(280 m i s s i n g  v a l u e s  g e n e r a t e d )
. r e p l a c e  d i s 2 = l  i f  d i s = = l  
(24 r e a l  c h a n g e s  made)
. r e p l a c e  d i s 2 = 2  i f  d i s = = 2  
(9 r e a l  c h a n g e s  made)
308
. r e p l a c e  d i s 2 = 0  i f  m o n t h s _ p o s t _ i n f l _ c l a s s e s = = - 6  / / p r e - i n f e c t i o n  c o n t r o l  g r o up  
(28 r e a l  c h a n g e s  made)
. x i : r e g r e s s  l og i ome annt  i . d i s 2  / / c o m p a r i s o n  o f  p r i m a r y  and s e c o n d a r y  and i n t r a  e p i d  
ab a t  f i r s t  10 d a y s .  B a s e  c l a s s  i s  t h e  p r e - i n f e c t i o n  c o n t r o l
i . d i s 2 _ I d i s 2 _ 0 - 2 ( n a t u r a l l y  c o d ed ; _ I d i s 2 _ 0  o m i t t e d )
S o u r c e  | SS d f MS Number o f  o b s  = 
F ( 2 ,  58)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Root  MSE
61 
6 2 .  ■ 
0 . 0 0 0 0  
0 . 6 8 2 9  
0 . 6 7 1 9  
. 2 9 0 3 3
Model  | 
R e s i d u a l  |
1 0 . 5 2 7 2 8 1 6
4 . 8 8 8 8 2 2 5 2
2
58
5 . 2 6 3 6 4 0 8 1
. 0 8 4 2 9 0 0 4 3
T o t a l  | 1 5 . 4 1 6 1 0 4 1 60 . 2 5 6 9 3 5 0 6 9
log i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
I d i s 2  1 | 
_ I d i s 2 _ 2  | 
_ c o n s  |
. 0 9 9 7 7 4
1 . 2 1 0 2 5 6
1 . 8 1 5 3 2 4
. 0 8 0 7 6 1 6
. 1 1 1 2 4 7 1
. 0 5 4 8 6 6 7
1 . 2 4
1 0 . 8 8
3 3 . 0 9
0 . 2 2 2
0 . 0 0 0
0 . 0 0 0
- . 0 6 1 8 8 8
. 9 8 7 5 7 1 1
1 . 7 0 5 4 9 6
. 2 6 1 4 3 6
1 . 4 3 2 9 4 2
1 . 9 2 5 1 5 2
x i : r e g r e s s  l og i ome annt  i b l . d i s 2 / / b a s e  c l a s s  - > p r i m a r y  i n f e c t i o n  a c u t e s a m p l e s
S o u r c e  I SS d f MS Number o f  o b s  =
F ( 2 ,  58)  = 
Prob > F 
R - s  qua red  
Adj R - s q u a r e d  
Root  MSE
61 
6 2 . 4 5  
0 . 0 0 0 0  
0 . 6 8 2 9  
0 . 6 7 1 9  
. 2  9033
Model  | 
R e s i d u a l  |
1 0 . 5 2 7 2 8 1 6
4 . 8 8 8 8 2 2 5 2
2
58
5 . 2 6 3 6 4 0 8 1
. 0 8 4 2 9 0 0 4 3
T o t a l  | 1 5 . 4 1 6 1 0 4 1 60 . 2 5 6 9 3 5 0 6 9
log i ome annt  | C o e f . S t d .  E r r . t P > | t | [95% Conf . I n t e r v a l ]
d i s 2  |
0 1 - . 0 9 9 7 7 4 . 0 8 0 7 6 1 6 - 1 . 2 4 0 . 2 2 2 - . 2 6 1 4 3 6 . 0 6 1 8 8 8
2 I 1 . 1 1 0 4 8 2 . 1 1 3 4 7 9 7 9 . 7 9 0 . 0 0 0 . 8 8 3 3 2 8 1 . 3 3 7 6 3 7
1
_ c o n s  | 1 . 9 1 5 0 9 8 . 0 5 9 2 6 2 8 3 2 . 3 2 0 . 0 0 0 1 . 7 9 6 4 7 2 . 0 3 3 7 2 5
. c i p l o t  l o g i o m e a n n t , b y  ( d i s 2 )
//==============================================================================
/ /  Code:  T h i s  c o d e  g e n e r a t e s  summary p l o t s  o f  t h e  mean PRNTs i n  3 c a l e n d a r  month
309
/ /  s t r a t a  f o r  c o h o r t  1 and 2 and c o mpa re s  t h e  mean PRNTs a t  one  t i m e  p o i n t  t o
/ /  t h e  n e x t  t i m e  p o i n t  i n  t h e  s e r i e s  u s i n g  a r e g r e s s i o n  m o d e l .  The p l o t s  a r e
/ /  g e n e r a t e d  r e l a t i v e  t o  t e m p o r a l  p o p u l a t i o n  l e v e l  t r a n s m i s s i o n  e s t i m a t e s
/ /  o b t a i n e d  f rom i n p a t i e n t  s u r v e i l l a n c e  d a t a
/ /
/ / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. / /  u s e  t h i s  modul e  t o  p l o t  compare  t h e  k i n e t i c s  o f  t h e  n e u t  r e s p o n s e  i n  t h e  2 
c o h o r t s  t o  s e a s o n a l  r s v  t r a n s m i s s i o n  
. u s e  " C: \Do cume n t s  and
S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a p e r 2 \ F u l l _ C 0 H 0 R T _ n e u t _ s u r v e i l l a n c e  o v e r l a y . d t a " , c l e a r  
/ /  d a t a s e t  c o n t a i n s  a merge  o f  k i n e t i c s  d a t a  and i n p a t i e n t  s u r v e i l l a n c e  d a t a
. summ s a m p l e _ d , d  / /  g e t  t h e  r a n g e  o f  s a m p l e  d a t e s  f o r  a l l  i n f a n t  s a m p l e s  i n  o r d e r  t o  
g e n e r a t e  a p p r o p r i a t e  c a l e n d e r  s t r a t a
s a m p l e _ d
1?
5?
1 0 ?
25°
P e r c e n t i l e s
15387
15455
15491
15667
S m a l l e s t
15372
1 5381
15387
15389
Obs
Sum o f  Wgt.
280
280
50?
75?
90?
95?
99?
1 5 9 0 6 . 5
1 6 1 6 2 . 5
1 6 2 7 3 . 5  
16382  
16490
L a r g e s t
16483
16490
1 6493
16572
Mean
S t d .  Dev.
V a r i a n c e
S ke w n es s
K u r t o s i s
1 5 9 0 8 . 9 5
2 9 4 . 4 3 9 6
8 6 6 9 4 . 7
. 0 2 0 4 0 7 7
1 . 9 8 9 9 8 8
. e g e n  s a m p l e _ d _ c l a s s = c u t  ( s a m p l e _ d ) , a t  ( 15372  ( 9 0 ) 1 6 5 7 2 )  / /  g e n e r a t e  3 c a l e n d e r
month s t r a t a  o f  a l l  s a m p l e s  i n  b o t h  c o h o r t  1 and 2 
(2047 m i s s i n g  v a l u e s  g e n e r a t e d )
. c o l l a p s e  (mean) 1 1 0 = l o g i 0meannt  ( sd)  s d l O = l o g i 0meannt  ( c o u nt )  c n t  = l o g i o m e a n n t , b y
( s a m p l e _ d _ c l a s s  c o h o r t )  / /  c a l c u l a t e  mean,  SDs and Ns f o r  e a c h  s t r a t u m
. g e n e r a t e  h i  = 110+ i n v t t a i l  ( c n t - 1 , 0 . 0 2 5 ) *  ( sdlO /  s q r t  ( c n t ) )  / /  c a l c u l a t e
u pp er  c o n f i d e n c e  l i m i t
. g e n e r a t e  l o  = 1 1 0 -  i n v t t a i l  ( c n t - 1 , 0 . 0 2 5 ) *  ( sdlO /  s q r t  ( c n t ) )  / /  c a l c u l a t e
l o w e r  c o n f i d e n c e  l i m i t
. c a p t u r e :  rename c o h o r t  c o h o r t 2
310
. append u s i n g  " C: \D o cume n t s  and
S e t t i n g s \ c s a n d e . K W T R P \ D e s k t o p \ p a p e r 2 \ F u l l _ C 0 H 0 R T _ n e u t _ s u r v e i l l a n c e  o v e r l a y . d ta"  
/ / a p p e n d  t o  k i n e t i c s / I P  d a t a s e t  
( l a b e l  ab a l r e a d y  d e f i n e d )
/ /  g e n e r a t e  l o g  n o r m a l i s e d  c o n f i d e n c e  e s t i m a t e s  f o r  c o h o r t  1 and 2 
. c a p t u r e :  g e n  1 10 a = 1 10  i f  c o h o r t 2 = = l  
. c a p t u r e :  g e n  110 b= 11 0  i f  c o h o r t 2 = = 2  
. c a p t u r e :  g e n  h i a = h i  i f  c o h o r t 2 = = l  
. c a p t u r e :  g e n  h i b = h i  i f  c o h o r t 2 = = 2  
. c a p t u r e :  g en  l o a = l o  i f  c o h o r t 2 = = l  
. c a p t u r e :  g e n  l o b = l o  i f  c o h o r t 2 = = 2
. e g e n  s c = c u t  ( s a m p l e _ d ) , a t  ( 15372  ( 9 0 ) 1 6 5 7 2 )  / /  r e - g e n e r a t e  3 m o n t h l y  s t r a t a
. / / n e u t  k i n e t i c s / t r a n m i s s i o n  p l o t s  
. / /  c o h o r t  1
. twoway ( s c a t t e r  1 10 a  s a m p l e _ d _ c l a s s ,  c o n n e c t  ( d i r e c t )  y a x i s  ( 1 ) )  ( r e a p  h i a  l o a  
s a m p l e _ d _ c l a
> s s ,  y a x i s  ( 1 ) )  (bar  w e e k l y _ a d m _ t o t  we e k ly _ ad m i f  d_ a dmi n< =t d  ( 0 1 j a n 2 0 0 6 )  & 
s e r i a l _ n = = l , y a x i
> s  ( 2 ) )
. x i : r e g r e s s  l og i ome annt  i b l 5 3 7 2 . s e  i f  c o h o r t = = l  
1 t o  t h a t  o f  s t r a t u m  2 f o r  c o h o r t  1
/ /  compare  t h e  mean t i t r e  o f  s t r a t u m
S o u r c e  | SS d f MS
Model  | 2 1 . 5 2 0 4 8 5 7  10 2 . 1 5 2 0 4 8 5 7
R e s i d u a l  | 2 9 . 7 8 0 1 8 5 5  160 . 1 8 6 1 2 6 1 6
T o t a l  I 5 1 . 3 0 0 6 7 1 2  170 . 3 0 1 7 6 8 6 5 4
Number o f  o b s  = 171
F ( 10 ,  160)  = 1 1 . 5 6
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 4 1 9 5
Adj R - s q u a r e d  = 0 . 3 8 3 2
Root  MSE = . 4 3 1 4 2
l og i ome annt  I C o e f . S t d .  E r r . P> 111 [95% C o n f .  I n t e r v a l ]
s c  | 
15462  |
15552  |
15642  I
. 5 72 5 6 7 5  . 1 4 5 0 8 6 1
. 9 2 2 0 4 06  . 1 5 5 7 0 2 7
, 97 5 51 6 5  . 1 6 6 1 6 9
- 3 . 9 5  0 . 0 0 0
- 5 . 9 2  0 . 0 0 0
- 5 . 8 7  0 . 0 0 0
- . 8 5 9 0 9 8 3  - . 2 8 6 0 3 6 7
- 1 . 2 2 9 5 3 8  - . 6 1 4 5 4 3 1
- 1 . 3 0 3 6 8 4  - . 6 4 7 3 4 9 1
311
15732 I - . 5 0 3 5 7 2 5 . 1 4 6 2 4 3 5 1 u> 0 . 0 0 1 - . 7 9 2 3 8 9 1 - . 2 1 4 7 5 6
15822 I - . 5 0 8 4 3 3 3 . 1 6 3 0 6 2 7 - 3 . 1 2 0 . 0 0 2 - . 8 3 0 4 6 6 1 - . 1 8 6 4 0 0 5
15912 I - . 8 1 0 7 6 1 . 1 6 0 3 2 2 - 5 . 0 6 0 . 0 0 0 - 1 . 1 2 7 3 8 1 - . 4 9 4 1 4 0 9
16002 I - . 8 7 2 9 0 0 8 . 1 8 4 3 2 4 2 - 4 . 7 4 0 . 0 0 0 - 1 . 2 3 6 9 2 3 - . 5 0 8 8 7 8 7
16092 I - . 1 7 9 2 7 6 7 . 1 5 3 7 3 7 - 1 . 1 7 0 . 2 4 5 - . 4 8 2 8 9 2 2 . 1 2 4 3 3 8 7
16182 I . 0 8 2 2 5 5 8 . 1 5 1 9 5 6 7 0 . 5 4 0 . 5 8 9 - . 2 1 7 8 4 3 8 . 3 8 2 3 5 5 3
16272 I - . 0 5 8 2 2 8 9 . 2 2 4 7 6 6 5 - 0 . 2 6 0 . 7 9 6 - . 5 0 2 1 2 0 5 . 3 8 5 6 6 2 7
c o n s
1
I 2 . 8 4 0 3 7 5 . 1 1 5 3 0 2 8 2 4 . 6 3 0 . 0 0 0 2 . 6 1 2 6 6 3 3 . 0 6 8 0 8 6
. x i : r e g r e s s l og io me annt  i b l 5 4 6 2 . s c  i f c o h o r t = =1 / / compare  t h e  mean t i t r e  o f
2 t o  t h a t  o f s t r a t u m  3 f o r c o h o r t  1
S o u r c e I SS d f MS Number o f  o bs 171
r  V- lu ,  i g u /  =  j . i . 3
Model I 2 1 . 5 2 0 4 8 5 7 10 2 . 1 5 2 0 4 8 5 7 Prob > F =  0 . 0 0 0 0
R e s i d u a l I 2 9 . 7 8 0 1 8 5 5 160 . 1 8 6 1 2 6 1 6 R - s q u a r e d = 0 . 4 1 9 5
Adj R - s q u a r e d = 0 . 3 8 3 2
T o t a l I 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4 Ro o t  MSE = . 4 3 1 4 2
log i ome annt I C o e f . S t d .  Er r . t P> 111 [95% Conf . I n t e r v a l ]
s c 1
15372 I . 5 7 2 5 6 7 5 . 1 4 5 0 8 6 1 3 . 9 5 0 . 0 0 0 . 2 8 6 0 3 6 7 . 8 5 9 0 9 8 3
15552 I - . 3 4 9 4 7 3 1 . 1 3 6 7 6 2 - 2 . 5 6 0 . 0 1 2 - . 6 1 9 5 6 4 7 - . 0 7 9 3 8 1 6
15642 I - . 4 0 2 9 4 9 . 1 4 8 5 6 8 7 - 2 . 7 1 0 . 0 0 7 - . 6 9 6 3 5 7 5 - . 1 0 9 5 4 0 5
15732 I . 0 6 8 9 9 4 9 . 1 2 5 8 8 7 6 0 . 5 5 0 . 5 8 4 - . 1 7 9 6 2 0 8 . 3 1 7 6 1 0 6
15822 I . 0 6 4 1 3 4 2 . 1 4 5 0 8 6 1 0 . 4 4 0 . 6 5 9 - . 2 2 2 3 9 6 6 . 3 5 0 6 6 5
15912 I - . 2 3 8 1 9 3 6 . 1 4 1 9 9 8 8 - 1 . 6 8 0 . 0 9 5 - . 5 1 8 6 2 7 3 . 0 4 2 2 4 0 2
16002 I - . 3 0 0 3 3 3 3 . 1 6 8 6 2 9 6 - 1 . 7 8 0 . 0 7 7 - . 6 3 3 3 6 0 2 . 0 3 2 6 9 3 5
16092 I . 3 9 3 2 9 0 7 . 1 3 4 5 1 9 9 2 . 9 2 0 . 0 0 4 . 1 2 7 6 2 7 2 . 6 5 8 9 5 4 2
16182 I . 6 5 4 8 2 3 2 . 1 3 2 4 8 1 6 4 . 9 4 0 . 0 0 0 . 3 9 3 1 8 5 1 . 9 1 6 4 6 1 3
16272 I . 5 1 4 3 3 8 6  
1
. 2 1 2 0 8 6 2 . 4 3 0 . 0 1 6 . 0 9 5 4 8 9 5 . 9 3 3 1 8 7 6
_ c o n s
1
I 2 . 2 6 7 8 0 7 . 0 8 8 0 6 3 9 2 5 . 7 5 0 . 0 0 0 2 . 0 9 3 8 9 2 . 4 4 1 7 2 5
. x i : r e g r e s s l og i ome annt  i b l 5 5 5 2 . s c  i f o o tr o H rt II II 1 / / compare  t h e  mean t i t r e  o f
s t r a t u m  3 t o t h a t  o f  s t r a t u m  4 f o r  c o h o r t  1
S o u r c e I SS d f MS Number o f  o bs 171
£  \ X v /  X O v /  “  1 1 i J v
Model I 2 1 . 5 2 0 4 8 5 7 10 2 . 1 5 2 0 4 8 5 7 Prob > F = 0 . 0 0 0 0
R e s i d u a l I 2 9 . 7 8 0 1 8 5 5 160 . 1 8 6 1 2 6 1 6 R - s q u a r e d = 0 . 4 1 9 5
Adj R - s q u a r e d = 0 . 3 8 3 2
T o t a l I 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4 Ro o t  MSE = . 4 3 1 4 2
l og i ome annt  | C o e f .  S t d .  E r r .  t  P > | t |  [95% Conf .  I n t e r v a l ]
312
s c 1
15372 I . 9 2 2 0 4 0 6 . 1 5 5 7 0 2 7 5 . 9 2 0 . 0 0 0 . 6 1 4 5 4 3 1 1 . 2 2 9 5 3 8
15462 I . 3 4 9 4 7 3 1 . 1 3 6 7 6 2 2 . 5 6 0 . 0 1 2 . 0 7 9 3 8 1 6 . 6 1 9 5 6 4 7
15642 I - . 0 5 3 4 7 5 9 . 1 5 8 9 5 2 8 - 0 . 3 4 0 . 7 3 7 - . 3 6 7 3 9 2 . 2 6 0 4 4 0 3
15732 I . 4 1 8 4 6 8 1 . 1 3 7 9 8 9 3 3 . 0 3 0 . 0 0 3 . 1 4 5 9 5 2 8 . 6 9 0 9 8 3 3
15822 I . 4 1 3 6 0 7 3 . 1 5 5 7 0 2 7 2 . 6 6 0 . 0 0 9 . 1 0 6 1 0 9 8 . 7 2 1 1 0 4 8
15912 I . 1 1 1 2 7 9 6 . 1 5 2 8 3 0 . 7 3 0 . 4 6 8 - . 1 9 0 5 4 4 6 . 4 1 3 1 0 3 8
16002 I . 0 4 9 1 3 9 8 . 1 7 7 8 4 6 2 0 . 2 8 0 . 7 8 3 - . 3 0 2 0 8 9 . 4 0 0 3 6 8 6
1 6092 I . 7 4 2 7 6 3 9 . 1 4 5 9 0 7 3 5 . 0 9 0 . 0 0 0 . 4 5 4 6 1 1 3 1 . 0 3 0 9 1 6
16182 I 1 . 0 0 4 2 9 6 . 1 4 4 0 3 0 2 6 . 9 7 0 . 0 0 0 . 7 1 9 8 5 0 8 1 . 2 8 8 7 4 2
16272 I . 8 6 3 8 1 1 7 . 2 1 9 4 8 5 4 3 . 9 4 0 . 0 0 0 . 4 3 0 3 4 9 7 1 . 2 9 7 2 7 4
_ c o n s
1
I 1 . 9 1 8 3 3 4 . 1 0 4 6 3 5 5 1 8 . 3 3 0 . 0 0 0 1 . 7 1 1 6 8 9 2 . 1 2 4 9 7 9
. x i , : . r e g r e s s l og i ome annt  i b l 5 6 4 2 . s c  i f c o h o r t = = l / / compare t h e  mean t i t r e  o f
4 t o  t h a t  o f s t r a t u m  5 f o r c o h o r t  1
S o u r c e I SS d f MS Number o f  o b s  = 171
F ( 10 ,  160) 1 1 . E
Model | 2 1 . 5 2 0 4 8 5 7 10 2 . 1 5 2 0 4 8 5 7 Prob > F 0 . 0 0 0 0
R e s i d u a l I 2 9 . 7 8 0 1 8 5 5 160 . 1 8 6 1 2 6 1 6 R - s q u a r e d  - 0 . 4 1 9 5
Adj R - s q u a r e d 0 . 3 8 3 2
T o t a l I 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4 Root  MSE . 4 3 1 4 2
l og iomeannt I C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
s c 1
15372 I . 9 7 5 5 1 6 5 . 1 6 6 1 6 9 5 . 8 7 0 . 0 0 0 . 6 4 7 3 4 9 1 1 . 3 0 3 6 8 4
15462 I . 4 0 2 9 4 9 . 1 4 8 5 6 8 7 2 . 7 1 0 . 0 0 7 . 1 0 9 5 4 0 5 . 6 9 6 3 5 7 5
1 5552 I . 0 5 3 4 7 5 9 . 1 5 8 9 5 2 8 0 . 3 4 0 . 7 3 7 - . 2 6 0 4 4 0 3 . 3 6 7 3 9 2
15732 I . 4 7 1 9 4 4 . 1 4 9 6 9 9 2 3 . 1 5 0 . 0 0 2 . 1 7 6 3 0 2 8 . 7 6 7 5 8 5 1
15822 I . 4 6 7 0 8 3 2 . 1 6 6 1 6 9 2 . 8 1 0 . 0 0 6 . 1 3 8 9 1 5 8 . 7 9 5 2 5 0 5
15912 | . 1 6 4 7 5 5 5 . 1 6 3 4 8 0 3 1 . 0 1 0 . 3 1 5 - . 1 5 8 1 0 2 . 4 8 7 6 1 3
16002 | . 1 0 2 6 1 5 7 . 1 8 7 0 7 7 7 0 . 5 5 0 . 5 8 4 - . 2 6 6 8 4 4 4 . 4 7 2 0 7 5 8
16092 I . 7 9 6 2 3 9 7 . 1 5 7 0 2 7 8 5 . 0 7 0 . 0 0 0 . 4 8 6 1 2 5 2 1 . 1 0 6 3 5 4
16182 I 1 . 0 5 7 7 7 2 . 1 5 5 2 8 5 3 6 . 8 1 0 . 0 0 0 . 7 5 1 0 9 9 2 1 . 3 6 4 4 4 5
16272 I . 9 1 7 2 8 7 6 . 2 2 7 0 3 4 . 0 4 0 . 0 0 0 . 4 6 8 9 2 5 6 1 . 3 6 5 6 5
c o n s
1
I 1 . 8 6 4 8 5 8 . 1 1 96 5 5 3  " '• 1 5 . 5 9 0 . 0 0 0 1 . 6 2 8 5 5 1 2 . 1 0 1 1 6 6
. x i : r e g r e s s l og i ome annt  i b l 5 7 3 2 . s e  i f c o h o r t = = l / / compare  t h e  mean t i t r e
s t r a t u m  5 t o t h a t  o f  s t r a t u m  6 f o r  c o h o r t  1
S o u r c e I SS d f MS Number o f  o bs 171
£ \ £ v / 1 vv / “ j. £ • «.
Model I 2 1 . 5 2 0 4 8 5 7 10 2 . 1 5 2 0 4 8 5 7 Prob > F = 0 . 0 0 0 0
R e s i d u a l I 2 9 . 7 8 0 1 8 5 5 160 . 1 8 6 1 2 6 1 6 R - s q u a r e d = 0 . 4 1 9 5
313
T o t a l  | 5 1 . 3 0 0 6 7 1 2  170 . 3 0 1 7 6 8 6 5 4
Adj R - s q u a r e d  = 0 . 3 8 3 2  
Root  MSE = . 4 3 1 42
log i ome annt  I C o e f . S t d .  E r r . t P> 111 [95% Co nf . I n t e r v a l ]
s c  |
15372  | . 5 0 3 5 7 2 5 . 1 4 6 2 4 3 5 3 . 4 4 0 . 0 0 1 . 2 1 4 7 5 6 . 7 9 2 3 8 9 1
15462  | - . 0 6 8 9 9 4 9 . 1 2 5 8 8 7 6 - 0 . 5 5 0 . 5 8 4 - . 3 1 7 6 1 0 6 . 1 7 9 6 2 0 8
15552  | - . 4 1 8 4 6 8 1 . 1 3 7 9 8 9 3 - 3 . 0 3 0 . 0 0 3 - . 6 9 0 9 8 3 3 - . 1 4 5 9 5 2 8
15642  | - . 4 7 1 9 4 4 . 1 4 9 6 9 9 2 - 3 . 1 5 0 . 0 0 2 - . 7 6 7 5 8 5 1 - . 1 7 6 3 0 2 8
15822  | - . 0 0 4 8 6 0 8 . 1 4 6 2 4 3 5 - 0 . 0 3 0 . 9 7 4 - . 2 9 3 6 7 7 3 . 2 8 3 9 5 5 8
15912  | - . 3 0 7 1 8 8 5 . 1 4 3 1 8 1 2
mCM1 0 . 0 3 3 - . 5 8 9 9 5 7 2 - . 0 2 4 4 1 9 7
16002  | - . 3 6 9 3 2 8 3 . 1 6 9 6 2 6 4 - 2 . 1 8 0 . 0 3 1 - . 7 0 4 3 2 3 8 - . 0 3 4 3 3 2 8
16092  | . 3 2 4 2 9 5 8 . 1 3 5 7 6 7 4 2 . 3 9 0 . 0 1 8 . 0 5 6 1 6 8 5 . 5 9 2 4 2 3
16182  | . 5 8 5 8 2 8 3 . 1 3 3 7 4 8 1 4 . 3 8 0 . 0 0 0 . 3 2 1 6 8 9 . 8 4 9 9 6 7 6
16272  | . 4 4 5 3 4 3 6 . 2 1 2 8 7 9 5 2 . 0 9 0 . 0 3 8 . 0 2 4 9 2 7 6 . 8 6 5 7 5 9 6
c o n s  | 2 . 3 3 6 8 0 2 . 0 8 9 9 5 8 . 2 5 . 9 8 0 . 0 0 0 2 . 1 5 9 1 4 4 2 . 5 1 4 4 6
. x i : r e g r e s s  
s t r a t u m  6 t o
l og i ome annt  i b l 5 8 2 2 . s c  i f  c o h o r t = = l  
t h a t  o f  s t r a t u m  7 f o r  c o h o r t  1
/ /  compare  t h e  mean t i t r e
S o u r c e I SS d f  MS Number o f  o b s  
F ( 10 ,  160)  = 
Prob > F 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Root  MSE
171
1 1 .
0 . 0 0 0 0
0 . 4 1 9 5
0 . 3 8 3 2
. 4 3 1 4 2
Model
R e s i d u a l
I 2 1 . 5 2 0 4 8 5 7  
I 2 9 . 7 8 0 1 8 5 5
10 2 . 1 5 2 0 4 8 5 7  
160 . 1 8 6 1 2 6 1 6
T o t a l I 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4
log i ome annt  | C o e f . S t d .  E r r . t P > | t | [95% Conf . I n t e r v a l ]
s c  | 
15372  | . 5 0 8 4 3 3 3 . 1 6 3 0 6 2 7 3 . 1 2 0 . 0 0 2 . 1 8 6 4 0 0 5 . 8 3 0 4 6 6 1
15462  | - . 0 6 4 1 3 4 2 . 1 4 5 0 8 6 1 - 0 . 4 4 0 . 6 5 9 - . 3 5 0 6 6 5 . 2 2 2 3 9 6 6
15552  | - . 4 1 3 6 0 7 3 . 1 5 5 7 0 2 7 - 2 . 6 6 0 . 0 0 9 - . 7 2 1 1 0 4 8 - . 1 0 6 1 0 9 8
15642  | - . 4 6 7 0 8 3 2 . 1 6 6 1 6 9 - 2 . 8 1 0 . 0 0 6 - . 7 9 5 2 5 0 5 - . 1 3 8 9 1 5 8
15732  | . 0 0 4 8 6 0 8 . 1 4 6 2 4 3 5 0 . 0 3 0 . 9 7 4 - . 2 8 3 9 5 5 8 . 2 9 3 6 7 7 3
15912  | - . 3 0 2 3 2 7 7 . 1 6 0 3 2 2 - 1 . 8 9 0 . 0 6 1 - . 6 1 8 9 4 7 8 . 0 1 4 2 9 2 4
16002  | - . 3 6 4 4 6 7 5 . 1 8 4 3 2 4 2 - 1 . 9 8 0 . 0 5 0 - . 7 2 8 4 8 9 6 - . 0 0 0 4 4 5 4
16092  | . 3 2 9 1 5 6 6 . 1 5 3 7 3 7 2 . 1 4 0 . 0 3 4 . 0 2 5 5 4 1 1 . 6 3 2 7 7 2
16182  | . 5 9 0 6 8 9 1 . 1 5 1 9 5 6 7 3 . 8 9 0 . 0 0 0 . 2 9 0 5 8 9 5 . 8 9 0 7 8 8 6
16272  | 
1
. 4 5 0 2 0 4 4 . 2 2 4 7 6 6 5 2 . 0 0 0 . 0 4 7 . 0 0 6 3 1 2 8 . 8 9 4 0 9 6
1
c o n s  | 2 . 3 3 1 9 4 1 . 1 1 5 3 0 2 8 2 0 . 2 2 0 . 0 0 0 2 . 1 0 4 2 3 2 . 5 5 9 6 5 3
. x i : r e g r e s s  l og i ome annt  i b l 5 9 1 2 . s c  i f  c o h o r t = = l  / /  compare  t h e  mean t i t r e  o f
s t r a t u m  7 t o  t h a t  o f  s t r a t u m  8 f o r  c o h o r t  1
314
S o u r c e  | SS d f MS
Model  | 2 1 . 5 2 0 4 8 5 7  10 2 . 1 5 2 0 4 8 5 7
R e s i d u a l  | 2 9 . 7 8 0 1 8 5 5  160 . 1 8 6 1 2 6 1 6
T o t a l  | 5 1 . 3 0 0 6 7 1 2  170 . 3 0 1 7 6 8 6 5 4
Number o f  o b s  = 171
F ( 10 ,  160)  = 1 1 . 5 6
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 4 1 9 5
Adj R - s q u a r e d  = 0 . 3 8 3 2
Root  MSE = . 4 3 1 4 2
l og i ome annt  | C o e f .  S t d .  E r r .  t  P > I t |  [95% C o n f .  I n t e r v a l ]
s c  | 
15372  | . 8 1 0 7 6 1 . 1 6 0 3 2 2 5 . 0 6 0 . 0 0 0 . 4 9 4 1 4 0 9 1 . 1 2 7 3 8 1
15462  | . 2 3 8 1 9 3 6 . 1 4 1 9 9 8 8 1 . 6 8 0 . 0 9 5 - . 0 4 2 2 4 0 2 . 5 1 8 6 2 7 3
15552  | - . 1 1 1 2 7 9 6 . 1 5 2 8 3  , - 0 . 7 3 0 . 4 6 8 - . 4 1 3 1 0 3 8 . 1 9 0 5 4 4 6
15642  | - . 1 6 4 7 5 5 5 . 1 6 3 4 8 0 3 - 1 . 0 1 0 . 3 1 5 - . 4 8 7 6 1 3 . 1 5 8 1 0 2
15732  | . 3 0 7 1 8 8 5 . 1 4 3 1 8 1 2 2 . 1 5 . 0 . 0 3 3 . 0 2 4 4 1 9 7 . 5 8 9 9 5 7 2
15822  | . 3 0 2 3 2 7 7 . 1 6 0 3 2 2 1 . 8 9 0 . 0 6 1 - . 0 1 4 2 9 2 4 . 6 1 8 9 4 7 8
16002  | - . 0 6 2 1 3 9 8 . 1 8 1 9 0 4 1 - 0 . 3 4 0 . 7 3 3 - . 4 2 1 3 8 2 4 . 2 9 7 1 0 2 9
16092  | . 6 3 1 4 8 4 3 . 1 5 0 8 2 6 9 4 . 1 9 0 . 0 0 0 . 3 3 3 6 1 6 . 9 2 9 3 5 2 5
16182  | . 8 9 3 0 1 6 8 . 1 4 9 0 1 1 8 5 . 9 9 0 . 0 0 0 . 5 9 8 7 3 3 1 1 . 1 8 7 3
16272  | 
■
. 7 5 2 5 3 2 1 . 2 2 2 7 8 6 1 3 . 3 8 0 . 0 0 1 . 3 1 2 5 5 1 5 1 . 1 9 2 5 1 3
1
_ c o n s  | 2 . 0 2 9 6 1 4 . 1 1 1 3 9 3 1 8 . 2 2 0 . 0 0 0 1 . 8 0 9 6 2 3 2 . 2 4 9 6 0 4
. x i : r e g r e s s  l og i ome annt  i b l 6 0 0 2 . s c  i f  c o h o r t = = l  
s t r a t u m  8 t o  t h a t  o f  s t r a t u m  9 f o r  c o h o r t  1
/ /  compare  t h e  mean t i t r e  o f
S o u r c e  | SS d f MS
Model  | 2 1 . 5 2 0 4 8 5 7  10 2 . 1 5 2 0 4 8 5 7
R e s i d u a l  | 2 9 . 7 8 0 1 8 5 5  160 . 1 8 6 1 2 6 1 6
T o t a l  | 5 1 . 3 0 0 6 7 1 2  170 . 3 0 1 7 6 8 6 5 4
Number o f  o b s  = 171
F ( 10 ,  160)  = 1 1 . 5 6
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 4 1 9 5
Adj R - s q u a r e d  = 0 . 3 8 3 2
Root  MSE = . 4 3 1 4 2
meannt  | C o e f . S t d .  E r r . t P > | t | [95% Co nf . I n t e r v a l ]
s c  | 
15372  | . 8 7 2 9 0 0 8 . 1 8 4 3 2 4 2 4 . 7 4 0 . 0 0 0 . 5 0 8 8 7 8 7 1 . 2 3 6 9 2 3
15462  | . 3 0 0 3 3 3 3 . 1 6 8 6 2 9 6 1 . 7 8 0 . 0 7 7 - . 0 3 2 6 9 3 5 . 6 3 3 3 6 0 2
1 5552  | - . 0 4 9 1 3 9 8 . 1 7 7 8 4 6 2 - 0 . 2 8 0 . 7 8 3 - . 4 0 0 3 6 8 6 . 3 0 2 0 8 9
15642  | - . 1 0 2 6 1 5 7 . 1 8 7 0 7 7 7 - 0 . 5 5 0 . 5 8 4 - . 4 7 2 0 7 5 8 . 2 6 6 8 4 4 4
15732  | . 3 6 9 3 2 8 3 . 1 6 9 6 2 6 4 2 . 1 8 0 . 0 3 1 . 0 3 4 3 3 2 8 . 7 0 4 3 2 3 8
15822  | . 3 6 4 4 6 7 5 . 1 8 4 3 2 4 2 1 . 9 8 0 . 0 5 0 . 0 0 0 4 4 5 4 . 7 2 8 4 8 9 6
15912  | . 0 6 2 1 3 9 8 . 1 8 1 9 0 4 1 0 . 3 4 0 . 7 3 3 - . 2 9 7 1 0 2 9 . 4 2 1 3 8 2 4
16092  | . 6 9 3 6 2 4 1 . 1 7 6 1 2 7 9 3 . 9 4 0 . 0 0 0 . 3 4 5 7 8 8 8 1 . 0 4 1 4 5 9
16182  | . 9 5 5 1 5 6 6 . 1 7 4 5 7 6 1 5 . 4 7 0 . 0 0 0 . 6 1 0 3 8 6 1 1 . 2 9 9 9 2 7
16272  | . 8 1 4 6 7 1 9 . 2 4 0 6 3 6 5 3 . 3 9 0 . 0 0 1 . 3 3 9 4 3 8 5 1 . 2 8 9 9 0 5
315
1 . 9 6 7 4 7 4 .143 8 07 8 1 3 . 6 8 0 . 000 1 . 6 8 3 4 6 8 2 . 2 5 1 4 8
. x i : r e g r e s s  l og i ome annt  i b l 6 0 9 2 . s c  i f  c o h o r t = = l  
s t r a t u m  9 t o  t h a t  o f  s t r a t u m  10 f o r  c o h o r t  1
/ /  compare  t h e  mean t i t r e  o f
S o u r c e  | SS d f MS Number o f  o bs  = 171  
F ( 10 ,  160)  = 1 1 . .+
Model  | 2 1 . 5 2 0 4 8 5 7 10 2 . 1 52 04 8 5 7 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 2 9 . 7 8 0 1 8 5 5 160 1 86 1 2 6 1 6 R - s q u a r e d = 0 . 4 1 9 5
. . .  _ , = 0 . 3 8 3 2AQJ .i\“ SCJUcUTGQ
T o t a l  | 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4 Root  MSE = . 4 3 1 4 2
l og i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
s c  |
15372  | . 1 7 9 2 7 6 7 . 1 5 3 7 3 7 1 . 1 7 0 . 2 4 5 - . 1 2 4 3 3 8 7 . 4 8 2 8 9 2 2
1 5462  | - . 3 9 3 2 9 0 7 . 1 3 4 5 1 9 9 - 2 . 9 2 0 . 0 0 4 - . 6 5 8 9 5 4 2 - . 1 2 7 6 2 7 2
15552  | - . 7 4 2 7 6 3 9 . 1 4 5 9 0 7 3 - 5 . 0 9 0 . 0 0 0 - 1 . 0 3 0 9 1 6 - . 4 5 4 6 1 1 3
15642  | - . 7 9 6 2 3 9 7 . 1 5 7 0 2 7 8 - 5 . 0 7 0 . 0 0 0 - 1 . 1 0 6 3 5 4 - . 4 8 6 1 2 5 2
15732  | - . 3 2 4 2 9 5 8 . 1 3 5 7 6 7 4 - 2 . 3 9 0 . 0 1 8 - . 5 9 2 4 2 3 - . 0 5 6 1 6 8 5
15822  | - . 3 2 9 1 5 6 6 . 1 5 3 7 3 7 - 2 . 1 4 0 . 0 3 4 - . 6 3 2 7 7 2 - . 0 2 5 5 4 1 1
15912  | - . 6 3 1 4 8 4 3 . 1 5 0 8 2 6 9 - 4 . 1 9 0 . 0 0 0 - . 9 2 9 3 5 2 5 - . 3 3 3 6 1 6
16002  | - . 6 9 3 6 2 4 1 . 1 7 6 1 2 7 9 - 3 . 9 4 0 . 0 0 0 - 1 . 0 4 1 4 5 9 - . 3 4 5 7 8 8 8
16182  | . 2 6 1 5 3 2 5 . 1 4 1 9 0 3 1 . 8 4 0 . 0 6 7 - . 0 1 8 7 1 1 9 . 5 4 1 7 7 6 9
16272  | . 1 2 1 0 4 7 8 . 2 1 8 0 9 5 3 0 . 5 6 0 . 5 8 0 - . 3 0 9 6 6 9 . 5 5 1 7 6 4 7
1
_ c o n s  | 2 . 6 6 1 0 9 8 . 1 0 1 6 8 7 5 2 6 . 1 7 0 . 0 0 0 2 . 4 6 0 2 7 5 2 . 8 6 1 9 2 1
. x i : r e g r e s s  l og i ome annt  i b l 6 1 8 2 . s c  i f  c o h o r t = = l  
s t r a t u m  10 t o  t h a t  o f  s t r a t u m  11 f o r  c o h o r t  1
/ /  compare  t h e  mean t i t r e  o f
S o u r c e 1 SS d f MS Number o f  o b s  = 171  
F ( 10 ,  160)  = 1 1 .1
Model 1 2 1 . 5 2 0 4 8 5 7 10 2 . 1 5 20 48 5 7 Prob > F = 0 . 0 0 0 0
R e s i d u a l 1 2 9 . 7 8 0 1 8 5 5 160 1 8 6 1 2 6 1 6 R - s q u a r e d = 0 . 4 1 9 5
= 0 . 3 8 3 2Adj k."■'Sq u a re d
T o t a l 1 5 1 . 3 0 0 6 7 1 2 170 . 3 0 1 7 6 8 6 5 4 Root  MSE = . 4 3 1 4 2
l o g 10meannt C o e f . S t d .  E r r . t P> 111 [95% Co n f . I n t e r v a l ]
s c 1
15372 1 - . 0 8 2 2 5 5 8 . 1 5 1 9 5 6 7
o1 0 . 5 8 9 - . 3 8 2 3 5 5 3 . 2 1 7 8 4 3 8
15462 1 - . 6 5 4 8 2 3 2 . 1 3 2 4 8 1 6 - 4 . 9 4 0 . 0 0 0 - . 9 1 6 4 6 1 3 - . 3 9 3 1 8 5 1
15552 1 - 1 . 0 0 4 2 9 6 . 1 4 4 0 3 0 2 - 6 . 9 7 0 . 0 0 0 - 1 . 2 8 8 7 4 2 - . 7 1 9 8 5 0 8
15642 1 - 1 . 0 5 7 7 7 2 . 1 5 5 2 8 5 3 - 6 . 8 1 0 . 0 0 0 - 1 . 3 6 4 4 4 5 - . 7 5 1 0 9 9 2
15732 1 - . 5 8 5 8 2 8 3 . 1 3 3 7 4 8 1 - 4 . 3 8 0 . 0 0 0 - . 8 4 9 9 6 7 6 - . 3 2 1 6 8 9
15822 1 - . 5 9 0 6 8 9 1 . 1 5 1 9 5 6 7 - 3 . 8 9 0 . 0 0 0 - . 8 9 0 7 8 8 6 - . 2 9 0 5 8 9 5
316
15912  | - . 8 9 3 0 1 6 8 . 1 4 9 0 1 1 8 - 5 . 9 9 0 . 0 0 0 - 1 . 1 8 7 3 - . 5 9 8 7 3 3 1
16002  | - . 9 5 5 1 5 6 6 . 1 7 4 5 7 6 1 - 5 . 4 7 0 . 0 0 0 - 1 . 2 9 9 9 2 7 - . 6 1 0 3 8 6 1
16092  | - . 2 6 1 5 3 2 5 . 1 4 1 9 0 3 - 1 . 8 4 0 . 0 6 7 - . 5 4 1 7 7 6 9 . 0 1 8 7 1 1 9
16272  | - . 1 4 0 4 8 4 7 . 2 1 6 8 4 4 1 - 0 . 6 5 0 . 5 1 8 - . 5 6 8 7 3 0 3 . 2 8 7 7 6 1
_ c o n s  | 2 . 9 2 2 6 3 . 0 9 8 9 7 5 3 2 9 . 5 3 0 . 0 0 0 2 . 7 2 7 1 6 4 3 . 1 1 8 0 9 7
. / / c o h o r t  2
. twoway ( s c a t t e r  110b  s a m p l e _ d _ c l a s s ,  c o n n e c t  ( d i r e c t )  y a x i s  ( 1 ) )  ( r e a p  h i b  l o b  
s a m p l e _ d _ c l
> a s s ,  y a x i s  ( 1 ) )  (bar  w e e k l y _ a d m _ t o t  we e k ly _a d m i f  d_ad mi n< =td  ( 0 1 j a n 2 0 0 6 )  & 
s e r i a l _ n = = l , y a
> x i s  ( 2 ) )
. x i : r e g r e s s  l og i ome annt  i b l 5  6 4 2 . s e  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  1 
t o  t h a t  o f  s t r a t u m  2 f o r  c o h o r t  2 -  n o t e  s t r a t u m  1 f o r  c o h o r t  2
/ / i s  s t r a t u m  2 f o r  c o h o r t  1 s i n c e
c o h o r t  2 d o e s n o t  h a v e  d a t a f o r  t h e v e r y  f i r s t s t r a t u m a s  i t  had  n o t
/ /  b e e n r e c r u i t e d  y e t
S o u r c e SS d f MS Number o f  o b s 83
£ \ / / J / “  11
Model 1 2 . 6 9 0 1 0 4 9 9 1. 4 10 0 1 16 5 Prob > F = 0 . 0 0 0 0
R e s i d u a l 8 . 9 5 1 6 4 2 2 2 73 . 1 2 2 6 2 5 2 3 6 R - s q u a r e d = 0 . 5 8 6 4
Adj R - s q u a r e d n rr>c a— U ♦ o sj o 4
T o t a l 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5 R oot  MSE = . 3 5 0 1 8
log i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
s c
15732 - . 4 9 4 8 6 4 4 . 2 1 2 0 4 3 8 - 2 . 3 3 0 . 0 2 2 - . 9 1 7 4 6 7 2 - . 0 7 2 2 6 1 7
15822 - . 6 9 6 4 7 7 7 . 1 9 9 6 3 2 7 - 3 . 4 9 0 . 0 0 1 - 1 . 0 9 4 3 4 5 - . 2 9 8 6 1 0 4
15912 - 1 . 1 0 9 3 1 1 . 2 0 5 0 4 3 7 - 5 . 4 1 0 . 0 0 0 - 1 . 5 1 7 9 6 3 - . 7 0 0 6 5 9 8
16002 - 1 . 1 3 9 1 1 5 . 2 1 2 0 43 8 - 5 . 3 7 0 . 0 0 0 - 1 . 5 6 1 7 1 8 - . 7 1 6 5 1 2 5
16092 - 1 . 0 1 3 4 2 8 . 1 8 2 4 3 9 - 5 . 5 5 0 . 0 0 0 - 1 . 3 7 7 0 2 8 - . 6 4 9 8 2 7 2
16182 - . 4 1 1 5 3 1 7 . 1 8 0 8 3 1 6 - 2 . 2 8 0 . 0 2 6 - . 7 7 1 9 2 8 6 - . 0 5 1 1 3 4 9
16272 - 1 . 0 3 6 2 4 5 . 2 2 1 4 7 2 6 - 4 . 6 8 0 . 0 0 0 - 1 . 4 7 7 6 3 9 - . 5 9 4 8 5 1 1
16362 - . 7 3 0 2 4 3 8 . 1 9 1 8 0 0 9 - 3 . 8 1 0 . 0 0 0 - 1 . 1 1 2 5 0 2 - . 3 4 7 9 8 5 2
16452 . 1 0 6 9 9 1 6 . 2 0 5 0 4 3 7 0 . 5 2 0.  603 - . 3 0 1 6 6 . 5 1 5 6 4 3 2
_ c o n s 2 . 9 4 5 9 6 1 . 1 5 6 6 0 4 7 1 8 . 8 1 0 . 0 0 0 2 . 6 3 3 8 4 8 3 . 2 5 8 0 7 4
317
. x i : r e g r e s s  l og i ome annt  i b l 5 7 3 2 . s c  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  2 
t o  t h a t  o f  s t r a t u m  3 f o r  c o h o r t  2
S o u r c e  | SS d f  MS Number o f  o b s  = 83
£ V 1 O) — ±±  .
Model  | 1 2 . 6 9 0 1 0 4 9 9 1 . 4 1 0 0 1 1 6 5 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 8 . 9 5 1 6 4 2 2 2 73 . 1 2 2 6 2 5 2 3 6 R - s q u a r e d = 0 . 5 8 6 4
Adj R - s q u a r e d  = 
R oot  MSE
0 . 5 3 5 4
. 3 5 0 1 8T o t a l  | 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5
l og i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
s c  | 
15642  | . 4 9 4 8 6 4 4 . 2 1 2 0 4 3 8 2 . 3 3 0 . 0 2 2 . 0 7 2 2 6 1 7 . 9 1 7 4 6 7 2
1 5822  | - . 2 0 1 6 1 3 3 . 1 8 9 1 1 8 2 - 1 . 0 7 0 . 2 9 0 - . 5 7 8 5 2 5 3 . 1 7 5 2 9 8 7
15912  | - . 6 1 4 4 4 7 . 1 9 4 8 2 1 5 - 3 . 1 5 0 . 0 0 2 - 1 . 0 0 2 7 2 6 - . 2 2 6 1 6 8 2
16002  | - . 6 4 4 2 5 0 8 . 2 0 2 1 7 5 9 - 3 . 1 9 0 . 0 0 2 - 1 . 0 4 7 1 8 7 - . 2 4 1 3 1 4 9
1 6092  | - . 5 1 8 5 6 3 1 . 1 7 0 8 6 9 8 1 CO o CO 0 . 0 0 3 - . 8 5 9 1 0 6 1 - . 1 7 8 0 2 0 1
1 6182  | . 0 8 3 3 3 2 7 . 1 6 9 1 5 2 5 0 . 4 9 0 . 6 2 4 - . 2 5 3 7 8 7 7 . 4 2 0 4 5 3 1
16272  | - . 5 4 1 3 8 0 8 . 2 1 2 0 4 3 8 - 2 . 5 5 0 . 0 1 3 - . 9 6 3 9 8 3 5 - . 1 1 8 7 7 8 1
16362  | - . 2 3 5 3 7 9 4 . 1 8 0 8 3 1 6 - 1 . 3 0 0 . 1 9 7 - . 5 9 5 7 7 6 2 . 1 2 5 0 1 7 5
16452  |
i
. 6 0 1 8 5 6 . 1 9 4 8 2 1 5 3 . 0 9 0 . 0 0 3 . 2 1 3 5 7 7 3 . 9 9 0 1 3 4 8
1
_ c o n s  | 2 . 4 5 1 0 9 6 . 1 4 2 9 5 9 9 1 7 . 1 5 0 . 0 0 0 2 . 1 6 6 1 7 8 2 . 7 3 6 0 1 5
. x i : r e g r e s s  l og i ome annt  i b l 5 8 2 2 . s c  i f  c o h o r t = = 2  
t o  t h a t  o f  s t r a t u m  4 f o r  c o h o r t  2
/ / c o m p a r e  t h e  mean t i t r e  o f  s
S o u r c e | SS . d f  MS Number o f  o b s  = 
F ( 9,  73)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Ro ot  MSE
83
i i . ;
0 . 0 0 0 0
0 . 5 8 6 4
0 . 5 3 5 4
. 3 5 0 1 8
Model
R e s i d u a l
| 1 2 . 6 9 0 1 0 4 9  
I 8 . 9 5 1 6 4 2 2 2
9 1 . 4 1 0 0 1 1 6 5  
73 . 1 2 2 6 2 5 2 3 6
T o t a l I 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5
l og i ome annt  | C o e f . S t d .  Er r . t P> 111 [95% Co n f . I n t e r v a l ]
SC 1
15642  | . 6 9 6 4 7 7 7 . 1 9 9 6 3 2 7 3 . 4 9 0 . 0 0 1 1 29 86104 1 . 0 9 4 3 4 5
15732  | . 2 0 1 6 1 3 3 . 1 8 9 1 1 8 2 1 . 0 7 0 . 2 9 0 - . 1 7 5 2 9 8 7 . 5 7 8 5 2 5 3
15912  | - . 4 1 2 8 3 3 7 . 1 8 1 2 3 4 8 - 2 . 2 8 0 . 0 2 6 - . 7 7 4 0 3 4 1 - . 0 5 1 6 3 3 3
16002  | - . 4 4 2 6 3 7 5 . 1 8 9 1 1 8 2 - 2 . 3 4 0 . 0 2 2 - . 8 1 9 5 4 9 5 - . 0 6 5 7 2 5 5
16092  | - . 3 1 6 9 4 9 8 . 1 5 5 2 0 0 2
oCMI 0 . 0 4 5 - . 6 2 6 2 6 3 4 - . 0 0 7 6 3 6 3
16182  | . 2 8 4 9 4 6 . 1 5 3 3 0 7 4 1 . 8 6 0 . 0 6 7 - . 0 2 0 5 9 5 3 . 5 9 0 4 8 7 3
16272  | - . 3 3 9 7 6 7 5 . 1 9 9 6 3 2 7 1 M O 0 . 0 9 3 - . 7 3 7 6 3 4 8 . 0 5 8 0 9 9 8
16362  | - . 0 3 3 7 6 6 1 . 1 6 6 1 0 4 4 - 0 . 2 0 0 . 8 3 9 - . 3 6 4 8 1 1 7 . 2 9 7 2 7 9 6
16452  | 
1
. 8 0 3 4 6 9 3 . 1 8 1 2 3 4 8 4 . 4 3 0 . 0 0 0 . 4 4 2 2 6 8 9 1 . 1 6 4 6 7
318
2 . 2 4 9 4 8 3 . 1 2 3 8 0 6 9 1 8 . 1 7 0 . 000 2 . 0 0 2 7 3 6 2 . 4 9 6 2 3
. x i : r e g r e s s  l og i ome annt  i b l 5 9 1 2 . s c  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  4 
t o  t h a t  o f  s t r a t u m  5 f o r  c o h o r t  2
S o u r c e  | SS d f MS • Number o f  obs 83
' F ( 9,  73)  = 1 1 .
Model  | 1 2 . 6 9 0 1 0 4 9 9 1. 4 1 0 0 11 6 5 Prob > F = 0 . 0 0 0 0
R e s i d u a l  | 8 . 9 5 1 6 4 2 2 2 73 . 1 2 2 6 2 5 2 3 6 R - s q u a r e d = 0 . 5 8 6 4
Adj R - s q u a r e d = 0 . 5 3 5 4
T o t a l  | 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5 Root  MSE = . 3 5 0 1 8
l og i ome annt  I C o e f . S t d .  E r r . t P>l 11 [95% Conf . I n t e r v a l ]
s c  |
1 5642  | 1 . 1 0 9 3 1 1 . 2 0 5 0 4 3 7 5 . 4 1 0 . 0 0 0 . 7 0 0 6 5 9 8 1 . 5 1 7 9 6 3
1 5732  | . 6 1 4 4 4 7 . 1 9 4 8 2 1 5 3 . 1 5 0 . 0 0 2 . 2 2 6 1 6 8 2 1 . 0 0 2 7 2 6
15822  | . 4 1 2 8 3 3 7 . 1 8 1 2 3 4 8 2 . 2 8 0 . 0 2 6 . 0 5 1 6 3 3 3 . 7 7 4 0 3 4 1
16002  | - . 0 2 9 8 0 3 8 . 1 9 4 8 2 1 5 - 0 . 1 5 0 . 8 7 9 - . 4 1 8 0 8 2 6 . 3 5 8 4 7 5
16092  | . 0 9 5 8 8 3 9 . 1 6 2 1 0 1 3 0 . 5 9 0 . 5 5 6 - . 2 2 7 1 8 3 6 . 4 1 8 9 5 1 3
16182  | . 6 9 7 7 7 9 7 . 1 6 0 2 9 0 1 4 . 3 5 0 . 0 0 0 . 3 7 8 3 2 2 1 1 . 0 1 7 2 3 7
16272  | . 0 7 3 0 6 6 2 . 2 0 5 0 4 3 7 0 . 3 6 0 . 7 2 3 - . 3 3 5 5 8 5 4 . 4 8 1 7 1 7 8
16362  | . 3 7 9 0 6 7 6 . 1 7 2 5 7 2 . 2 0 0 . 0 3 1 . 0 3 5 1 3 6 1 . 7 2 2 9 9 9 2
16452  |
i
1 . 2 1 6 3 0 3 . 1 8 7 1 7 8 5 6 . 5 0 0 . 0 0 0 . 8 4 3 2 5 6 9 1 . 5 8 9 3 4 9
1
_ c o n s  | 1 . 8 3 6 6 4 9 . 1 3 2 3 5 5 2 1 3 . 8 8 0 . 0 0 0 1 . 5 7 2 8 6 6 2 . 1 0 0 4 3 3
. x i : r e g r e s s  l og i ome annt  i b l 6 0 0 2 . s c  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  5 
t o  t h a t  o f  s t r a t u m  6 f o r  c o h o r t  2
S o u r c e  I SS d f MS Number o f  o b s  = 83
TP / Q T3\ -  11£ \ 1.j / j-j- .
Model  | 1 2 . 6 9 0 1 0 4 9 9 1. 4 1 0 01 1 6 5 Prob > F = 0 . 0 0 0 0
R e s i d u a l  I 8 . 9 5 1 6 4 2 2 2 73 . 1 2 2 6 2 5 2 3 6 R - s q u a r e d = 0 . 5 8 6 4
= 0 . 5 3 5 4Adj r —s q u a r e d
T o t a l  | 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5 Root  MSE = . 3 5 0 1 8
log i ome annt  I C o e f . S t d .  E r r . t P> 111 [95% Co n f . I n t e r v a l ]
s c  |
15642  | 1 . 1 3 9 1 1 5 . 2 1 2 0 4 3 8 5 . 3 7 0 . 0 0 0 . 7 1 6 5 1 2 5 • 1 . 5 6 1 7 1 8
15732  | . 6 4 4 2 5 0 8 . 2 0 2 1 7 5 9 3 . 1 9 0 . 0 0 2 . 2 4 1 3 1 4 9 1 . 0 4 7 1 8 7
15822  | . 4 4 2 6 3 7 5 . 1 8 9 1 1 8 2 2 . 3 4 0 . 0 2 2 . 0 6 5 7 2 5 5 . 8 1 9 5 4 9 5
15912  | . 0 2 9 8 0 3 8 . 1 9 4 8 2 1 5 0 . 1 5 0 . 8 7 9 - . 3 5 8 4 7 5 . 4 1 8 0 8 2 6
16092  | . 1 2 5 6 8 7 7 . 1 7 0 8 6 9 8 0 . 7 4 0 . 4 6 4 - . 2 1 4 8 5 5 3 . 4 6 6 2 3 0 7
16182  | . 7 2 7 5 8 3 5 . 1 6 9 1 5 2 5 4 . 3 0 0 . 0 0 0 . 3 9 0 4 6 3 1 1 . 0 6 4 7 0 4
1 6272  | . 1 0 2 8 7 . 2 1 2 0 4 3 8 0 . 4 9 0 . 6 2 9 - . 3 1 9 7 3 2 8 . 5 2 5 4 7 2 7
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16362
16452
| . 4 0 8 8 7 1 4  
| 1 . 2 4 6 1 0 7
. 1 8 0 8 3 1 6  2 . 2 6  
. 1 9 4 8 2 1 5  6 . 4 0
0 . 0 2 7
0 . 0 0 0
. 0 4 8 4 7 4 6
. 8 5 7 8 2 8 1
. 7 6 9 2 6 8 3
1 . 6 3 4 3 8 6
_ c o n s
1
I 1 . 8 0 6 8 4 6 . 1 4 2 9 5 9 9  1 2 . 6 4 0 . 0 0 0 1 . 5 2 1 9 2 7 2 . 0 9 1 7 6 4
. x i : r e g r e s s  
6 t o  t h a t  o f
l og i ome annt  i b l 6 0 9 2 . s c  i f  c o h o r t = = 2  
s t r a t u m  7 f o r  c o h o r t  2
/ / c o m p ar e  t h e  mean t i t r e  o f
S o ur c e I SS d f  MS Number o f  o bs  = 83 
F ( 9,  73)  = 1 1 . !  
Prob > F = 0 . 0 0 0 0  
R - s q u a r e d  = 0 . 5 8 6 4
Model
R e s i d u a l
I 1 2 . 6 9 0 1 0 4 9  
| 8 . 9 5 1 6 4 2 2 2
9 1 . 4 1 0 0 1 1 6 5  
73 . 1 2 2 6 2 5 2 3 6
T o t a l | 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5 Root  MSE = . 3 5 0 1 8
l og i ome annt  | C o e f . S t d .  Er r . t P> 111 [95% Conf . I n t e r v a l ]
s c  | 
15642  | 1 . 0 1 3 4 2 8 . 1 8 2 4 3 9 5 . 5 5 0 . 0 0 0 . 6 4 9 8 2 7 2 1 . 3 7 7 0 2 8
15732  | . 5 1 8 5 6 3 1 . 1 7 0 8 6 9 8 3 . 0 3 0 . 0 0 3 . 1 7 8 0 2 0 1 . 8 5 9 1 0 6 1
15822  | . 3 1 6 9 4 9 8 . 1 5 5 2 0 0 2 2 . 0 4 0 . 0 4 5 . 0 0 7 6 3 6 3 . 6 2 6 2 6 3 4
15912  | - . 0 9 5 8 8 3 9 . 1 6 2 1 0 1 3 - 0 . 5 9 0 . 5 5 6 - . 4 1 8 9 5 1 3 . 2 2 7 1 8 3 6
16002  | - . 1 2 5 6 8 7 7 . 1 7 0 8 6 9 8 - 0 . 7 4 0 . 4 6 4 - . 4 6 6 2 3 0 7 . 2 1 4 8 5 5 3
16182  | . 6 0 1 8 9 5 8 . 1 3 0 1 3 0 6 4 . 6 3 0 . 0 0 0 . 3 4 2 5 4 6 . 8 6 1 2 4 5 7
16272  | - . 0 2 2 8 1 7 7 . 1 8 2 4 3 9 - 0 . 1 3 0 . 9 0 1 - . 3 8 6 4 1 8 1 . 3 4 0 7 8 2 8
16362  | . 2 8 3 1 8 3 8 . 1 4 4 9 8 7 8 1 . 9 5 0 . 0 5 5 - . 0 0 5 7 7 6 6 . 5 7 2 1 4 4 1
16452  | 1 . 1 2 0 4 1 9 . 1 6 2 1 0 1 3 6 . 9 1 0 . 0 0 0 . 7 9 7 3 5 1 7 1 . 4 4 3 4 8 7
c o n s  | 1 . 9 3 2 5 3 3 . 0 9 3 5 8 9 2 2 0 . 6 5 0 . 0 0 0 1 . 7 4 6 0 1 2 . 1 1 9 0 5 6
. x i : r e g r e s s  
7 t o  t h a t  o f
log i ome annt  i b l 6 1 8 2 . s c  i f  c o h o r t = = 2  
s t r a t u m  8 f o r  c o h o r t  2
/ / c o m p a r e  t h e  mean t i t r e  o f
S o u r c e I SS d f MS Number o f  o b s  = 
F ( 9,  73)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  
Root: MSE
83
1 1 . .
0 . 0 0 0 0
0 . 5 8 6 4
0 . 5 3 5 4
. 3 5 0 1 8
Model
R e s i d u a l
1 1 2 . 6 9 0 1 0 4 9  
I 8 . 9 5 1 6 4 2 2 2
9
73
1 . 4 1 0 0 1 1 6 5
. 1 2 2 6 2 5 2 3 6
T o t a l | 2 1 . 6 4 1 7 4 7 1 82 . 2 6 3 9 2 3 7 4 5
l o g 10meannt  | C o e f . S t d .  E r r . t P> 111 [95% C o n f . I n t e r v a l ]
SC 1 
15642  | . 4 1 1 5 3 1 7 . 1 8 0 8 3 1 6 2 . 2 8 0 . 0 2 6 . 0 5 1 1 3 4 9 . 7 7 1 9 2 8 6
15732  | - . 0 8 3 3 3 2 7 . 1 6 9 1 5 2 5 1 o KD 0 . 6 2 4 - . 4 2 0 4 5 3 1 . 2 5 3 7 8 7 7
15822  | - . 2 8 4 9 4 6 . 1 5 3 3 0 7 4 - 1 . 8 6 0 . 0 6 7 - . 5 9 0 4 8 7 3 . 0 2 0 5 9 5 3
15912  | - . 6 9 7 7 7 9 7 . 1 6 0 2 9 0 1 - 4 . 3 5 0 . 0 0 0 - 1 . 0 1 7 2 3 7 - . 3 7 8 3 2 2 1
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16002  | - . 7 2 7 5 8 3 5 . 1 6 9 1 5 2 5 - 4 . 3 0 0 . 0 0 0 - 1 . 0 6 4 7 0 4 - . 3 9 0 4 6 3 1
16092  | - . 6 0 1 8 9 5 8 . 1 3 0 1 3 0 6 - 4 . 6 3 0 . 0 0 0 - . 8 6 1 2 4 5 7 - . 3 4 2 5 4 6
1 6272  | - . 6 2 4 7 1 3 5 . 1 8 0 8 3 1 6 - 3 . 4 5 0 . 0 0 1 - . 9 8 5 1 1 0 3 - . 2 6 4 3 1 6 7
16362  | - . 3 1 8 7 1 2 1 . 1 4 2 9 5 9 9 - 2 . 2 3 0 . 0 2 9 - . 6 0 3 6 3 0 8  ■ - . 0 3 3 7 9 3 4
16452  | . 5 1 8 5 2 3 3 . 1 6 0 2 9 0 1 3 . 2 3 0 . 0 0 2 . 1 9 9 0 6 5 7 . 8 3 7 9 8 1
_ c o n s  | 2 . 5 3 4 4 2 9 . 0 9 0 4 1 5 8 2 8 . 0 3 0 . 0 0 0 2 . 3 5 4 2 3 1 2 . 7 1 4 6 2 8
. x i : r e g r e s s  l og i ome annt  i b l 6 2 7 2 . s c  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  
t o  t h a t  o f  s t r a t u m  9 f o r  c o h o r t  2
S o u r c e  | SS d f MS
Model  | 1 2 . 6 9 0 1 0 4 9  9 1 . 4 1 0 0 1 1 6 5
R e s i d u a l  | 8 . 9 5 1 6 4 2 2 2  73 . 1 2 2 6 2 5 2 3 6
T o t a l  | 2 1 . 6 4 1 7 4 7 1  82 . 2 6 3 9 2 3 7 4 5
Number o f  o b s  = 83
F ( 9,  73)  = 1 1 . 5 0
Prob > F  = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 5 8 6 4
Adj R - s q u a r e d  = 0 . 5 3 5 4
Root  MSE = . 3 5 0 1 8
log i ome annt  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
s c  | 
15642  i 1 . 0 3 6 2 4 5 . 2 2 1 4 7 2 6 4 . 6 8 0 . 0 0 0 . 5 9 4 8 5 1 1 1 . 4 7 7 6 3 9
15732  | . 5 4 1 3 8 0 8 . 2 1 2 0 4 3 8 2 . 5 5 0 . 0 1 3 . 1 1 8 7 7 8 1 . 9 6 3 9 8 3 5
15822  | . 3 3 9 7 6 7 5 . 1 9 9 6 3 2 7 1 . 7 0 0 . 0 9 3 - . 0 5 8 0 9 9 8 . 7 3 7 6 3 4 8
15912  | - . 0 7 3 0 6 6 2 . 2 0 5 0 4 3 7 - 0 . 3 6 0 . 7 2 3 - . 4 8 1 7 1 7 8 . 3 3 5 5 8 5 4
16002  | - . 1 0 2 8 7 . 2 1 2 0 4 3 8 - 0 . 4 9 0 . 6 2 9 - . 5 2 5 4 7 2 7 . 3 1 9 7 3 2 8
16092  | . 0 2 2 8 1 7 7 . 1 8 2 4 3 9 0 . 1 3 0 . 9 0 1 - . 3 4 0 7 8 2 8 . 3 8 6 4 1 8 1
16182  | . 6 2 4 7 1 3 5 . 1 8 0 8 3 1 6 3 . 4 5 0 . 0 0 1 . 2 6 4 3 1 6 7 . 9 8 5 1 1 0 3
1 6362  | . 3 0 6 0 0 1 4 . 1 9 1 8 0 0 9 1 . 6 0 0 . 1 1 5 - . 0 7 6 2 5 7 1 . 6 8 8 2 6
1 6452  |
i
1 . 1 4 3 2 3 7 . 2 0 5 0 4 3 7 5 . 5 8 0 . 0 0 0 . 7 3 4 5 8 5 2 1 . 5 5 1 8 8 8
1
c o n s  | 1 . 9 0 9 7 1 6 . 1 5 6 6 0 4 7 1 2 . 1 9 0 . 0 0 0 1 . 5 9 7 6 0 3 2 . 2 2 1 8 2 8
. x i : r e g r e s s  l og i ome annt  i b l 6 3 6 2 . s c  i f  c o h o r t = = 2  / / c o m p a r e  t h e  mean t i t r e  o f  s t r a t u m  9 
t o  t h a t  o f  s t r a t u m  10 f o r  c o h o r t  2
S o u r c e SS
Model  | 1 2 . 6 9 0 1 0 4 9  
R e s i d u a l  | 8 . 9 5 1 6 4 2 2 2
T o t a l 2 1 . 6 4 1 7 4 7 1
d f MS
9 1 . 4 1 0 0 1 1 6 5
73 . 1 2 2 6 2 5 2 3 6
82 . 2 6 3 9 2 3 7 4 5
Number o f  o b s  = 83
F ( 9,  73)  = 1 1 . 5 0
Prob > F = 0 . 0 0 0 0
R - s q u a r e d  = 0 . 5 8 6 4
Adj R - s q u a r e d  = 0 . 5 3 5 4
Root  MSE = . 3 5 0 1 8
l og i ome annt  | C o e f .  S t d .  E r r .  t  P >I t I  [95% Co n f .  I n t e r v a l ]
s c  |
15642  | . 7 3 0 2 4 3 8  . 1 9 1 8 0 0 9  3 . 8 1  0 . 0 0 0  . 3 4 7 9 8 5 2  1 . 1 1 2 5 0 2
321
15732 . 2 3 5 3 7 9 4 . 1 8 0 8 3 1 6 1 . 3 0 0 . 1 9 7 - . 1 2 5 0 1 7 5 . 5 9 5 7 7 6 2
15822 . 0 3 3 7 6 6 1 . 1 6 6 1 0 4 4 0 . 2 0 0 . 8 3 9 - . 2 9 7 2 7 9 6 . 3 6 4 8 1 1 7
15912 - . 3 7 9 0 6 7 6 . 1 7 2 5 7 - 2 . 2 0 0 . 0 3 1 - . 7 2 2 9 9 9 2 - . 0 3 5 1 3 6 1
16002 - . 4 0 8 8 7 1 4 . 1 8 0 8 3 1 6 - 2 . 2 6 0 . 0 2 7 - . 7 6 9 2 6 8 3 - . 0 4 8 4 7 4 6
16092 - . 2 8 3 1 8 3 8 . 1 4 4 9 8 7 8 - 1 . 9 5 0 . 0 5 5 - . 5 7 2 1 4 4 1 . 0 0 5 7 7 6 6
16182 . 3 1 8 7 1 2 1 . 1 4 2 9 5 9 9 2 . 2 3 0 . 0 2 9 . 0 3 3 7 9 3 4 . 6 0 3 6 3 0 8
16272 - . 3 0 6 0 0 1 4 . 1 9 1 8 0 0 9 - 1 . 6 0 0 . 1 1 5 - . 6 8 8 2 6 . 0 7 6 2 5 7 1
16452 . 8 3 7 2 3 5 4 . 1 7 2 5 7 4 . 8 5 0 . 0 0 0 . 4 9 3 3 0 3 8 1 . 1 8 1 1 6 7
2 . 2 1 5 7 1 7 .110 73 6 3 2 0 . 0 1  0 . 0 0 0 1 . 9 9 5 0 2 2 . 4 3 6 4 1 4
APPEN DIX  3
Matlab Code: Multi Dimensional Scaling of RSV B genetic relationships 
Pairwise distances generated using MEGA software
o,
*o
% This code performs multi dimensional scaling analysis using 
distance data
% obtained from MEGA using RSV B G gene sequences obtained from 
infants
% infected with different RSV B strains. Also different test strains 
are
% included for comparison
o,_________________________________________________________________________ ___
'O ----------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
clear
clc
% change working directory
chdir 1C :\Documents and Settings\csande.KWTRP\Desktop\paperl\thesis 
chapter 7\'
%load data
RSVB_data = textread ('C:\Documents and
Settings\csande.KWTRP\Desktop\paperl\thesis chapter 7\distance matrix 
- RSV Bs-matlab-pded.csv1, ' 'delimiter1, 'emptyvalue1, NaN)
%run classical mds
[ya,e]=cmdscale (RSVB_data)
%truncate the mds matrix, to strain components 
ken_ba_2008=ya (1:1,:)
BA=ya (2:21,:) 
swe_b_1960=ya (22:22,:)
SAB=ya (23:42,:)
%A2=ya (41:41,:)
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%plot the data - 2d
%SAB infant samples
plot (SAB {:,!),SAB (:,2),'bo*,
'MarkerEdgeColor','bf, 'Markersize1,12,'MarkerFaceColor','y') 
%text (SAB (:,1),SAB (:,2),'SAB') 
hold on
%ba infant samples
plot (BA (:, 1) ,BA (:,2),'bo',
'MarkerEdgeColor1,'b1,'Markersize1,12,'MarkerFaceColor','g') 
%text (BA (:,1),BA (:,2),'BA') 
hold on
%swe_b test strain
plot (swe_b_1960 (:,1),swe_b_1960 (:,2),'bo',
'MarkerEdgeColor','b','Markersize',12,'MarkerFaceColor', 'b') 
%text (swe_b_1960 (:,1),swe_b_1960 (:,2),'Swe/B/1960') 
hold on
%ken_ba test strain
plot (ken_ba_2008 (:,1),ken_ba_2008 (:,2),'bo', 
'MarkerEdgeColor','b','Markersize',12,'MarkerFaceColor', 'r') 
%text (ken_ba_2008 (:,1),ken_ba_2008 (:,2),'Ken/BA/2008') 
hold on
legend ('Contemporary non-BA strains (SAB)','Contemporary BA 
strains','Swe/B/1960','Ken/B/2008') 
grid on
o."o
% This code performs multi dimensional scaling analysis using cross
324
% reactive neutralising antibody data against representative BA and 
non-BA
% strains of RSV B. Test sera was obtained from infants who underwent 
% natural infection with BA and non-BA strains. Reactivity is 
expressed in
% terms of fold rise in titre from the acute to convalescent phases
of
% infection
o,_____________________________________________________________________________~o-------------------------------------------- - ------------------------------------------- - --------------------------
% change working directory
chdir 'C:\Documents and Settings\csande.KWTRP\Desktop\paperl\thesis 
chapter 7\'
%load data
RSVB_data = textread ('C:\Documents and
Settings\csande.KWTRP\Desktop\paperl\thesis chapter 7\RSV_B_mds_data- 
matlab matrix.csv', '', 'delimiter', ',', 'emptyvalue', NaN)
%generate p distances and reformat the matrix to square form 
a=pdist (RSVB_data) 
b=squareform (a)
% perform, classical mds 
[ya,e]=cmdscale. (b)
% truncate mds matrix to individual parts - sera of individuals 
infected
% with different strains
sab=ya (1:20, :) 
ba=ya (21:40,:)
%plot the graphs 
figure
%sab infected children
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plot (sab (:,l),sab (1,2 ),'bo',
'MarkerEdgeColor', 'b ','Markersize',12, 'MarkerFaceColor',1g 1)
%text (sab (:,l),sab (:,2)#1 SAB') 
hold on
%ba infected children
plot (ba (:,l),ba (:,2),'bo1,
'MarkerEdgeColor1,1b 1,'Markersize',12,'MarkerFaceColor','r ')
%text (ba (:,l),ba (:,2),'BA') 
grid on
legend ('Contemporary BA strains', 'Contemporary Non-BA strains') 
axis ([-50 55 -20 28])
% This code performs multi dimensional scaling analysis using 
distance data
% obtained from MEGA using RSV A G gene sequences obtained from 
infants
% infected with RSV A.
o.  ____________________________________________________________ 1________"o-----------------------------------------------------------------------------------------------------------------------------------------------------------
clear
clc
% change working directory
chdir 'C:\Documents and Settings\csande.KWTRP\Desktop\paperl\thesis 
chapter 7\'
%load data
RSVA_data = textread ('C:\Documents and
Settings\csande.KWTRP\Desktop\paperl\thesis chapter 7\distance matrix 
- RSV As-matlab-pded.csv ' , '', 'delimiter', ',', 'emptyvalue', NaN)
%run classical mds
[ya,e]=cmdscale (RSVA_data)
%truncate the mds matrix to strain components 
Ken_A_20°6=ya (1:1,:)
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RSVA_NP12=ya (2:20,:) 
A2=ya (21:21, :)
%plot the data - 2d
%NP12 infant samples
plot (RSVA_NP12 (:,1),RSVA_NP12 (:,2),,bo', 
'MarkerEdgeColor1,'b ','Markersize',12,'MarkerFaceColor','y ') 
%text (SAB (:,1),SAB (:,2),'SAB') 
hold on
%A2 test strain
plot (A2 (:,1),A2 (:,2),1 b o 1,
'MarkerEdgeColor','b','Markersize',12,'MarkerFaceColor', 'g') 
%text (A2 (:,1),A2 (:,2),'A2')
hold on
%Ken/A/2006 test strain
plot (Ken_A_2006 (:,1),Ken_A_2006 ( : , 2 ) , ' b o ' ,
'MarkerEdgeColor*, 'b','Markersize',12,'MarkerFaceColor','b') 
%text (Ken_A_2006 (:,1),Ken_A_2006 (:,2), 'Ken_A_2006') 
hold on
legend ('Contemporary RSV A strains','A2/A/1961','Ken/A/2006') 
grid on
axis ([ -0.0105 0.035 -0.0065 0.0085])
STATA CODE:
. n
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Code:  T h i s  c o d e  co mp ar e s  t h e  m a g n i t u d e  o f  t h e  serum n e u t r a l i s i n g  
r e s p o n s e  t o  A2 and K e n / A / 2 0 0 6  by  i n f a n t s  i n f e c t e d  w i t h  
c o n t e m p o r a r y  RSV A s t r a i n s  i n  t h e  2 0 0 5 / 2 0 0 6  RSV A e p i d e m i c  
i n  K i l i f i
. c a p t u r e :  drop  g i d  
. c a p t u r e :  l a b e l  drop  g i d
. gen  g i d = .  / /  c o n t a i n s  1 i f  s e r a  f rom RSV A i n f e c t e d  k i d s  was t e s t e d  a g a i n s t  A2 
(329 m i s s i n g  v a l u e s  g e n e r a t e d )
/ /  and 2 i f  i t  was t e s t e d  a g a i n s  K e n / A / 2 0 0 6  
. l a b e l  d e f i n e  g i d  1 "A2 ( A u s / A / 1 9 6 1 ) " 2 "Ken/ A/ 2006"
. l a b e l  v a l u e s  g i d  g i d
. r e p l a c e  g i d = l  i f  i _ g p = = l  & t _ v i r u s _ d e s c = = l  / / A 2  
(45 r e a l  c h a n g e s  made)
. r e p l a c e  g i d = 2  i f  i _ g p = = l  & t _ v i r u s _ d e s c = = 2  / /  k e n / a / 2 0 0 6  
(45 r e a l  c h a n g e s  made)
. x i :  r e g r e s s  
i . g i d
l o g i o f o l d r i s e  i .  
I g i d _ l - 2
. g i d
( n a t u r a l l y  c o d e d ; _ I g i d _ l  o m i t t e d )
S o u r c e  |I SS d f MS Number o f  o b s  = 
F ( 1,  64)  
Prob > F = 
R - s q u a r e d  = 
Adj R - s q u a r e d  = 
Root  MSE =
. 66 
o.:
0 . 7 5 6 4
0 . 0 0 1 5
- 0 . 0 1 4 1
. 4 6 2 3 7
Model  | 
R e s i d u a l  I
. 0 2 0 7 4 1 0 2 4
1 3 . 6 8 2 0 9 3 9
1
64
. 0 2 0 7 4 1 0 2 4
. 2 1 3 7 8 2 7 1 8
T o t a l  | 1 3 . 7 0 2 8 3 5 65 . 2 1 0 8 1 2 8 4 6
l o g i 0f o l d r ~ e  | C o e f . S t d .  E r r . t P> 111 [95% Conf . I n t e r v a l ]
_ I g i d _ 2  | - . 0 3 5 4 5 4 6 . 1 1 3 8 2 6 7 - 0 . 3 1 0 . 7 5 6 - . 2 6 2 8 4 9 7 . 1 9 1 9 4 0 4
_ c o n s  | . 5 3 3 9 4 8 2 . 0 8 0 4 8 7 7 6.  63 0 . 0 0 0 . 3 7 3 1 5 5 6 . 6 9 4 7 4 0 7
. d i  1 0 A. 53 39 4 82  / / f o l d  r i s e  t o  A2 
3 . 4 1 9 3 8 6 6
. d i  1 0 A ( . 5 3 3 9 4 8 2  - . 0 3 5 4 5 4 6 )  / / f o l d  r i s e  t o  k e n / a / 2 0 0 6
3 . 1 5 1 3 2 7 9
.  / / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. / /  T h i s  c o d e  compar e s  a n t i b o d y  r e s p o n s e s  t o  t h e  RSV A and B c o n s t a n t  r e g i o n s
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. / / o f  t h e  G p r o t e i n  i n  a c u t e  and c o n v a l e s c e n t  s e r a  o b t a i n e d  from  
. / /  i n f a n t s  w i t h  RSV A and B i n f e c t i o n s  
.  / / = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = = =
. / /  r e s p o n s e s  t o  c o n s t a n t  r e g i o n  o f  RSV A G p r o t e i n
. t t e s t  o d _ a _ a g _ a c u t e  = = o d _ a _ a g _ c o n v  i f  i _ g p = = l  / /  a c u t e / c o n v  r e s p o n s e s  b y  RSV A 
i n f e c t e d s
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . I n t e r v a l ]
o d _ a _ a ~ e  | 57 1 . 0 4 0 5 4 4 . 0 9 0 7 8 5 6 . 6 8 5 4 1 6 1 . 8 5 8 6 7 8 5 1 . 2 2 2 4 0 9
o d _ a _ a ~ v  | . 57 1 . 8 0 0 2 9 2 . 0 8 9 3 2 8 2 . 6 7 4 4 1 3 1 1 . 6 2 1 3 4 7 1 . 9 7 9 2 3 8
d i f f  | 57 - . 7 5 9 7 4 8 5 . 1 1 7 8 5 3 4 . 8 8 9 7 7 3 6 - . 9 9 5 8 3 7 3 - . 5 2 3 6 5 9 8
mean ( d i f f )  = mean (od_a_ a g _ a c u t e  -  od__a_ag_conv) t  = - 6 . 4 4 6 6
Ho: mean ( d i f f )  = 0 d e g r e e s  o f  f r e e d o m  = 56
Ha: mean ( d i f f )  < 0 Ha: mean ( d i f f )  != 0 Ha: mean ( d i f f )  > 0
Pr (T < t ) = 0 . 0 0 0 0 Pr ( I T | > 111 ) = 0 . 0 0 0 0 Pr (T > t )  = 1 . 0 0 0 0
. t t e s t od  a a g _ a c u t e  ==od_a a g _ c o n v  i f  i _gp==2 / / a c u t e / c o n v r e s p o n s e s  b y  RSV
i n f e c t e d s
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r . S t d .  Dev. [95% Conf . . I n t e r v a l ]
o d _ a _ a ~ e  | 34 1 . 2 2 6 0 7 8 . 0 7 9 8 4 2 5 . 4 6 5 5 5 8 1 1 . 0 6 3 6 3 8 1 . 3 8 8 5 1 9
o d _ a _ a ~ v  | 34 1 . 2 4 2 2 1 6 . 1 1 3 9 7 6 4 . 6 6 4 5 9 0 8 1 . 0 1 0 3 2 9 1 . 4 7 4 1 0 2
d i f f  | 34 - . 0 1 6 1 3 7 2  . 1 2 8 5 6 1  . 7 4 9 6 3 2 8  - . 2 7 7 6 9 6 5  . 2 4 5 4 2 2
mean ( d i f f )  = mean ( o d _ a _ a g _ a c u t e  -  o d _a _ a g _ c o n v )  t  = - 0 . 1 2 5 5
Ho: mean ( d i f f )  = 0 d e g r e e s  o f  f r e e d o m  = 33
Ha: mean ( d i f f )  < 0  Ha: mean ( d i f f )  != 0 Ha: mean ( d i f f )  > 0
Pr (T < t )  = 0 . 4 5 0 4  Pr ( | T |  > | t | )  = 0 . 9 0 0 9  Pr (T > t )  = 0 . 5 4 9 6
. / / r e s p o n s e s  t o  c o n s t a n t  r e g i o n  o f  B G p r o t e i n
. t t e s t  o d _ b _ a g _ a c u t e  = = o d _ b _ a g_ c o n v  i f  i _ g p = = l  / /  a c u t e / c o n v  r e s p o n s e s  b y  RSV A 
i n f e c t e d s
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r .  S t d .  Dev .  [95% Co n f .  I n t e r v a l ]
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o d _b _a ~e 1 57 1 . 6 3 9 5 4 4  . 1 0 7 4 7 4  . 8 1 1 4 1 0 9 1 . 4 2 4 2 4 8 1 . 8 5 4 8 4
od _b _a ~v 1 57 1 . 6 9 2 9 0 1  . 1 2 1 1 3 3  . 9 1 4 5 3 4 4 1 . 4 5 0 2 4 2 1 . 9 3 5 5 5 9
d i f f 1 57 - . 0 5 3 3 5 6 7  . 0 8 9 5 7 4 9  . 6 7 6 2 7 5 7 - . 2 3 2 7 9 6 8 . 1 2 6 0 8 3 4
mean  
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( o d _ b _ a g _ a c u t e  -  o d _ b_ a g_ c o n v)  t  = - 0 . 5 9 5 7  
0 d e g r e e s  o f  f r e e d o m  = 56
Ha: mean ( d i f f )  < 0 Ha: mean ( d i f f )  != 0 Ha: mean ( d i f f )  > 0
Pr (T < t )  = 0 . 2 7 6 9  Pr ( | T |  > | t | )  = 0 . 5 5 3 8 Pr (T > t )  = 0 . 7 2 3 1
. t t e s t  
i n f e c t e d s
od  b ag_ a c u t e  ==od_b a g  c o n v  i f  i _ gp = =2  / / a c u t e / c o n v r e s p o n s e s  by  RSV
P a i r e d  t  t e s t
V a r i a b l e  | Obs Mean S t d .  E r r .  S t d .  Dev. [95% Conf . I n t e r v a l ]
od _b _ a~ e  I 34 1 . 3 8 9 8 0 4  . 1 2 8 4 2 0 2  . 7 4 8 8 1 1 8 1 . 1 2 8 5 3 1 1 . 6 5 1 0 7 7
od_b a ~ v  | 34 3 . 1 5 3 7 9 4  . 1 0 5 2 4 5 9  . 6 1 3 6 8 3 5 2 . 9 3 9 6 7 3 . 3 6 7 9 1 8
d i f f  | 34 - 1 . 7 6 3 9 9  . 1 7 1 7 8 2 6  1 . 0 0 1 6 5 6 - 2 . 1 1 3 4 8 5 - 1 . 4 1 4 4 9 6
mean  
Ho: mean
( d i f f )  = 
( d i f f )  =
mean ( o d _ b _ a g _ a c u t e  -  o d_ b _a g _ c o n v)  t  = - 1 0 . 2 6 8 7  
0 d e g r e e s  o f  f r e e d o m  = 33
Ha: mean ( d i f f )  < 0 Ha: mean ( d i f f )  != 0 Ha: mean ( d i f f )  > 0
Pr (T < t )  = 0 . 0 0 0 0  Pr ( | T !  > 111) = 0 . 0 0 0 0 Pr (T > t )  = 1 . 0 0 0 0
. / / c o m p a r i s o n  o f  s e r o c o n v e r s i o n  r a t e s
. t a b  a s e r o c o n  i _ g p , c h i 2  / / s e r o c o n v e r s i o n  r a t e s  t o  RSV A c o n s t a n t  r e g i o n  b y  RSV A/B  
i n f e c t e d  
> s
I i _ g p
a s e r o c o n  | A B | T o t a l
No | 41 34 | 75
Yes | 16 0 | 16
T o t a l  | 57 34 | 91
P e a r s o n  c h i 2  (1) = 1 1 . 5 7 9 9  Pr = 0 . 0 0 1
. t a b  b s e r o c o n  i _ g p , c h i 2  / / s e r o c o n v e r s i o n  r a t e s  t o  RSV B c o n s t a n t  r e g i o n  b y  RSV A/B  
i n f e c t e d  
> s
I i _ g p
b s e r o c o n  | A B | T o t a l
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No | 57 27 | 84
Yes | 0 7 | 7
 +  + ---------------------
T o t a l  | 57 34 | 91
P e a r s o n  c h i 2  (1) = 1 2 . 7 1 3 2  Pr = 0 . 0 0 0
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